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ABSTRACT 
 
Type 2 diabetes mellitus is a chronic disease of pandemic magnitude, increasingly 
contributing to the disease burden of countries in the developing world, largely because 
of the effects of unhealthy lifestyles fuelled by unbridled urbanisation. In certain settings, 
patients with diabetes are more likely to have a healthcare encounter with a pharmacist 
than with any other healthcare provider. The overall aim of the study was to investigate 
the potential of South African community pharmacists to positively influence patient 
adherence and metabolic control in Type 2 diabetes. The designated primary endpoint 
was glycated haemoglobin, with the intermediate health outcomes of blood lipids, serum 
creatinine, blood pressure and body mass index serving as secondary endpoints. 
 
Community pharmacists and their associated Type 2 diabetes patients were recruited 
from areas throughout South Africa using the communication media of various non-
statutory pharmacy organisations. Although 156 pharmacists initially indicated interest in 
participating in the study, only 28 pharmacists and 153 patients were enrolled prior to 
baseline data collection. Of these, 16 pharmacists and 57 patients participated in the 
study for the full twelve months.  
 
Baseline clinical and psychosocial data were collected, after which pharmacists and their 
patients were randomised, nine pharmacists and 34 patients to the intervention group 
and 8 pharmacists and 27 patients to the control group. The sample size calculation 
revealed that each group required the participation of a minimum of 35 patients. Control 
pharmacists were requested to offer standard pharmaceutical care, while the 
intervention pharmacists were provided with a scope of practice diabetes care plan to 
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guide the diabetes care they were to provide. Data were again collected 12-months post-
baseline. 
 
 At baseline, proportionally more intervention patients (82.4%) than control patients 
(59.3%) were using only oral anti-diabetes agents (i.e. not in combination with insulin), 
while insulin usage, either alone or in combination with oral agents was conversely 
greater in the control group (40.7%) than in the intervention group (17.6%) (Chi-squared 
test, p=0.013). Approximately half of the patients (53.8% control and 47.1% intervention) 
reported having their HbA1c levels measured in terms of accepted guidelines. There was 
no significant difference in HbA1c between the groups at the end of the study 
(Independent t-test, p=0.514). In the control group, the mean HbA1c increased from 
7.3±1.2% to 7.6±1.5%, while for the intervention patients the variable remained almost 
constant (8.2±2.0% at baseline and 8.2±1.8% at post-baseline). Similarly, there were no 
significant differences between the groups with regard to any of the designated 
secondary clinical endpoints. Adherence to medication and self-management 
recommendations was similarly good for both groups. There were no significant 
differences between the two groups for any of the other psychosocial variables 
measured. 
 
In conclusion, intervention pharmacists were not able to significantly influence glycaemic 
control or therapeutic adherence compared to  the control pharmacists. 
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   CHAPTER 1  
 INTRODUCTION 
  
1.1 Rationale and motivation for the study 
 
This study investigated the potential of South African community pharmacists to 
influence patient adherence to long-term therapies and self-care recommendations, and 
to improve metabolic control in Type 2 diabetes mellitus (DM2). 
 
Prior to the introduction of the managed care principle of pharmacy benefit management 
in South Africa during the 1990s, almost all chronically ill patients who were medically 
insured had unfettered access to what the local health insurance industry termed 
‘chronic medicine benefits’. Patients were able to access medicines prescribed for their 
chronic conditions without having to make co-payments or without having their chronic 
illness benefit prescribed or limited by any medicine formulary. Despite the apparent 
largesse of the health insurers in providing open access to chronic medication, 
anecdotal evidence revealed that many chronically ill patients were not having their 
prescriptions refilled at the expected 30 day intervals, while others simply ceased to refill 
their prescriptions altogether.  
 
There was consensus amongst members of the Faculty of Pharmacy at Rhodes 
University, that a critical lack of knowledge existed on the subject of patient adherence to 
long-terms therapies in a South African pharmacy practice context and that research to 
address the contribution of pharmacists to this subject was relevant in contributing to 
establishing an evidence base for South African community pharmacy practice.   
 
The World Health Organization (WHO) published a report in 2003  entitled, Adherence to 
long-term therapies: evidence for action1 in which the economic, clinical and humanistic 
cost of poor levels of therapeutic adherence –  the term ‘compliance’ having by now 
been rejected by many authorities in favour of the less condescending term of 
‘adherence’ – are discussed and possible solutions considered.  
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The report set the scene by defining adherence, describing the magnitude of the 
problem and considering the implications of poor adherence in terms of health policy and 
management. The report then dealt with improving adherence from the perspective of 
lessons learnt, i.e. factors affecting adherence and the discussion of interventions in 
terms of five dimensions of adherence, namely socio-economic, therapy-related, patient-
related, condition-related and healthcare system factors. The report then went on to 
consider adherence in terms of specifically identified disease entities. Special mention 
was made of the behavioural mechanisms explaining adherence. 
 
The following “take home messages” which were included in the report, highlighted the 
magnitude and consequences of the problem, the benefit of finding solutions and the 
potential of pharmacists to play key roles in improving scope of practice aspects of 
therapeutic adherence.  
  “Poor adherence to the treatment of chronic diseases is a worldwide problem of striking 
magnitude”. 
 “Adherence to long-term therapy for chronic illnesses in developed countries averages 50%. 
In developing countries, the rates are even lower”. 
 “The consequences of poor adherence to long-term therapies are poor health outcomes and 
increased health care costs”. 
 “Increasing the effectiveness of adherence interventions may have a far greater impact on the 
health of the population than any improvement in specific medical treatment”. 
 “There is no single intervention strategy, or package of strategies that has been shown to be 
effective across all patients, conditions and settings, Consequently, interventions that target 
adherence must be tailored to the particular illness-related demands experienced by the 
patient.” 
 “Pharmacists are well positioned to play a primary role in improving adherence to long-term 
therapy because they are the most accessible health care professionals and because they 
have extensive training in pharmaceuticals”.  
 
It was decided to focus the study on the disease entity of DM2 as it received special 
mention in the WHO adherence report.1 DM2 is a disease of pandemic proportions 
increasingly making its presence felt in the developing world where, it is predicted, most 
of the world’s diabetes burden will in future be borne.1,2 Furthermore, it is a disease 
where pharmacotherapy and lifestyle modification play major roles in the treatment and 
management of the condition,3,4 and where health promoting interventions in both these 
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therapeutic areas are accommodated within the pharmacist’s defined scope of  
practice.4-11 
 
Most, if not all, DM2 patients make use of long-term pharmacotherapy to manage their 
disease. The prescription refill dynamic provides for frequent personal and informed 
contact between the patient and the pharmacist and thus positions the community 
pharmacist for roles in diabetes care beyond the traditional medicine-dispensing role.8-11 
Encounters of this nature present pharmacists with ideal opportunities to provide 
pharmaceutical care across a range of chronic diseases.12-15  
 
Pharmacists in South Africa, in concert with their colleagues elsewhere, have for some 
time expressed a desire to play expanded roles in the delivery of primary health care.16,17 
While a number of studies have reported on the positive effect of pharmacist co-
ordinated interventions in promoting patient adherence to therapy and/or influencing 
patient health outcomes in DM2,5,8-10,12,18-22 the position in South Africa is less certain due 
to a paucity of published local practice based research.17 A Pubmed search using the 
search term, ‘pharmaceutical care or cognitive pharmaceutical services AND Type 2 
diabetes AND South Africa’, produced no results. Discussions with the South African 
Pharmacy Council and the Pharmacy training institutions at both the University of the 
North West in Potchefstroom and the Nelson Mandela Metropolitan University in Port 
Elizabeth confirmed the absence of published literature relating to diabetes care in 
pharmacy practice in South Africa. A further motivating factor, therefore, is the desire to 
contribute to the body of knowledge in an important, if neglected, area of pharmacy 
practice and to be able to share such knowledge with colleagues in the profession, other 
interested parties and the students who are charged with taking the profession into the 
future.  
 
1.2 Research problem and questions  
 
The research problem is subject to the influence of a number of factors including: the 
nature of the disease, the influence of therapeutic adherence on health outcomes, 
accepted models of care in DM2, international evidence relating to pharmacist 
interventions designed to promote adherence in DM2 and, most importantly, the capacity 
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of South African community pharmacists to deliver diabetes care given the dynamics of 
pharmacy practice in the country. 
  
In formulating the research problem the following questions were considered: 
 Why did the WHO single out DM2 for special attention in the adherence report? 
 What are the key components of care in DM2? 
 What evidence exists to support roles for pharmacists in patient care in DM2?   
 Is there a need for the study and is it likely to be of value in informing practice, 
education and further research? 
 
The study hypothesis that South African community pharmacists are able to apply scope 
of practice diabetes care interventions capable of improving patient adherence and 
intermediate health outcomes in DM2 was informed by five main constructs: national and 
international guidelines for the treatment and management of DM2, the chronic care 
model, aspects of health behaviour theory, pharmacy practice-based evidence derived 
from the literature, and South African legislation mandating the practice of 
pharmaceutical care. 
 
1.3 Structure of the thesis 
 
The earlier chapters that provide the theoretical basis for the study include a review of 
the literature and a health care consumer survey designed to inform aspects of this 
research. The chapters following the consumer survey are concerned with the study 
methodology, the results, a discussion of the results, and the conclusions and 
recommendations. In addition to the annexures, lists of abbreviations, tables, figures and 
references are provided. 
 
Chapters 2, 3, 4 and 5 are devoted to a literature review appropriate to the scope of 
practice of a community pharmacist.6 Chapter 2 reviews the growing contribution of DM2 
to the world’s total disease burden.2 Clinical aspects of the disease are explored in the 
context of international guidelines.4  
 
Chapter 3 describes key aspects of community pharmacy practice with a focus on 
extended roles for pharmacists in providing disease management, pharmaceutical care 
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and other cognitive pharmaceutical services.23 An overview of relevant aspects of the 
health care system of South Africa is provided and pharmacy in South Africa, with an 
emphasis on community pharmacy practice, is discussed. Pharmacist-directed 
interventions provided internationally in DM2 and other chronic diseases are contrasted 
with the situation in South Africa. The state of practice-based research in South Africa is 
briefly examined. Aspects of patient care, including disease state management and the 
evolving paradigm of patient-centred care are discussed in this chapter.24,25  
  
Behavioural change theories, models and interventions,26 patient self-management 
behaviours,27  and a review of the literature relating to patient adherence are discussed 
in Chapter 4 
 
As the main study is a randomised controlled trial, the design of such trials as well as 
trials involving complex interventions are discussed in Chapter 5.28,29 The conceptual 
framework of the study is described in this chapter. 
 
The study hypothesis is founded, in part, on certain assumptions pertaining to the 
interaction and relationship existing between the patient and the pharmacist. These 
assumptions are associated with patient access to pharmacists and issues relating to the 
provision of cognitive pharmaceutical services. International literature has described key 
aspects of the professional relationship between the patient and pharmacist,30-34 but the 
South African situation regarding the patient-pharmacist relationship is less clear. As a 
result a sample of randomly selected insured health care consumers was surveyed in 
order to test selected assumptions related to this relationship,17 and this study is 
described in Chapter 6. 
 
The study design presented in Chapter 7 is a randomised controlled trial of a diabetes-
related pharmaceutical care intervention,28,35 with the methodology informed by the 
literature and previous studies9,12,15,19,36-38 and adapted for use in the South African health 
care setting of community pharmacy. In Chapter 8, the results relating to the primary and 
secondary endpoints of glycated haemoglobin, other intermediate clinical outcomes and 
aspects of therapeutic adherence are presented.  
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The results are discussed in Chapter 9 in terms of the study hypothesis and are 
contextualized within the literature. The limitations of the study are addressed in this 
chapter. 
 
An alternate design for the intervention, some opportunities for community pharmacy 
practice and recommendations for future practice-based research are discussed in 
Chapter 10. 
 
Chapter 11 discusses  certain  key conclusions arising from the study. 
 
 
 
 
 
 
 
 
 - 7 - 
 
CHAPTER 2 
TYPE 2 DIABETES MELLITUS 
 
2.1. Introduction  
 
In a report entitled Preventing Chronic Diseases: a vital investment, the World Health 
Organization (WHO) states that more than 60% of all deaths worldwide in 2005 were 
attributable to chronic diseases, with 80% of these occurring in low and middle income 
countries.39 Cardiovascular disease, with 17 million deaths in 2005, is by far the largest 
contributor to global disease-related mortality.39,40 Diabetes is a major risk factor for 
cardiovascular disease, which accounts for between 50% and 80% of diabetes-related 
deaths.44  Once considered to be a disease of minor importance it is now viewed as one 
of the major threats to human health.42 The cost of the diabetes pandemic in humanistic 
terms is enormous. Diabetes was estimated to directly affect 171 million people 
worldwide in 2000 and to account for at least 3.2 million deaths, or six deaths every 
minute.41 Diabetes is the seventh leading cause of death in the USA, where it is also the 
leading cause of lower-limb amputation, end-stage renal disease and blindness in 
people aged between 18 and 65 years.1,43  
 
The psychosocial impact of diabetes on the community and family providing socio-
emotional and tangible support to diabetics is considerable.44 Absenteeism from places 
of employment results in extra work-related burdens for colleagues. The microvascular 
and macrovascular complications of diabetes, resulting in blindness, stroke, renal failure, 
amputation, cardiovascular disease, diabetes distress and depression, hospitalization 
and premature death, have an enormous emotional and psychological impact on family 
and friends.41,45,46  
 
2.2 The epidemiology of type 2 diabetes mellitus  
 
Industrialisation has given rise to the rapid urbanisation of many previously rural 
communities. More recently globalisation has provided additional impetus to the 
epidemiological transition with the result that traditional lifestyle and dietary practices 
have increasingly disappeared and been replaced by less healthy, more sedentary 
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lifestyles and diets.47-49 The net result is the increasing level of obesity which is evident 
world-wide, especially in developing countries.48,49   
 
DM2 is a chronic disease and a cardiometabolic risk factor of increasing importance in 
the context of global disease burden.1,42-44  More women than men have DM2, which 
accounts for between 85% and 95% of all diabetes in the developed world, with even 
higher percentages in some developing countries.47,48 Current data reveal that DM2 is 
more prevalent in the developed than the developing world but that the latter will bear 
most of the brunt of the burgeoning pandemic.47 In 1985 an estimated 30 million people 
suffered from diabetes.48 The IDF predicts that by 2025 some 380 million people will 
have diabetes, with approximately 70% of these living in low and middle income 
countries.1,48  
 
In developed countries the age group over 65 reflects the highest prevalence for the 
disease whereas in the developing world greater prevalence occurs in the age group 45-
64 years.50 The pancreatic β-cell dysfunction which is characteristic of DM2 is at the 
same time a natural consequence of aging and thus contributes to the increased 
prevalence of the disease in older persons.51,52 
 
The genetic propensity for diabesity tends to manifest when people are exposed to a so-
called Western lifestyle.53,54 Type 1 diabetes is the most prevalent form of diabetes in 
children, but as the prevalence of diabesity in children and adolescents is expected to 
increase within the next 10 to 20 years, so too is DM2 expected to replace type 1 
diabetes at the apex of the non-adult diabetes pyramid.49 
 
Diabetes prevalence in South Africa in 2000 was estimated to be 3.4% and predicted to 
increase to 3.9% by 2025.48 Stratification by age-group reveals that 5.5% of South 
Africans over the age of 30 have diabetes. Prevalence increases with age in all race 
groups with the incidence peaking at age 60-69 for South African Indians (30%) and 
urban Blacks (10.8%), and age 70-79 for people of mixed race (26.9%) and for Whites 
(10.8%). Non-urban Blacks in age groups over 60 (5.4%) had the lowest prevalence.55 
Females have a greater prevalence for DM2 in all adult age groups except between age 
30-44 years.   
 
 - 9 - 
 
2.3 Definition, diagnosis, pathophysiology and clinical characteristics of DM2 
 
Type 2 diabetes is a well documented disease characterised by hyperglycaemia and is 
often associated with microvascular, macrovascular and neuropathic complications.4,56 
The American Diabetes Association (ADA) defined diabetes mellitus as “…a group of 
metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, 
insulin action, or both”.
59  The WHO and IDF diagnostic criteria for DM2 are either a fasting 
plasma glucose of ≥7.0 mmol/l or a 2-hour postload  plasma glucose of  ≥11.1 mmol/l 
during an oral glucose tolerance test.57  The ADA modified their diagnostic criteria in 
2003 to include “…symptoms of diabetes plus casual plasma glucose concentration ≥ 200 mg/dl 
(11.1 mmol/l). Casual is defined as any time of day without regard to time since last meal. The 
classic symptoms of diabetes include polyuria, polydipsia, and unexplained weight loss”.59 
 
It is insulin deficiency that determines the primary development of hyperglycaemia in 
DM2.56,58,59 The hyperglycaemia that characterises diabetes mellitus results from a lack 
of endogenous insulin which can either be absolute as is the case with Type 1 diabetes 
or relative as in DM2.56 In the case of DM2, the pathophysiology includes a combination 
of insulin-related mechanisms including pancreatic β-cell failure and peripheral insulin 
resistance. The pancreatic β-cell dysfunction results in decreased insulin secretion, 
decreased peripheral glucose uptake, elevated hepatic glucose production and 
increased lipolysis.56,59 The hyperinsulinaemia common in the early stages of DM2 is due 
to increased pancreatic β-cell activity in an effort to overcome the developing insulin 
insensitivity. As the disease progresses the insulin levels decrease as pancreatic β-cell 
activity decreases.58,59 Pancreatic β-cell function naturally decreases at a rate of 
approximately 1% per year over time. In DM2, this loss may increase to approximately 
7% per year.59  
 
DM2 is a heterogeneous metabolic disease influenced by both genetic and clinical risk 
factors. The genetic component of DM2 is complex and not well understood, with a 
number of genes possibly associated with the disease.56,59 Evidence of a genetic 
influence is provided by the increased prevalence of the disease in certain ethnic groups 
and in the children of diabetic parents.60 Both pancreatic β-cell failure and insulin 
resistance appear to be heritable components of DM2, and although most people with 
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DM2 will have both some degree of insulin deficiency and be insulin resistant, not all of 
those presenting as insulin resistant will have DM2.56 This is particularly the case with 
obese insulin resistant persons who are not necessarily glucose intolerant.56  
 
The lifestyle and clinical risk factors associated with the development of DM2 include the 
following: 60 
 Increasing age. The greatest prevalence occurs in people over the age of 45 years in 
developing countries and in those over 65 years in developed countries.50   
 Obesity and waist circumference. There is a direct correlation between DM2 and 
body mass index (BMI) in excess of 30 kg/m2, and  a waist circumference in excess 
of 102 cm for men and 88 cm for women.62,63  
  Ethnicity. The ‘thrifty genotype’ theory has been postulated to explain the propensity 
for DM2 in certain urbanised ethnic populations.66  
 Low birth weight. This is a risk factor that appears to have its origins in pancreatic 
dysfunction occurring as a result of foetal malnutrition.66    
 Family history of diabetes. The prevalence of DM2 increases fourfold with one 
diabetic parent and almost eightfold if both parents have the disease.66 
 Impaired glucose tolerance, impaired fasting glucose and gestational diabetes. 
These are dysfunctional metabolic states that precede DM2.67,68  Gestational 
diabetes predicts the later development of DM2 in women.69,70 
 Diet. Poor nutrition is a modifiable risk factor in DM2.71  Diets that are associated with 
a high demand for insulin may play a role in compromising pancreatic β-cell function 
over time. Diet is also a well-known contributing factor in obesity which is in turn 
associated with increased insulin resistance.72-74 
 Sedentary lifestyle. This modifiable risk factor increases the risk of DM2 by between 
20% and 40%, independent of BMI.48,61 Exercise may improve insulin resistance 
even in the absence of any accompanying weight loss.61,67 
 Hypertension. Studies have noted hypertension and/or the use of antihypertensive 
agents to be a risk factor in DM2.75,76   
 Dyslipidaemia. Hypertriglyceridaemia and low levels of High Density Lipoprotein-
Cholesterol (HDL-C) are considered to be predictors of DM2.77 
 
In addition, polycystic ovary disease,56  tobacco smoking and abstention from alcohol are 
considered to be possible risk factors in the development of DM2.61 There is evidence to 
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suggest that a moderate consumption of alcohol is associated with a reduction of 
approximately 30%  in the risk of developing DM2.78,79  There is a correlation between the 
onset of hyperglycaemia and DM2, and the use of antipsychotic medications such as 
chlorpromazine, olanzapine and clozapine,80  as well as with the use of corticosteroids,81  
and the presence of other diseases that interfere with actions of insulin such as 
Cushing’s syndrome, acromegaly and phaeochromocytoma.56  Of particular relevance in 
South Africa is the reported association between the use of combination antiretroviral 
therapy and the increased risk of the development of diabetes.83 
 
It is estimated that DM2 occurs some four to seven years before presenting clinically in 
patients.84 Patients often present asymptomatically with the hyperglycaemia being 
discovered incidentally during the course of laboratory screening associated with non 
diabetes-related medical interventions. On interview, patients are most likely to describe, 
in varying degrees, any of the following symptoms know to be associated with DM2; 
nocturia, polyuria, fatigue, polydipsia, visual disturbance (i.e. blurred vision), weight loss, 
infections, pruritis, paraesthesia and erectile dysfunction.45,59,84  
 
2.4 Microvascular and macrovascular complications of DM2 
 
The main health objective in DM2 is the prevention or amelioration of the complications 
of hyperglycaemia and the cluster of co-morbidities associated with the disease. DM2 is 
associated with progressive long-term microvascular and macrovascular 
complications,85-87 The landmark Diabetes Control and Complications Trial (DCCT) and 
the United Kingdom Prospective Diabetes Study (UKPDS) both demonstrated the value 
of intensive glycaemic control in moderating the risk of microvascular complications.85,86 
Epidemiological evidence points to an association between HbA1c and cardiovascular 
disease even within the normal range of HbA1c, and thus targeting levels lower than 
6.5% would seem desirable.4  A recent study has, however, reported that attempting to 
reduce HbA1c below 6% in patients with cardiovascular disease or with additional 
cardiovascular risk factors is associated with increased mortality.88 The consequences of 
the findings of the study are important given that approximately 70% of DM2 patients 
present with hypertension, an important cardiovascular co-morbidity.89 
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There is an association between sustained hyperglycaemia over time and the 
development of microvascular complications of retinopathy, nephropathy and 
neuropathy.85,86,90,91 The UKPDS demonstrated that intensive glycaemic control reduced 
progression to retinopathy by between 20% and 30%.87 Glycaemic control should be 
exercised gradually in the presence of existing retinopathy as too rapid a reduction may 
exacerbate the condition.91 The blood pressure control arm of UKPDS revealed a further 
13% reduction in microvascular complications for every 10 mm Hg decrease in systolic 
blood pressure.93 
 
Macrovascular disease, in particular coronary heart disease, cerebrovascular disease 
and peripheral vascular disease, in which the underlying pathology is atherosclerosis, is 
the most common cause of diabetes-related morbidity and mortality.94 Prospective 
epidemiological studies have confirmed the association between hyperglycaemia and 
the risk of major vascular events.95  Coronary heart disease occurs more frequently and 
at an earlier age in diabetics than in the general population.94 Diabetic men have a 
twofold and women a fourfold risk of a coronary event, in part due to the frequent 
association of diabetes with other cardiometabolic risk factors.92  In men with diabetes, 
sudden death occurs 50% more often than in men without the disease. In women with 
diabetes the differential increases 300%.94 
 
Intensive glycaemic control in the UKPDS demonstrated significant risk reduction for 
microvascular complications and for myocardial infarct in DM2 but not for the combined 
cardiovascular outcome.87,96 More recent studies have not been able to demonstrate that 
intensive glycaemic control leads to a reduction in major cardiovascular events in 
patients with established cardiovascular disease or with additional cardiovascular risk 
factors.88,95 There may well be a negative correlation between intensive glycaemic 
control in high risk patients with DM2. A recent study, the Action to Control 
Cardiovascular Risk in Diabetes (ACCORD) study, was discontinued after 3.5 years of 
follow up due to higher mortality in the intensive therapy arm than in the group receiving 
conventional therapy.88 Research has, however, demonstrated the benefit of reducing 
the modifiable risk factors for cardiovascular disease in DM2.94,97-100 
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2.5 Commonly associated co-morbidities of DM2  
 
The clustering of the cardiometabolic risk factors of hypertension, dyslipidaemia, obesity 
and diabetes is commonly referred to as the metabolic syndrome. Metabolic syndrome 
occurs in approximately 86% of patients with DM2, and the prevalence of cardiovascular 
disease increases substantially in patients with this syndrome.101  
 
2.5.1 Hypertension 
 
In addition to being a possible risk factor for DM2, hypertension is a commonly 
associated co-morbidity factor that presents in up to 70% of patients with DM2.45,61,64,89  
Hypertension is a continuous risk factor for both macrovascular and microvascular 
complications including cardiovascular disease, stroke, peripheral vascular disease, 
retinopathy, nephropathy, and possibly neuropathy in people with diabetes.64,93,102,103   
 
 In a randomised controlled trial, UKPDS demonstrated the value of tight blood pressure 
control. In comparing a group assigned to achieve a blood pressure of less than 150/85 
mm Hg with a group where the target was a blood pressure of less than 180/105 mm Hg, 
the intensive group had 32% fewer diabetes-related deaths, 44% fewer strokes and 37% 
fewer microvascular endpoints.104 
 
For hypertensive diabetics, the Southern African Hypertension Society’s hypertension 
management algorithm recommends including agents from the Angiotensin-Converting 
Enzyme (ACE) Inhibitor or Angiotensin Receptor Antagonist (ARB) classes, usually in 
combination with a diuretic (Annexure 3.1). The SEMDSA guideline for the treatment and 
management of DM2 suggests low dose diuretics (hydrochlorothiazide or indapamide) 
as first line agents, especially in Black hypertensive diabetics. Both the IDF and 
SEMDSA favour therapy based on ACE inhibitors especially in the presence of 
albuminuria and for patients over the age of 55 who present with other cardiovascular 
risk factors.4,105 The National Institute for Health and Clinical Excellence (NICE) guideline 
suggests adding a diuretic or calcium-channel blocker as first line therapy for patients of 
black African origin.106 Patients with a history of myocardial infarction or angina are 
suitable candidates for the use of β-adrenergic blockers although care must be 
exercised in their use (as with thiazide diuretics) as these agents may affect metabolic 
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control.4 Most patients will require more than one agent, and the UKPDS demonstrated 
that three or more agents were often required to effect blood pressure control.104 
 
2.5.2 Dyslipidaemia 
 
The dyslipidaemia of DM2 is typically associated with low HDL-C, slightly elevated or 
near normal Low Density Lipoprotein-Cholesterol (LDL-C) and raised triglycerides.107   
This dyslipidaemia, i.e. triglycerides greater than 1.7 mmol/l and HDL-C less than 1 
mmol/l for males and 1.3 mmol/l for females, occurs well before the onset of 
dysglycaemia and is considered to be one of the diagnostic criteria of the metabolic 
syndrome.72  In addition to being an independent risk factor for both microvascular and 
macrovascular disease, blood lipid abnormalities of dyslipidaemia may be implicated in 
the development of DM2.61,77  
 
The IDF’s Global Guideline for Type 2 diabetes makes the following comment with 
regard to informing blood lipid therapy: “The evidence that people with Type 2 diabetes have 
an abnormal, atherogenic, lipid profile (high triglycerides, low HDL cholesterol, small dense LDL 
cholesterol) is generally accepted, and leads all the major guidelines which have addressed the 
area to recommend assessment of a full serum lipid profile as a guide to therapy”.
4  In terms of 
recommended treatment regimens for dyslipidaemia, lifestyle interventions in the form of 
modified diet and increased physical exercise are considered first line therapy.4,105 
Therapeutic lifestyle modification includes a reduction in intake of saturated fats and 
dietary cholesterol, an increased intake of dietary fibre, increased physical exercise and 
a reduction in body mass.108 The SEMDSA guidelines recommend the introduction of a 
statin in incremental doses if dietary intervention does not result in a LDL-C level below 3 
mmol/l.105 Statins are considered to be the pharmacotherapeutic option of choice in 
diabetic dyslipidaemia. 4,105,99,100,109  
 
Recent large randomized controlled trials have demonstrated the substantial benefit of 
statin therapy in patients with DM2.99,100 The Heart Protection Study found that 40 mg of 
simvastatin taken daily will translate into approximately one third fewer myocardial 
infarctions, strokes and coronary revascularisations.99 The Collaborative Atorvastatin 
Diabetes Study (CARDS) reported similarly and found that for DM2 patients, an 
atorvastatin regimen of 10 mg daily could be expected to yield a 36% reduction in acute 
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coronary heart disease events, a 31% reduction in coronary revascularisation and a 48% 
reduction in the incidence of stroke.100   
 
2.5.3 Obesity 
 
Globalisation and urbanisation have led increasingly to the over-consumption of diets 
high in refined carbohydrates, saturated fats, trans-fats and sugars.39,42,47 The 
management of obesity is complex and involves a range of long-term strategies that start 
with population-based environmental support for improved access to healthy food and 
facilities that promote physical activity.39,47 Body mass control in DM2 is often a 
frustrating and unrewarding exercise for both patient and healthcare provider as 
fluctuations in body mass are common and sustained weight loss rare.110-113 The 
problem is compounded by the tendency for weight gain resulting from the effects of a 
number of the more effective DM2 treatment modalities (sulphonylurea and insulin).111  
 
Obesity is a major DM2 risk factor and the increased prevalence of obesity is 
contributing to the world-wide diabetes pandemic.1,47,49,50,114  Obesity is generally more 
prevalent in older people than in the young although childhood obesity is wide spread in 
some countries.49 A person with a BMI in excess of 25 kg/m2 is considered to be 
overweight and with a BMI greater than 30 kg/m2 to be obese.49  
 
 Women with a BMI in the range 25-26.9 kg/m2 were five times more likely to self-report 
DM2 than women whose BMI was less than 22 kg/m2. Men with waist-hip ratios greater 
than 0.99 or waist circumferences of more than 101 cm were significantly more likely to 
self-report DM2.115 For women increased risk is indicated where the waist-hip ratio 
exceeds 0.75 and the waist circumference exceeds 76 cm.115 The Diabetes 
Cardiovascular Risk-Evaluation: Targets and Essential Data for Commitment of 
Treatment (DETECT) study found that there was little difference in the anthropometric 
parameters of waist-hip, waist circumference or BMI, in their ability to predict prevalent 
cardiovascular risk.116 The South African Demographic and Health Survey found that 
about a third of men and over 50% of the women were either overweight or obese and 
that central adiposity occurred more often in women than in men by a ratio of four to 
one.117  
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Physical exercise along with nutrition is a key aspect in the non-surgical treatment of 
obesity.118 Lack of exercise is associated with the development of DM2 even after 
adjusting for BMI.119 Conversely, increased physical activity is associated with the 
prevention of and improved health outcomes in DM2.118,120 The Finnish Diabetes 
Prevention Study demonstrated a 58% reduction in the risk of DM2 with a lifestyle 
intervention that included diet and exercise, and which resulted in weight loss and 
improved biochemical markers.121 Despite the well documented benefits of physical 
exercise, many DM2 patients do not exercise at all or exercise less than the 
recommended 30 minutes per day.118  
 
Restrictive dietary programmes are often associated with a preoccupation with food, 
depression and, paradoxically, overeating and other inappropriate eating 
behaviours.111,112 There is almost no evidence that significant and sustained weight loss 
is possible and in the long-term most patients return to their baseline weight.111  
 
2.6 Treatment guidelines for DM2 
 
In the United Kingdom the National Institute for Health and Clinical Excellence 
developed NICE guideline 66 Type 2 diabetes: the management of type 2 diabetes.106 
The American Diabetes Association published the Standards for Medical Care in 
Diabetes.122 South Africa, under the auspices of the Society for Endocrinology, 
Metabolism and Diabetes of South Africa, has the Revised SEMDSA Guidelines for 
diagnosis and management of type 2 diabetes mellitus for primary healthcare.105 The 
SEMDSA recommendations for glycaemic control and lipid and blood pressure goals are 
included in Table 2.1.  
 
The IDF, recognising the complexity of diabetes care, the enormous and comprehensive 
amount of existing evidence-based data, the paucity of cost-effective resources available 
to implement best-practice diabetes care and the diversity of standards of clinical 
practice throughout the world, developed an internationally accepted guideline for DM2 
entitled Global Guideline for Type 2 Diabetes, which was published in 2005 and which 
was used to inform aspects of this study.4   
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In addition to national and international guidelines, DM2 treatment in the South African 
private insured healthcare sector is informed by an algorithm developed by the Council 
for Medical schemes, a statutory body that regulates the insured healthcare sector.123 
The algorithm (Annexure 3.2) is particularly focused on guiding pharmacotherapy for 
glycaemic control in DM2 and does not address therapeutic options for any of the 
commonly associated co-morbidities. 
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Table 2.1. SEMDSA recommendations for glycaemic control and lipid and blood 
pressure goals  
Recommendations for glycaemic control 
a 
Biochemical Index Optimal Acceptable Additional Action Suggested 
b 
Capillary blood glucose values 
c 
   
Fasting (mmol/l) 4 – 6 6 – 8 > 8 
2-hour post-prandial (mmol/l) 4 – 8 8 – 10 >10 
Glycated haemoglobin (%) < 7 7 – 8 >8 
Anthropometric measurements    
BMI (kg/m
2
) <25  >27
 d 
Male Waist circumference (cm) <94  >102 
Female Waist circumference 
(cm) 
     <82                          >88 
a 
These values are for non-pregnant adults 
b
 “Additional action suggested” depends on individual patient circumstances. Such actions may 
include enhanced diabetes self-management education, co-management with a diabetes team, 
referral to an endocrinologist/diabetologist, change in pharmacotherapy, initiation or increased self-
monitoring of blood glucose or more frequent contact with the patient. HbA1c is referenced to a non-
diabetic range of 4.0 – 6.0%. Note that  action should ideally be instituted before these levels are 
reached. 
c
 Preferably assessed over several visits. 
d
 In the presence of diabetes mellitus this level is 27 and not 30. 
Lipid and blood pressure goals (For non-pregnant adults) 
Blood pressure (mm Hg) Lipids (mmol/l) 
 
Systolic  <130 
Diastolic < 80 
 
 
If persistent dipstick proteinuria 
(macroalbuminuria) 
Systolic   <120 
Diastolic  < 70 
 
 
Total-cholesterol  < 5.0 
LDL-cholesterol   ≤ 3.0
 e 
HDL-cholesterol   < 1.2 
Triglycerides        < 1.5 
 
 
e
American National Cholesterol Education 
Program (NCEP) III recommends a level of 
<2.6 mmol/l especially in the presence of 
existing vascular disease (stroke, peripheral 
vascular disease, and ischaemic heart 
disease). 
Reproduced with the permission of SEMDSA
105 
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2.7 Clinical variables and indicators: DM2 and associated co-morbidities 
 
The monitoring of blood glucose and other biochemical and clinical markers associated 
with diabetes and  common co-morbidities form part of evidence-based diabetes care.4 
The SEMDSA guidelines include recommended key tests and examinations (Table 
2.2).105  
 
 
2.7.1 Glycated haemoglobin and self-monitored blood glucose 
 
The key variable in DM2 is glycaemia which is measured as blood or plasma glucose 
and HbA1c, the latter being the standard by which long-term glycaemic control is 
determined.4,56,105 The IDF guideline suggests an HbA1c value of less than 6.5%, while 
 
Table 2.2 SEMDSA  guideline: key tests and examinations 
 
 
Key tests and examinations 
a 
Test / Examination Frequency 
Glycated hemoglobin • Quarterly if treatment changes or if not meeting goals 
• At least twice a year if stable 
Dilated eye exam Once a year 
Comprehensive foot exam At least once a year ( more often in high-risk foot conditions) 
Lipid profile Once a year (less frequently if normal) 
Serum creatinine  Once a year 
Microalbumin Once a year (if no persistent dipstick proteinuria - macroalbuminuria) 
Blood pressure At each regular diabetes consultation 
BMI  & waist circumference Initially and weigh at each regular diabetes consultation  
ECG Once a year (if possible) 
a 
All tests and examinations to be done at the initial diabetes consultation     
Reproduced with the permission of SEMDSA
105 
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SEMDSA recommends an HbA1c of less than 7%.
4,105  The SEMDSA guideline suggests 
an HbA1c every three months for patients with poor glycaemic control  and a bi-annual 
HbA1c for patients with good glycaemic control.  
 
The other glycaemia-related indicator that is important in diabetes care is the capillary 
plasma or blood glucose value, although there is some debate as to the value of self-
monitored blood glucose (SMBG) in non-insulin dependant  DM2.124 SMBG has proven 
invaluable in Type 1 diabetes and in insulin-dependant DM2 as it serves to increase 
patient awareness of the level of very recent glycaemic control, provides a basis for 
clinical decisions (to inform any adjustments to therapy which is especially important 
where insulin is being used) and to alert patients to potential hypo- or 
hyperglycaemia.124,125  
 
SMBG data provides patients with a reliable method of assessing their level of diabetes 
control as it provides real-time feedback on the results of their medication therapy, diet 
and exercise. SMBG targets included in the SEMDSA guideline are fasting blood 
glucose of 4 to 6 mmol/l and 2-hour post-prandial blood glucose of 4 to 8 mmol/l.105 The 
IDF’s equivalent target levels are fasting values of less than 6.0 mmol/l and 1–2 hour 
post-prandial values of less than 8.0 mmol/l.4 
 
2.7.2 Dilated eye examination 
 
Diabetic retinopathy, which is asymptomatic in the early stages of the condition, is the 
most common microvascular complication of DM2 and is a major cause of impaired 
vision, especially in adults aged 20–74 years.4,122,126 An initial screening by a competent 
healthcare professional followed by annual re-examination is recommended.4,105,122 
Patient awareness of diabetes-related eye problems, in turn, helps to foster awareness 
about the need to optimise both glycaemic and blood pressure control.64  
 
2.7.3 Comprehensive foot examination 
 
Diabetic neuropathy is the most common form of neuropathy in the developed world.90 It 
presents most often as a symmetrical distal peripheral sensory motor neuropathy, and 
approximately 50% of diabetics will eventually develop some degree of neuropathy.127  
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All diabetics should receive an annual foot examination and high-risk individuals (those  
who have had diabetes for ten years or more, or have experienced foot ulceration, 
amputation, poor glycaemic control, cardiovascular disease, retinopathy or nephropathy) 
should be assessed more frequently.122 Patient self-management education should  
include self-assessment techniques as well as preventative measures to promote foot 
care.122 
 
2.7.4 Blood lipid profile 
 
SEMDSA, IDF and ADA guideline values for the individual components of the lipid profile 
vary slightly within narrow parameters (Table 2.3).4,105,122 The SEMDSA guideline 
suggests an annual lipid profile except for those patients who do not meet guideline or 
who are at increased risk of vascular disease.105 The IDF suggests more frequent 
reassessment at routine clinical encounters in order to attain blood lipid targets.4 
 
 
While point-of-care cholesterol testing has increased in recent years, the utility of these 
tests is generally limited to screening for serum total cholesterol. Currently a full lipogram 
remains largely within the province of the medical laboratory as there is, as yet, 
insufficient evidence to support the use of point-of-care monitors for this purpose.128 
 
 
 
 
Table 2.3 ADA, IDF and SEMDSA blood lipid targets in non-high risk patients with 
DM2 
Blood lipid targets (mmol/l) 
Variable ADA IDF SEMDSA 
Total-cholesterol - - < 5.0 
HDL-cholesterol > 1.1 > 1.0 > 1.2 
LDL-cholesterol < 2.6 < 2.5 ≤ 3.00 
Triglycerides < 1.7 < 2.3 < 1.5  
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2.7.5 Serum creatinine 
 
The early detection of microalbuminuria is an essential element in the process of 
preventing the development of progressive diabetic nephropathy. Diabetes guidelines 
suggest an annual test for renal function. 4,105,122 A simple and inexpensive test is 
provided by the proteinuria dipstick method, although this test is subject to false-positive 
and false-negative results.122 The estimated glomerular filtration rate (eGFR) is a reliable 
index of kidney function and it may be calculated by means of the Modification of Diet in 
Renal Disease predictive equation,  which factors in the patient variables of age, sex, 
ethnicity and serum creatinine. The equation is available free online.129 
 
2.7.6 Blood pressure 
 
Both the IDF and SEMDSA (Table 2.1) recommend a target blood pressure of 130/80 
mm Hg for DM2 patients whose diabetes is uncomplicated by nephropathy.4,105 The 
target is reduced to 120/70 mm Hg in the presence of macroalbuminuria.126 Guidelines 
generally recommend measuring blood pressure at every diabetes 
consultation.4,105,106,122  
 
2.7.7 Body mass index  
 
While waist circumference and waist-hip ratio are accepted measures of central 
adiposity, the standard anthropometric measure for obesity and overweight remains the 
BMI, which is calculated by dividing body mass in kilograms by the square of  height in 
metres (kg/m2). A person with a BMI of 25 to 29.9 kg/m2 is considered to be overweight 
and anyone with a BMI in excess of 29.9 kg/m2 is considered obese.49,115 The  SEMDSA 
guideline recommends that patients be weighed at every diabetes consultation.105 
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CHAPTER 3 
 COMMUNITY PHARMACY PRACTICE AND PATIENT CARE 
 
3.1 Introduction  
 
Pharmacy practice has evolved significantly since prescriptions were first written, 
thought to be around 2700BC, although medicines were probably used before this with 
their genesis “…lost in the remoteness of history”.130  Healthcare systems throughout the 
world continue to evolve as society attempts to respond to the ever increasing need for  
quality cost-effective healthcare.131 The growing burden of disease, especially chronic 
disease, which is fuelled by the effects of increasing globalisation, urbanisation, 
unhealthy lifestyle practices and ageing populations, demands a response from society 
to the challenge of having to care for increasing numbers of chronically ill 
people.42,47,132,133   
 
3.2 Scope of practice of a pharmacist 
 
Most countries provide a combination of private and public healthcare and this 
dichotomy influences the practice of pharmacy, especially with regard to the range of 
services provided, and to the reimbursement of pharmacists.134  The advent of state 
sponsored social health systems (public sector) and health insurance (private sector) led 
to third-party payers, rather than the patients themselves, reimbursing pharmacists for 
the supply of medicines.  
 
World-wide, community pharmacists tend to be private practitioners who derive income 
from the sale of pharmaceuticals, other products and, to a lesser extent, from the 
provision of clinical and other services. In addition, some countries such as the United 
States of America and the United Kingdom have deepened pharmacy’s reach into the 
clinical domain with the recent introduction of pharmacist prescribing.135,136  
 
Blenkinsopp et al,133 in a systematic review of the effectiveness of community pharmacy 
interventions, draws attention to an important feature of community pharmacy practice, 
namely that for most urban populations, and some rural communities, relatively easy 
access to trained healthcare providers is made possible, firstly due to  the physical 
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location of most community pharmacies, and secondly because the consumer-
pharmacist encounter is not usually subject to prior appointment. The easy access that 
individuals have to pharmacy practice has been described as community pharmacy’s 
most significant characteristic, as pharmacists often are the first point of contact for 
individuals seeking health-related information or advice.137  
 
The practice of pharmacy has evolved from being essentially product orientated to 
becoming more patient focused. This evolutionary process, spurred on by the advent of 
clinical pharmacy, gave rise in the early 1990s to the professional practice of 
pharmaceutical care, which has expanded the role of the pharmacist and redefined the 
value of pharmacy practice.23 
 
3.3 Pharmaceutical care  
 
The acceptance of pharmaceutical care by the profession has heralded a new focus for 
pharmacy practice.138,139 Cipolle et al,140 defined the philosophy of pharmaceutical care 
as “…(1) the recognition of a social need, (2) the patient-centered approach, (3) caring as a 
modus operandi, and (4) specific responsibilities to identify, resolve and prevent drug therapy 
problems”.  
 
Patient-centredness is a central aspect in the pharmaceutical care process as it informs 
the development and maintenance of therapeutic relationships essential in addressing 
patient medication-related needs.141,142 
 
Pharmacists are able to contribute to disease risk reduction especially in populations 
such as the elderly, smokers, obese individuals and those with diseases such as 
hypertension, cardiovascular disease and obesity.143-145 Identifying individuals from 
pharmacy records, assessing risk indicators, providing health-related education and 
educational materials, counselling on the appropriate use of medication, discussing and 
agreeing on self-management options, on-going monitoring, and referral for further 
investigation are scope of practice pharmacy services that fall within the ambit of disease 
prevention and management. 24,36,133 
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Professional pharmacy-based services are variously referred to as pharmaceutical care 
services, cognitive pharmaceutical services, cognitive services, patient clinical care 
services or medication therapy management services.146-149  The term ‘cognitive 
pharmaceutical services’ (CPS), which identifies the activities associated with the 
practice of pharmaceutical care, is used in this manuscript for the purpose of 
standardisation.150 
 
Pharmacists, while recognising both the desirability and value of pharmaceutical care,  
believe that barriers exist preventing the widespread implementation of CPS, especially 
at community pharmacy level.12,133,151 The main barriers to the provision of these services 
appear to be financial and economic such as pharmacist reimbursement, human 
resources and time constraints.152  At the opposite end of the care continuum, the 
paucity of robust research that unequivocally demonstrates the economic, clinical and 
humanistic value of pharmaceutical care across a range of disease entities continues to 
be an obstacle to the broad-based acceptance of the practice by the stakeholders and 
funders of healthcare.12,152-154 
 
Collaboration with patients and other healthcare providers is an essential element of 
pharmaceutical care and evidence-based disease management,24,155-158 with the benefit 
to patients of inter-professional collaboration noted.5,155,159 The most common 
impediments to collaboration between medical practitioners and pharmacists include ill-
defined or unspecified areas of responsibility, lack of trust, or simply failure to initiate the 
collaboration process.160-162  These problems are barriers to the delivery of 
pharmaceutical care and contribute to this high ideal of pharmacy practice remaining  
largely “…aspirational in many parts of the world”.163 
 
Anderson et al,164 in a systematic review of healthcare consumer perceptions and 
experience of services provided by community pharmacists, concluded that consumers 
tended to view pharmacists as ‘drug experts’ and not as a readily available source of 
health-related advice and information. Nevertheless, those consumers who did access 
and make use of pharmacy-based health initiatives expressed satisfaction with their 
experiences. The reviewers conclude that if community pharmacy is to extend its reach 
in healthcare, consumer awareness of the pharmacist as a potential source of valuable 
health-related advice must be enhanced. 
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3.3.1 Cognitive pharmacy services and diabetes 
 
Patient orientated CPS, which covers a wide range of activities designed to optimise the 
use of medication and improve health outcomes,158,165,166  creates opportunities for the 
pharmacist to:158,167,168 
 
 Record salient patient demographic data and a brief medical history.  
 Develop or enhance relationships with both patients and providers. 
 Develop an understanding of patient health beliefs and a level of knowledge 
about their conditions. 
 Discuss patient therapeutic goals and concordantly develop pharmaceutical care 
plans to support these goals. 
 Comprehensively assess the appropriateness of all medicine being used. 
 Assess the patient’s medicine-taking behaviour. 
 Address medication and other scope of practice-related problems and, where 
possible, agree on remedial action. 
 Provide tailored medication-related counselling, and health-related education and 
information.  
 Reinforce patient self-efficacy and self-management behaviours. 
 Monitor patient response to pharmacotherapy and self-management 
recommendations. 
 Evaluate the care process and outcomes, consult with other healthcare 
professionals and, if necessary, refer for escalated care.  
 
These services should be aligned with the principles of the continuous patient care 
process described by Cipolle et al169 (Figure 3.1). In addition,  advice-giving should be 
kept to a minimum,170 with the pharmacist-patient discourse preferably informed by 
evidence-based counselling methods such as that of brief Motivational Interviewing.171 
All elements of care should be recorded in a manner that allows for assessment of the 
pharmaceutical care provided and for easy and appropriate access by other healthcare 
providers.158,167,172 
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Figure 3 .1 The patient-care process169 
 
 
The importance and ongoing nature of pharmacotherapy in DM2 facilitates relatively 
frequent encounters between patients and their community pharmacists,11  whom 
patients generally trust and value17,25 and who have demonstrated the ability to provide 
diabetes care services.8,9,38,173 The main elements of diabetes care provided by 
pharmacists include the scheduling of appointments,173  medication counselling,18,174 
setting diabetes-related goals,175 providing self-management education and 
support,174,176,177 health-related information,175 patient reminders,38 monitoring key 
diabetes variables,9,173 and collaborating with and referring to other healthcare 
providers.19,178  
 
In studies investigating the effect of pharmacist interventions in diabetes management, 
patient adherence to therapy and the effect of the interventions on glycaemic control, 
expressed as HbA1c, are most often reported in the literature, and psychosocial and 
economic outcomes are reported less frequently.9,10,38,173,176,179 Table 3.1 includes 
examples of diabetes-related CPS studies. 
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Table 3.1 Cognitive pharmaceutical services in diabetes 
Author Intervention Outcome measure 
Garret et al
176 
 
Scheduled appointments, 
collaborative coaching and 
reinforcement  of  self-
management, medication review, 
goal setting, monitoring, 
evaluation and referral. 
Adherence, economic, clinical and 
quality of life measures. 
 
Cranor et al
9,19,178
 
 
Diabetes education, goal setting,  
self-monitored blood glucose 
(SMBG) training and review, 
reinforcement of medication 
adherence, foot examination, 
monitoring of indicators. 
HbA1c, self-management 
adherence. 
 
Coast-Senior et al
179 
 
Scheduled consultations, 
assessment, diabetes education, 
monitoring of indicators, 
adjustment of therapy, SMBG 
review, medication review, 
collaboration with medical 
practitioners, telephonic follow-up. 
HbA1c, fasting blood glucose, and 
random blood glucose. 
 
Berringer et al
10
 
 
Collaboration with medical 
practitioners,  monitoring of 
indicators, review of diabetes-
related data, quality of care 
assessment. 
Fasting blood glucose, 
adherence, frequency of SMBG. 
 
Lindenmeyer et al
38
 
 
Self-management  education, 
patient reminders, adjustment of 
therapy, review of SMBG data, 
referral. 
Adherence, fasting blood glucose, 
random blood glucose, quality of 
life measures, persistence, 
economic outcomes. 
Fera et al
173 Collaborative patient-centred 
programme (medical practitioner, 
patient, employer, pharmacist) 
that included scheduled 
consultations, clinical 
assessments, goal setting, 
adjustments to therapy, referral. 
Biochemical and clinical  markers, 
influenza vaccination, foot and 
eye examination, self-
management goals for nutrition 
and exercise and body mass, 
diabetes-related knowledge and 
satisfaction with care. 
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3.3.2 Barriers to cognitive pharmaceutical services 
 
Pharmacists may have difficulty providing CPS in practice due to structural and process 
constraints that mitigate against the successful provision of such services.12,180  Barriers 
to the provision of CPS may be broadly classified as attitudinal barriers i.e.  
resistance on the part of patients, funders, pharmacists and other healthcare providers; 
environmental or structural barriers i.e. healthcare systems that do not support the 
practice of pharmaceutical care, infrastructural limitations, and economic barriers, 
especially those relating to the reimbursement of pharmacists.151,152,181 Other barriers 
include the lack of sustainable business models supporting the provision of CPS, 
inadequate maintenance and quality assurance of pharmaceutical care programs, a lack 
of access to clinical data, and a shortage of skilled and motivated pharmacists.147  
 
Although many CPS studies have reported positive clinical outcomes, minimal robust 
data on cost-effective and humanistic outcomes exists,182-184 and this further compounds 
the matter of pharmacist reimbursement.152,185 There is also a paucity of data on patient 
willingness to pay which is a surrogate marker for value in pharmaceutical care.152,185 
While some progress in addressing barriers to CPS is evident in a number of countries, 
pharmacist reimbursement remains a significant challenge for the profession and, in 
many instances, pharmacists continue to provide these services free of charge.17,147,152  
 
3.4 Community pharmacy practice research 
 
The need for the practice of pharmacy to be informed by the evidence of applied 
practice-based research is a view shared by a range of healthcare stakeholders 
including pharmacists in practice and in academia, organised pharmacy and the 
WHO.6,181,184,186,187 
 
Evidence of positive economic, clinical and humanistic outcomes is the “hard” currency 
of value in healthcare.184,186 However, there appears to be little rigorous research 
investigating the effectiveness of CPS provided by community pharmacy.133 Beney et 
al,183  in reviewing studies relating to expanded roles for pharmacists in community 
pharmacies, found so few studies that satisfied the initial review criteria that they 
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broadened their scope to include other outpatient settings. The reviewers, in concert with 
other researchers, had difficulty in interpreting their findings because of the 
heterogeneity of the interventions and a lack of clarity about their nature. Problems 
relating to the methodological quality of CPS studies have been reported, and doubts 
expressed concerning the generalisability of some studies. 183,184,188 
 
Benrimoj,189  in discussing the matter of pharmacy practice research, noted the need for 
a “…symbiotic relationship between practitioners and academic researchers”. Pharmacists in 
practice who undertake research without adequate academic oversight may suggest 
practical solutions to problems, but the work may not stand the test of scientific rigour. 
Academic researchers, on the other hand, working isolated from the realities of day-to-
day pharmacy practice may, in turn, produce well designed studies but their application 
in practice may be of limited value. It has been suggested that in order to stimulate 
interest in practice research, joint practice-based research symposia may be held to 
bridge the research gap between practicing and academic pharmacists.189  
 
Barriers to practice-based research include inadequate funding, lack of national research 
agenda, and pharmacist disinterest.14 Armour et al181 reported that pharmacist 
unwillingness to participate in research was informed mainly by attitude i.e. a lack of 
confidence in their ability to participate effectively, and a negative perception of the value 
of research. Insufficient communication regarding the objectives, requirements and 
benefits of research and a lack of resources including infrastructure, time, money and 
staff were also noted as significant factors.  Some positive factors included the stated 
realisation that practice research was essential if community pharmacy was to advance 
its cause in healthcare. Pharmacist participation in research was often fuelled by 
personal interest in research topics, and a sense of professional satisfaction.181 
 
There appears to be a lack of published research relating to community pharmacy 
practice in South Africa despite research being a defined good pharmacy practice 
standard and a pharmacist scope of practice function.6  As universities are the primary 
drivers of practice research, funding is largely dependant on grants. Sponsorship by 
organised pharmacy, the pharmaceutical industry, private foundations, or organs of the 
state, rarely occurs in most countries.14,147 In keeping with the situation in many 
countries, South African pharmacy practice research is limited by inadequate funding, 
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the  lack of a national research agenda and an absence of a research culture amongst 
practising pharmacists. 
 
3.5 Patient care  
 
3.5.1 The evolution of patient care 
 
Acute models of care that rely on expert healthcare providers interacting with naive 
patients have proved inadequate in addressing the complex needs of the chronically 
ill.1,190,191  In general, acute ambulatory models of care are designed to provide patients 
with ready access to healthcare in systems that are focused on those conditions 
requiring consultations of short duration and where, following diagnosis and brief didactic 
advice, treatments for the alleviation of symptoms are most often prescribed. Such 
treatments may require further laboratory or other investigation and often involve the use 
of medication.155,190  Chronically ill patients are unlikely to have their needs met in such a 
healthcare environment.191 The management of their conditions should be primarily 
focused on preventing the development or exacerbation of disease-related 
complications.155  
 
3.5.2 Disease management 
 
The term ‘disease management’ was first coined in the USA in the early 1990’s and was 
advocated in response to the spiralling healthcare costs resulting from the 
epidemiological shift from acute to chronic disease.192,193  It was initially used without 
specific definition to describe informal activities that included aspects of evidence-based 
medicine and the use of multidisciplinary teams to deliver care.194,195 Disease 
management is focused on a systematic approach to the long-term management of 
chronic disease,196  and has  been defined as  “A systematic, population-based approach to 
identify persons at risk, intervene with specific programs of care, and measure clinical and other 
outcomes”.
197  
 
Disease management has matured and although the early promise of substantial cost 
savings has generally not materialised, with few studies able to prove this early 
objective, it has been (and continues to be) associated with the healthcare 
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process.174,192,198,199 However, the varied and interacting components of disease 
management make assessing the effectiveness of individual elements difficult. In a 
review of disease management programmes designed to improve clinical and economic 
outcomes in 11 chronic conditions, Ofman et al192 found that few studies were able to 
demonstrate significant cost reduction.  Weingarten et al,200 in a meta-analysis of English 
language articles on disease management published between 1987 and 2001, revealed 
that patient education was the most studied intervention, with programmes using 
education, reminders or financial incentives the most successful in improving disease 
control.  
 
In a systematic review of controlled trials of interventions designed to improve the 
management of diabetes in primary care outpatient and community settings, Renders et 
al188 reported that in all settings the studies were multifaceted, and that complex 
interventions were required in order to demonstrate improvements in the care process. 
Interventions aimed at improving provider adherence to clinical guidelines, with regular 
and structured patient review, improved the care process. The addition of patient 
education and/or enhancement of the nurse’s role led to both improved process of care 
and patient outcomes.  
 
The IDF guideline for the management of DM2 notes that evidence-based and cost 
effective diabetes care should be made available to all people with the disease. The 
guideline suggests a range of care delivery elements to be incorporated into diabetes 
care plans.4 Close consideration of the IDF recommendations reveals the collaborative 
nature of the care delivery being suggested, which underpins the relatively new 
paradigm of patient-centred care that recognises the pivotal role of the empowered and 
expert patient in diabetes care.201,202 
 
3.5.3 Patient-centred care  
 
 Patient centredness is a foundational element of collaborative care and the practice of 
patient self-management.202-206 While the provision of healthcare has always been 
underpinned by a desire to provide for the patient’s welfare, the practice of medicine has 
historically focused on provider-centred models of care. In these models patient 
participation is largely limited to compliance with provider instructions, with provider-
 - 33 - 
patient relationships often being paternalistic.207  Patient-centred care has been defined 
as “…healthcare that is closely congruent with and responsive to patients’ wants, needs, and 
preferences”.
207   
 
Wagner,155 in developing the Chronic Care Model (Figure 3.2) described an ‘ideal world’ 
scenario for chronic care as one in which an informed and motivated patient’s interaction 
with an adequately resourced healthcare system would include planned and 
collaborative consultations with prepared and proactive members of the patient’s 
multidisciplinary team. The collaborative interaction between the patient and healthcare 
team allows for systematic assessments to be made in terms of accepted treatment 
protocols, decision support and support for appropriate patient self-management 
initiatives.  
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Figure 3.2 The Chronic Care Model
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In addition the model proposes the monitoring of key indicators and recording of all 
patient data in readily accessible information systems with regular follow-up by the 
healthcare providers.  
  
A number of studies have reported on the application of individual elements of the 
Chronic Care Model.143,157,191,208,209 Tsai et al,191 in a meta-analysis of interventions 
designed to improve care in chronic disease, including diabetes, firstly investigated the 
extent to which outcomes were improved when one or more of the elements of the 
model were implemented, and secondly evaluated the relative effectiveness of elements 
of the model. Four elements of the model i.e. delivery system design, support of self-
management, decision support and clinical information systems were found to be 
associated with both improved care processes and outcomes. Interventions relating to 
delivery system design and self-management support occurred more frequently than 
interventions relating to the other elements of the model. At a clinical outcome level, 
interventions that incorporated one or more elements were associated with improved 
surrogate outcomes.  
 
 Patient-centred care has been described as having five main domains: 201  
 Exploring – the patient’s experience, feelings, ideas and problems related to the 
disease and illness. 
 Understanding – the whole person in the context of personal and social (family) 
needs and realities of life. 
 Collaborating – finding common ground about treatment goals, priorities, 
interventions, problems and role assignments. 
 Promoting – monitoring and implementing health enhancement practices (to 
ensure risk reduction). 
 Enhancing – healthcare provider and patient relationships and care delivery.  
 
Patient-centred care philosophy encourages and facilitates patient involvement in 
healthcare decision-making with the result that the emphasis shifts from compliance with 
instructions to acceptance of the right of patients to make decisions, and of the 
obligation of the provider to support the patient empowering process.207  
The individualized care that characterises patient-centred care in chronic illness has 
been described as a stepped process in which collaboration between patient and 
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provider results in the setting of agreed goals, the developing of a care plan, training and 
support to facilitate self-management, monitoring, and the modification of care as is 
necessary.202,210 Supported self-management, monitoring and active follow-up, guided by 
evidence-based protocols, are the main interventions required to prevent the 
development and exacerbation of disease-related complications.211  
 
Barriers to patient-centred care in chronic illness include the over-emphasis on diagnosis 
and treatment. Healthcare providers, because they are often faced with the competing 
demands of time and attention, tend to neglect preventative aspects and services.211 
Furthermore, disparities in healthcare provision continue to exist with socioeconomic 
status, ethnicity and race being significant barriers to patient-centred care in chronic 
disease.157,212,213  
 
The advent of managed care has introduced commercial considerations to the practice 
of medicine and as a result the relationship between the insured patient and the 
healthcare provider may be subject to economic rather than clinical considerations.214. 
Managed care may constitute an impediment to patient-centred care.207,215 In South 
Africa managed care is generally perceived in a negative light as the managed care 
organisations may withhold or limit diagnostic procedures and treatment modalities in an 
effort to control utilisation.216-218 In addition, some believe that managed care in South 
Africa has in recent times contributed to healthcare provider emigration thereby 
negatively impacting on the health system’s capacity to deliver patient-centred care.218  
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CHAPTER 4 
BEHAVIOURAL CHANGE AND PATIENT SELF-MANAGEMENT 
 
4.1 Introduction 
 
A significant proportion of the global disease burden is associated with aberrant health 
behaviours, especially those related to lifestyle.132  Health behaviours may be influenced 
by a broad spectrum of factors such as learning, social norms, reinforcement and 
modelling, genetics, emotional factors including anxiety, stress and fear, the severity of 
symptoms, personal beliefs and the beliefs of significant others such as a spouse or 
partner and healthcare providers.219 
 
The increased recognition of the relevance of health behaviours in determining health 
outcomes has fostered the development of biopsychosocial approaches to the treatment 
and management of illness.220,221  In chronic disease management, models of care such 
as the patient-centred Chronic Care Model are providing the impetus for growing 
acceptance of the biopsychosocial paradigm.222 
 
The newly diagnosed diabetic is faced with the physical and psychosocial impact of 
having a serious chronic disease. The patient will have to manage the disease on a day-
to-day basis, and this includes lifestyle modification and adherence to a range of self-
management recommendations,223,224 all of which involves significant health-related 
behavioural change.225,226 The lifestyle behaviours include physical activity, diet, smoking 
and alcohol use as well as those behaviours associated with clinical practice guidelines, 
i.e. keeping appointments, having tests done and being examined, self-monitoring (e.g. 
body mass, blood glucose), and using medication appropriately.105,227  
 
Incorporating behavioural and psychosocial screening into routine care enhances the 
quality of the healthcare encounter as the process allows for the identification, and 
possible resolution of specific problems. If the provider is competent to deal with the 
problem and has the agreement of the patient, then appropriate remedial interventions 
may be identified and implemented. Should the provider or patient feel that the provider 
is not qualified to engage any further with the problem, or if the patient requests further 
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investigation by another provider, then screening serves the care process by providing 
an informed basis for such referral.122,221  
 
4.2 Adult education theory 
 
Adults often interpret new health-related experiences and information based on their 
beliefs and their past experiences or those of others, especially significant others 199 and 
use this amalgam of belief and experience to facilitate learning experiences both for 
themselves and for others. 228   
 
In discussing diabetes education in their book, The Art of Empowerment: stories and 
strategies for diabetes educators, Anderson and Funnell229  state that while many thousands 
of lectures have been delivered by diabetes educators in an effort to teach patients 
about diabetes and how to care for themselves (‘what to do’), this didactic approach has 
failed to consider that patients and providers view diabetes from very different 
perspectives. Providers are mostly educated and trained to view diabetes as a disease – 
as a subject (i.e.’ theoretical diabetes’), whereas patients are generally not interested in 
diabetes as a subject – they are interested in their own diabetes (i.e. ‘real diabetes’). The 
teaching and learning approaches that appear best suited to educating adult patients are 
egalitarian, respectful and empathetic. They are furthermore based on theories that 
incorporate problem-solving, and that recognise the patient’s past experience and their 
expertise in attempting to resolve their own real-life challenges.229 
 
Anderson and Funnell,229 suggest a stage-based model that reduces the process of 
adopting (learning) a new behaviour to the following four stages: (i) experience – which 
is defined as the total sum of an individual’s perceptions, (ii) reflection – the element that 
melds past experience, aspirations and anticipated actions, (iii) insight – flowing from 
reflection, which allows for the bridging of past and current experience and informs the 
realisation of new models, objectives opportunities and relationships, (iv) change – in 
knowledge, perceptions, attitudes and behaviour. The process of learning (change) is 
cyclical and continuous with new learning giving rise to new experiences which 
encourages more reflection and greater insight.   
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The Kolb model of experiential learning has been extensively used to provide a 
theoretical framework for adult education, informal education (e.g. patient education) and 
life-long learning such as that to be found in programmes designed to deliver continued 
education and continuous professional development.230 The Kolb model is comprised of 
four elements: concrete experiences, reflective observation, abstract conceptualisation 
and active experimentation, all underpinned by two preference dimensions of learning, 
namely a perception dimension and a processing dimension. Individuals will exhibit 
preferences along these continuums.  
 
Both the stage-based model suggested by Anderson and Funnell229 and the Kolb 
model230 may be used to underpin the two main lifelong formal educational approaches 
to maintaining the professional competency of pharmacists and to meeting new and 
developing standards of practice.231 The traditional method employed by professional 
associations and bodies is the continuing education (CE) option, which is designed to 
provide for the broad-based educational needs of pharmacists.232 The other and more 
recent approach is termed continuous professional development (CPD), which is 
focused on the professional development of the individual pharmacist.231  
 
The main difference between CE and CPD appears to lie in the method of assessment. 
CE relies on the quantitative evaluation of the pharmacist, whereas CPD, which may be 
more time consuming and resource demanding than CE, is based on a connecting circle 
of reflection, planning, action and evaluation. Both CE and CPD may make use of a 
range of methods of instruction including lectures, workshops, meetings, printed material 
and Internet-based resources. However, research shows that pharmacists are far more 
likely to obtain CE from printed materials than from any other source.232 
 
4.3 Health-related behavioural change: models and theories  
 
A variety of theories and models have been used to explain and influence health-related 
behaviours in primary care.233  The most common appear to be: Social Cognitive Theory, 
Self-regulation, Learning Theories, the Health Belief Model, Self-efficacy Theory, Theory 
of Reasoned Action, Theory of Planned Behaviour, and the Stages of Change         
Model.233-237  
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Bandura,238 who first developed Social Cognitive Theory, postulated that behaviour is 
determined by an individual’s sense of expectancy that a behaviour may be dangerous 
e.g. that smoking may cause lung cancer (situation outcome expectancy), that the 
individual is capable of a behaviour that will mitigate such harm e.g. stop smoking 
(outcome expectancy) and that the individual is capable of effecting remedial behaviour 
e.g. able to stop smoking (self-efficacy expectancy). In addition to expectancy, Bandura 
suggested that incentives and social cognitions were other determinants of behaviour. 
Incentives in the context of behaviour relate to consequences e.g. smoking cessation 
may lead to less anxiety about developing lung cancer. Social cognitions are central to 
these models as they include “…measures of the individual’s representations of their social 
world. Accordingly social cognition models attempt to place the individual within the context both 
of other people and the broader social world”.
239  
 
The self-regulatory model proposed by Leventhal240 assumes that people who are ill or 
who have the symptoms of an illness view such a state of affairs as a problem and will 
approach the illness or symptoms in much the same way as they approach other 
problems. Problem solving thus lies at the heart of self-regulatory theory with motivation 
being provided by an innate desire to return to a perceived state of normality.240 Problem 
solving is said to occur in three stages. Firstly there is interpretation through symptom 
perception (e.g. pain) and/or social messages (e.g. diagnosis by medical practitioner). A 
combination of symptom perception and social messages informs the development of 
illness cognitions within the dimensions of identity, cause, consequences, time-line, 
management or cure. These cognitive elements assign meaning to the problem and 
allow the patient to develop coping strategies which define the second stage of the self-
regulatory model. Two main strategies of coping have been defined as approach coping 
which involves positive action (e.g. taking medication, changing unhealthy behaviour) 
and avoidance coping (e.g. being in denial). The third or appraisal stage of the model 
involves the evaluation of the coping strategy by the individual and a decision on 
whether to continue with the chosen strategy or to adopt another in an attempt to return 
to a state of perceived normality.241    
 
Learning theories stress that the complex pattern of behaviour, which is associated with 
behavioural change, may be learned incrementally. These theories suggest that complex 
pattern behaviour (e.g. walking for one hour every day) is learnt gradually by reducing 
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the behaviour to manageable proportions or components (e.g. starting with 10 minutes 
and then slowly increasing the time spent walking). Component behaviours that are part 
of the ultimate goal (walking for an hour every day) require reinforcement and must first 
be established if the goal is to be obtained.236 Competing past behaviour (e.g. watching 
TV instead of walking) is often a complicating factor when attempting to introduce new 
behaviours. Thus, in addition to reinforcement, rewards and incentives may play 
important roles in establishing and sustaining behaviour, although extrinsic 
reinforcement has not proved reliable in sustaining behavioural change over the long 
term.236  
 
The Health Belief Model, which was first proposed by Rosenstock233 and developed by 
others, has been used to predict patient behaviour in both acute and chronic 
diseases.233,242,243  Behaviour is premised on a set of core beliefs: susceptibility to 
disease, the severity of the disease, the cost of a modifying behaviour, the benefit of 
such behaviour, and action indicators which may be internal (e.g. symptoms) or external 
(e.g. advice of a significant other).233 The original model was subsequently modified to 
include self-efficacy which is an expression of confidence by the individual in his/her 
ability to accomplish set objectives (e.g. change behaviour). It is a prerequisite for 
successful behavioural change and reflects a combination of the experience of earned 
past success and learned competency.242,244  In addition to being a key element of the 
Health Belief Model, self-efficacy informs a number of theories including the Theory of 
Reasoned Action and  the Theory of Planned Behaviour.236,239 
 
The Theory of Planned Behaviour is informed by the suggestion that many behaviours 
may be predicted by the individual’s intentions with regard to performing such 
behaviours.239 Behavioural intentions result from the following beliefs:239 
 Attitude – which is derived from the positive and negative evaluation of a 
behaviour together with beliefs about the outcome (expected value). 
 Subjective norms – perception of what important others may think and the 
motivation to comply with this pressure. 
 Perceived behavioural control (or self-efficacy beliefs) – perception of being able 
to effect the behaviour by overcoming barriers. 
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Other influences which may affect intentions such as demographic, personality and 
environmental factors, are assumed to do so via their influence on the primary 
determinants of attitude, subjective norms and perceived control. The Theory of Planned 
Behaviour allows that the relative importance of the three primary determinants in 
influencing behavioural intentions may vary within an individual or in populations.245    
 
A number of theories and models have been used to specifically describe and evaluate 
pharmacist practice-related behaviours, the most common of which appear to be the 
Theory of Planned Behaviour 246-248 and the Stages of Change Model.249 Others include 
the Health Belief Model246 role theory,250 organisational theory,251 self-efficacy  theory,252 
and the Pharmacists’ Implementation of the Pharmaceutical Care model.253 The latter 
model was developed in an effort to provide a theoretical framework for pharmaceutical 
care and it identifies the following key behavioural factors relevant to the design and 
implementation of pharmaceutical care interventions: attitude, perceived behavioural 
control, social norm, intention, psychological appraisal processes and recent behaviour.  
 
4.3.1 Stages of Change Model or Transtheoretical Model 
 
The Stages of Change Model or Transtheoretical Model (TTM) is the most commonly 
used stage-based model and includes concepts from the Health Belief Model, the Locus 
of Control model and elements of Cognitive Behavioural Therapy.254 The framework of 
the TTM has been used to describe a range of health behaviours including those 
associated with smoking and alcohol cessation, physical exercise and diet.254 The model 
has proved popular as it appears to offer some explanation as to why group-based 
interventions are often ineffective. It supports the notion that interventions tailored for an 
individual are more likely to be effective than a ‘one-size-fits-all’ approach, as the model 
is premised on an individual being at a specific stage along the change continuum at any 
given time.255 It is suggested that an individual changes behaviour by a gradual process 
and that the barriers individuals face will differ given the particular stage that the 
individual finds him/herself in.256 The model has also been used to inform the 
development of other behavioural interventionist strategies and methods such as 
Motivational Interviewing (Section 5.4.2).235,257 
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The TTM involves five distinct identifiable stages: 234 
 Precontemplation – not intending to change for at least the next six months   
 Contemplation – intending to change within the next one to six months 
 Preparation – intending to change within the immediate future (within the month)  
 Action –  engaged in a new behaviour for less than six months 
 Maintenance –  sustained behavioural change for more than six months.  
Termination, which is the ultimate goal for persons who have changed aberrant 
behaviour, is only possible if regression is unlikely (e.g. having been an ex-smoker for 
many years).234  
 
Precontemplation, contemplation and preparation are described as motivational stages, 
while action and maintenance are orientated towards achievement. The model intends 
that individuals proceed sequentially from one stage to the next, but this does not 
always happen and they may relapse to an earlier stage before advancing once 
again.234 In addition to the five stages, the model suggests that there are 10 processes 
of change (activities) which individuals utilize in an effort to overcome any barriers to 
change that they may encounter in a particular stage. The most widely used of these 
processes is termed consciousness-raising, i.e. raising one’s level of awareness by 
increasing the amount of information available either about one’s self or the problem 
one faces. The model further proposes that readiness to change is a key aspect in 
effectively moving from one stage to another. 234 
 
While the TTM has been used to inform self-management behavioural change in a 
number of chronic conditions including diabetes,235,257-260 recent systematic reviews of 
interventions based on the model have reported some problems associated with the 
stage-based studies.255,256,261 These included methodological difficulties such as lack of 
validation of the instruments and a lack of explanation of the interventions used. The 
problems associated with the model may be founded in the complex nature of stage-
based interventions, which require development and evaluation on more than one 
level.262 The reviewers concluded that there is often insufficient evidence to suggest that 
these interventions were likely to be any more effective than non-stage-based 
interventions, and sounded a word of caution with regard to the elevated status that the 
model appears to enjoy.  
 
 - 43 - 
Despite concluding that applying the model to complex behaviours may be problematic, 
Brug et al,263 state that the interventions have shown promise in some instances and 
that, contrary to other apparently negative findings relating to the effectiveness of the 
model, such evidence may be interpreted differently. In their book entitled, Health 
Behavior Change; a guide for practitioners,  Rollnick et al,170 comment on the danger of 
equating the TTM to a single method of intervention when no such method exists. They 
remind readers that it is a transtheoretical model and that those who apply the model in 
practice will invariably do so using a variety of interventions.  
 
4.3.2 Motivational Interviewing  
 
Miller et al,264 in developing the counselling style of Motivational Interviewing, drew on 
the TTM in an attempt to cross the divide between theory and practice, in particular with 
regard to the assessment of motivation in terms of the change concepts of readiness, 
importance and confidence.  
 
Motivational Interviewing has been described as a counselling style where “…it is the 
practitioner’s task to expect and recognise ambivalence, and to be directive in helping the patient 
examine and resolve the ambivalence”.
265 The method was initially developed as a patient-
centred counselling tool for use in patients with addictions, but it has subsequently been 
adapted for use in other healthcare settings, including in caring for individuals with 
chronic diseases.235, 244, 265-268   
 
Motivational Interviewing has been suggested for use in pharmacy171,266 and it is the 
counselling method suggested in the conceptual framework of the diabetes care plan 
discussed in Chapter 5 (Section 5.4.2). The pharmacist, in applying its principles, 
assumes the role of a behavioural change agent by assisting patients to recognise and 
resolve ambivalence or resistance to change.171,269,270 This approach is very different 
from the traditional view of pharmacist counselling which is essentially based on advice 
giving.6,271  Research reveals that only 5-10% of patients modify health-related behaviour 
as a result of advice-giving interventions.264  Furthermore, few patients request advice, 
and many patients do not want to be given prescriptive advice especially if the 
healthcare provider only emphasises the benefits of change. Unsolicited advice-giving 
may also be viewed as confrontational by the patient and so increase ambivalence or 
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resistance to change.235 Overcoming resistance to change or resolving ambivalence 
requires motivation to change, which is strongly influenced by the patient’s sense of 
importance and confidence in effecting behavioural change.235 
 
Motivational Interviewing is founded on the core sequential process elements of 
elicitation, provision and elicitation, and for each of the core elements five counselling 
principles apply.264,265  Elicitation in the first instance involves encouraging the patient to 
identify disease or condition-related needs, and any barriers preventing the needs from 
being met. The use of open-ended questions assists the pharmacist to identify any 
patient resistance to change or ambivalence.265 
 
Ambivalence and resistance to change result from a cost-benefit analysis that is 
fundamental to therapeutic decision making. Patients weigh up the need to change a 
particular health-related behaviour (perceived benefit) versus concerns they may have 
about any possible negative effect that might result from such a change (perceived 
cost).272 The ‘provision’ element of the Motivational Interviewing process allows the 
pharmacist to provide information in a manner that is directional (i.e. the pharmacist has 
a goal in mind in engaging with the patient), but without being dictatorial, argumentative 
or confrontational as any of these approaches may result in a defensive patient arguing 
against change.235  
 
Elicitation in the second instance recognises the patient’s ambivalence and continues 
the directive open-ended questioning approach by restating the problem together with 
any decision that the patient may have reached. As a result of providing patients with 
appropriate information and answering their questions it is possible that other concerns 
may be elicited. An important aspect of Motivational Interviewing in providing information 
is seeking patient permission before offering unsolicited advice. This underscores the 
collaborative and supportive nature of the pharmacist-patient discourse in Motivational 
Interviewing.270 Five principles or skills underpin this “elicit, provide, elicit” process. 
These principles are: rolling with resistance, expressing empathy, avoiding arguments, 
developing discrepancy, and supporting self efficacy.265 
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Rolling with resistance.  
Patients who appear ambivalent or who resist change are not confronted directly. 
Instead resistance or ambivalence is used to facilitate the development of 
dissonance.265,270 Dissonance so created plays a complementary role in motivating 
patients to change behaviour. Rolling with resistance encourages the development of 
dissonance whereas the alternative i.e. confrontation often results in the patient 
assuming a defensive position.  Pharmacists are able to utilise dissonance to 
directionally foster behavioural change. Rolling with resistance furthermore signals 
pharmacist acceptance of the patient’s right to ultimately determine and be responsible 
for their own healthcare.273  
  
 Expressing empathy 
Expressing empathy tangibly demonstrates the pharmacist’s acceptance, in a non-
judgemental manner, of  the patient’s reality of living with chronic disease.171,235 
Identifying and developing an understanding of the patient’s apparent resistance to 
change or ambivalence through a process that includes reflective listening and 
empathetic responses promotes the development of trusting relationships between 
patients and pharmacists and improves the effectiveness of the counselling 
intervention.171,228 
 
Avoiding arguments 
Arguments between pharmacists and patients may lead to patients becoming defensive 
and to resistance to change becoming entrenched.265 While Motivational Interviewing is 
non-confrontational it is nevertheless directive as it encourages patients to confront their 
disease-related problems, including any aberrant behaviour, and to find solutions without 
confrontation or argument.265,270 
 
Developing discrepancy 
Creating dissonance results from the misalignment of the patient’s health-related 
behaviour and a desired health outcome. Motivational Interviewing encourages patients 
to weigh up their current health status in terms of their diabetes-related goals. If 
dissonance results, then patients are more likely to be motivated to change behaviour 
than if there is little or no dissonance.259,270  
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Supporting self-efficacy 
Patients are not only required to accept that a particular intervention may improve their 
health-related quality of life, but must also be confident they are capable of implementing 
it.235 In supporting patient self-efficacy, the pharmacist tangibly demonstrates support for 
the fundamental role of self-management.265,274 Practical ways in which the pharmacist 
can assist the patient to develop self-efficacy include providing relevant and 
unambiguous information, expressing sincere interest in the patient’s welfare, 
encouraging persistence and adherence in a non-judgemental manner in times of 
relapse, praising and rewarding success and ensuring regular patient follow-up.171,274  
  
The process of Motivational Interviewing is not a linear one, as in practice patient 
behaviour and the patient-pharmacist discourse are subject to a number of competing 
and interacting factors. 131,171,228 Motivational Interviewing while not a universal panacea 
for resolving poor patient health-related behaviour,266 is able to direct patient decisions 
towards appropriate behavioural change.171,264 
 
4.3.3  The 5 A’s Behavioural Change Model 
 
The 5 A’s model (assess, advise, agree, assist and arrange) has been suggested as a 
unifying framework to inform the development and implementation of behavioural 
change educational interventions designed to support the improvement of chronic 
disease self-management in primary healthcare settings.275,276  The model, included as 
Figure 4.1, identifies five change concepts (Assess, Advise, Agree, Assist and Arrange) 
and makes suggestions for the collaborative interaction between the patient and the 
provider (the nexus of the Chronic Care Model). 
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Assess: 
Beliefs, Behaviours & Knowledge 
 
 
 
    Arrange:   Advise: 
   
 
 
 
 
 
 
 
 
 
 
          Assist:                                                                                           Agree: 
 
 
 
 
 
 
 
Figure 4.1. The 5 A’s Behavioural Change Model for Adapted for Self-Management Support
275 
 
 
4.4 Effecting behavioural change  
 
The task of the healthcare provider, in attempting to influence patient behaviours in the 
course of day-to-day clinical practice, is made difficult by a lack of time (work overload), 
lack of training and skills, the absence of an integrated screening and intervention 
approach applicable to multiple risk behaviours, as well as the mitigating influence of the 
provider’s own behaviours and socio-ecological perspectives.237,276  
 
Rollnick et al,277 in discussing the training of healthcare professionals as facilitators of 
behavioural change in patients, note that there is very little that may be applied to health 
behavioural change in patients that does not apply to practitioners. The authors go on to 
state that the training of providers involved in promoting patient health behavioural 
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 - 48 - 
change “is sometimes viewed as an inconvenient by-product of a more worthy endeavour: 
getting the patients to change”.
277 They caution against the oversimplification of the process 
of skills acquisition by providers who are charged with working with patients to effect 
behavioural change. A common but mistaken notion is that all that is needed is a 
workshop or two for the provider to be sufficiently skilled to influence behavioural 
change. Just as patients are unlikely to change behaviour overnight, neither are 
healthcare professionals. A balanced approach to training that is based on structured 
skills acquisition within the provider’s real-world practice environment appears to offer 
the most promise.  
 
In a Cochrane systematic review of the effects of continuing education meetings and 
workshops on professional practice and health outcomes, the reviewers noted 
educational meetings and the dissemination of printed educational materials were the 
two most common forms of continuing education for healthcare providers.278 Reviewers 
found that there was a great deal of variation in the complexity of targeted behaviours 
and that stand-alone interactive workshops produced  mixed results whereas a 
combination of workshop and didactic lectures produced significant results. There were 
no statistically positive results for studies based only on didactic presentations. 
 
A systematic review of provider behavioural change noted that there are no “magic 
bullets” for changing provider behaviour, and while some interventions had some effect 
in certain circumstances, none were effective in all situations. Furthermore, multifaceted 
rather than single interventions were more likely to be successful.279 Interventions 
identified in the review, and which may be relevant to pharmacy practice, include 
continuing education, the provision of practice guidelines and printed educational 
material, reminders and computerized decision support. Guideline effectiveness 
increased when active educational methods were used, and if consideration were given 
to local conditions and supported with patient specific reminders.279 Others have found 
good evidence that training to improve cultural competence resulted in improved 
knowledge, attitudes and skills of providers, as well as in patient satisfaction.280 
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4.4.1 Provider-patient communication 
 
Allied to both provider and patient behavioural change is the key aspect of provider – 
patient communication.281 Communication between the provider and patient that is 
respectful, compassionate and empathetic is a key aspect of patient-centred care, and 
has been shown to have a positive effect on patient health outcomes.281 No matter how 
well constructed an intervention, it is inconceivable that pharmacists would be able to 
influence patient health behaviour or outcomes in the event of poor communication.282 
Pharmacist-patient communication is commonly referred to as patient counselling, 
although the term patient education has also been used.228,283   
 
In a review of studies relating to patient counselling by pharmacists, Shah et al,283 noted 
that almost half of the studies reviewed (19 out of 39) conceptualised this form of 
counselling as solely providing patients with basic information (e.g. the name of the 
medication, the dosage and adverse effects). A total 16 studies included aspects of the 
interpersonal behaviour of pharmacists in addition to the information provision element. 
These interpersonal aspects include the time taken in engaging patients, willingness to 
offer assistance, demonstrations of empathy, and pharmacist accessibility. The 
reviewers noted that very little attention had been paid to studying patient 
communication behaviour and the processes involved in the exchange of information 
between the dyad.  
  
van Dam et al,284 in a systematic review of randomised controlled trials designed to 
examine the effect of provider – patient interaction and provider consulting style on the 
process of care and patient outcomes in diabetes, tentatively concluded that focusing on 
improving collaborative care held more promise from both a process and outcomes 
perspective than did attempts to change provider behaviour. An important advantage of 
a primary care provider, such as a community pharmacist, in facilitating behavioural 
change in patients who are chronically ill, lies in the often good relationship between the 
two and the potential for frequent contact (and thus for multiple “teachable moments”26) as 
a result of the prescription refill dynamic.17 Added to this is the increasing acceptance of 
collaborative and empowering patient-centred approaches to chronic disease self-
management.285,286  
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4.4.2 Effectiveness of behavioural interventions  
 
Effecting behavioural change is often difficult as behaviour is dictated by a multitude of 
personal, societal and environmental influences in effect at the level of the individual, 
between the individual and others, and at the level of broader society.237 The difficulties 
associated with behavioural change are exacerbated by the clustering of risk behaviours 
within individuals, e.g. smokers who may be overweight and lead a sedentary lifestyle.276  
 
A review of evidence relating to multiple risk factor interventions in primary care noted 
that the complexity and difficulty of promoting behavioural change in primary care 
settings is demonstrated by the modest and often inconclusive results of health 
promotion programmes and services aimed at increasing physical activity, improving 
diet, smoking cessation and modifying alcohol consumption.276  Such modest or 
inconclusive results are often in contrast to the successful behavioural modification 
outcomes achieved in specialised clinical settings.120,121 The challenge for primary care 
providers, such as community pharmacists, is to translate the research conducted in 
these specialised settings into day-to-day patient care in their own practice settings.   
 
A Canadian study which used the constructs of community pharmacist beliefs, self-
efficacy, behavioural control and evaluations to develop a causal model to predict 
pharmacist behaviour in providing pharmaceutical care, found that pharmacists were 
generally positive about pharmaceutical care. Pharmacists rated their beliefs about the 
benefits of pharmaceutical care outcomes highly but assigned a much lower rating to 
behavioural control, which indicated that they were not confident about turning strategy 
into action.246 In terms of self-efficacy, they were moderately confident, which when 
considered with the relatively high rating for beliefs in the benefits of pharmaceutical 
care, corresponded with the findings of an earlier study which considered an intervention 
to change patterns of community pharmacy practice.253 The latter study found that 
pharmacists often did not provide pharmaceutical care despite have high intention to do 
so. The authors suggest that this discrepancy may be due to low social norm with regard 
to medical practitioners, low behavioural control, low self-efficacy and low affect. 
 
The Canadian authors suggest that applying a stage-based interpretation to their 
findings reveals that many of the pharmacists were either in a precontemplative or 
 - 51 - 
contemplative stage because of their perceived difficulty of converting intention into 
action.246 They suggested that in order to foster changes in practice, pharmacist 
perceptions of behavioural control need to be addressed, as this variable may impact 
directly on beliefs, self-efficacy and evaluation. Programmes that include enabling 
enhancements to the practice environment of pharmacists together with positive 
perceptions of behavioural control may lead to improved self-efficacy and evaluations, 
and consequently to improved pharmaceutical care.246,253 
 
4.4.3 Behavioural change intervention strategies 
 
The following intervention strategies have been associated with positive outcomes in 
studies aimed at modifying behaviours:276 
 Assessment and tailoring to address patient needs19,287 
 Self-monitoring, goal setting and problem solving173,288 
 Empowering patient education288 
 Combination of pharmacotherapeutic and behavioural interventions289,290 
 Internal (patient and provider) and external (community) support25,291 
 Multiple modalities188,290 
 Regular follow-up contacts287,292 
 Use of multidisciplinary teams18,293 
 Targeted elements of a health system25,291  
 
Goldstein et al,26 in their review of behavioural interventions in primary care note that 
most individuals are at risk for multiple behavioural risk factors. This is especially so in 
chronic conditions such as DM2 where, in addition to hyperglycaemia, patients may be 
hypertensive, obese, dyslipidaemic, depressed, smoke, lead a sedentary lifestyle and 
suffer from any number of complications often associated with diabetes.227 The multi-
component nature of behavioural interventions has led to their classification as complex 
interventions,294 requiring an approach that is different from that more appropriate for a 
single (component) intervention.295 Both CONSORT296 and the Medical Research 
Council of the United Kingdom294 have published guidelines for consideration in the 
development and evaluation of complex interventions.  Complex interventions are further 
discussed in more detail in Section 5.3.  
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4.5 Patient self-management in chronic disease 
 
The main drivers of desired patient health outcomes in chronic disease management are 
pharmacotherapy, lifestyle modification and the monitoring of clinical indicators,4 all of 
which involve self-managed health-related behaviours.143,297 Resistance to modifying 
behaviour is a major barrier to effective self-management in chronic disease.171, 235,265 
 
Self-management is often the defining component in the overall care continuum for most 
chronic illnesses. For example, it provides for approximately 95% of the care diabetics 
receive.67,226,298-300  An important role for providers is to support the chronically ill patient's 
efforts to acquire the necessary information and skills to be able to effectively care for 
themselves.301-303 The nature of DM2 dictates that the patient should not be a passive 
recipient of diabetes care but should be empowered to be actively involved in all aspects 
of their care, including identifying diabetes-related needs, setting goals, discussing and 
agreeing on strategy, implementing interventions and monitoring outcomes.275,299,304,305 
 
The empowerment approach to both behavioural change and self-management 
education in diabetes care has resulted in a shift from provider-centred care to more 
patient-centred models that acknowledge the primacy of patients in providing care, i.e. 
recognition of the reality that most patients are ultimately responsible for their care 
choices and the consequences of these choices.222,306-308  Patient empowerment does 
not occur simply by inviting patients to participate in their care, nor does it result if 
providers discount the patient’s experience of living with the disease or if they fail to 
provide the resources needed to foster problem solving, informed decision making and 
self-efficacy.301,309 Self-efficacy, which has been defined as the “…confidence to carry out a 
behaviour necessary to reach a desired goal”,301 is an outcome of patient empowerment and 
the central component of self-management.310,311 Furthermore, self-efficacy is the result 
of a transformational process, developing as patients become increasingly successful in 
identifying and resolving diabetes-related problems.301,303  
 
There seems to be a lack of consensus about what constitutes a successful chronic 
disease self-management programme, which elements should be universally applied 
regardless of the disease, or which elements are disease specific.177  While the 
mechanism by which self-management education effects improves patient outcomes 
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remains unclear,312  there appears to be substantial support for self-management 
education aimed at promoting the key process outcome of patient adherence to the 
behavioural and clinical aspects of evidence-based care.52,306,313 
 
The features of evidence-based diabetes self-management education include the 
application of appropriate theories of behavioural change, concordant goal setting, a 
combination of individualized didactic and practical instruction, simplification of treatment 
regimens, provider support, follow up and patient feed back, and participation by family 
and significant others.224,314  
 
Traditional diabetes patient education is based on providing information about diet, 
exercise and medicines as well as technical skills such as those associated with SMBG. 
Diabetes self-management education complements traditional patient education by 
providing training in problem solving and coping skills.224,301  Self-management education 
that is focused on empowering patients to develop their self-management skills appears 
to be more effective in improving clinical outcomes than education that is simply based 
on information transfer. 224,301   
 
The findings of the DCCT and UKPDS support the need for self-management as many 
of the activities associated with improved disease control and the prevention or arresting 
of complications are undertaken directly by the patient.92,315-317 Diabetes self-
management education provides for an evidence-based approach to disease-related risk 
reduction.301 In the USA it has been reported that only 52% of diabetics received self-
management education and yet between 50% and 80% of patients lack sufficient 
diabetes-related capacity to be able to effectively manage their disease.316 Adherence to 
self-management recommendations is substantially lower among patients who have not 
received diabetes self-management education and these patients are four times as likely 
to develop complications.316 
 
There appear to be three main barriers to the provision of diabetes self-management 
education: a paucity of trained and culturally competent personnel; the continued 
socialization of patients to dependant relationships with providers where acute models of 
care are in effect rather than collaborative patient-centred chronic care models; and 
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lastly the reluctance of the funders of healthcare to reimburse educators for providing 
self-management education.301 
 
 4.5.1 Compliance, concordance and adherence  
 
The medical narrative dating back to the time of Hippocrates reveals that the medical 
establishment has long been concerned about patients not “…following doctors orders”.318 
Patients with tuberculosis in the early 1900’s who did not follow medical practitioner 
instructions were often chastised and even described in the literature as “…ignorant and 
vicious consumptives”.
318  It was, however, only with an improved understanding of the 
aetiology and pathophysiology of diseases such as tuberculosis that the compliance 
aspect of evidenced-based disease management became therapeutically meaningful.318  
The terms compliance and non-compliance began to appear in the literature in the 
1960s. Sackett and Haynes,319 who pioneered much of the early research, stimulated the 
discourse about therapeutic compliance with their books in the 1970s.  
 
Developments in health psychology have given rise to a number of theoretical models 
used to describe aspects of adherence.272,320 Horne and Weinman272 state that “Social 
cognition models and the self-regulatory theory share the common assumption that individuals 
develop beliefs that influence the interpretation of information and experiences and which guide 
behaviour”. Social cognition models such as the theory of planned behaviour have been 
used to explain medication adherence variability, for example, in hypertension, diabetes 
and kidney disease.272 These models are used to predict behaviour and/or behavioural 
intentions as well as examine the reasons why individuals fail to sustain behaviours.239 
 
The psychology of adherence suggests that adherence behaviour is strongly influenced 
by the patient’s belief about the illness and the result of weighing up the perceived costs 
and benefits of a particular therapy (e.g. taking medication, stop smoking) versus any 
concerns about taking the action (e.g. adverse effect of the medication or weight 
gain).233,272,321-323   
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4.5.2. Compliance 
 
Compliance has been defined in terms of three process elements: matching the patient’s 
actual consumption of medication with that of the prescribed regimen; matching the 
patient’s medicine taking or lifestyle behaviour with the advice provided by the 
healthcare professional; and the actual doses of medication not taken, or taken 
incorrectly.324 An alternative outcomes-based definition of compliance is less concerned 
with the number of doses taken than with the outcome of the regimen.324 
 
Haynes et al319 defined compliance as “…the extent to which a person’s behaviour (in terms 
of taking medications, following diets, or executing lifestyle changes) coincides with medical or 
health advice”. However, as compliance appears to be associated with patient blame i.e. a 
non-compliant patient is seen as being incompetent, deviant or recalcitrant in following 
provider instructions,325 the term has been superceded in the recent literature by the 
term adherence,321 which has been formally adopted by the WHO.1  However, there are 
those who hold that the concepts of compliance and adherence are not appropriate in 
chronic disease care as the focus of healthcare providers should be constrained to 
collaborating with and empowering patients to optimise self-management.301,327 
 
4.5.3 Concordance 
 
The term concordance has more recently appeared in the literature, particularly that 
emanating from the United Kingdom.327-329  Concordance is not a synonym for either 
adherence or compliance but is an evolving concept that refers to the consensual 
agreement reached between a patient and a healthcare provider, and reflects the 
patient’s considered choice.324,328-330  
 
Concordance, in a pharmacotherapeutic context, has been defined  by the Medicines 
Partnership Group as “…agreement between the patient and the healthcare professional, 
reached after negotiation that respects the beliefs and wishes of the patient in determining 
whether, when and how their medicine is taken, and (in which) the primacy of the patient’s 
decision (is recognised)
”
.
331 Promoting concordance requires flexibility and skill on the part 
on the provider in order to elicit the approach favoured by the patient.324,331,332  The term 
is, however, not without problems. In the USA for example, concordance has been 
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defined as “…a similarity, or shared identity, between physician and patient based on a 
demographic attribute such as race, sex, or age”.333    
 
Concordance may possibly be a condition precedent for improving adherence but this 
does not mean that where concordance exists adherence is guaranteed. For example, a 
patient and a provider may agree on the need for the patient to use medication, 
however, the patient may simply forget or find the regimen too complex.327,328  
 
There is a paucity of literature relating to the effect of concordance on patient outcomes, 
and little evidence exists with regard to key aspects such as the information needs of 
patients and providers, which interventions improve communication between patients 
and providers, and whether or not enhanced communication necessarily translates into 
improved outcomes.328,334  The complex and interdependent (or sometimes conflicting) 
nature of the various elements of concordance make it a difficult subject to research. 
Added to this is the need for substantial change to values and practice dynamics if 
concordance is to become an entrenched healthcare model.334,335 
 
4.5.4 Adherence 
 
The advent of patient-centred care has encouraged the abandonment of language that 
speaks of ‘recalcitrant’ or ‘deviant’ behaviour for those patients who, for whatever 
reason, choose not to follow healthcare provider advice. Terminology that excludes 
pejorative terms such as non-compliance is increasingly being used to accommodate the 
reality that the chronically ill make the important day-to-day decisions about their care 
and are thus responsible for, and in control of, the care process.273,326 
 
The WHO defined adherence as “…the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations from a healthcare provider”.
1 A previous definition included the phrase “the 
extent to which the patient follows medical instructions”. However, the WHO adherence 
meeting in June 2001 held that the term “medical” did not allow for the inclusion of non-
medical interventions, crucial in chronic disease care. Similarly, “instructions” inferred that 
collaboration only extended to the patient being a submissive recipient of expert provider 
treatment and care.1 
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4.5.4.1 Importance of adherence  
 
Adherence to therapy is an important chronic disease self-management behaviour.1 
However, no more than 50% in high-income countries, and even less in medium and low 
income countries adhere to long-term therapy conscientiously.1 Inadequate therapeutic 
adherence is associated with economic, clinical and humanistic outcomes as it increases 
the financial cost of healthcare, diverts scarce healthcare resources and results in poor 
patient quality of life.1,336 The WHO endorsed the profound view expressed by Haynes et 
al330 that “Increasing the effectiveness of adherence interventions may have a far greater impact 
of the health of the population than any improvement in specific medical treatments”.
1 Krumholz 
et al337 underscored the relevance of adherence in a disease management context by 
describing medication adherence as a patient-centred measure that should be included 
in the clinical outcomes domain of a disease management taxonomy. Importantly, there 
should always be sound clinical reasons for attempting to increase adherence rates, and 
there should be patient-provider concordance, as such interventions are always 
associated with ethical considerations.330 For example, in certain instances intentional 
non-adherence may well be in the patient’s interest and the pharmacist may have an 
ethical obligation to support such a decision. 
 
Most adherence-related research has been focused on pharmacotherapy, especially 
with regard to the causes of non-adherence and the strategies and interventions to 
improve adherence.188,324,330 In addition to emphasising medication persistence and 
adherence in diabetes care, the importance of adherence to non-pharmacological self-
management recommendations such as nutrition, exercise and self-monitoring is 
increasingly receiving due consideration.225,338,339 
 
4.5.4.2 Factors influencing adherence 
 
Non-adherence may be intentional or unintentional. Intentional non-adherence, which 
occurs when the patient decides against following advice or instructions, is informed by 
both health beliefs and motivation.272,324,340  Unintentional non-adherence is influenced by 
cognitive, physical and socioeconomic constraints and is thus a function of skill, ability 
and capacity. 321,341-343  A number of psychosocial factors including economic status, 
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patient-provider communication, emotional stability and a supportive social environment 
affect adherence,224,344,345  whereas demographic characteristics appear to have less 
leverage on adherence.324 Of all the psychosocial correlates associated with adherence, 
patient health beliefs may have the strongest influence.272,321,344,345 
 
In the WHO report on adherence in diabetes, five core and interacting health-related 
factors influencing patient adherence to therapy were identified: socioeconomic factors 
where cost of care is most often cited; health system factors with patient-provider 
relationship being key; disease-related factors with duration of disease and co-morbid 
depression having most influence; therapy-related factors mainly expressed as 
complexity of treatment; and patient-related factors where lack of self-efficacy and poor 
self-management capacity are most important.1 
 
Other adherence influencing factors that have been identified include forgetfulness, 
health beliefs especially beliefs about medicines and denial about health status, adverse 
effects of medication, medication effectiveness,  lack of concordance, poor healthcare 
provider communication, alcohol abuse, lack of social support, linguistic and cultural 
differences between patient and provider, absence of diabetes education, low levels of 
diabetes-related knowledge, and anxiety.175,318,324,346-349 Neither the disease itself nor the 
clinical settings are necessarily indicators of adherence.  
 
In DM2, monotherapy, diabetes education and diabetes related knowledge are 
associated with adherence and outcomes.4,106,318  Diabetes education is, however, not 
always associated with improved adherence or disease-risk reduction, possibly because 
of the confounding effect of focusing diabetes educational efforts on patients with poor 
glycaemic control.318,324 While improved understanding of medication use may improve 
adherence, acquiring diabetes-related knowledge may exacerbate concerns about the 
adverse effects of medication or about the possibility of a negative prognosis.349    
 
Adherence is a ‘moving target’. As patient circumstances are subject to change so too 
are the variables influencing patient adherence. The dynamic and multifaceted nature of 
adherence contributes to the difficulties associated with the behaviour that is often 
encountered in practice.349 A review of  adherence-related studies noted that of almost 
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200 provider-patient encounter variables studied none were found to consistently predict 
adherence.324  
 
4.5.4.3 Adherence interventions 
 
Adherence to therapy facilitates the bridging of the process of care with the outcome of 
the intervention.350,351 Patient adherence to therapy is a complex health-related 
behaviour.1,175,330 Haynes et al319 listed the three fundamental criteria that should be 
satisfied when designing and implementing adherence promoting interventions: a correct 
diagnosis of the disease is required; the intervention in question must do more good 
than harm, and lastly the patient must be informed and willingly participate in the 
process. The design of adherence-promoting interventions should incorporate the 
enhancement of patient understanding, recall motivation and self-management skills.324 
 
Interventions designed to improve adherence in chronic disease may be classified 
according to the following five broad themes: technical, educational, behavioural, 
affective and multimodal.346 
 
Technical interventions 
Technical interventions generally relate to the medication regimen and include patient 
reminder services (computerized alerts), simplifying medication regimens (tailoring 
therapy and fixed-dose combinations), unit-dose packaging, and dosing 
schedules.324,344,352-354  
 
Educational interventions 
These interventions are primarily aimed at informing the patient’s knowledge base with 
regard to key aspects of the disease including principles of self-management education, 
offering individualised disease-related training (e.g. use of monitoring devices) and  
providing health-related information.38,188,355,356 
 
Behavioural interventions 
Interventions for behavioural change include those concerned with diet, exercise, body 
mass, smoking cessation, alcohol consumption, medicine taking, making and keeping 
appointments and monitoring clinical indicators. 9,338,357-361 
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Affective interventions 
These interventions are psychosocial in nature and include individual counselling 
sessions, social support, telephonic follow-up, empowering patient-provider 
relationships, facilitating self-motivation, reinforcement and reward 
programmes.225,266,308,330,360,362-366 
 
Multimodal interventions 
Multimodal or multifaceted interventions are those that combine elements from the other 
four major categories e.g. a counselling session for both spouse and patient on meal 
planning, exercise, self-monitoring of blood glucose and education on the correct use of 
insulin.324,330,346,360,367-369 
 
Interventions to improve adherence to medication are generally complex, labour 
intensive and their effectiveness inconsistent in many instances.324,330,353,354 Even the 
most effective interventions do not produce large improvements in adherence or health 
outcomes.324,330  
 
The interventions that appeared most effective include prescription-refill reminders 
simplifying regimens and unit-dose packaging and these should be first-line 
strategies.324,352-354,370 While integrated educational interventions are effective, the 
provision of educational material or advice as stand-alone interventions appear to have 
little or no effect on adherence.38,352,371,372  
 
Reasons why interventions often appear ineffective include inadequacies in the 
development-evaluation-implementation process, e.g. lack of a coherent underpinning 
theory, lack of evidence supporting the likelihood of a successful cost-effective 
intervention (ideally substantiated by systematic reviews), inappropriate design, lack of 
clarity regarding interventions, impractical interventions, lack of adequate feasibility 
studies (pilot studies) and lack of process evaluation.294  
 
Other methodological problems commonly identified in systematic reviews include the 
recruitment of only those patients willing to participate in the research rather than the 
wider population (i.e. patients may already have high baseline adherence levels), small 
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numbers of participants and per-protocol rather than intention to treat analysis. Issues 
such as non-blinding of researchers and payment of researchers raise questions about 
generalisability of results in practice. Uncertainty as to whether an effect was due to the 
intervention in question or due to the effect of simply being experimentally measured 
(Hawthorne effect) constitutes a potential problem as does an absence of any 
assessment of the individual components of a complex intervention. Control patients are 
often referred to as having received usual or standard care without such care being fully 
described. Furthermore, there are very often problems associated with measuring 
adherence, with a frequent reliance on imprecise self-reported adherence data as well 
as a lack of clarity on acceptable adherence cutoff points.153,324,330,348,32,368 
 
Provider-related factors that may negatively impact on the effectiveness of adherence 
interventions include the poor quality of provider-patient interactions,324,373  and the 
provider’s failure to negotiate priorities with patients, follow clinical practice guidelines,324 
tailor interventions to meet individual patient needs,374 monitor and reinforce adherence 
at each visit and follow up with patients regarding missed appointments or prescription 
refills Providers should implement medication regimens that are simple and cost-
effective and that avoid multiple medications and dosages, complicated or unclear 
instructions and use medication that is effective, inexpensive, and free of unwanted side 
effects.369 
 
In a review claimed by van Wijk et al153 to be the first systematic review of the 
effectiveness of adherence promoting interventions by community pharmacists, the 
authors noted the paucity of published studies and consequently that it was not possible 
to identify and overall strategy that may result in improved adherence to medication 
prescribed for chronic conditions. 
 
Patient-related factors that may contribute to lack of effectiveness of adherence 
interventions include health-related beliefs,324,374 forgetfulness,369,375 past experience of 
illness and the role of medication,324 the complexity and the behavioural demands of 
multifaceted treatment regimes (which may include taking and/or using a number of 
medications at various times during the day and night),369 adverse effects of 
medication,368 following eating plans, exercise or smoking cessation programmes, self-
monitoring blood pressure and or blood glucose levels,369  and attending appointments 
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and having biochemical and other tests done.294,324 Further potential confounders include 
psychological (e.g. depression),324 socio-economic (e.g. lack of social support, poverty 
and other financial constraints and transport related factors)375  and health-system 
factors (limited healthcare resources including medicines, personnel and infrastructure). 
In addition, patients may wish to make their own decisions regarding care, or simply 
decide independently to disengage from care (intentional non-adherence).229,324 Negative 
reinforcement such as threatening or coercing patients may produce results opposite to 
that intended.229  
 
4.5.4.4 Measuring adherence  
 
One of the most problematic aspects of adherence research concerns the measurement 
of adherence.330,353,376 Vermeire et al324 refer to the lack of a ‘gold standard’ in measuring 
adherence, largely due to variations in definition and because of the heterogeneity and 
complexity of the interventions.  
 
Methods that have been used to assess medication adherence include the direct 
measurement of medication or metabolite levels in blood, urine and saliva.324,377,378 
Biological markers or tracers have been used but their utility is limited as they tend to 
mirror recent and not sustained patient behaviour.346,377  Direct observation is another 
direct measurement method but its application is largely limited in practice to research 
settings, single dose therapy or for use with hospitalised patients.324,346 While direct 
measures provide the most accurate assessment of medication adherence, the methods 
may be considered invasive, expensive, labour intensive and not applicable for all 
medication or practice settings.324,346,377  
 
Biochemical and clinical indicators (HbA1c, LDL-C, blood pressure) have been used as 
surrogate markers for adherence but because of possible confounding influences such 
as the patient’s health status, the appropriateness of prescribed medication, sub-optimal 
dosing, and possible adverse medication effects, they may be less reliable than other 
more direct measures.346,348 
 
Indirect methods of measuring adherence have greater practical utility than the direct 
methods and, despite shortcomings, are the most often reported methods in the 
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literature.366 These methods include the process measures of tablet or pill count, patient 
interviews, pharmacy claims data, prescription refill data, patient self-report, provider 
report (including therapeutic response assessment) and micro-processor enabled 
medication event monitoring system (MEMS).324,366,376,377,379 MEMS may have little 
practical application in practice as the technology remains relatively expensive. Tablet or 
pill counts as well as any surreptitious assessment of adherence raises ethical questions 
as such measures involve invasion of patient privacy and, where applied, should require 
patient consent.377 
 
Pharmacy prescription refill data has been used in studies as an adherence measure 
and is generally well accepted.330,376,380  Patient self-report is a convenient and easily 
applied adherence measure, but has been associated with the overestimation of 
adherence.346,376,377,381,382 Patient self-report has been found to correlate with MEMS as a 
general measure of non-adherence i.e. less than perfect adherence.383  Patient interview, 
conducted with open-ended questioning and reflective listening in a non-threatening and 
non-judgemental manner, is an applicable method of assessing adherence,377,381 and 
when combined with patient self-report and pharmacy prescription refill data, may offer 
the best opportunity of measuring patient adherence to medication therapy in practice 
settings.346,376 Adherence to self-management recommendations including diet, exercise 
and blood glucose monitoring have been measured by means of validated instruments 
developed in collaboration with patients and providers.384-386   
 
The lack of standardisation of key aspects of adherence to medication and self-
management recommendations continues to confound the measurement process. 
Furthermore, none of the direct or indirect methods of measuring adherence have been 
able to demonstrate unequivocally that any health-promoting behaviour is being adhered 
to, or that medication has actually been used by the patient. Consequently the search 
continues for the ‘holy grail’ to measure patient adherence to therapy.346,348 
 
4.5.4.5 Improving adherence in diabetes 
 
The literature relating to adherence in diabetes is fairly modest, and has been largely 
informed by related studies in other chronic diseases, especially hypertension and 
cardiovascular disease.350 Interventions to improve adherence traditionally focused on 
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didactic diabetes education and emphasised patient knowledge. More recently 
behavioural and psychosocial interventions in the realm of diabetes self-management 
have been applied and investigated.1,357,387 The benefits of self-management adherence 
in diabetes include improvements in patient comprehension, self-care behaviour, the 
alleviation of symptoms and ultimately in glycaemic control and reduction of the risk of 
diabetes-related complications.1,347,388,389 
 
Lifestyle interventions in DM2, particularly those related to behaviour changes in diet, 
exercise and pharmacotherapy, are associated with improved glycaemic control and 
health outcomes,1,4 although patients often have difficulty sustaining these behaviours.351 
Individualized or tailored and multimodal diabetes self-management education 
programmes appear to best serve the patient’s desired outcomes.36,350,390-392 
 
A number of diabetes-related interventions have been investigated including prescription 
refill reminders, verifying patient recall, understanding treatment regimens, clarification 
and reinforcement of the benefits of treatment, setting diabetes-related goals, 
simplification of regimens, unit-dose packing,  regular self-monitoring of blood glucose, 
electronic monitoring, telephonic and email follow-up, mobile phone short message 
services, lifestyle coaching, home visits, psychosocial interventions such as improved 
problem solving skills, emotional support (including family/friends, referral for 
psychological counselling, and the use of generic medicines to ease financial 
burdens).38,347,350,363,393-396 However, the adherence literature reveals inconsistent 
findings, and even when effects are reported these are often small and short-lived, being 
associated with the length of time the intervention is applied.350,395 The heterogeneity of 
studies, including the key aspect of measuring adherence, render assessment and 
comparison of interventions problematic.1,330 Glasgow et al326 noted the methodological 
shortcomings of some studies relating to adherence in diabetes, including matters 
relating to conceptualization when adherence is viewed as a “…single unitary construct” 
rather than as a complex collection of multifaceted behaviours. These authors, in concert 
with others such as Anderson et al,273 furthermore question the appropriateness of the 
concept of adherence, given the nature of diabetes and the primacy of self-management 
in providing comprehensive diabetes care. 
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Many of the interventions designed to improve adherence are interdependent, e.g. 
patient education and counselling are likely to be more effective if a member of the 
family or significant other is supportive of the intervention.397  Similarly, self-management 
in chronic disease is more likely to occur if patients understand the implications of self-
care and are motivated.370  Importantly, adherence is not constant and varies from time 
to time as the interacting processes involved vary in response to any of a range of 
influencing factors.349  
 
4.5.5 Assessment of beliefs, behaviours and knowledge for DM2 self-management  
 
The behavioural, psychological and social status of diabetics can impact considerably on 
their ability to self-manage their disease.143,319,397 The diabetes care encounter between 
patient and healthcare provider creates opportunities for the provider to appropriately 
assess or screen patients for aspects of their psychosocial status and health-related 
behaviours 122,275,357, and pharmacists are well positioned to measure certain key 
psychosocial variables using validated scales.355,399-401 There is a  comprehensive array 
of screening tools available that may be used in behavioural and psychosocial screening 
in primary healthcare settings. 
 
Behavioural and psychosocial screening in DM2 includes, but is not limited to, the 
patient issues of health beliefs, attitudes about the disease, expectations relating to 
diabetes care provided by healthcare professionals, satisfaction with care, planning 
diabetes care, self-management practices and behaviours, including adherence, 
knowledge and understanding of key aspects of the condition, empowerment, self-
efficacy, coping skills, problem solving, social support and depression.4,122,221,357,402 
 
The 5 A’s Behavioural Change Model275 (Section 4.3.3) includes a provision for the 
periodic assessment of patient health-related beliefs, behaviours and knowledge, which 
allows for informed discussion about clinical status and most challenging barriers to self-
management (identified by patient and directed by provider), including readiness, 
importance and confidence.  Surveys allow for personalized assessment and feedback 
on aspects of and factors affecting self-management such as patient medication-related 
beliefs, satisfaction with care, empowerment, adherence, disease-related knowledge, 
and the monitoring of risk indicators.  
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4.5.5.1 Assessment of health-related beliefs  
 
Adherence to prescribed pharmacotherapy is strongly influenced by the patient’s 
perception of the necessity of taking medicines versus any concern the patient may have 
about possible adverse effects associated with using the medication.272,321,384 
Researchers have used a variety of instruments to measure patient medication-related 
beliefs, with the most popular in recent times appearing to be the Beliefs about 
Medicines Questionnaire (BMQ), which consists of two parts.384 The first section 
considers patient beliefs in terms of the key adherence-related domains of necessity and 
concerns about the medication prescribed for the patient. The second part of the 
questionnaire refers to patient perceptions in general about the harm that medicines may 
cause and the possible overuse of medicines by medical practitioners.384 The BMQ may 
identify aspects of the patient’s medication belief construct requiring clarification or 
remedial intervention.174,340 
 
Patient satisfaction, together with understanding aspects of the disease and recall ability 
plays a pivotal role in the adherence dynamic.403 Patient satisfaction correlates positively 
with therapeutic persistence and adherence and to intermediate health outcomes in 
chronic disease management.9,359,404,405  It is also a measure of healthcare provider 
competency.405 Various scales have been developed to measure patient satisfaction 
including the Patient Satisfaction Scale, which has three subscales: technical, 
information and patient support,406 and the 17-item Satisfaction with Information about 
Medicines Scale, which is designed to assess the extent to which patients feel satisfied 
with the level of information they receive when medication is prescribed.407 Patient 
satisfaction, in terms of specific medication experiences (e.g. perceived effectiveness, 
adverse effects, convenience), has been investigated by the Treatment Satisfaction 
Questionnaire for Medication.408 
 
A study that investigated the provision of CPS in diabetes included a 12-item instrument 
that considered satisfaction in terms of the quality of  information provided, the perceived 
competence of the pharmacist and an overall rating of care.409 The Diabetes satisfaction 
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Scale is a three part sub-scale of the Diabetes History scale designed by the Michigan 
Diabetes Research and Training Center (MDRTC).410 The first section relates to 
satisfaction with the current level of diabetes care being received; the second section 
identifies the patient’s main provider of diabetes care, and the third section considers 
satisfaction during the previous 12 months with the information transfer process (from 
provider to patient) and the patient’s opinion about the degree of collaboration between 
the providers.  
 
Diabetes self-efficacy is positively associated with health outcomes.398  Self-efficacy may 
be fostered by patients focusing on their success in problematic areas of diabetes self-
management. Identifying and re-enforcing self-management successes may set in 
motion additional positive behavioural changes leading to further self-management 
success.357,411  Instruments used to measure patient self-efficacy in diabetes include the 
Confidence in Diabetes Self-care Scale, a 20-item self-report of the patient’s perceived 
ability to perform diabetes self-management tasks,412  and the Diabetes Empowerment 
Scale-Short Form (DES-SF) was developed by the MDRTC from a comprehensive 37-
item questionnaire designed to assess patient diabetes-related psychosocial self-
efficacy.413 The latter instrument examines patient self-efficacy in eight domains which 
include recognising the need for change, developing a diabetes care plan, identifying 
and overcoming barriers, being solution focused, positively developing coping skills, 
identifying and requesting support, becoming self-motivated and making appropriate 
self-management decisions.413 
 
4.5.5.2 Assessment of health-related behaviours 
 
The significant behavioural and lifestyle changes demanded of diabetes patients places 
the patient and the patient’s social support structure (relatives or friends) at the centre of 
the collaborative treatment continuum.174,414,415 As self-management adherence is 
strongly associated with diabetes-related attitude,416 an improved understanding of this 
behaviour may assist in the design and implementation of diabetes self-management 
plans.416,417 Tools that have been used to assess diabetes self management include the 
Summary of Diabetes Self-Care Activities self-report which, because of the 
multidimensional nature of diabetes self-management, assesses each component 
separately rather than by combining scores across components.418 Other self-report 
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scales such as the Diabetes Regimen Adherence Questionnaire have, however, 
combined scores in different areas in order to produce a total adherence score.418  The 
Self-management Adherence Scale, a 4 part sub-scale of the Attitudes Towards 
Diabetes Scale, is a section of the MDRTC’s Diabetes Care Profile.385  Patients are 
requested to self-report adherence in four  areas of diabetes self-management: 
glycaemic control, body mass, other self-care activities i.e. diet, exercise and medicine 
use, and emotions or feelings i.e. fear, worry or anger.  
 
The value of patient self-reported adherence is well documented, despite being 
associated with an overestimation of adherence.1,286,376,419,420  The literature concerning 
medication adherence is voluminous,38,330,344,353 and a number of instruments have been 
developed to assess this important variable. Among the instruments that appear to be 
more commonly used are the Morisky Medication Adherence Scale consisting of four 
items, each requiring either a yes or no answer,421 and the Medication Adherence Report 
Scale (MARS).422  The latter instrument is a 5-item scale used to examine self-reported 
medication use in five medicine adherence domains: forgetfulness, dose alteration, 
discontinuing therapy, intermittent use of medication and dosage reduction.   
 
Depression, with an estimated prevalence of 15%–20%, is a relatively common co-
morbidity in diabetes compared with prevalence in the general population of between 2% 
and 9%.423 This condition results in increased patient self-report of diabetes symptoms, 
poorer physical functioning and a decrease in adherence to pharmacotherapy and to the 
lifestyle imperatives of diet, exercise and other self-management behaviours.423-425  A 
number of self-report instruments have been used to screen for depression including the 
Centers for Epidemiologic Studies-Depression (CES-D) Scale,425 the Beck Depression 
Inventory,426 and the Zung Self-Rating Depression Scale.427 The Major Depression 
Inventory (MDI) is a diagnostic and rating scale for depression developed by the 
Psychiatric Research Unit of the WHO’s Collaborating Center for Mental Health.428 The 
MDI has proved reliable in indicating depression symptomatology and is a useful 
screening tool for onward referral for patients requiring further investigation.428,429 As a 
depression rating scale, the MDI consists of 10 items with total scores ranging from 0 to 
50. Mild depression is said to be associated with a total score of 20 to 24, moderate 
depression with a score of 25 to 29 and major depression with a score >30.  
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4.5.5.3 Assessment of diabetes-related knowledge 
 
Improved patient understanding of diabetes can lead to improved glycaemic control and 
can impact positively on other intermediate health outcomes.398,430 The Mutual 
Understanding Scale includes the investigation of patient understanding of aspects of 
the consultation process (e.g. self-management education).431  The capacity of patients 
to understand and use health information in order to make informed and appropriate 
health-related decisions has been investigated using newly developed scales for 
measuring health literacy in terms of the functional, communicative and critical  aspects 
of diabetes self-care.432  
 
Glycaemic control is associated with diabetes knowledge across different age groups 
and levels of literacy.182,433,434  Instruments used to assess patient knowledge of diabetes 
include the Diabetes Knowledge Scales,435 the Spoken Knowledge in Low Literacy in 
Diabetes Scale,433  and the Brief Diabetes Knowledge Test,436 which was designed by 
the MDRTC as a 23-item diabetes knowledge questionnaire. The first part of the MDRTC 
instrument consists of a 14-item general diabetes knowledge test which includes four 
questions about diet, six that are glycaemia related and four relating to knowledge about 
aspects of the more common complications of diabetes. The second part is a 9-item 
insulin-specific test.436 
 
The Understanding Self-management Practices Scale, a 10-item sub-scale of the 
Diabetes Care Profile, is derived from the MDRTC’s Understanding Management 
Practice.385 Patients are asked if they had received diabetes education, and if so then to 
rate their understanding of the following cardinal aspects of diabetes self-management: 
diet and glycaemic control, management of body mass, physical exercise, medication 
use, adherence to pharmacotherapy, foot care, diabetes-related complications, eye care, 
SMBG, and alcohol consumption.  
 
The IDF guideline recommends that patients using insulin structure SMBG in line with 
their insulin therapy.4 For those patients using oral agents only, the IDF is less 
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prescriptive about SMBG but recommends that it should be ongoing and used to assess 
glycaemic control, especially for potential hypoglycaemia, in instances where 
modification to lifestyle and medication therapy occur, and in times of concurrent illness.4 
The ADA suggest SMBG of three or more times daily for patients on multiple injections 
of insulin.  
 
 Scales that have been used to measure aspects of SMBG include a Visual Analogue 
Scale which was used to measure SMBG frequency in intensive insulin therapy in 
children and adolescents.437 A large Italian study of patients with DM2 investigated 
SMBG frequency by means of a questionnaire that included a six-point scale and a 
further question in another section of the questionnaire about the number of times 
SMBG had been performed in the past 14 days. The answers to the two questions were 
found to correlate strongly, thus confirming the reliability of data collected in this 
manner.438 The Blood Sugar Adherence Monitoring Questionnaire, which is informed by 
the MDRTC Diabetes Care Profile,385 asks patients if they self-monitor blood glucose 
levels and, if so, how often (days per week and times per day), and if they keep a record 
of their readings.  
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CHAPTER 5  
RANDOMISED CONTROLLED TRIALS AND CONCEPTUAL FRAMEWORK 
 
5.1 Introduction 
 
A critical element of the research process relates to selecting an appropriate design for 
the study. A number of different study designs have been used to evaluate the services 
provided by pharmacists including randomised controlled trials (RCTs), quasi-
experimental designs, pre-post studies, cohort studies and descriptive studies.439  
 
Quasi-experimental designs, although weaker than RCTs, are used when randomisation 
is problematic. Non-random allocation is effected by a process of ‘matching’ in order to 
maximise group equivalence. Examples of the use of this design in pharmacy practice 
research include the Asheville Project, a well documented study of the long-term clinical 
and economic outcomes of a community pharmacy diabetes care program,19 which also 
assessed the factors affecting participation in and the benefits of a pharmaceutical care 
programme designed for patients with chronic conditions.440 
 
Pre-post or before-and-after designs rely on the comparison of baseline and post-
intervention data. While this design has been successfully used in a number of 
pharmacy studies,183,441 the lack of a control group may confound the results and thus be 
a limiting factor.442 
 
Cohort studies follow patients longitudinally. A number of important diabetes-related 
studies have employed this design, including the UKPDS.85  Other examples include a 
year-long observational study where pharmacists working in three university-based 
primary care clinics provided diabetes education and management services to a cohort 
of 191 patients with diabetes,443 and a study of a community pharmacy-based  smoking 
cessation programme.444 A problem with this design, in the absence of a control group, 
is that it may not be possible to attribute an outcome to a particular antecedent 
intervention rather than to other variables.445 
 - 72 - 
 
Descriptive studies are often used in pharmacy practice research and most studies that 
investigate patient counselling by pharmacists are descriptive.445-447 The survey of 
patient opinions about pharmacists discussed in Chapter 6 is a descriptive study.   
 
5.2 Randomised controlled trials 
 
A randomised controlled trial (RCT) has been defined as “a trial in which subjects are 
randomly assigned to one of two groups: one (the experimental group) receiving the intervention 
that is being tested, and the other (the comparison group or control) receiving an alternative 
(conventional) treatment.” 
448 The results of a RCT, which are derived from the comparative 
analysis of the two groups, are used to assess the effectiveness of the intervention.  
 
 The RCT is considered to be a ‘gold standard’, i.e. “provide the best evidence on the 
efficacy of health care interventions.
35  A well designed healthcare-related RCT has the 
following features:448 
 It should have a sufficient number of participants to allow for a high probability of 
detecting differences between treatments, should such differences exist.  
 The participant sample should be apposite to the hypotheses being tested in 
order to ensure generalisability of the findings. 
 Randomisation to control and intervention groups should be concealed in order to 
prevent selection bias. 
 The researcher and participants should be blinded to group allocation so as to 
ensure that groups are treated equally in all respects save for the intervention to 
be applied. 
 The researcher should be blinded to the allocation of the intervention and 
participants analysed within the group to which they were allocated irrespective 
of whether or not they experienced the intended intervention (i.e. subject to 
intention to treat analysis). 
 Analysis should be focused on the research question that led to the trial (i.e. 
aligned with the a priori hypotheses). There should be no attempt to ‘trawl’ for 
significant differences. 
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 Given the potential for methodological flaws, it is important that every effort 
should be made to consult with an experienced researcher well versed in the 
design of RCTs early on in the process.  
Furthermore, it is suggested that the Consolidated Standards of Reporting Trials 
(CONSORT) guidelines be referred to throughout the process.35,448  
 
RCTs, despite enjoying ‘gold standard’ status, are not without problems in evaluating 
healthcare services, and for this reason their use has, on occasion, been questioned 449 
for example, where there may be contextual issues in that the research setting may not 
necessarily reflect the real-world conditions in which patients and providers interact. 
Cultural and linguistic differences between the researcher and participants are 
potentially confounding issues, with the result that the sample may not be representative 
of the population at large and the results not generalizable. Furthermore, variabilities in 
the skill and expertise of providers involved in applying the interventions may have an 
influence on study outcomes.450 Selective participation by subjects, whether this occurs 
overtly or inadvertently, may jeopardise the generalisability of the findings.449,451,452 
Willing participants may be more likely to adhere to a study protocol and thus provide a 
more complete set of data than would be the case in the wider population.451   
 
Blinding researchers and participants to allocation to either control or intervention is a 
major difficulty in RCTs, and shielding patients from the knowledge that they are 
receiving an intervention is often difficult. Patient awareness that they are participants in 
a study may give rise to the placebo effect.453 Other potential errors associated with a 
RCT include bias and chance. Selection bias, which occurs as a result of a systematic 
difference between the groups, and observer bias, which results when there are 
systematic differences between the groups in the way information is collected, are the 
main forms of bias encountered. Chance is a random error more likely to be a problem 
with small sample sizes.448 
 
The CONSORT statement was originally developed for parallel group RCTs in which the 
unit of randomisation was the individual.35 However, in some settings it is preferable to 
randomise organisationally-based units rather than individuals. These organisational 
units are referred to as ‘clusters’, and randomised trials involving these clusters are 
referred to as cluster RCTs.454  In the event that contamination of the control group is a 
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possibility (leading to biased estimates of effect size) then a cluster randomised design 
may be preferable. Cluster RCTs are more complex to design and are subject to more 
complex analysis and require larger numbers of participants in order to achieve a similar 
statistical power to that of individual RCTs.454,455    
 
A number of systematic reviews of pharmacist interventions in outpatient settings have 
included RCTs and in a number of instances there is good evidence of the value of 
interventions in both disease prevention and disease management.12,133,183,456-458  
However, reviewers often reported methodological and other limitations. Beney et al,183 
in a  Cochrane review that included RCTs, concluded that the interventions were often 
poorly defined, lacked patient outcomes data and cost-effectiveness data and had 
questionable generalisability. Roughead et al12 noted that open allocation of participants 
to the groups and assessment of outcomes by investigators who were aware of the 
allocation, were common methodological limitations. The reviewers suggested that 
studies would be improved if pharmacists were not made aware of allocation, or 
alternatively if the pharmacy was designated as the unit of allocation and if independent 
reviewers were used to monitor outcomes. 
 
Blenkinsopp et al133 and 
 Wubben et al458 noted that there were relatively few RCTs of 
interventions that were community pharmacy-based, with findings limited by design 
flaws, including high levels of selection bias. In a review of pharmacist interventions in 
diabetes management, Machado et al456 found that while a number of outcomes 
sensitive to pharmacist interventions were identified, too few studies were available for 
quantitative summary.   A common thread running through the abovementioned reviews 
was the propensity for design flaws, the low numbers of community pharmacy-based 
RCTs and the recommendation for more rigorous research.  
 
5.3 Complex interventions 
 
 The CONSORT statement was published as a guideline in an effort to improve the 
reporting of RCTs, most of which evaluated a single intervention (e.g. the effects of a 
medicine).296 However, there has been increased recognition of the need to submit non-
pharmacological interventions to rigorous review. CONSORT in its original form was 
found to be inadequate in addressing these trials as they are often complex in design.296  
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Complex interventions are defined as being comprised of “interventions that contain several 
interacting components”.
294 Examples include health promotion interventions aimed at 
individual patients or groups of individuals, strategies designed to promote the 
implementation of treatment guidelines, and those interventions aimed at effecting 
patient or healthcare provider behavioural change.295 
 
Complex interventions are, by their very nature, difficult to develop, describe, 
standardise, administer and reproduce on a consistent basis, which makes the 
evaluation of these trials difficult.295,296 Further confounding influences which add to the 
complexity include contextual issues (i.e. local conditions), variations in provider 
expertise, available resources and time to devote to administering a trial, all of which 
may impact on the treatment effect of a given intervention.296 
 
The United Kingdom Medical Research Council (UKMRC), in recognising the complexity 
of many interventions aimed at improving healthcare, published a revised guideline for 
the development and evaluation of RCTs for complex interventions entitled “Developing 
and evaluating complex interventions: new guidance”.
294
 Developing, piloting, evaluating, 
reporting and implementing complex interventions involves a number of stages and is 
likely to be time-consuming because of the non-linear nature of the process. Each stage 
is important and undue neglect of any stage may lead to trials of poor quality i.e. weak 
interventions that are difficult to evaluate and are less likely to be considered for 
implementation or implemented in practice.    
 
The overall process of developing and evaluating a complex intervention has been 
summarised by the UKMRC as discussed below294 
 
5.3.1 Developing an intervention 
 
The development stage includes reviewing current evidence (preferably from systematic 
reviews), identifying or developing underpinning theory and modelling. Identifying or 
developing a theoretical understanding of the process of change is likely to require the 
collaboration of experts. Modelling a complex intervention, for example by conducting a 
pre-trial economic evaluation prior to undertaking a full-scale evaluation, is likely to 
benefit both the design and evaluation of the intervention as problems may be identified 
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in the early stages and remedied. It may even become apparent that the anticipated full-
scale evaluation is unwarranted.   
 
In developing a complex intervention, consideration should be given to:  
 the relationship between what needs to be done, what outcome is expected and 
how such an outcome is likely to lead to change  
 ensuring that sound theory and existing evidence underpins the proposed 
intervention, and that the intervention is likely to be cost-effective and both 
implementable and replicable.  
 
Lack of effect may be due to implementation problems rather than to the apparent 
ineffectiveness of an intervention, and a comprehensive appraisal of the implementation 
process is required to pre-empt problems at this stage. Increased variability may 
necessitate larger sample sizes and, in some circumstances, it may be advisable to 
consider the use of cluster RCTs rather than RCTs randomised at the level of the 
individual. The study protocol may need to accommodate local conditions and be 
adapted accordingly. The key questions relating to complex interventions include 
consideration of (i) how the intervention works i.e. the key success factors and the 
mechanism of exerting effect, and (ii) the likelihood of the intervention working in every-
day practice. 
 
5.3.2 Piloting and feasibility 
 
Key aspects of this stage include testing procedures, estimating the ability to recruit and 
retain participants and determining sample size. It is suggested that a pilot study (or a 
series of studies in order to progressively refine the process) be undertaken in order to 
ensure the overall feasibility of the study given the assumptions made with regard to 
effect sizes, recruitment, retention and other key variables are likely to impact on the 
main study.  
 
5.3.3 Evaluating the intervention 
 
Randomisation should wherever possible be considered in experimental designs as it is 
the most robust method of preventing selection bias. Should an individually randomised 
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parallel group design not be feasible, then consideration may be given to using either a 
randomised cluster trial (population level intervention), a stepped wedge design (the 
whole population receives the intervention but with randomisation occurring during 
phased implementation of the intervention), preference trials (treatment allocation based 
on patient preference), randomised consent trials (randomisation of subjects prior to 
obtaining consent) or N-of-1 trials (randomised trial in single or individual subjects).  
 
 An essential aspect of the evaluation process relates to the choice of outcomes, which 
should be based on a sound understanding of the theoretical underpinning of the 
intervention. A single primary outcome together with a small number of secondary 
outcomes may be the most uncomplicated manner in which to statistically view the data. 
However, this may not allow for the most effective assessment of an intervention, 
especially where the effects of the intervention may be observed in a number of areas. 
Measures adopted (e.g. self-report, biochemical, provider-report, etc.) should be 
appropriate for the design of the evaluation.  
 
 An overall assessment of the effectiveness of the intervention and developing an 
understanding of the process of behavioural change forms the basis of the evaluation 
stage. In pursuance of the Economic Clinical Humanistic Outcomes approach to 
interventions,19 it is suggested that an economic evaluation of the intervention be 
included as a cost-benefit analysis is likely to be a major factor in deciding on the 
possible widespread implementation of an intervention. Where possible, process 
evaluation should be included as this allows for the monitoring of the delivery of the 
intervention as well as the overall conduct of the evaluation. Process evaluation also 
may offer some explanation with regard to any discrepancies that may arise between the 
anticipated and observed outcomes, as well as provide some understanding relating to 
the local context and insight into the overall implementation process.   
 
5.3.4 Reporting of the study 
 
The report should be presented in an accepted format (e.g. for a RCT, as set out in the 
CONSORT statement296) and with as much detail to allow for careful evaluation and 
possible replication studies or broad-based implementation. Wherever possible, the 
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results should be discussed in the context of existing research, preferably systematic 
reviews. 
 
5.3.5 Implementation 
 
Despite the allocation of substantial resources to interventions designed to advance the 
cause of healthcare, translating research into practice remains a challenge as is 
demonstrated by the numerous examples of evidence-based research that are only 
partially adopted in practice, if at all.459 The key issues for the implementation stage 
include ensuring that the results are made available in a readily accessible format and 
that they are explicit and detailed enough to be able to present persuasive argument to 
policy and decision-makers. Post-implementation surveillance should include ongoing 
(long-term) practice-based process evaluation and the continued monitoring of 
outcomes. The UKMRC note that “while some aspects of good practice are clear, methods for 
developing, evaluating and implementing complex interventions are still being developed, and on 
many important issues there is no consensus yet on what is best practice.”
294  
 
As previously mentioned, the CONSORT group recognised the inadequacy of the 
original statement to fully address complex interventions such as non-pharmacological 
interventions involving behavioural change. This limitation was subsequently addressed 
in an extended version of the CONSORT statement, which now includes a 
comprehensive checklist for reporting non- pharmacological RCTs.296 This checklist is a 
useful tool in the hands of a researcher contemplating a RCT of a complex intervention, 
especially when read in conjunction with the abovementioned UKMRC guideline on 
complex interventions.294   
 
5.4 Conceptual framework: a diabetes care plan 
 
In developing a disease management taxonomy, Krumholz et al337 noted that 
pharmacists are well positioned to deliver disease management interventions. 
Therapeutic guidelines and treatment protocols for most chronic diseases include long-
term pharmacotherapy. The almost universal use of medication as an important tool in 
the management of chronic diseases facilitates relatively frequent encounters and 
interaction between patients and pharmacists.1,11 It is the potential for providing care 
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inherent in these encounters, especially in supporting patient self-management 
initiatives, together with the pharmacist’s expertise as a medication specialist, that lends 
substance to the claim that pharmacists are well positioned to contribute to disease risk 
reduction and consequently positively influence patient outcomes in DM2.1,9,36,175,460,461  
 
The hypothesis and the conceptual framework of the intervention for this study has 
largely been underpinned by the practice of pharmaceutical care, and the demonstrated 
value of those CPS that are patient orientated.9,19,33,147,175,462 The process of providing 
care to individuals with DM2 is complex and long-term, requiring the collaboration of 
multidisciplinary healthcare providers in support of patient self-management.4,346,415,419,432 
Given the primacy of self-management in diabetes care,314,389 it follows that CPS should 
be designed to support patients in their self-management endeavours. Furthermore, 
given the professional role of the pharmacist, it is reasonable that matters relating to the 
use of medication by patients should be the focus of such services. 
 
The CPS that informed the conceptual framework in this study were collated into a 
diabetes-related pharmaceutical care plan,5 referred to as a diabetes care plan (DCP) in 
this manuscript. The DCP, which is comprehensively described in Chapter 7, provides 
the intervention framework for the study. The plan was developed and informed by the 
practice of pharmaceutical care, diabetes-related CPS identified from the literature and 
by my own experience as a community pharmacist, and was refined after consultations 
with a number of health professionals from diverse disciplines. The DCP served to 
bridge the divide between theoretical evidence from literature and the CPS provided 
during the intervention phase of the study in an attempt to translate various aspects of 
research into practice.306 
 
The development and evaluation of the DCP is schematically represented in Figure 5.1. 
The core elements of the DCP framework include (i) the existing evidence regarding 
pharmacist-directed diabetes care interventions (Section 3.3.1), (ii) the theories and 
models underpinning changes in patterns of practice by pharmacists (Section 4.3), (iii) 
the training and education of pharmacists to enable them to effectively develop and 
evaluate interventions (Section 4.2), and (iv) the development of appropriate clinical and 
patient education and counselling interventions, which are discussed below in Section 
5.4.1 and Section 5.4.2. The aim of the DCP is to facilitate improved patient health 
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outcomes by supporting patient self-management both in terms of optimising adherence 
to prescribed pharmacotherapy and agreed non-pharmacologic self-care 
recommendations (Section 2.6 and Section 4.5 ).  
 
 
 
 
 
 
 
                              
 
 
                                          
                                  
 
                                      
 
 
 
                             
                                                              
 
 
 
 
 
 
 
 
Figure 5.1 The conceptual framework of a diabetes care plan intervention 
 
 
No single model appears to exist that fits the DCP, and therefore a framework was 
developed by integrating the following guidelines, models and methods:  
 “Good Pharmacy Practice Standards” from the South African Pharmacy Council.6 
These standards or rules define good pharmacy practice in South Africa.  
  “Revised guidelines for the diagnosis and management of type 2 diabetes 
mellitus for primary healthcare in 2002”, from the Society for Endocrinology 
Metabolism and Diabetes of South Africa(SEMDSA).105 This guideline informed 
aspects of the clinical intervention.  
 “Global Guidelines for Type 2 Diabetes 2005”, from the International Diabetes 
Federation (IDF).4  
  “ASHP Guidelines on Pharmacist-conducted Patient Education and Counseling”, 
from the American Society of Health-System Pharmacists. These guidelines offer 
a practical approach to the  medication review process.172  
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 The “Chronic Care Model”, which conceptualises and positions collaborative 
patient-centred care and empowered patient self-management ( Figure 3.2).155 
 The “5 A’s Behavioural Change Model”, which has been adapted for self-
management support in chronic disease.275 
 The method of “Motivational Interviewing”, an evidence-based brief counselling 
method appropriate for the healthcare setting of community pharmacy.171,264 
 
The DCP, which links the key clinical and psychosocial aspects of disease risk reduction 
in DM2 with the practice of pharmaceutical care provided by community pharmacists, 
was comprised of two interdependent elements, a clinical intervention and a patient 
education and counselling intervention. While they are described as separate elements 
for the purposes of this study, in practice the boundaries between the two are blurred 
with each mutually influencing the other.  
 
5.4.1 Clinical intervention 
 
Pharmacists have demonstrated their ability to monitor clinical indicators and other 
variables such as adherence to pharmacotherapy, body mass index and satisfaction with 
pharmacy services, and to use the ensuing data to influence patient adherence to 
therapies and to effect improvements in health outcomes.9,38,173 The key elements of the 
clinical intervention included medication review,158,172 diabetes-related needs and goals 
analysis,4  and monitoring, evaluation and review of clinical and other variables.126  
 
The ASHP guidelines on pharmacist-conducted patient education and counseling 
informed the medication review process.172 Medication review is a fundamental element 
of the practice of pharmaceutical care. 158,172,463,464  The objective of this key aspect of the 
clinical intervention was to identify and address any existing or potential medication 
problems.6,17,462 
 
The SEMDSA and IDF DM2 guidelines served to inform and benchmark patient 
diabetes-related goals.4,105 Many other organizations provide excellent patient resources 
and materials,465 and pharmacists are able to support self-management by facilitating 
access to these materials and resources, as well as by appropriately referring patients to 
other healthcare providers.36,158,466,467 
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The monitoring intervention, which involves the collection, interpretation and discussion 
of the data, need not be time consuming.92,173,355 The prescription refill encounter 
presents the pharmacist with an ideal opportunity to monitor key clinical indicators and to 
optimise therapy and self-management regimens,10,468 Telephonic follow-up of patients 
between pharmacy visits has been shown to be a cost-effective monitoring and 
adherence- promoting intervention.358,469 Further remedial action may include patient 
referral.36,178,470 
 
5.4.2 Patient education and counselling intervention 
 
The theoretical framework on which the principal aspects of the patient education and 
counselling intervention is based is informed by the Motivational Interviewing method264 
(Section 4.3.2) which has been adapted for use in community pharmacy.171,269,270 Patient 
education and patient counselling are terms that have been used interchangeably to 
define a category of pharmacist activity and collectively they are the CPS most often 
described in the pharmacy literature.471 For the purposes of this study these are 
discussed as two separate but interdependent activities. 
  
Patient education is viewed primarily as a collaborative interaction between pharmacist 
and patient in order to address deficiencies in diabetes-related knowledge, rather than a 
one-way didactic intervention.182,472 Enhanced patient knowledge of DM2 and an 
understanding of the significance of clinical indicators may contribute to improved 
diabetes self-management.32,36,466  
 
Patient counselling is intended to encourage and facilitate the empowerment of patients 
to make informed decisions about medication use and other self-management 
behaviours.225,357,466 It is associated with fostering good relationships between patients 
and pharmacists,32  with informing the process of eliciting patient needs and 
goals,20,473,474 and with facilitating the identification of barriers to diabetes self-
management.338,347,461 In counselling patients, pharmacists should be culturally sensitive, 
take cognisance of patient health beliefs,272,341,473  and encourage family support.397,475   
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5.4.3 Research question, hypotheses, aims and objectives 
 
This study is important given that community pharmacists are a key resource in the 
South African healthcare continuum, and given that South African pharmacists have 
begun to extend their healthcare reach and provide pharmaceutical care to the 
chronically ill.137,4476  
 
The rationale for the study and the development of the research problem and main 
hypothesis are discussed in Section 1.1 and Section 1.2 respectively. In formulating the 
research question, “Are South African community pharmacists able to positively 
influence patient adherence and surrogate health outcomes in DM2?”, the following 
three related hypotheses were considered: 
 The relationship between the patient and pharmacist is such that pharmacists 
who have received appropriate diabetes-related continuing education are well 
positioned to provide diabetes-related CPS.  
 Patients with DM2 who have been exposed to pharmacist-delivered 
individualised diabetes-related interventions are more likely to adhere to their 
therapies and self-management recommendations than patients who only 
experience usual or standard care. 
 Improved patient health outcomes in DM2 may be reflected as improvements to 
the surrogate health outcomes such as glycated haemoglobin (primary 
endpoint) and other clinical indicators (secondary endpoints). 
 
The abovementioned hypotheses are examined by means of a consumer survey 
described in Chapter 6, and a randomised controlled trial of a diabetes care intervention 
described in Chapter 7 and discussed in Chapter 9.   
 
The aims and objectives of the consumer survey and the diabetes care study are as 
follows: 
 
Aim of the consumer survey 
To establish if foundational support exists within the insured patient – community 
pharmacist dyad for the provision of CPS. 
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Objectives of the consumer survey 
These are described in more detail in Section 6.2. The objectives are concerned with key 
aspects of the professional relationship existing between the patient and the pharmacist, 
i.e.  the provision of medication counselling and disease-related information and other 
CPS (i.e. monitoring of disease indicators), patient satisfaction with pharmacist advice, 
pharmacist reimbursement for CPS and the relative accessibility of pharmacists. 
 
Aim of the diabetes care study 
To conduct an empirical evaluation of pharmacist influence on surrogate health 
outcomes in DM2, as well as patient adherence to therapy and other self-management 
recommendations, by means of a randomised controlled trial.  
 
Objectives of the diabetes care study  
 To train pharmacists, using a distance education module, to deliver advanced 
diabetes care services. 
 To assess the influence of community pharmacists on surrogate health 
outcomes including glycated haemoglobin, blood lipids, serum creatinine, 
blood pressure and body mass index. 
 To assess the influence of community pharmacists on diabetes self-
management including adherence to pharmacotherapy and self-care 
recommendations and monitoring practices. 
 To assess the influence of community pharmacists on patient medication-
related beliefs, diabetes-related knowledge, patient empowerment and 
satisfaction with diabetes care.  
 To compare baseline versus post-baseline data of patients at goal for certain 
variables in terms of the national guideline for DM2, published by the Society 
for Endocrinology, Metabolism and Diabetes of South Africa.  
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CHAPTER 6 
THE DISCOVERY HEALTH  SURVEY: PATIENT OPINIONS AND PERCEPTIONS OF 
PHARMACY 
 
6.1 Introduction        
 
Internationally, pharmacists practice pharmaceutical care and provide CPS.12,20,147,149,456 
However, a search of the literature using the terms, “pharmaceutical care OR cognitive 
pharmaceutical services AND Africa” revealed very few studies describing or 
investigating the practice of pharmaceutical care in African healthcare settings and there 
was a total  absence of any research relating to the value placed by consumers on these 
services in South African community pharmacy practice. It is obvious, therefore, that 
further research is urgently required if the profession is to assess, plan, implement and 
evaluate its pharmaceutical care offerings in an evidence-based manner. Ad-hoc 
attempts to implement pharmaceutical care without informed preparation and valid 
assessment does both the patient and the profession a disservice.  
 
Pharmacist co-ordinated interventions designed to promote patient adherence to long-
term therapies and self-care recommendations in DM2 are a function of pharmaceutical 
care.477 Inherent in the practice of pharmaceutical care are the CPS associated with the 
use of medication by patients and the provision of appropriate health-related 
empowering information and support by pharmacists.24,360,478-480 The effective provision 
of CPS is dependant on concordant and satisfying relationships existing between 
patients and empathetic pharmacists.9,365,481,482 
 
There are a number of factors influencing the patient-pharmacist relationship which, in 
turn, impact on the pharmacist’s ability to influence therapeutic adherence.  Importantly, 
these include easy access to competent and trusted pharmacists.133,137,164 Pharmacists, 
on the other hand, while recognising the need for and value of pharmaceutical care, are 
faced with a number of barriers that prevent the widespread implementation of the 
practice at community pharmacy level.12,133,151,476,483,484 Pharmacist reimbursement for 
CPS remains a major barrier. Perceived value and satisfaction with services on the part 
of patients are key determinants of the demand for the provision of those CPS.9,12,152,153  
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The survey was therefore designed to investigate if an evidence-based foundation 
existed within the South African community pharmacy practice dynamic to support the 
provision of cognitive pharmaceutical services, given that the profession in South Africa 
largely relies on off-shore evidence and anecdotal information with regard to key aspects 
of the practice of pharmaceutical care.17  
 
6.2 Aim and objectives 
 
The aim of the study was to determine if support for aspects of pharmaceutical care 
exists within the dynamic of South African community pharmacy practice. The objectives 
were to investigate patient opinion regarding the provision of prescription medication, the 
provision of and satisfaction with cognitive pharmaceutical services (including medication 
counselling, disease-related information and clinical services such as the monitoring of 
health-related variables), patient willingness to pay for the provision of such services, 
and pharmacist accessibility. 
 
6.3 Methodology 
 
6.3.1 Study setting 
 
Discovery Health (Discovery) is one of South Africa’s largest health insurers, currently 
providing healthcare benefits (‘medical aid’) to a membership base in excess of two 
million people (hereafter referred to as ‘patients’). This insurer was approached in 
preference to other South African health insurers as it has a large pool of potentially 
available patients, a good relationship exists between senior executives of the company 
and the researcher and Rhodes University, and a Discovery executive had previously 
indicated interest in the project when it was first mooted and promised assistance in 
facilitating company support.  
 
6.3.2 Survey instrument 
 
The conceptual framework underpinning the survey was developed from personal 
experience of 25 years of community pharmacy practice. This ontology was augmented 
epistemologically by the health belief model (previously discussed in Chapter 4 Section 
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4.3), the pharmaceutical care model,23 and relevant aspects of the primary provider 
theory,485 a paradigm for patient-centred satisfaction which is based on the following: 
“only patients judge quality, a network of satisfaction constructs where all measures are patient-
centered, patients have a priori hierarchy of expectations, primary providers have the greatest 
utility to patients and satisfaction is set in motion at the nexus of provider power and patient 
expectations.” 
485 In addition, a framework for understanding the utilisation of pharmacy 
services proposed by Hassell et al,486 which draws on a number of models in order to 
explain help-seeking and health services utilisation, was considered. These models, 
which include the health belief and socio-behavioural models,486 incorporate factors 
more in keeping with community orientated primary care such as patient clinical and 
socio-economic factors, perceptions of the professional role of the pharmacist, the 
efficacy of self-care, lay referral (i.e. by family or friends), the siting of pharmacies, as 
well as organisational factors (e.g. pharmacist access), financial and other resource 
factors. 
 
The draft questions, informed by both personal experience in community pharmacy 
practice and the abovementioned constructs, were developed and refined after 
consultation with colleagues in the Faculty of Pharmacy at Rhodes University. The 
design, operationalisation and management of the webform version of the instrument 
were undertaken by the Webmaster at the university.  
 
The questionnaire was tested for validity and reliability by a process that included a 
review of all questions by two experienced pharmacists, professional pharmacy 
colleagues at the university, and by piloting the questionnaire in a sample of 20 
randomly selected medically insured employees of the university.449,485 This process 
included ensuring that the questionnaire was able to collect the information required to 
meet the survey objectives, that the questions were unambiguous, easily answered and 
that they reflected the theoretical constructs underpinning the survey.   
 
The pilot study was conducted in July 2004. Twenty Rhodes University employees were 
randomly selected by name from the university’s internal telephone directory. All 
university employees listed in the directory with a surname beginning either with the 
letter A or B, and who were either members or the dependants of members of a 
registered medical aid scheme, other than any employee of the Faculty of Pharmacy, 
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were eligible to participate in the pilot. The researcher identified and telephoned 
prospective respondents by selecting every third surname. Four potential respondents 
declined to participate in the pilot. 
 
The following statement was used to introduce the researcher and explain the survey 
during the pre-test: 
“Good day. My name is Peter Hill and I am a post-grad student in the faculty of 
pharmacy. As part of my research I need survey medical aid members with regard to 
aspects of their relationship with community pharmacists. If you are a member of a 
medical aid, are you willing to give me a few minutes of your time to answer a few 
questions for a pilot survey?”  
 
Data were electronically captured using a beta version of the electronic form. The pilot 
confirmed that the survey was easily administered, that the length of the survey and 
number of questions was acceptable, and that generally the questions were 
unambiguous and easily answered. Only one question out of a total of 39 required 
changes: question 2.4.1, was amended to include a “more than once a month” option. 
There was also a technical design problem that required attention. The pilot revealed 
that once the form was uploaded to the host server by selecting the ‘submit’ button, it 
was necessary to exit and then re-enter the website before a new form appeared on the 
computer monitor. These problems were attended to by the Webmaster and the 
webform was declared ready for use in the Discovery survey. 
 
6.3.3 Study population 
 
All Discovery patients residing within the borders of South Africa were eligible to 
participate in the survey. Discovery provided the researcher with access to two trained 
call-centre operators, working in their outbound call-centre, between the hours of 08:00 
and 17:00 for 10 working days in September 2004.  
 
A data analyst at Discovery was briefed by the researcher and she was instructed to 
identify a convenience sample of patients from which a random sample would be 
identified. Discovery advised that it would not be possible to include their entire active 
claims database in effecting a sample size calculation. A pragmatic approach was 
 - 89 - 
therefore adopted and the first 3000 patients who submitted medical aid claims during a 
defined six month period in 2004 were identified.  From this sample, a total of 1000 
patients were randomly selected for interview using an online random number 
generator.459 The decision to randomly select 1000 patients was based on a pre-survey 
estimation of the maximum number of patients that two call-centre operators would be 
able to telephonically survey during the 10 working days allocated to the researcher by 
Discovery. The call-centre operators and researcher were blinded to the selection of the 
initial sample of 3000 and to the subsequent randomisation of the final sample of 1000 
patients.  
 
6.3.4 The survey  
 
The study protocol was approved by the Rhodes University Ethical Standards 
Committee prior to the commencement of the survey.  
 
The call centre operators were briefed by the researcher and provided with a written 
script to ensure a degree of uniformity in their approach to patients. The operators were 
given two days to perfect telephone etiquette and to familiarise themselves with the 
survey questions and the capturing of patient data by telephoning and surveying 
members not included in the initial sample of 3000. 
 
At the end of the two day trial period, the list of the 1000 randomly selected patients was 
equally divided between the two operators. Patients were telephoned and advised that 
the survey would take the form of a telephonic questionnaire and that the research 
would assist in informing the design and implementation of future patient-centred 
pharmacy services. Furthermore, they were advised that their participation was 
voluntary, that their personal details would not be captured and that all information 
provided would be treated as confidential. Responses were electronically recorded on 
the webform by the operators and each completed questionnaire was automatically 
saved to the university web-server. The operators experienced intermittent Internet 
connectivity problems during the 10-day survey period, with the result that a number of 
completed questionnaires were duplicated. A total of 703 responses were recorded 
during the 10 day period and of these, 75 responses were identified as duplicates and 
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deleted by the Webmaster, giving a total of 628 valid responses which were included in 
the final data set. 
 
Each operator kept a log of the number of telephone calls made each day, the number of 
positive responses, the number of patients that declined participation and a record of the  
reasons why they declined participation. A total of 59 patients (8.6%) refused to 
participate in the survey.  Insufficient time available to answer questions was the main 
reason given for non-participation. Examination of the logs revealed very little difference 
in performance between the two operators, who administered 318 and 310 
questionnaires respectively.   
 
6.3.5 Data analysis 
 
Data were analysed using Statistica software (Stasoft Inc). Pearson’s chi-squared test of 
independence was used to test for gender, age and ethnic group effects shown in Table 
6.1, for pharmacist-related categorical variables in Table 6.2 and in examining the 
association between patient demographic and pharmacist-related variables in Table 6.4. 
The level of significance in all instances was set at 5%. 
 
6.4 Results  
 
As Table 6.1 reflects, there were significantly more female (63.9%) than male (36.1%) 
patients (Chi-squared test, p<0.0001) and significantly more White patients (64.6%) than 
Black patients (22.9%), patients of Asian descent (7.3%) and Mixed-race patients (5.1%) 
(Chi-squared test, p<0.0001). There were significantly fewer patients in the age groups 
less than 30 years old (12.1%) and over 65 years old (13.7%), than for those aged 30-45 
years old (37.4%), and 46-65 years old (36.8%)( Chi-squared test, p<0.0001).  
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Approximately 80% of patients (N=507) received prescription medicines (Table 6.2), with 
a significant majority having received them from pharmacists only (60.2%). Just over a 
quarter (25.8%) received medicines from doctors only and the balance of 14.0% 
reported that they received prescription medicines from both pharmacists and doctors 
(Chi-squared test, p<0.0001). Those patients who had their medicines dispensed by 
pharmacists were significantly less likely to be counselled on the use of the medicine 
and to be provided with information on their diseases or conditions (78.5%), than were 
those patients who made use of the services of dispensing medical practitioners (98.5%) 
(Chi-squared test, p<0.0001). 
 
While less than half of the patients (46.2%) consulted pharmacists for advice on health 
related matters, there was a significant difference between those that rated the advice as 
good (87.9%) and those that considered it to be adequate (12.1%) with none rating the 
advice provided as poor (Chi-squared test, p<0.0001). 
 
Table 6.1 Patient demographics  
 
 
 
 
Variable N     (%) p value 
Chi-squared test 
 
Gender  
  Male 
  Female 
 
 
 
227 (36.1) 
401 (63.9) 
 
 
 
 
p < 0.0001 
Ethnic group   
  Asian 
  Black 
  Mixed-race 
  White 
 
 
  46 (7.3) 
144 (23.0) 
  32 (5.1) 
406 (64.6)  
 
 
 
 
 
 
 
p < 0.0001 
Age  
  <30 years old 
  30-45 years old 
  46-65 years old 
  >65 years old 
 
 
  76 (12.1) 
235 (37.4) 
231 (36.8) 
  86 (13.7) 
 
 
 
 
 
 
 
p < 0.0001 
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The term “professional services” was defined before patients were asked, “Do you think 
that pharmacists should be paid for providing professional services?” There was no 
significant difference (Chi-squared test, p=0.078) between those patients who believed 
that pharmacists should be paid (46.4%) and those who said that they should not 
(53.6%).   
 
Table 6.2  Patient-provider  variables  
 
 
 
 
Variable  “Yes”    
N     (%)         
p-value 
Chi-squared test 
Received prescription medicines (N=507) 
  from a pharmacy only 
  from a dispensing medical practitioner only 
  from both  pharmacy and dispensing medical practitioner 
 
305 (60.2) 
131 (25.8) 
  71 (14.0)  
 
 
 
 
p <0.0001 
Received counselling and information from healthcare provider 
  when medicine received from a pharmacist (N=376) 
  when medicine received from a medical practitioner (N=202) 
 
295 (78.5)  
199 (98.5) 
 
 
 
p <0.0001 
Consulted pharmacist for advice on health related matters 
(N=290) 
  rated advice as “Good” 
  rated advice as “Adequate” 
  rated advice as “Poor” 
 
 
255 (87.9) 
  35 (12.1) 
    0 (0) 
 
 
 
 
p <0.0001 
Willing to pay for cognitive services (N=625) 
 yes 
 no 
 
290 (46.4) 
335 (53.6) 
 
 
 
p = 0.078 
Rating of relationship with pharmacist (N=602) 
 good 
  adequate 
  poor / no relationship  
 
412 (68.4) 
  88 (14.6) 
102 (17.0) 
 
 
 
 
p <0.0001 
Healthcare provider access (N=627) 
  pharmacist most accessible 
  medical practitioner most accessible 
  nurse practitioner most accessible 
 
 
229 (36.5) 
389 (62.0) 
    9 (1.5) 
 
 
 
 
p <0.0001 
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In considering the quality of the relationship between the patient and the pharmacist, a 
significantly higher percentage of patients considered their relationships with their 
pharmacists to be good (68.4%), as opposed to adequate (14.6%) or poor/no 
relationship at all (16.9%) (Chi-squared test, p<0.0001). 
 
 In an attempt to standardise the definition of “healthcare provider access” used in the 
context of the survey, the operators defined accessibility as “conveniently situated, 
readily available to talk to, gives free advice or advice that you would be willing to pay 
for”. Table 6.2 shows that a significantly higher percentage of patients (62.0%) rated 
medical practitioners as being more readily accessible than pharmacists (36.5%) (Chi-
squared test, p<0.0001). 
 
Table 6.3 shows that approximately 40% of patients said that their pharmacy either had 
an in-house clinic (39.1%) and/or employed the services of a nurse (38.4%). In terms of 
accessing monitoring services, approximately 10% of patients had had their blood 
pressure (10.6%) and cholesterol (10.5%) monitored in a pharmacy. Fewer patients had 
their blood glucose (4.3%) and body mass (2.6%) measured by pharmacy staff and 5.3% 
said that they availed themselves of a pharmacy-based vaccination service. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.3 Pharmacy-provided clinical services 
Variable “Yes” 
N    (%) 
Pharmacies providing clinical services 
(N=578) 
  pharmacy has an in-house clinic  
  pharmacy employs a nurse 
 
 
226 (39.1) 
222 (38.4) 
Used monitoring and vaccination 
services 
   blood pressure (N=611) 
   cholesterol (N=610) 
   blood glucose (N=607) 
   body mass (N=605) 
   vaccination (N=606) 
 
 
   
65 (10.6) 
  64 (10.5) 
  26 (4.3) 
  16 (2.6) 
  32 (5.3) 
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Table 6.4 shows the association of demographic data with selected pharmacist-related 
variables. Significant differences are reported for gender and race for the patients who 
said that they received prescription medicines, with proportionately more females 
(83.3.%) than males (76.2%) having received prescription medicines (p=0.033), and 
more Whites (89.9%) than Asians (82.6%), people of Mixed-Race (78.1%) and Blacks 
(54.9%) (p<0.0001). 
 
 
 
There was a significant difference in prescription medicine utilisation between the oldest 
and youngest groups. Amongst the patients in the over 65 year-old group, 93.0% 
reported that they received prescription medicines, whereas only 56.6% of the under 30 
year-old group had received prescription medicines (Chi-squared test, p<0.0001).  
 
Table 6.4 Association of demographic and pharmacist-related variables 
 
Variable 
 
Received 
prescription 
medicines 
Received counselling 
and information from 
pharmacist  
Willing to pay for 
cognitive 
services 
Relationship with 
pharmacist rated 
as ‘good’ 
Provider access: 
pharmacist most 
accessible  
 
N     (%) N     (%) N      (%) N     (%) N     (%) 
Gender 
  Male 
  Female 
  p value
a 
 
173 (76.2) 
334 (83.3) 
0.033     
 
   97 (78.2) 
198 (78.6) 
 0.568 
 
110 (48.7) 
180 (45.1) 
 0.391 
 
148 (69.8) 
264 (67.7) 
 0.692 
 
   69 (30.4) 
160 (39.9) 
 0.054 
Ethnicity  
  Asian 
  Black 
Mixed-race 
  White  
p value
a 
 
  38 (82.6) 
  79 (54.9) 
  25 (78.1) 
365 (89.9) 
 < 0.0001 
 
  24 (82.8) 
  42 (76.4) 
  10 (55.6) 
219 (80.0) 
 0.084 
 
   26 (56.5) 
   56 (39.2) 
   13 (40.6) 
195 (48.3) 
 0.116 
 
  36 (81.8) 
  54 (42.5) 
  16 (53.3) 
306 (76.3) 
< 0.0001 
 
   22 (47.8) 
   46 (31.9) 
     8 (25.0) 
153 (37.7) 
  0.002 
Age  
  <30 
  30-45 
  46-65 
  >65 
  p value
a 
 
  43 (56.6) 
173 (73.6) 
211 (91.3) 
   80 (93.0) 
< 0.0001 
 
   25 (75.8) 
102 (72.9) 
126 (83.4) 
   42 (80.8) 
  0.125 
 
   30 (39.5) 
102 (44.0) 
118 (51.1) 
   40 (46.5) 
  0.256 
 
   31 (41.9) 
131 (60.1) 
181 (80.1) 
   69 (82.1) 
< 0.0001 
 
   35 (46.1) 
105 (44.7) 
  76 (32.9) 
  13 (15.1) 
< 0.0001 
a
Chi-squared test 
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Males (78.2%) and females (78.6%) were equally likely to receive counselling and 
information from pharmacists (Chi-squared test, p=0.568). There was no significant 
difference (p=0.084) in the provision of counselling and information to the different ethnic 
groups with approximately 80% of patients reporting that they received these services. 
Those most likely to receive counselling and information were in the age groups 46-65 
years (83.4%) and over 65 years of age (80.8%)( Chi-squared test, p=0.125). 
 
There was no significant difference between male and female responses in supporting 
pharmacist compensation (48.7% and 45.1%, respectively) (Chi-squared test, p=0.391). 
Although patients of Asian descent (56.5%) were more likely to support pharmacist 
reimbursement and Blacks least likely, (39.2%) the difference between ethnic groups 
was not found to be significant (Chi-squared test, p=0.116). Similarly, there was no 
significant difference between the age groups for this variable (Chi-squared test, 
p=0.256). 
 
In investigating the association of pharmacist reimbursement with the patient’s 
relationship with the pharmacist (not reflected in a table), it was noted that of the 290 
patients who supported pharmacist reimbursement, a significant percentage (78.3%) 
categorised their relationship with their pharmacist as good, whereas significantly fewer 
who stated that pharmacists should not be compensated (54.9%), described their 
relationship with their pharmacist as good (Chi-squared test, p<0.0001). 
 
Both females (67.7%) and males (69.8%) were equally likely to view their relationships 
with pharmacists as good (Chi-squared test, p=0.692). Asian patients (81.8%) and 
Whites (76.3%) were significantly more likely to consider their pharmacist relationships 
as good than were the other ethnic groups (Chi-squared test, p<0.0001). A significantly 
lower proportion of Black patients (57.5%, n=73) said that their relationships were either 
average, poor, or that they did not have relationships with pharmacists (Chi-squared test, 
p<0.0001).  
 
There was a significant association between age and the perceived quality of patient-
pharmacist relationship, with a majority (82.1%) of those over 65 years of age reporting a 
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good relationship with their pharmacist. This was followed by 80.1% in the age group 46-
65 years-old, after which the approval rating dropped significantly to 60.1% in the group 
between 30 and 45 years of age, with a further drop to 41.9% for patients under the age 
of 30 (Chi-squared test, p<0.0001). 
 
Table 6.4 shows that although more females than males (39.9% vs 30.4%) were likely to 
consider pharmacists to be the most accessible healthcare provider, the difference was 
not significant (Chi-squared test, p=0.054). Asians (47.8%) were significantly more likely 
to consider pharmacists more accessible than were Whites (37.7%), Blacks (31.9%) and 
people of Mixed-Race (25.0%) (Chi-squared test, p=0.002). There was a significant 
difference across age groups for those participants who viewed pharmacists as being 
most accessible. The older age groups were less likely to consider pharmacists to be the 
most accessible healthcare provider than were the two younger age groups Chi-squared 
test, (p<0.0001).  
 
The association of patient-pharmacist relationship with healthcare provider accessibility 
(not shown in a table) was found to be a significant one, in that 41.1% (n=169) of the 
participants who rated their relationships as good said that pharmacists were the most 
accessible healthcare providers, whereas only 21.9% (n=21) of those who reported ‘no 
relationship’ with pharmacists held similar views (Chi-squared test, p<0.0001). 
 
6.5 Discussion  
 
The General Household Survey for 2004, published by Statistics South Africa,488  
revealed that less than 15% of the population had health insurance at the time of the 
Discovery patient survey, therefore comparing survey data with these national 
demographic data serves little purpose. A comparison of the study data with the national 
insured data revealed that the study population was not demographically representative.  
For example, national insured data revealed that 49% of this population was under the 
age of 30 years old, compared with 12% in the study. Similarly, 44% of the total insured 
population were White compared with 65% in the study. The differences between the 
national insured and study demographics may be due to the market segmentation 
strategy adopted by Discovery in marketing their product offering i.e. targeting specific 
groups of people thought to limit Discovery’s exposure to insured benefit (financial) risk.   
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The importance of pharmacotherapy in the therapeutic continuum is evidenced by the 
data that reveals that more than 80% of patients surveyed used prescription medicines. 
This high proportion supports the notion of community pharmacists being 
opportunistically positioned to engage with patients on lifestyle and other health-related 
matters.490 Changes within healthcare systems, especially changes driven by increased 
patient access and patient demand for services and information, as well as increased 
costs, have caused pharmacists in various practice settings to investigate and develop 
health promotional aspects of pharmaceutical care that may be unrelated to the 
dispensing of medication.490 Research from around the world indicates that pharmacists 
are engaged in a variety of health promotion practices,12,147,173,491  and that patients value 
the contributions that pharmacists make in this regard.9,12 
 
In South Africa, medical practitioners may dispense medicines to their patients provided 
they have been licensed to do so.492 The licensing process involves a competency-based 
examination conducted under the auspices of the National Department of Health. 
Currently the number of registered self-dispensing medical practitioners exceeds the 
number of registered community pharmacists by a ratio exceeding two to one (personal 
communication J Bothma, Pharmaceutical Society of South Africa). Despite this ratio, 
almost two thirds of all prescription medicines provided to the patients surveyed were 
dispensed by pharmacists.  
 
Organised pharmacy in South Africa, as represented by the South African Pharmacy 
Council and the Pharmaceutical Society of South Africa, has long argued that 
pharmacist-only dispensing provides essential oversight with regard to the use of 
prescription medicines and that there should be a clear functional separation between 
the prescribing and dispensing of medicines. Their position has been that pharmacists 
provide patients with a superior level of CPS than do doctors who dispense 
medication.493 The survey, however, suggests that patients may not support this 
perception, and this should be of concern to the profession in South Africa.6   
 
The results suggest that while more than three quarters of Discovery Health patients 
were counselled on the use of medicines and provided with disease-related information, 
this was not happening at a level commensurate with the pharmacy profession’s position 
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on pharmaceutical care.6,23 It is unacceptable that at least two out of every 10 patients 
leave the country’s pharmacies armed with powerful pharmacotherapeutic agents but 
without having been adequately counselled on their use. This finding, when considered 
in conjunction with the unfavourable finding on healthcare provider accessibility, 
demands of pharmacists further research and remedy. 
 
There is growing per capita workload for pharmacists, who consequently have less and 
less time available to spend on patient-centred CPS. This unsatisfactory situation is 
largely due to the cumulative effects of community pharmacy consolidation, mainly as a 
result of the closure of small independent pharmacies and the advent of large 
corporately owned pharmacies, increased administration brought about by the advent of 
managed care, a national shortage of pharmacists (fuelled by the continuing emigration 
of pharmacists494), as well as improved access to insured healthcare by individuals from 
previously disadvantaged communities. 
 
A sizeable percentage of patients (≈40%) stated that the pharmacies they frequented 
offered certain clinical services. Although advances in technology relating to point-of-
care biochemical testing are increasingly bringing investigative interventions within the 
ambit of community pharmacy practice, the relatively small percentage of patients (7%) 
who were screened or monitored for certain chronic disease-related clinical indicators 
indicates that the value of such services are not yet fully recognised.19,23,173,470  
 
A systematic review by Anderson et al,164 published in 2004, concluded that consumers 
did not generally view pharmacists as a health advice resource. An earlier 1998 study by 
the same author noted that fewer than 20% of consumers consulted pharmacists for 
advice, although those who made use of community pharmacy services were well 
satisfied with these services.491 The Discovery survey found similarly in terms of patient 
satisfaction with almost 90% expressing satisfaction with the quality of pharmacist advice 
provided. However, a greater percentage (46%) of the Discovery patients indicated that 
they consulted pharmacists on health-related matters that was the case with the 
Anderson study.491 Encouragingly, the survey reveals that patients who consulted 
pharmacists were overwhelmingly pleased with the quality of the advice provided, and 
that almost half were willing to pay for CPS. This indicates substantial potential to 
improve pharmacy’s position as a healthcare advice/information resource.  
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A claim of community pharmacy world-wide is that pharmacist accessibility is facilitated 
mainly because of the physical location of most community pharmacies and because the 
consumer-pharmacist encounter is not usually subject to prior appointment.133,137 The 
survey data did not support this claim, and this is a disturbing finding for the profession 
as patients wishing to consult doctors in a private healthcare setting in South Africa must 
both make appointments and pay for consultations. Patients generally do not have to 
make appointments nor do they have to pay pharmacists for advice and yet almost two 
thirds considered pharmacists to be less accessible than doctors.  
 
This surprising finding may offer some explanation as to why more consumers do not 
consult pharmacists about health-related matters. Patients may have been socialised by 
past pharmacy practice experiences to seeing the pharmacist simply as a dispenser of 
medicines.14 It is also possible that other variables, such as privacy, confidentiality and 
uninterrupted consultation, may have a mediating effect on perception and definition of 
healthcare provider access.495-497 As a number of authors have commented on the 
relative ease with which patients are able to access pharmacists,146,252,498 it is possible 
that this question may have been misinterpreted despite having the term explained 
during the interview.  
 
For much of the world, the twin effects of increased life expectancy and decreasing 
fertility rates have given rise to an increasingly “greying” population.499 The elderly are 
the fastest growing segment of the population in a number of developing countries, and 
world-wide the number of people over the age of 60 is set to double between 2000 and 
2025.499  Given the importance of attending to the complex health needs of this sector of 
the population, it is disturbing that the survey found that patients over the age of 65 were 
less inclined to consult pharmacists than were the rest of the survey population. As one 
would expect, the level of medicine utilisation reported by patients over 65 years of age 
reflected an association between the increasing prevalence of chronic disease and 
advancing age.500 In a multi-centre study involving elderly patients in seven European 
countries, the authors noted that very few studies have, to date, examined the impact of 
pharmaceutical care on the elderly as a group.501   
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More than two thirds of patients viewed their relationships with their pharmacists as 
good. This, in turn, suggests that almost a third of patients felt that their relationships 
with pharmacists were problematic to some degree, and this finding must be of some 
concern given the association between the quality of the relationship and the patients’ 
willingness to collaborate with healthcare providers.30 Those patients reporting a good 
relationship were far more willing to pay pharmacists for CPS than those who reported 
negatively.  
 
Black patients and those of Mixed-Race generally did not rate their relationships with 
pharmacists as good. In part, this may be due to the demographics of community 
pharmacists who are mostly White, the cultural and linguistic differences between 
patients and pharmacists, and the accessibility of the majority of community pharmacies 
which tend to be situated in urban shopping centres or within residential areas that, prior 
to 1994, were almost exclusively reserved for the White population. It is important, both 
economically and professionally, that pharmacists improve relationships with these 
apparently disenchanted sections of the South African population. Furthermore, it is 
incumbent upon pharmacists to ensure that they are able to offer CPS that are 
educationally, linguistically and culturally aligned with the needs of individuals from these 
communities, not only because of their demographic weight but because of the 
increasing prevalence of chronic conditions such as cardiovascular disease, 
hypertension, obesity and diabetes in these populations.41  
 
The administration of the survey via telephonic interview was found to be a convenient 
and practical method of surveying patients. The major advantages of this method, when 
compared to postal self-completed questionnaires, were convenience, the high strike 
rate, the opportunity for immediate clarification of any patient query and real-time 
efficient data capture. The structured nature of the questionnaire facilitated operator 
adherence to a standard protocol in administering the questionnaire. The level of 
comprehensibility of questions may be greater with telephonic surveys than with self-
completed postal surveys as patients are able to seek clarification.449   
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6.6 Limitations 
 
The absence of similar practice-based research in South Africa prevented the 
benchmarking of the questionnaire for local conditions. The survey was conducted at a 
time when community pharmacy in South Africa was on the receiving end of 
unfavourable media coverage relating to the proposed changes to the pricing of 
pharmaceuticals and to the structure of the dispensing fee, and this effect on public 
perception may have introduced a level of bias.  
 
The determinants of patient attitudes and beliefs which underpin the survey constructs 
are complex.449 Both the conceptual framework and the design of the survey would have 
benefited from a more rigorous review of other studies.  Validated instruments exist 
which measure constructs similar to those conceptualised for this survey,502-504 and these 
could have been adapted for this study rather than designing an entirely original survey 
instrument.  
 
The procedure used to generate the sample frame involved two stages – a convenience 
sample of patients who submitted health insurance claims within a given period, followed 
by the random selection of patients from within the convenience sample. Given that it 
would not have been practical to have selected a survey sample that would have been 
fully representative of the national insured database, an improved sampling frame would 
have included a list of all members who submitted claims rather than only the first 3000. 
Other enhancements to the sampling frame that could have been considered include: 
the use of multistage sampling with potential respondents stratified geographically 
(according to postal code), ethnically and by gender in order to ensure greater 
representativity before final randomisation.35 
 
The survey may have benefited from the inclusion of the Nominal Group Technique prior 
to embarking on the pilot study, i.e. by involving an expert group of pharmacists in order 
to establish the explicit criteria to be addressed as well as to fine-tune the actual 
questions to be posed in operationalising the survey.505 In addition to defining criteria in 
the absence of local studies, the Nominal Group Technique, notwithstanding its own set 
of limitations, would have generated face, content and a level of consensual validity.505 
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As interviews were not conducted by the researcher but by trained operators, the 
potential for operator error and their ability to clarify queries may have impacted on the 
validity and reliability of the questionnaire. The survey relied on self-reported 
retrospective quantitative data collected via telephonic interview which may have 
subjected the answers to recall bias, which has been identified as a limitation in other 
studies.506  However, the potential for recall bias is smaller in the case of cross sectional 
descriptive studies than in cross sectional analytical studies.507 
 
Other possible limitations associated with the real-time interview method include lack of 
time to reflect on the questions, operator interviewer bias, and limitations with regard to 
the level of complexity of questions, i.e. they were constrained to being simple in 
structure. There may have been an element of selective attention on the part of the 
patients, i.e. individuals tend to select and pay attention only to certain variables in a 
given situation.507 
 
6.7 Conclusion 
 
Patient opinion clearly indicated that pharmacists provide certain cognitive 
pharmaceutical services including medication counselling, disease-related information 
and health-related advice. Furthermore, these services are valued by patients who 
generally have good relationships with pharmacists, with a significant number of patients 
being willing to pay pharmacists for such services. The survey therefore demonstrated 
that support exists within the practice dynamic of South African community pharmacy to 
reasonably allow for the implementation of a pharmacist-based diabetes care plan 
intervention as envisaged in the empirical study described in Chapter 7.  
 
The survey helped to identify aspects of community pharmacy practice that may benefit 
from further research. It is recommended that organised pharmacy consider undertaking 
formal market research relating to the provision of CPS with a view to developing an 
evidence-based strategy aimed at the effective marketing of the profession.508 Research 
within groups and communities classified demographically and by disease state would 
assist the profession in identifying and facilitate the targeting of CPS. The pharmacist as 
an accessible community-based healthcare information and counselling resource 
requires further investigation given the South African Pharmacy Council’s statutory 
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requirement with regard to Good Pharmacy Practice, as well as the professional 
imperative of providing pharmaceutical care.6,23   
 
Research investigating the range and utility of the clinical services on offer in South 
African community pharmacy is suggested, especially as services such as biochemical 
monitoring play a key role in informing both the initiation and adjustment of therapies. 
Such research should include investigation into the skill and accessibility of pharmacists 
(and auxiliary staff) responsible for providing these services.  
  
There is a paucity of local data describing the medicine-related knowledge, beliefs, 
attitudes and pharmacy related needs of consumers from previously disadvantaged 
communities, those with chronic diseases and those who may be classified as elderly. 
Community pharmacy could benefit from the availability of such information as these 
groups represent potentially important target markets. Well structured patient satisfaction 
surveys are useful tools in the hands of pharmacists wishing to assess practice 
performance and to plan remedial action.  
 
If CPS are to be meaningfully provided by South African community pharmacists then, in 
concert with colleagues elsewhere in the world, pharmacists will have to be 
compensated for these services. Funders of the pharmacy benefit, including patients, 
are more likely to be willing to pay if they perceive value in the services. This, in turn, 
means that the apparent deficiencies in the elements of CPS identified by the survey 
and any barriers to pharmacist access will need to be addressed. Strategies should be 
developed that will encourage pharmacists to professionally market CPS. Appropriate 
marketing campaigns should increase healthcare consumer awareness.  
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CHAPTER 7 
RESEARCH DESIGN AND METHODOLOGY 
 
7.1 Introduction 
 
This study was informed by a WHO report on adherence to long-term therapy.1 The 
influence of the report on the rationale for the study is discussed in more detail in 
Section 1.1. The report notes that therapeutic adherence in DM2 is sub-optimal and 
constitutes a world-wide problem and also states that community pharmacists are well 
positioned to positively influence patient adherence in a number of chronic diseases 
including DM2.1 The study hypothesis has largely been informed by the literature relating 
to aspects of the management of the disease by pharmacists, given the scope of 
practice of South African community pharmacists.6,173   
 
7.2 Aim and objectives 
 
The aim of the study was to investigate the influence of South African community 
pharmacist intervention on certain intermediate health outcomes and therapeutic 
adherence in DM2. The objectives underpinning this aim are noted in Section 5.5. 
 
7.3 Study setting and design  
 
Unemployment, poverty, low levels of education, poor public health practices, an under-
resourced public health sector, together with the ravages of infectious diseases 
(especially HIV/AIDS and tuberculosis), and the emerging pandemic of diabetes and 
obesity, renders a large proportion of the South African population vulnerable to a 
substantial burden of disease. 132,509 
 
South Africa, with an ethnically diverse population of approximately 47 million people,  
has a healthcare system unequally divided between public and private health sectors.510 
The public health sector is state funded and services the healthcare needs of 
approximately 85% of the population.509,510 The private sector, which caters for about 
15% of the population, is mostly funded by a combination of self funding and a form of 
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medical insurance, colloquially referred to as “medical aid”.511 Private healthcare 
expenditure, which accounted for 60% of South Africa’s total healthcare funding in 2005, 
reflects the inequality existing within healthcare.512 The disparity in healthcare financial 
resource allocation between the public and insured private sector has encouraged a 
number of government initiatives aimed at limiting private healthcare spending.  
 
The cost of pharmacy-only medicines, or scheduled medicines as they are known in 
South Africa, accounted for a significant portion of the private healthcare budget in 
2004.511 Accordingly, legislation aimed at controlling the price of medicines was 
promulgated in 2005, which reduced and fixed the mark-up of scheduled medicines and 
introduced price control on medicines via a legislated transparent medicine pricing 
system, referred to as the Single Exit Price for scheduled medicines.513 The Single Exit 
Price model applies to all scheduled medicines. Community pharmacists have seen 
medicine margins eroded and revenue reduced as a result of the single exit pricing of 
medicines, and are thus being forced by economic necessity to identify additional 
revenue streams, including the delivery of services for which they may be able to levy 
fees.17,514 
 
There were approximately 11100 pharmacists and 2700 community pharmacies in 2007, 
with approximately 40% of the pharmacists employed in community pharmacy. 
(Moselakgomo M. Personal communication, Registration Officer, South African 
Pharmacy Council, May 2007). Community pharmacy focuses almost exclusively on 
providing pharmaceutical services to the private healthcare sector, 137,515 and there are a 
number of community pharmacy practice models in existence, with independent 
pharmacist ownership dominating. Prior to 2003, community pharmacies in South Africa 
could only be owned by registered pharmacists, but ownership regulations changed in 
May 2003 when legislation was enacted that allowed for non-pharmacist ownership. 
There are also corporately owned private sector hospitals and clinics with pharmacies, 
as well as six courier pharmacies, similar in operation to the mail-order pharmacies 
found in the USA.509 The prescription medicine market in the private healthcare sector is 
further fragmented by the existence of more than 8000 registered medical practitioners 
licensed to dispense medicines. 17,493,516 
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Although community pharmacists have for many years had an expanded role in South 
African healthcare, there exists very little evidence, other than anecdotal evidence, 
relating to the provision and value of these services.17,137  The consumer survey reported 
in Chapter 6 was conducted in order to inform the researcher’s understanding of the 
insured healthcare consumer’s perspective regarding the CPS provided by South African 
community pharmacists.17 The survey revealed that in most instances pharmacists 
counselled patients on the use of medication and provided health-related information, 
that relationships with pharmacists were good and valued, and that almost half of 
respondents believed that pharmacists should be reimbursed for providing CPS.17  
 
Notwithstanding the limitations of the survey, and a possible negative finding regarding 
pharmacist access, the results of survey demonstrated that South African community 
pharmacists are positioned to deliver chronic disease-related CPS. There appeared to 
be, therefore, sufficient foundational support to warrant an investigation of the study 
hypothesis, namely that South African community pharmacists are positioned to 
influence adherence to long-term therapy and key intermediate health outcomes in DM2. 
 
The study was conducted in 17 community pharmacies in five of South Africa’s nine 
provinces. A randomized controlled trial (RCT) informed by the CONSORT statement 
was adopted as the study design.35 Post-baseline randomization to either control or 
intervention occurred at pharmacy level in order to prevent contamination of the groups. 
Ethical approval for the study was obtained from the Rhodes University Ethical 
Standards Committee. 
 
7.4 Study population 
 
7.4.1 Estimation of the sample sizes in the control and intervention groups 
 
Pharmacist participation was canvassed as broadly as was possible using the 
communication media of pharmacy organisations, mainly the PSSA (Annexure 6.1), as 
this is a method commonly used to solicit pharmacist participation in practice for 
continuing professional development or education programmes. A gross response rate 
of approximately 4.6% (156/3400) was initially achieved. 
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The sample size calculation for patients was based on determining the minimum number 
of patients required to be able to detect a 0.5% difference in HbA1c with 95% confidence. 
If the sample size calculation was based on detecting a 1% difference in HbA1c between 
the two groups with a standard deviation of 1%, then  a fixed sample size of 20 patients 
per group would yield a power of 88.5%517 
 
7.4.2 Pharmacist participants 
 
All community pharmacists working in community pharmacies within the borders of 
South Africa were eligible to participate in the study. No other eligibility criteria, such as 
access to computerised records or provision of private counselling areas, were applied 
as all registered pharmacists are permitted by law to provide CPS from registered 
pharmacies. Pharmacist recruitment and participation was effected via the 
communication media of community pharmacist organisations who collectively represent 
approximately 75% of all South African community pharmacies.  
 
There were two randomizations using a web-based random number generator noted in 
Section 7.4.3 below. The first involved patients only and was applied in order to inform 
the patient selection process. The second randomization occurred post-baseline four 
months later when pharmacists and their associated patients were randomized to either 
a control or intervention group. The key elements of the randomizations, namely 
sequence generation at recruitment and post-baseline group allocation, were concealed 
from the participants. 
 
Prior to post-baseline randomization the pharmacists were stratified within three key 
employment/location domains, corporately owned and urban location (six pharmacies), 
independently owned and urban location (four pharmacies) and independently owned 
and rural location (seven pharmacies). Pharmacists were randomized to control or 
intervention separately in each of the domains and the results collated. Stratified 
randomization resulted in reasonably well-matched control and intervention groups in 
terms of the pharmacy location and ownership variables. The control group consisted of 
8 pharmacists and 27 patients and the intervention group of 9 pharmacists and 34 
patients.  
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The control pharmacists were telephonically contacted by the researcher and requested 
not to provide any form of additional diabetes care to their DM2 patients other than the 
‘standard’ or ‘usual’  pharmaceutical care that they were accustomed to providing prior to 
the initiation of the study. Typically usual care would counselling patients on the use of 
their medicines. However, given that practice environments vary from pharmacy to 
pharmacy, and given that it was essential to try and prevent observation bias, no attempt 
was made to further describe usual care.  The intervention pharmacists were provided 
with a diabetes care plan (DCP) intervention framework (see Section 7.5) to guide the 
‘enhanced’ pharmaceutical care that they were requested to provide.  
 
7.4.3 Patient participants 
 
The inclusion criteria for patients are noted in Table 7.1. Patients were not excluded from 
the study on the basis of co-morbidity, health-risk rating, history of non-adherence to 
therapy, cognitive ability, race, age, or gender.  
 
Pharmacists identified, listed and numbered all their DM2 patients and provided the 
researcher with the number of patients on file. In order to minimise selection bias a web-
based random number generator (http://www.randomizer.org/form.htm)487 was used to 
determine the selection sequence for potential patient participants. A patient selection 
sequence was then forwarded to each pharmacist with the request to recruit up to a 
maximum of 10 patients. Patients complying with the inclusion criteria were approached 
by their pharmacists and asked if they would be interested in participating in a research 
project that would examine aspects of diabetes care being provided by South African 
community pharmacists. Pharmacists provided these patients with a brief overview of the 
study, together with copies of a patient study information and informed consent letter 
(Annexure 6.3).  
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Table 7.1 Inclusion criteria for patients 
 Minimum 18 years of age.  
 Diagnosed with DM2 at least 6 months prior to recruitment.  
 Receiving a minimum of one prescribed anti-diabetic agent regularly from a participating pharmacy. 
 Able to read and understand English.  
 Willing to provide informed consent. 
 
 
Patients who signed letters of consent subsequently received correspondence from the 
researcher reiterating the importance of completing the questionnaires and having the 
biochemical and clinical tests done, and thanking them for their participation. Patients 
were then contacted by their respective pharmacists and requested to meet in the 
pharmacy to discuss the contents of the patient study pack.   
 
Throughout the duration of the study, pharmacists were encouraged to emulate ‘real 
world’ standards of day-to-day community pharmacy practice as closely as possible and 
to avoid any activities and interventions which could be construed as being limited to 
‘research practice’. In support of this objective, and in an effort to minimise participation 
bias, neither the pharmacists nor the patients were offered any form of compensation for 
their participation. 
 
7.5 The Diabetes Care Plan (DCP) intervention   
 
Practice conditions vary from pharmacy to pharmacy, and both pharmacists and 
patients, as individuals, are unlikely to approach adherence or any aspect of diabetes 
care in a structured uniform manner.518 It was not the intention, therefore, to prescribe 
precise stage-specific diabetes care interventions, but rather to encourage pharmacists 
to tailor component interventions to suit individual patient needs within the reality of the 
pharmacist’s day-to-day practice environment.480,519 It was for this reason that, in 
correspondence addressed to intervention pharmacists, the DCP intervention framework 
was referred to in the following terms: “The intervention document, IDF guidelines and any 
other published article or paper that I send you are resource materials and provide a framework 
for individualized diabetes care plans that I trust you will develop with each of your patients. But, 
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and this is important, it’s up to you to decide on how you go about working with and assisting your 
patients” (Annexure 6.4). 
 
As mentioned in the conceptual framework,( Section 5.4) two key aspects of the DCP 
intervention were the clinical and patient education and counselling interventions. A 
major component of the clinical intervention was the monitoring of clinical indicators and 
other variables. Intervention pharmacists were provided with a suggested monitoring 
schedule, which was informed by the SEMDSA and IDF guidelines.4,105 The schedule 
plus explanatory notes, which are shown in Annexure 6.5, linked the forms, 
questionnaires, validated scales and other instruments provided in the manual with 
consultations, monitoring and review activities in the following domains: diabetes history 
and medication review, diabetes knowledge and self-management, key clinical 
indicators, provider referral, and behavioural indicators. Although the clinical and patient 
education and counselling interventions are described separately, in practice the two are 
integrated by the 5 A’s model for behavioural change,275 which is described in Section 
4.3.3 as a unifying framework to inform the development and implementation of 
behavioural change educational interventions designed to support the improvement of 
chronic disease self-management in primary healthcare settings. 
 
At the beginning of the recruitment process the researcher canvassed pharmacist 
opinion with regard to their willingness to attend after-hours training. Pharmacist 
reluctance to make such time available, together with the widespread geographical 
distribution of relatively few willing participants, meant that face-to-face training would 
not be a viable option.  Intervention pharmacists were trained to provide the DCP using a 
self-study distance-learning method based largely on written material, which is a 
common format for South African CE programmes aimed at pharmacists. Intervention 
pharmacists were also encouraged to access web-based resources and to contact the 
researcher if further assistance was required.  The resource material, in the form of a 
written DCP manual which  is more fully described in Annexure 6.5, was designed to 
encourage collaboration between pharmacists and patients in the development and 
application of individualized DCP interventions. The manual, which was forwarded to 
pharmacists in December 2006, consisted of the following sections, (i) an executive 
summary, (ii) an overview of the DCP intervention, (iii) patient education and counselling 
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intervention (iv) clinical intervention, (v) scales and questionnaires and (vi) additional 
resource materials for the pharmacists.   
 
The executive summary briefly described the clinical and patient education key elements 
of the DCP in terms of assessing patient needs, goals and problems, collaboratively 
planning strategies to address needs, goals and problems, implementing agreed 
interventions, monitoring key variables and reviewing the results forthcoming from the 
monitoring process.   
 
The overview suggested roles for both patients and pharmacists before further outlining 
the clinical and patient education and counselling interventions. With regard to the role of 
the patient, it was stressed that patients should not be seen as passive recipients of 
diabetes care but that a collaborative patient-centred approach should be taken in 
support of self-management initiatives. The pharmacist’s role was defined in terms of 
collaboratively providing evidence-based enabling diabetes care. 
 
The detailed sections dealing with the patient education and counselling intervention and 
the clinical intervention followed the DCP overview. The patient education and 
counselling section briefly discussed the Chronic Care Model, patient self-management 
and patient behaviour in terms of readiness to change, before dealing with the 
counselling method of Motivational Interviewing, which was discussed in some detail as 
it formed the crux of this intervention. The clinical intervention was discussed in terms of 
the monitoring by pharmacists of key diabetes-related variables (set out in a suggested 
monitoring schedule on page 21 of Annexure 6.5). 
 
7.5.1 Materials  
 
The resource materials provided to support the patient education and counselling 
intervention are included in Table 7.2 
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Table 7.2  Resource material  for patient education & counselling intervention 
Aspect Source 
Motivational Interviewing Motivational interviewing helps patients confront change.
171
   
Assessing and interviewing patients for meaningful behavioral 
change. Part 1.
269
   
Assessing and interviewing patients for meaningful behavioral 
change.Part 2.
270 
Motivational interviewing in health settings: a review.
265 
Communication Persuasive communication. Part 1
497 
Persuasive communication. Part 2
520 
Change Change is a multistep process.
521
  
Helping patients face change.
522
 
 
 
The diabetes-related resource materials, primarily DM2 guidelines, provided in support 
of the clinical intervention are shown in Table 7.3  Pharmacists were furthermore 
reminded to refer to “Good Pharmacy Practice in South Africa”, published by the South 
African Pharmacy Council, with regard to the statutory requirements for the provision of 
pharmaceutical care.6  The procedures relating to the use of these resource materials 
are further discussed in Annexure 6.5 and Section 7.5.2. 
 
Table 7.3  Resource material in support of the clinical intervention 
Aspect Source 
Guideline and medicine review A Desktop Guide to Type 2 Diabetes Mellitus.
523
  
Revised Guidelines for the diagnosis and management of type 2 
diabetes mellitus for primary health care in 2002.
105 
Algorithm for Diabetes Mellitus Type 2, from the South African 
Council for Medical Schemes.
123
 
Guidelines on Pharmacist-Conducted Patient Education and 
Counseling 2001 from the ASHP.
172
  
Diabetes education Education: IDF global guidelines for type 2 diabetes.
4 
Self-management adherence Improving adherence to diabetes self-management 
recommendations.
350
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The forms, scales and questionnaires that pharmacists and patients were requested to 
complete at baseline and post-baseline are shown in Table 7.4, and further discussed in 
Annexure 6.5 and Section 7.5.2.   
 
Table 7.4 Forms, questionnaires and scales to be completed by patients and 
pharmacists 
 Form/ Scale/ 
Questionnaire 
Aspect Baseline ( B) 
Post-baseline (PB) 
Completed by 
Patient  or Pharmacist 
Patient Profile Brief diabetes-related  
medical history 
B Patient 
Beliefs about Medicines 
Questionnaire 
Health-related beliefs B & PB 
Patient 
Diabetes Satisfaction 
Scale 
Health-related beliefs PB 
Patient 
Diabetes Empowerment 
Scale 
Health-related beliefs PB 
Patient 
Self-management 
Adherence Scale 
Health-related behaviours B & PB 
Patient 
Medication Adherence 
Report Scale 
Health-related behaviours PB 
Patient 
Major Depression 
Inventory 
Health-related behaviours PB 
Patient 
Brief Diabetes 
Knowledge Test 
Diabetes-related knowledge PB 
Patient 
Understanding Self-
management Practices 
Scale 
Diabetes-related knowledge PB 
Patient 
Self-monitored Blood 
Glucose 
Diabetes-related knowledge PB 
Patient 
Clinical data form Biochemical and clinical 
variables  
B & PB Pharmacist 
Prescribed Medication 
and Refill Questionnaire 
Prescription refill data PB Pharmacist 
Adjustments to oral anti-
diabetic therapy 
Prescription refill data PB Pharmacist 
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7.5.2 Procedures for implementing the Diabetes Care Plan (DCP) 
 
Procedures relating to the DCP intervention, including suggestions on the process to be 
followed, were included in the DCP manual (Annexure 6.5) as well as in covering 
correspondence (Annexure 6.4).  Pharmacists were requested to reflect on their practice 
situations and to take cognisance of the individual patient’s language, cultural and ethnic 
preferences and psychosocial and socioeconomic status when designing, implementing 
and monitoring interventions. The core elements of the DCP intervention framework are 
presented in Table 7.5. 
 
Table 7.5 Core elements of the DCP intervention framework 
 Assess patient diabetes-related problems, needs and goals in behavioural terms. 
 Discuss and agree strategies and interventions required to address needs and goals. 
 Specify follow-up plan and  implement agreed interventions. 
 Share plan with practice team.  
 Monitor key clinical variables. 
 Regularly review and appropriately modify the DCP. 
 
 
It was suggested that pharmacists discuss and agree on an individualized monitoring 
schedule with each patient. Given the time constraints generally faced by pharmacists in 
practice, it was suggested that pharmacists risk-rate patients in order to determine 
monitoring frequencies,525,526 i.e.  increased risk for morbidity may require more frequent 
and comprehensive monitoring. It was also suggested that pharmacists structure fixed-
time appointments for the initial study consultation and for subsequent consultations, 
with provision made for more frequent consultations that may be required for those 
patients who may be considered to be at high-risk for complications.  
 
Pharmacists were requested to pay particular attention to identifying and addressing 
possible medication-related problems. In particular, it was suggested that pharmacists 
refer to the ASHP patient education and counselling guidelines when conducting 
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medication reviews.172 Pharmacists were advised to refer to the indicators recorded at 
baseline and the SEMDSA and IDF guidelines in order to guide goal setting and inform 
interventions. Pharmacists were encouraged to use opportunities created during patient-
pharmacist encounters, especially those associated with the medication refill process, to 
facilitate the care process. It was further suggested that pharmacists maintain regular 
contact with their patients and that they use electronic and telecommunication 
technologies to follow-up with patients.  
 
The psychosocial patient education and counselling intervention and the biomedical 
clinical intervention are mutually supporting elements of the DCP. In counselling 
patients, pharmacists were encouraged to use the non-judgemental method of brief 
Motivational Interviewing to explore patient health beliefs, attitudes and concerns in 
order to identify barriers to diabetes care and concordantly agree on suitable remedial 
action. 
 
Patient education, in the context of the study, referred to the appropriate communication 
of DM2-related knowledge from the pharmacist to the patient in order to foster 
foundational support for diabetes self-management. Pharmacists were requested to 
ensure that their patients were appropriately grounded in key facets of diabetes self-
management education as summarised in Table 7.6.   
 
 
 
Table 7.6 Key features of diabetes self-management education  
 Basic pathophysiology of DM2. 
 Complications and co-morbidities commonly associated with the disease. 
 Key tests and examinations recommended by SEMDSA.  
 Recommendations for glycaemic control including the relevance of SMBG and HbA1c monitoring. 
 The role of anthropometric measures. 
 The importance of blood pressure, blood lipid, and renal function values. 
 Treatment options including diet, exercise and pharmacotherapy. 
 Accessing psychosocial support. 
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The intervention group of 8 pharmacists was requested to implement the DCP 
intervention during the period December 2006 to May 2007. During June and July 2007, 
12-month post-baseline clinical indicators and other variables were measured for both 
intervention and control patients. 
 
7.6. Collection of baseline data  
 
Each patient received a study pack from their pharmacist containing the following 
baseline forms and questionnaires (Annexure 6.2 and Table 7.4): 
 
To be completed by the patient 
 A patient profile form for recording demographic and diabetes-related data.  
 Three  baseline questionnaires  
 - Beliefs about Medicines Questionnaire384 
 - Diabetes Satisfaction Scale410 
 - Self-management Adherence Scale385 
 
To be completed by the pharmacist 
 A baseline clinical data form for the pharmacist to record biochemical and clinical 
indicators (proteinuria, blood pressure, waist-hip ratio, and body mass index).  
 Pathology request forms to be used by the pharmacist to request biochemical 
tests (glycated haemoglobin, lipogram and serum creatinine).  
 A medical practitioner study information letter to be signed by the pharmacist and 
forwarded to the patient’s medical practitioner. 
 
All instruments were previously validated and were used in this study with the permission 
of the authors. The scales were applied at baseline to benchmark adherence-related 
indicators in the areas of: medication-related health beliefs, planning and monitoring, 
satisfaction with care received, and self-reported adherence to self-management 
recommendations. 
 
During April/May 2006 participants were requested to complete patient profile forms and 
provide data relating to the variables listed in Table 7.7  
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The following clinical indicators were recorded at baseline:  
 
  HbA1c 
 Total cholesterol  
 HDL-cholesterol 
 LDL-cholesterol 
 Triglycerides 
 Serum creatinine 
 Proteinuria (urine dipstick) 
 Systolic blood pressure 
 Diastolic blood pressure 
 BMI 
 Waist – Hip ratio 
 
In order to standardise the biochemical tests and to facilitate the reporting of results, 
HbA1c, blood lipids and serum creatinine tests requested by pharmacists were performed 
in medical laboratories affiliated to the Ampath group. The balance of the clinical 
variables including proteinuria, blood pressure, BMI and waist-hip ratio were measured 
in the participating pharmacies either by pharmacists themselves, or under the 
supervision of pharmacists. Ampath emailed the biochemical test results directly to the 
researcher who, in turn, made these data available to the pharmacists. Pharmacists 
faxed the balance of the recorded clinical data to the researcher. Patients were 
Table 7.7 Summary of patient profile data collected at baseline 
 Demographic data. 
 Duration and family history of DM2. 
 Providers of medical care and frequency of consultations. 
 Diabetes education and lifestyle issues of diet, exercise, social support, alcohol and tobacco use. 
 Co-morbidities, medication used for DM2 and other co-morbidities. 
 The monitoring of clinical indicators as specified in the SEMDSA guidelines. 
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responsible for the costs of the biochemical tests performed by Ampath and settled 
these accounts directly or via their health insurers. In keeping with standard community 
pharmacy practice in South Africa, pharmacists did not levy fees for the in-pharmacy 
tests and measurements.  
 
7.7 Collection of post-baseline data  
 
In March 2007, pharmacists were provided with post-baseline clinical data forms and 
Ampath laboratory forms and asked to conduct a 12-month evaluation of their patients 
during April/May 2007 (covering letter Annexure 6.7 and Table 7.4)  
 
12-month patient data to be provided by pharmacists 
 HbA1c 
 Total cholesterol  
 HDL-cholesterol 
 LDL-cholesterol 
 Triglycerides 
 Serum creatinine 
 Proteinuria (urine dipstick) 
 Systolic blood pressure 
 Diastolic blood pressure 
 BMI 
 Waist – Hip ratio 
 
The use of clinical practice guidelines such as those published by SEMDSA serve not 
only to guide provider and patient behaviour, but provide an evidence-based standard 
for diabetes-related biochemical and other clinical indicators. Baseline patient profile 
data were analysed to determine patient adherence to the guideline recommendations 
with regard to attending examininations and having tests done. A comparative analysis 
of baseline and 12-month data including key biochemical and clinical indicator values 
was conducted.  
 
Pharmacists were provided with the following questionnaires (described in Section 4.5.5) 
for their patients to complete under a covering letter (Annexure 6.8 and Table 7.4). 
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12-month patient data to be provided by patients 
 Beliefs about Medicines Questionnaire384 
 Diabetes Satisfaction Scale410 
 Self-management Adherence Scale385 
 Diabetes Empowerment Scale Short Form413 
 Medication Adherence Report Scale422 
 Major Depression Inventory428 
 Self-monitoring Blood Glucose Scale385 
 Brief Diabetes Knowledge Test436 
 Understanding Self-care Practices Scale385 
 
Pharmacists were also requested to complete two questionnaires (Table 7.4). The first 
was a Prescribed Medication and Refill Questionnaire (Annexure 6.9) that identified oral 
medication used by patients for hyperglycaemia, dyslipidaemia and hypertension, as well 
as the number of prescription refills obtained during the 6-month study period (December 
2006 to May 2007). In addition, 12-month data was recorded relating to any adjustments 
made to the prescribed oral anti-diabetic therapy, as specified in Table 7.8  
 
Table 7.8 Post-baseline adjustments to oral anti-diabetic therapy 
 Increase in dosage. 
 Alternative agent or agents prescribed.  
 Addition of an agent or agents to the existing regimen.  
 Insulin added to the regimen or substituted for any of the oral agents.  
 
Pharmacists recorded patient clinical and prescription medication data and ensured that 
patients completed the questionnaires used in the study. Other than patient data 
provided by the pathology laboratories, all forms, clinical data and questionnaires were 
forwarded to the researcher by the pharmacists. The researcher captured the data 
directly from the forms, laboratory reports and questionnaires. Data capture errors were 
identified and corrected by verifying all entries prior to the data being submitted for 
statistical analysis. 
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Pharmacists were requested to return all post-baseline clinical data forms, patient and 
pharmacist questionnaires to the researcher during June/July 2007. As was the case 
with the collection of baseline data, numerous follow-up attempts were required before 
the data collection process could be completed.  
 
7.8 Data analysis methods 
 
Data analysis was premised on pharmacist influence on patient adherence to long-term 
therapy being evaluated by means of a RCT in which the differences in the primary 
endpoint of HbA1c and the secondary endpoints (e.g. blood lipids, blood pressure and 
body mass index) for intervention and control patients served as surrogate outcomes. 
 
Independent t-test analyses involved direct comparisons of group means between the 
control sample and intervention sample at both baseline and post-baseline intervals 
separately, on all biochemical and other clinical variables, as well as in health-related 
beliefs and behaviours and diabetes-related variables. Dependent t-test analyses were 
conducted on the data from the control sample and intervention sample between 
baseline and post-baseline intervals to investigate differences in biochemical and other 
clinical variables. Chi-squared tests were used to test for significant differences between 
the control and intervention groups in the frequency distributions of patient demographic 
and diabetes-related variables.  
 
To guard against Type I error, Bonferroni adjustment to the level of significance was 
applied to the biochemical and other clinical variables test comparisons according to the 
number of participant characteristics investigated, including control or intervention group, 
gender, marital status, monitoring body mass, receiving diabetes education, consulting 
general practitioners or specialists, smoking, following a diabetes eating plan, exercising 
regularly, consuming alcohol (two or less units per day), and receiving social support (i.e. 
k=11 participant characteristics). Accordingly the alpha adjustment for the test 
comparisons, allowing for the Bonferroni adjustment to ensure that the overall level of 
significance does not exceed α = 0.05, is α/k = α/11 = 0.05/11 = 0.0045.527 All tests were 
performed using Statistica (Statsoft Inc.).528 
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CHAPTER 8  
RESULTS   
 
8.1 Introduction  
 
The results of the DM2-related pharmaceutical care study described in Chapter 7 are 
presented in this chapter. As the questionnaires and forms used in the study were 
completed by patients or pharmacists without the assistance of the researcher, certain 
fields were occasionally left blank, and for this reason participant numbers may not be 
consistent within certain results tables presented in this chapter.  
 
8.2 Pharmacist participants 
 
The flow diagram (Figure 8.1) shows the pharmacist and patient participant flow through 
the study. The process of recruiting pharmacists to the study was both time-consuming 
(requiring a great deal of coaxing and follow-up) and disappointing, as evidenced by the 
fact that only 16 community pharmacists out of a potential pool in excess of 3000 were 
prepared to participate for the full 12 month period.    
 
By the end of the initial phase of the recruitment process in September 2005, a total of 
156 pharmacists had responded to the ‘request for participation’ correspondence 
(Annexure 6.1) and indicated in-principle interest in participating in the study. Seventeen 
pharmacists subsequently withdrew their offers of participation citing time and human 
resource constraints as the main reasons for their withdrawal. During October and 
November 2005, 139 pharmacists were requested to interrogate their prescription 
databases and identify, list and consecutively number all DM2 patients who met the 
study inclusion criteria. Sixty two pharmacists identified 4055 patients that they deemed 
eligible for study participation by the end of November 2005. 
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                Figure 8.1 Study design: participant flow 
Canvassed pharmacist participation 
Pharmacists n ≈ 3400 
Pharmacist response n = 156 
Pharmacist identification of patients        
Pharmacists n = 62    
Data not provided & 
pharmacist resource 
constraints 
Pharmacists n = 94 
Randomized patient selection 
Pharmacists n = 28 Patients n = 153 
 
 
Patients not recruited 
Pharmacists n = 34 
Baseline clinical indicators 
Pharmacists n = 17 Patients n = 61 
Data not provided 
Pharmacists n = 11 
Patients n = 92 
 
Randomization of pharmacists and 
patients to intervention and control                           
Pharmacists n = 17 Patients n = 61 
 
Allocated to  
Control cohort 
Pharmacists n = 8 
Patients n = 27 
 
Allocated to   
Intervention cohort 
Pharmacists n = 9 
Patients n = 34 
 
Control no intervention 
Pharmacists n = 8 
Patients n = 27 
 
Intervention received 
intervention 
Pharmacists n = 9 
Patients n = 34 
Analyzed Control       
12 month data 
Pharmacists n = 8 
Patients n = 27 
 
Analyzed Intervention 
12 month data 
Pharmacists n = 8 
Patients n = 30 
 
Pharmacy Closure 
Pharmacists n = 1 
Patients n = 2 
Death  
Patient n =2 
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Twenty eight pharmacists recruited 153 patients by the due date in February 2006. Sixty 
one patients associated with 17 pharmacists remained in the study by the baseline due 
date of 31 May 2006.  
 
At a provincial level, five pharmacists each from Gauteng and the Eastern Cape, one 
from KwaZulu-Natal, three from the Western Cape and two from Mpumalanga were 
recruited to the study. There were no participants from the Northern Cape, Limpopo, 
Free State or the North West Province. One of the Mpumalanga pharmacies closed after 
baseline collection of data and the pharmacist and associated patients were 
consequently lost to the study. 
 
8.3 Patient demographics 
 
A total of 61 DM2 patients participated in the study and of these 27 were randomly 
assigned to the control group and 34 to the intervention group.  Four patients were lost 
to the study, two as the result of the closure of a pharmacy and two due to death.  
 
Table 8.1 reveals that there were no significant differences between the control and 
intervention groups at baseline for any of the demographic characteristics other than for 
language (Chi-squared test, p<0.001), where in the control group English (74.1%) was 
more prevalent, whereas Afrikaans (76.5%) was the dominant language in the 
intervention group. Ethnically, the majority of the participants were white (85.2%). There 
were more male than female patients in both control (59.3%) and intervention (73.5%) 
groups, and the mean age was 59.8±11.8 years for the control group and 57.1±10.7 
years for the intervention cohort (independent t-test, p=0.349). Almost 90% of patients 
were married or living with partners, and equal numbers of patients completed 
secondary and tertiary education. 
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8.4 Baseline data 
8.4.1 Type 2 diabetes-related variables 
 
Table 8.2 reveals that there were no significant differences between the groups for any 
of the self–reported diabetes-related variables. The length of time following first 
diagnosis of DM2 was 9.5±8.7 years for the control group and 5.6±4.9 years for the 
intervention group (independent t-test, p=0.057). Just over 50% of patients reported that 
they had received diabetes self-management education, approximately 70% stated that 
they had consulted dieticians and followed diabetes eating plans, and a similar 
percentage (69%) reported having a family history of diabetes.  
Table 8.1  Patient demographics: baseline N(%) 
 
Characteristic 
 
Control 
N (%) 
 
Intervention  
N (%) 
 
 
p-value    
Gender   0.238
c 
 Male 16  (59.3) 25  (73.5)  
Female 11  (40.7)   9  (26.5)  
Age in years –(mean ±SD) 59.81±11.8 57.09±10.7 0.349
d 
Ethnicity   0.179
c 
Black   0  (0.0)   1  (2.9)  
White 25  (92.6) 27  (79.4)  
Mixed race   1  (3.7)   6  (17.7)  
Asian   1  (3.7)   0  (0.0)  
Marital status   0.978
c 
Married
a 
23  (88.5) 30  (88.2)  
Single
b 
  3  (11.5)   4  (11.8)  
Education – highest level completed   0.383
c 
Secondary 11  (42.3) 18  (54.6)  
Tertiary 15  (57.7) 14  (42.4)  
No schooling   0  (0.0)   1  (3.0)  
Home language    < 0.001
c 
isiXhosa   0  (0.0)   1  (2.9)  
Afrikaans   7  (25.9) 26 (76.5)  
English 20  (74.1)   6  (17.7)  
Sesotho   0  (0.0)   1  (2.9)  
a
Married = living with a partner,  
b 
Single = living alone 
 
c
 Chi-square test, 
d
 Independent t-test 
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Data not in a table reveals that while there was a difference in HbA1c between those with 
a family history of the disease (8.0±1.9), those without such a history (7.5±1.8) and those 
who were uncertain (7.2±0.9), the difference was not significant (independent t-test, 
p=0.521).  
 
Table 8.2 shows that the most prevalent of the self-management elements were social 
support and exercise-related advice. However, although over 80% of patients received 
advice on exercise, just over 50% exercised regularly and between a quarter and a third 
of patients (22.2% intervention and 35.3% control) did not follow meal plans designed to 
optimise glycaemic control. 
 
A higher percentage of control patients (70.4%) consulted general practitioners about 
their DM2 than patients in the intervention group (55.9%), and proportionately more 
intervention patients consulted specialists (32.4% vs 22.2%). Six patients (two control 
and four intervention) were uncertain if their practitioners were specialists or general 
practitioners. Intervention patients consulted general practitioners and specialist 
physicians more often (3.7±5.0 times per year) than patients in the control group 
(2.7±1.3 times a year) but again this difference was not significant (independent t-test, 
p=0.356).  
 
Table 8.2 shows that in addition to DM2, patients reported an average of almost two co-
morbidities, with hypertension the most common condition (59.3% of control and 58.8% 
of intervention patients, Chi-squared test, p=0.973). Over a third of patients reported 
being dyslipidaemic, approximately one in five said they had heart disease and just over 
10% said that they had been diagnosed with depression. Although the self-reported 
depression prevalence in the control group (7.4%) was lower than that in the intervention 
group (14.7%), the difference was not significant (Chi-squared test, p=0.402) possibly 
due to the small sample sizes.   
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Table 8.2  Frequency distribution of diabetes-related variables: baseline N (%) 
 
Patient characteristic 
 
Control  
 
Intervention  
 
 
Years since diagnosis (mean ± SD) 9.5±8.7 5.6±4.9 0.057
a 
Number of annual doctor consultations  (mean ± SD) 2.7±1.3 3.7±5.0 0.356
a 
Medical practitioner consulted for diabetes   0.639
b 
General Practitioner 19  (70.4) 19  (55.9)  
Specialist   6  (22.2) 11  (32.4)  
Not sure   2  (7.4)   4  (11.7)  
With family history of diabetes 19  (70.4) 23  (67.6) 0.968
b 
Received diabetes education 14  (53.8) 21  (61.8) 0.538
b 
Consulted a dietician 20  (74.1) 22  (66.7) 0.533
b 
Follow a diabetes friendly meal plan 21  (84.0) 22  (66.7) 0.135
b 
Advised by a healthcare professional to exercise 22  (81.5) 27  (81.8) 0.973
b 
Exercise regularly  3 – 5 times a week 14  (53.8) 19  (55.9) 0.875
b 
Receive social support from family and or friends 21  (80.8) 29  (85.3) 0.641
b 
Smoke tobacco   5  (18.5)   8  (24.2) 0.592
b 
Consume  alcohol  ≤ 2 units per day 13  (48.1) 16  (47.1) 0.933
b 
Co-morbidities and complications    
 Heart disease   6  (22.2)   7  (20.6) 0.877
b 
 Stroke   1  (3.7) 1  (2.9) 0.868
b 
 Hypertension 16  (59.3) 20  (58.8) 0.973
b 
 Dyslipidaemia 10  (37.0) 11 (32.4) 0.702
b 
 Depression   2  (7.4)   5 (14.7) 0.402
b 
 Nephropathy   1  (3.8)   0  (0.0) 0.249
b 
 Neuropathy   6  (22.2)   8  (23.5) 0.904
b 
 Retinopathy 11  (42.3) 12  (35.3) 0.580
b 
 a 
Independent t-test,
 b 
Chi-squared test 
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Retinopathy was the most commonly reported complication with almost 40% of patients 
stating that they had vision acuity problems which they ascribed to DM2. Only one 
patient reported having kidney disease, and approximately 20% indicated that they 
suffered from some form of neuropathy. About 50% of participants reported consuming 
two units or less of alcohol per day, and approximately 20% said that they smoked 
tobacco. 
 
8.4.2 Prescribed medication 
 
While all of the patients used prescribed medication as an aid to effecting glycaemic 
control, there was a significant difference between the groups at baseline with regard to 
the route of administration of the anti-diabetic agents (Chi-squared test, p=0.013). Table 
8.3 shows that 59.3% of control patients and 82.4% of the intervention patients used oral 
agents exclusively, while insulin as monotherapy was used by six patients (22.2%) in the 
control group only. Data not shown in a table reveals that the mean HbA1c for patients 
only using oral anti-diabetic therapy (7.7±1.9) was lower than for those patients on 
insulin alone (8.3±1.1) or those who used a combination of insulin and oral agents 
(8.3±1.5, independent t-test, p=0.503).  
 
There was no significant difference between the groups for any of the other classes of 
agents prescribed and used to treat heart disease (Chi-squared test, p=0.910), 
hypertension (Chi-squared test, p=702), or dyslipidaemia (Chi-squared test, p=0.341). 
Patient self-reported use of anti-hypertensive medication (63.0% control and 67.6% 
intervention) approximated the incidence of hypertension reported in Table 8.2.   
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Table 8.3 reveals that approximately one third of all patients said that they used 
medication to treat dyslipidaemia (Chi-squared test, p=0.341). The prevalence of anti-
depressant medication therapy was lower (6.6%) than the self-reported incidence 
(11.5%) of depression. Four patients (6.6%) reported using complementary medicines as 
part of their diabetes regimen. Metformin was the most widely prescribed oral anti-
diabetic agent, accounting for 54.6% of all oral agents, followed by gliclazide (29.9%), 
glybenclamide (10.4%), glimepiride (2.6%), glipizide (1.3%) and pioglitazone (1.2%).   
 
ACE inhibitors, either alone or in combination with diuretics, accounted for 37% of the 28 
different agents prescribed for hypertension, followed by calcium channel blockers 
(21%), β-adrenergic blockers (20%), angiotensin receptor antagonists (15%) and 
diuretics (7%). Prescription refill data provided by pharmacists revealed that 
approximately 84% of the prescribed hipolipidaemic agents were statins, 13% were 
fibrates, and one patient used cholestyramine. Only one patient used both a statin and a 
fibrate.  
 
8.4.3 Patient self-reported adherence to SEMDSA guideline  
 
There were no significant differences between the groups in terms of self-reported 
adherence to the SEMDSA guideline parameters presented in Table 8.4, with neither 
Table 8.3  Pharmacotherapy for DM2 and co-morbidities: baseline N (%) 
 
Variable 
 
Control  
N=27 
 
Intervention  
N=34 
 
p-value  
Chi-squared test 
 
Medication used for Type 2 diabetes:   0.013 
   Oral only 16  (59.3) 28  (82.4)  
 Insulin only   6  (22.2)   0  (0.0)  
 Oral and insulin   5  (18.5)   6  (17.6)  
Medication used for:    
Heart disease   5  (20.0)   7  (21.2) 0.910 
 Hypertension 17  (63.0) 23  (67.6) 0.702 
Dyslipidaemia 11  (40.7) 10  (30.3) 0.341 
Depression   1  (4.0)   3  (9.0) 0.449 
Complementary medicines used for diabetes   2  (7.4)   2  (5.9) 0.643 
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group fully adherent to any of the recommendations. Adherence percentages ranged 
from 11.1% (regular waist and hip measurement in the control group) to 85.3% (blood 
pressure measured at every consultation for the intervention patients).  
 
Approximately 50% of all patients had an HbA1c measured every six months, 33% were 
not tested and 17% were unsure if they had been tested for this key variable. There was 
no significant difference between groups with regard to the number of patients who had 
their HbA1c measured bi-annually (Chi-squared test, p=0.643). Similarly, there were no 
significant differences in HbA1c (independent t-test p=0.326) for those patients who 
tested every 6 months (8.0±1.6), those who did not have the test every six months 
(7.7±2.0), and those who said that they were not sure if their levels were ever measured 
(7.7±1.9)( data not included in a table).   
 
 
 
 
 
Table 8.4 Patient self-reported adherence to SEMDSAa guideline: baseline N (%)  
 
Test/examination 
 
Control 
N=27  
 
 
Intervention  
N=34 
 
 
 
p-value 
Chi-squared test 
HbA1c  tested every 6 months  14  (53.8) 16  (47.1) 0.643 
Self monitor blood glucose regularly 19  (73.1) 27  (79.4) 0.565 
Annual lipogram  18  (66.7) 23  (67.6) 0.969 
Blood pressure measured at every diabetes consultation 22  (81.5) 29  (85.3) 0.942 
Annual kidney function test  12  (44.4) 11  (32.4) 0.223 
Body mass measured at each diabetes consultation 12  (44.4) 17  (50.0) 0.768 
Waist and hip measured regularly   3  (11.1)   6  (17.6) 0.551 
Annual foot examination 13  (48.1) 12  (35.3) 0.252 
Annual dilated eye examination 16  (59.3) 23 (67.6) 0.498 
Annual ECG  11  (40.7) 13  (38.2) 0.897 
a
SEMDSA : Society for Endocrinology, Metabolism and Diabetes of South Africa  
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Approximately 75% of all patients said that they self-monitored their blood glucose 
levels, and of these 50% monitored once a day, 39% once a week with the remaining 
11% testing once a month. Data not shown in a table reveals that daily monitoring was 
associated with a lower HbA1c than was weekly or monthly monitoring (7.8±1.7, 8.0±2.2, 
and 8.2±1.4 respectively), while those patients who never self-monitored blood glucose 
had a mean HbA1c of 7.6±1.7. However, there were no significant differences in HbA1c 
associated with frequency of self-monitoring (independent t-test, p=0.865).  
 
Approximately one in six patients (16.4%) did not have their blood pressure measured at 
each diabetes consultation, although patients were more likely to have this test than to 
have any of the other tests recommended by SEMDSA. Fewer than 50% of all patients 
were weighed at each diabetes consultation and only about 15% reported having their 
waist and hip circumference measured. Approximately 60% of all patients did not have 
an annual foot examination or electrocardiogram. Just over two thirds said they had an 
annual lipogram. Adherence to the guideline tests and examinations exceeded 50% in 
only five out of the 10 tests/examinations recommended by SEMDSA. 
 
8.4.4  Association of patient characteristics with primary and secondary clinical 
endpoints 
  
The means and standard deviations of the primary and secondary endpoints associated 
with certain patient characteristics measured at baseline are shown in Table 8.5 and 
represent total data from all patients in the study (control and intervention).  
 
Patients who said that they had received diabetes education had a higher average HbA1c 
than those who had not received diabetes education (8.3±2.0vs 7.2±1.3, independent t- 
test, p=0.026)1 and those patients who exercised regularly had a lower average HbA1c 
than those who did not (7.3±1.6 vs 8.4±1.9, independent t-test, p=0.022)1. Following a 
diabetes eating plan (independent t-test, p=0.314), and receiving social support 
(independent t-test, p=0.347) were associated with a lower HbA1c but the differences 
were not significant. 
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There were no significant differences in HbA1c for gender or for any of the other patient 
variables not shown in a table including age, duration of diabetes, marital status, 
monitoring body mass, consulting general practitioners or specialists, smoking, 
consuming alcohol.  
 
Neuropathy (independent t-test, p=0.312) and problems related to eyesight (independent 
t-test, p=0.294) were associated with higher HbA1c but these differences were not 
                                               
1
Significant (p < 0.0083, Bonferroni adjustment) 
Table 8.5 Association of participant characteristics with clinical variables: baseline  
 
 
Variable 
 
 
 
N 
 
HbA1c
a 
 
 
Mean±SD 
 
Total
b 
Cholesterol 
 
Mean±SD 
 
HDL-C
b 
 
 
Mean±SD 
 
LDL-C
b
 
 
 
Mean ±SD 
 
Triglycerides
b 
 
 
Mean±SD 
 
Systolic
 b
  
BP 
 
Mean±SD 
 
Diastolic
b 
 BP 
 
Mean±SD 
 
BMI
b 
 
 
Mean±SD 
Gender          
 Male  41 7.8±1.9 4.7±1.1 1.0±0.3 2.7±0.9 2.3±1.5 142±17 83±12 30.7±5.0 
 Female  20 7.8±1.7 5.7±1.2 1.3±0.4 3.9±1.0 1.9±1.0 142 ±18 77±12 32.7±6.9 
Independent t-test p 0.899 0.0011 0.0021 0.00011 0.259 0.955 0.082 0.262 
Diabetes education          
 Yes 35 8.3±2.0 5.2±1.3 1.1±0.3 3.2±1.2 2.2±1.5 143±17 82±13 31.9±5.9 
 No 25 7.2±1.3 4.8±1.1 1.1±0.4 3.0±1.0 2.2±1.2 140±18 81±12 30.9±5.4 
Independent t-test p 0.026
1 
0.227 0.638 0.596 0.880 0.510 0.823 0.494 
Follow a diabetes diet 
plan 
         
 Yes 43 7.6±1.7 5.0±1.3 1.1±0.4 3.2±1.2 2.0±1.0 142±17 81±12 31.5±5.7 
 No 15 8.1±1.9 5.1±1.2 1.0±0.4 2.8±1.0 2.8±2.1 139±19 82±13 30.8±6.3 
Independent t-test p 0.314 0.838 0.297 0.316 0.0291 0.631 0.781 0.723 
Exercise regularly          
 Yes 33 7.3±1.6 4.9±1.1 1.2±0.4 3.1±1.0 1.9±1.5 142±17 82±13 30.6±5.9 
 No 27 8.4±1.9 5.1±1.4 1.0±0.3 3.1±1.2 2.6±1.1 141±18 80±11 32.1±5.4 
Independent t-test p 0.022
1 0.460 0.056 0.947 0.075 0.920 0.387 0.337 
Social support          
 Yes 50 7.8±1.7 4.9±1.2 1.1±0.4 3.1±1.1 2.2±1.4 142±17 82±13 31.5±5.4 
 No 10 8.4±1.9 5.4±1.1 1.1±0.3 3.2±1.1 2.4±1.1 137±15 79±8 31.6±6.9 
Independent t-test p 0.347 0.222 0.975 0.730 0.577 0.377 0.413 0.947 
a = primary endpoint, b = secondary endpoint 
1
Significant (p < 0.0083, Bonferroni adjustment) 
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significant. There was a small and non-significant difference in HbA1c between those 
patients who self-monitored blood glucose and those who did not (independent t-test, 
p=0.863). 
 
Comparison of blood lipid data (Table 8.5) revealed that female participants had higher 
total cholesterol (5.7±1.2 vs 4.7±1.1, independent t-test, p=0.001)1, HDL-C (1.3±0.4 vs 
1.0±0.3, independent t-test, p=0.002)1 and LDL-C (3.9±1.0 vs 2.7±0.9, independent t-
test, p=0.0001)1 levels than did male patients. However, mean triglyceride levels were 
higher in males (2.3±1.5) than in females (1.9±1.0, independent t-test, p=0.259).  
Patients who said that they had a lipogram at least once a year (data not included in a 
table) had lower total cholesterol levels than those who did not have the test annually 
(4.8±1.0 vs 5.6±1.4, independent t-test, p=0.012)1. While the cohort that tested annually 
also reflected improved levels for the constituent lipid fractions, these differences were 
not statistically significant. There were no significant differences in the lipid profiles of 
those patients who followed eating plans and those that did not.  
 
Data not reflected in any table revealed that patients who used hipolipidaemic 
medication had non-significantly lower total cholesterol levels than those who used 
medication (4.8±1.2 vs 5.1±1.2, independent t-test, p=0.361). There were no significant 
differences in either systolic or diastolic blood pressure correlated with any of the patient 
variables included in Table 8.5. Data not shown in any table revealed that, as would be 
expected, there was a significant difference in mean systolic blood pressure between 
those who used anti-hypertensive medication and those who did not (147±17 vs 133±16, 
independent t-test, p=0.003). There was, however, no significant difference in diastolic 
blood pressure between these two groups of patients (82±12 vs 70±11, independent t-
test, p=0.287).  
 
Although patients who had their blood pressure monitored at each diabetes consultation 
had both higher systolic and diastolic blood pressure (143±18 and 82±12) than did those 
who were not regularly monitored (139±14 and 79±13), the differences were not 
significant (systolic blood pressure, independent t-test,  p=0.546 and diastolic blood 
pressure, independent t-test,  p=0.581 respectively). No significant association with any 
of the patient characteristics were found for BMI.  
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8.5 Baseline and post-baseline clinical endpoints 
8.5.1 Comparison of primary and secondary clinical endpoints 
 
The results of the biochemical and other clinical variable tests and examinations 
conducted at baseline and post-baseline (Table 8.6) show that there were no significant 
differences for the primary endpoint or secondary endpoints at baseline or post-baseline 
for either the control or intervention patients. Similarly, there were no significant 
differences between the control and intervention groups for any of  the endpoints at 
baseline or at post-baseline.  
 
 
 
 
 
 
 
 
Table 8.6 Primary and secondary endpoints: control and intervention, baseline and post baseline 
Control                                  Intervention                                                             p-values 
Variable 
 
Baseline Post-
baseline 
Baseline Post-
baseline 
Control 
Baseline v 
post-baseline 
p-value
1
 
Intervention 
Baseline v 
post-baseline 
p-value
2
 
Baseline 
Control v 
Intervention 
p-value
3
 
Post-baseline 
Control v 
Intervention 
p-value
4
 
HbA1c (%) 7.3±1.2 7.6±1.6 8.2±2.1 8.2±1.8 0.295 0.815 0.046
a 
0.226 
Total-C (mmol/l) 4.9±0.8 4.7 ±0.9 5.1±1.5 4.9±1.2 0.123 0.351 0.490 0.375 
HDL-C (mmol/l)
 
1.2±0.4 1.1±0.4 1.0±0.3 1.0±0.3 0.027
a 
0.748 0.116 0.562 
LDL-C (mmol/l)
 
3.0±1.0 3.0 ±0.7 3.2±1.2 3.0±1.0 0.775 0.308 0.590 0.584 
Triglycerides (mmol/l)
 
2.3±1.7 2.2±1.1 2.1±1.1 2.2±1.2 0.632 0.291 0.689 0.966 
S-creatinine (µmol/l)
 
88.2 ±30.6 88.0±26.1 80.7±16.8 84.0±15.8 0.086 0.065 0.172 0.611 
Systolic BP (mm Hg) 139±14 138±16 141±19 139±19 0.659 0.445 0.320 0.765 
Diastolic BP (mm Hg)
 
80±12 80±11 82±12 82±11 0.853 0.923 0.559 0.412 
BMI (kg/m
2
) 30.3±5.7 30.2±6.0 32.4±5.9 32.1 ±5.6 0.843 0.531 0.296 0.254 
p-value
1 
and p-value
2 
– Dependent t-tests  
p-value
3 
and p-value
4 
– Independent t-tests 
 
a
Significant if p < 0.0083( Bonferroni adjustment) 
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Table 8.6 shows that there was no real change in HbA1c between baseline and post-
baseline within the intervention group (8.2±2.0 to 8.2±1.8), and a small increase within 
the control group (7.3±1.2 to 7.6±1.6), and that these differences were not significant 
(independent t-test, p=0.514, Table 8.7). Similarly, evaluation of the secondary clinical 
endpoint data reveals that there were no significant differences between the control and 
intervention groups (Table 8.6) or within the individual clinical variables (Table 8.7).  
 
 
 
 
 
8.5.2 Comparison of patients at goal for SEMDSA guideline for primary and 
secondary clinical endpoints 
 
Table 8.8 shows that neither of the two groups demonstrated any significant difference 
between baseline and post-baseline in terms of patients being at goal for any of the 
clinical variables included in the SEMDSA guideline.  
 
 
 
 
 
 
Table 8.7 Comparison of baseline to post-baseline changes within endpoint variables  
 
Variable 
 
 
N 
 
Control 
Mean ±SD 
 
 
N 
 
Intervention 
Mean ±SD 
 
p-value 
Independent t-test 
 
Difference in HbA1c 27 0.3±1.3 29 0.1±1.2 0.514 
Difference in total-C 27 -0.2±0.7 30 -0.2±1.2 0.984 
Difference in HDL-C 27 -0.1±0.2 29 0.0±0.2 0.040*
 
Difference in LDL-C 26 -0.1±0.8 27 -0.2±1.0 0.540 
Difference in Triglycerides 27 -0.1±1.1 29 0.2±1.2 0.277 
Difference in S-creatinine 24 3.6±9.9 27 0.3±8.9 0.901 
Difference in Systolic BP 27 -1.7±19.4 30 -2.1±15.1 0.919 
Difference in Diastolic BP 27 -0.4±12.4 30 -0.2±11.2 0.938 
Difference in BMI 26 -0.1±2.1 29 -0.3±2.2 0.766 
 
*Significant (p < 0.0083, Bonferroni adjustment)  
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8.6 Post-baseline prescription data 
 
Pharmacist-provided prescription data for anti-diabetic, hipolipidaemic and anti-
hypertensive agents for the six month period 1 December 2006 to 31 May 2007 (Table 
8.9) indicated no significant differences in prescription refill frequency between the 
control and intervention groups. Medication refill rates varied from a minimum of 
approximately 5.1 per 6 months for hipolipidaemic agents in the intervention group to a 
maximum of approximately 5.5 per 6 months for anti-hypertensive agents used by 
control patients. 
 
 
 
 
 
 
Table 8.8 Patients at goal for SEMDSA guideline  baseline and post-baseline 
 
    
  
Control 
Baseline     Post-baseline 
 
Intervention 
Baseline       Post-baseline 
p-value  
Chi-squared test 
Variable  N (%) N (%) p -value N (%) N (%)  
SEMDSA 
guideline 
       
HbA1c < 7% 11  (40.7) 11  (40.7) 1.000   9  (31.0)   9  (31.0) 1.000 
Total 
cholesterol 
< 5.0 mmol/l 10  (37.0) 15  (55.6) 0.125 12  (40.0) 16  (53.3) 0.344 
HDL-
cholesterol 
> 1.2 mmol/l   8  (29.6)   5  (18.5) 0.375  5  (17.2)   6  (20.7) 1.000 
LDL-
cholesterol 
≤ 3.0 mmol/l 12  (46.2) 15  (57.7) 0.375 10  (37.0) 15  (53.6) 0.125 
Triglycerides < 1.5 mmol/l   8  (29.6)   9  (33.3) 1.000 10  (34.5)   8  (27.6) 0.687 
Systolic 
blood 
pressure 
< 130 mmHg   5  (18.5)   5  (18.5) 1.000   9  (30.0)   6  (20.0) 0.375 
Diastolic 
blood 
pressure 
<  80 mmHg 15  (55.6)   7  (25.9) 0.021 13  (43.3) 12  (40.0) 1.000 
Body mass 
index 
< 25 kg/m
2 
  6  (22.2)   5  (19.2) 1.000   1  (3.4)   2  (6.9) 1.000 
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During the study 13 patients (five control and eight intervention) had insulin added to 
their regimens (Table 8.10) and 14 patients (11 intervention and three control) had their 
oral anti-diabetic therapy adjusted during the study. Although more adjustments were 
made within the intervention group than within the control group, the test of significance 
was inconclusive possibly due to the small sample sizes. Therapeutic adjustments 
included increases in dosage, alternative oral agent prescribed or additional agent 
added to the regimen.  
 
 
Table 8.9 Prescribed medication refill frequency: post-baseline (N=57) 
 
Prescription refills 
1 December 2006 to 31 May 2007 
 
Number of  
observations 
 
Number of refills 
in 6 months 
 
Mean number  
of refills in 6 months 
 
p-value 
Independent t-test 
 
Oral anti-diabetic agents
a
       
Control   28 148 5.3±1.3 0.742 
Intervention 52 280 5.4±1.1  
Hipolipidaemic agents
a
     
Control   15 81 5.4±1.4 0.579 
 Intervention 18 92 5.1±1.5  
Anti-hypertensive agents
a
     
 Control   30 164 5.5±1.4 0.415 
Intervention 35 182 5.2±1.2  
a
Pharmacological classification as per Monthly Index of Medical Specialities* 2007;47(9): 1-513  
Table 8.10 Adjustments to diabetes pharmacotherapy:  post-baseline N(%) 
 
Variable 
 
Control 
N=23 
 
 
Intervention 
N=31 
 
 
p-value  
Chi-squared test 
 
Increased dosage of oral anti-diabetic agent
a
 1  (4.3) 4  (12.9) 0.283 
Alternative oral anti-diabetic agent
 
 prescribed 0  (0.0) 4  (12.9) 0.073 
Additional oral anti-diabetic agent  prescribed 2  (8.7) 3  (9.7) 0.902 
Insulin added to regimen  5  (21.7) 8  (25.8) 0.730 
a
Pharmacological classification as per Monthly Index of Medical Specialities 2007;47(9): 1-513  
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8.7 Health-related beliefs, behaviours and knowledge 
8.7.1 Comparison of baseline and post-baseline health-related beliefs and 
behaviours 
 
Medication-related beliefs 
 
Results for medication-related beliefs are presented as Necessity and Concerns scales 
which reflect adherence-related facets of patient beliefs concerning medication for 
personal use, and Overuse and Harm scales which considered aspects of patient beliefs 
about medicines in general.  The mean Necessity and Concerns scale scores for both 
the control and intervention groups included in Table 8.11 reflect higher scores for 
Necessity than for Concerns at both baseline and post-baseline. 
 
 
 
Table 8.11 shows that while there were no significant differences between the control 
and intervention groups for the Necessity, Concerns and Necessity-Concerns Differential 
(NCD) scales at baseline or at the end of the study, there were positive differences in 
mean scale scores between the perception of necessity and concerns about the 
Table 8.11  Scale scores of medication-related beliefsa: baseline and post-baseline 
Scale items 
 
 
Baseline 
 
Control                   Intervention 
N=25                      N=28 
Mean±SD               Mean±SD 
                                       
 
 
 
 
p-value 
Post-baseline 
 
Control                   Intervention 
N=27                      N=30 
Mean±SD               Mean±SD 
                      
 
 
p-value 
Independent  t-test 
 
Necessity(5) 20.3±3.1 19.3±3.5 0.280 20.2±3.4   19.1±3.6 0.250 
Concerns (5) 12.6±3.7 13.2±3.6 0.518 14.5±3.1 13.3±3.9 0.206 
NCD (5) 
 
7.8±5.4 
 
6.1±4.8 
 
0.240 
 
5.7±3.9 
 
5.8±5.4 
 
0.918 
 
Overuse (4) 
 
10.9±3.2 
 
11.9±2.5 
 
0.258 
 
12.8±2.7 8.9±2.5 
 
0.130 
 
Harm (4) 9.0±2.8 9.6±1.9 0.364 11.5±3.3 9.7±2.4 0.212 
 a
Beliefs about Medicines Questionnaire
384 
Range 1-5: 1 = strongly disagree, 2 = disagree, 3 = uncertain, 4 = agree, 5 = strongly agree 
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prescribed therapy at baseline, and at post-baseline for the control and intervention 
groups. There were no significant differences between the control and intervention 
groups for the Harm and Overuse scales at baseline or post-baseline.   
 
Table 8.12 confirms the importance patients attached to their belief about the necessity 
of using medication for DM2, with more than 90% of both control and intervention 
patients attaining scores above the scale midpoint at both baseline and post-baseline. 
Concerns and Overuse scores for control patients increased during the course of the 
study while Harm scores decreased for this cohort. For the intervention group, scores 
reflected very little change in perception for Necessity, Concerns and Overuse but a 
marked increase for Harm (from 28.6% to 46.7%).  A substantially greater proportion of 
intervention patients attained scale scores above mid-point for Harm than did the control 
group at the end of the study (46.7% vs 18.5%).  
 
 
Satisfaction with diabetes care 
 
There was no significant difference between the control and intervention groups at 
baseline and post-baseline for patient satisfaction measures in terms of general diabetes  
care recently received (Table 8.13). In both groups post-baseline, patients ‘agreed’ or 
‘strongly agreed’ that they were more satisfied with the level of recent care received 
(Item 1, control post-baseline 85.2%, intervention post-baseline 76.6%, Chi-squared test,  
p=0.599) than with care provided over the longer term (Item 3, control post-baseline 
48.1%, intervention post-baseline 53.4%,Chi-squared test, p=0.905). 
 
Table 8.12 Percentage of patients attaining scores above scale mid-points: baseline 
and post-baseline  
 Baseline Post-baseline 
Scale (items) Control Intervention Control Intervention 
Necessity (5) 
Concerns (5) 
Overuse (4) 
Harm (4) 
96.0% 
40.0% 
64.0% 
24.0% 
96.4% 
42.9% 
67.9% 
28.6% 
96.3% 
55.6% 
85.2% 
18.5% 
93.3% 
40.0% 
70.0% 
46.7% 
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However, while few patients were dissatisfied with recent care received at the end of the  
study, about 30% expressed dissatisfaction (‘strongly disagree’ and ‘disagree’) with 
personal longer-term care (Item 3, control post-baseline 29.6%, intervention post-
Table 8.13  General satisfaction with recent carea: baseline and post-baseline  
Item  Strongly 
Disagree 
N (%) 
Disagree 
 
N (%) 
Not Sure 
 
N (%) 
Agree 
 
N (%) 
Strongly 
Agree 
N (%) 
 
Baseline  
 
1.“ I’m very satisfied 
with the diabetes care 
that I receive”  
 
Control 
Intervention  
p= 0.991
b 
0  (0.0) 
0 (0.0) 
3 (12.5) 
4 (14.3) 
  3 (12.5) 
  3 (10.7) 
15 (62.5) 
18 (64.3) 
3 (12.5) 
3 (10.7) 
2.“ Most people receive 
diabetes care that could 
be better” 
  
Control 
Intervention  
p=0.741
b 
0 (0.0)   
0 (0.0) 
2 (8.7) 
2 (7.1) 
  9 (39.1) 
13 (46.4) 
12 (52.2) 
12 (42.9) 
0 (0.0) 
1 (3.6) 
3.“ The diabetes care 
that I have received in 
the last few years is just 
about perfect” 
 
Control 
Intervention  
p=0.450
b 
0 (0.0)   
0 (0.0) 
8 (33.3) 
4 (14.8) 
  6 (25.0) 
  8 (29.6) 
  8 (33.3) 
13 (48.1) 
2 (8.3) 
2 (7.4) 
4.“There are things 
about the diabetes care 
I receive that could be 
better” 
 
Control 
Intervention  
p=0.352
b 
1 (4.2) 
0 (0.0) 
4 (16.7) 
3 (10.7) 
  8 (33.3) 
11 (39.3) 
  9 (37.5) 
14 (50.0) 
2 (8.3) 
0 (0.0) 
 
Post-baseline 
 
1.“ I’m very satisfied 
with the diabetes care 
that I receive”  
 
Control 
Intervention  
p= 0.599
b 
0 (0.0) 
1 (3.3) 
2 (7.4) 
2 (6.7) 
 
 
2 (7.4) 
4 (13.3) 
20 (74.1) 
17 (56.6) 
3 (11.1) 
6 (20.0) 
2.“ Most people receive 
diabetes care that could 
be better” 
 
Control 
Intervention  
p=0.689
b 
0 (0.0) 
1 (3.3) 
4 (15.4) 
2 (6.7) 
 
 
9 (34.6) 
9 (30.0) 
12 (46.2) 
17 (56.7) 
1 (3.8) 
1 (3.3) 
3.“ The diabetes care 
that I have received in 
the last few years is just 
about perfect” 
 
Control 
Intervention  
p=0.905
b 
2 (7.4) 
1 (3.3) 
6 (22.2) 
8 (26.7) 
 
 
6 (22.2) 
5 (16.7) 
  8 (29.6) 
11 (36.7) 
5 (18.5) 
5 (16.7) 
4.“There are things 
about the diabetes care 
I receive that could be 
better” 
 
Control 
Intervention  
p=0.104
b 
0 (0.0) 
3 (10.0) 
8 (29.6) 
5 (16.7) 
 
 
8 (29.6) 
4 (13.3) 
  9 (33.3) 
17 (56.7) 
2 (7.4) 
1 (3.3) 
a
 Diabetes History Scale
410 
 b
 Chi-squared test 
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baseline 30.0%), and approximately 20% (Item 3, control post-baseline 22.2%, 
intervention post-baseline 16.7%) were undecided (‘Not Sure’) about the level of long-
term care received (p=0.905). Over a third of all patients (Item 2, control baseline 39.1%, 
intervention baseline 46.4%; Item 2, control post-baseline 34.6% and intervention post-
baseline 30.0%) expressed uncertainty about the general level of care provided to all 
diabetics.  
 
Close to 60% of all patients were satisfied with their healthcare providers (expressed as 
‘good’, ‘very good’ or ‘excellent’, Table 8.14) at baseline and at the end of the study. This 
meant that approximately 40% of patients were unhappy with provider care, rating it as 
either ‘poor’ or ‘fair’. There was no significant difference between the groups for any of 
the individual scale items reflected in Table 8.14, although patients were most satisfied 
when it came to knowing who to approach about aspects of diabetes care  
(Item 4, ±70%) and least satisfied with the perceived level of interdisciplinary 
communication (Item 3, ±50%).  
 
 
 
 
Table 8.14 Satisfaction with healthcare provider care over the past 12 monthsa   
Item 
 
Poor 
N (%) 
Fair 
N (%) 
Good 
N (%) 
Very good 
N (%) 
Excellent 
N (%) 
 
Baseline  
 
1.“Keeping you 
informed about what 
the next step in your 
care would be” 
 
Control 
Intervention  
p= 0.921
b 
6 (25.0) 
6 (22.2) 
5 (20.8) 
5 (18.5) 
 
 
  6 (25.0) 
  7 (25.9) 
4 (16.7) 
7 (25.9) 
3 (12.5) 
2 (7.4) 
2.“Different health care 
providers  up-to-date on 
your current treatments 
and recent test results”  
 
Control 
Intervention  
p=0.196
b 
4 (16.7) 
9 (33.3) 
4 (16.7) 
7 (25.9) 
12 (50.0) 
  6 (22.2) 
4 (16.7) 
5 (18.5) 
0 (0.0) 
0 (0.0) 
3.“Communication 
between different health 
care providers caring 
for you” 
 
Control 
Intervention 
p=0.598 
b 
 
4 (16.7) 
8 (29.6) 
6 (25.0) 
7 (25.9) 
10 (41.7) 
  7 (25.9) 
4 (16.7) 
5 (18.5) 
0 (0.0) 
0 (0.0) 
4.“Knowing who to ask 
when you had 
questions about your 
health” 
 
Control 
Intervention  
p=0.275
b 
5 (20.8) 
3 (10.7) 
1 (4.2) 
7 (25.0) 
  8 (33.3) 
  7 (25.0) 
9 (37.5) 
9 (32.1) 
1 (4.2) 
2 (7.1) 
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Patient opinion about aspects of the diabetes care provided by their pharmacists (Table 
8.15) revealed no significant differences between the groups for any of the items 
contained in the questionnaire. Patients appeared most likely to be satisfied (‘agree’ and 
‘strongly agree’) with the notion that their pharmacists are equipped to provide diabetes 
care (Item 3, control baseline 73.9%, intervention baseline 85.7%, Chi-squared test, 
p=0.758; Item 3, control post-baseline 61.6%, intervention post-baseline 80.0%, Chi-
squared test, p=0.406) and least satisfied with the perceived level of collaboration they 
believe exists between pharmacists and medical practitioners (Item 4, control baseline 
47.8%, intervention baseline 57.2%, Chi-squared test, p=0.962; Item 4, control post-
baseline 30.7%, intervention post-baseline 50.0%, Chi-squared test, p=0.482).  
 
 
 
 
 
Table 14 continued 
Post-baseline 
1.“Keeping you 
informed about what 
the next step in your 
care would be” 
 
Control 
Intervention  
p= 0.756
b 
5 (18.5) 
7 (23.3) 
4 (14.8) 
5 (16.7) 
 
 
11 (40.7) 
  9 (30.0) 
2 (7.4) 
5 (16.7) 
5 (18.5) 
4 (13.3) 
2.“Different health care 
providers  up-to-date on 
your current treatments 
and recent test results”  
 
Control 
Intervention  
p=0.726
b 
6 (24.0) 
9 (30.0) 
6 (24.0) 
6 (20.0) 
10 (40.0) 
  8 (26.7) 
2 (8.0) 
4 (13.3) 
1 (4.0) 
3 (10.0) 
3.“Communication 
between different health 
care providers caring 
for you” 
  
Control 
Intervention  
p=0.918
b 
9 (34.6) 
9 (30.0) 
4 (15.4) 
7 (23.3) 
  8 (30.8) 
  7 (23.3) 
3 (11.5) 
4 (13.3) 
2 (7.7) 
3 (10.0) 
4.“Knowing who to ask 
when you had 
questions about your 
health” 
 
Control 
Intervention  
p=0.311
b 
2 (7.4) 
5 (16.7) 
4 (14.8) 
 
4 (13.3) 
14 (51.9) 
11 (36.7) 
5 (18.5) 
3 (10.0) 
2 (7.4) 
7 (23.3) 
a
Diabetes History Scale
410 
 b
 Chi-squared test 
 - 142 - 
 
 
 
 
Table 8.15 Patient opinion of pharmacist diabetes care: baseline and post-baseline 
Item 
 Strongly 
disagree 
N (%) 
Disagree 
 
N (%) 
Not sure 
 
N (%) 
Agree 
 
N (%) 
Strongly 
agree 
N (%) 
 
Baseline  
 
1.“My pharmacist 
provides me with a 
good level of diabetes 
care”  
 
Control 
Intervention  
p= 0.127
a 
2 (8.7) 
0 (0.0) 
2 (8.7) 
9 (32.1) 
 
 
3 (13.0) 
1 (3.6) 
13 (56.5) 
15 (53.6) 
3 (13.0) 
3 (10.7) 
2.“I would like my 
pharmacist to do more 
to help me manage my 
diabetes” 
 
Control 
Intervention  
p=0.308
a 
0 (0.0) 
1 (3.6) 
7 (30.4) 
9 (32.1) 
5 (21.7) 
2 (7.1) 
10 (43.5) 
11 (39.3) 
1 (4.3) 
5 (17.9) 
3.“I think that my 
pharmacist is equipped 
to provide me with 
diabetes care” 
 
Control 
Intervention  
p=0.758
a 
1 (4.3) 
0 (0.0) 
1 (4.3) 
1 (3.6) 
4 (17.4) 
3 (10.7) 
13 (56.5) 
18 (64.3) 
4 (17.4) 
6 (21.4) 
4.My pharmacist and 
doctor work together to 
provide me with 
diabetes care” 
 
Control 
Intervention  
p=0.962
a 
1 (4.3) 
1 (3.6) 
7 (30.4) 
7 (25) 
4 (17.4) 
4 (14.3) 
  9 (39.1) 
12 (42.9) 
2 (8.7) 
4 (14.3) 
Post-baseline 
 
1.“My pharmacist 
provides me with a 
good level of diabetes 
care”  
 
Control 
Intervention  
p= 0.821
a 
2 (7.7) 
4 (13.3) 
7 (26.9) 
6 (20.0) 
 
 
3 (11.5) 
2 (6.7) 
10 (38.5) 
11 (36.7) 
4 (15.4) 
7 (23.3) 
2.“I would like my 
pharmacist to do more 
to help me manage my 
diabetes” 
 
Control 
Intervention  
p=0.724
a 
0 (0.0) 
1 (3.3) 
9 (36.0) 
8 (26.7) 
5 (20.0) 
4 (13.3) 
10 (40.0) 
15 (50.0) 
1 (4.0) 
2 (6.7) 
3.“I think that my 
pharmacist is equipped 
to provide me with 
diabetes care” 
 
Control 
Intervention  
p=0.406
a 
0 (0.0) 
1 (3.3) 
2 (7.7) 
1 (3.3) 
8 (30.8) 
4 (13.3) 
12 (46.2) 
18 (60.0) 
4 (15.4) 
6 (20.0) 
4.“My pharmacist and 
doctor work together to 
provide me with 
diabetes care” 
 
Control 
Intervention  
p=0.482
a 
2 (7.7) 
4 (13.3) 
7 (26.9) 
5 (16.7) 
9 (34.6) 
6 (20.0) 
  5 (19.2) 
  9 (30.0) 
3 (11.5) 
6 (20.0) 
 a
 Chi-squared test 
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Adherence to self-management recommendations 
 
Results for the diabetes self-management adherence items presented in Table 8.16 
revealed no significant differences between the groups either at baseline or post-
baseline. Overall approximately 60% of the control group said that they were always 
adherent to DM2 self-management recommendation, other than for the item relating to 
managing body mass, where 41.7% of patients said that they were able to keep their 
weight under control. Similarly, 38.5% of intervention patients claim to always to have 
their body mass under control with about 50% of this cohort always adherent to the 
remainder of the self-management recommendations .  
 
Patients seldom reported ‘never’ being adherent, with body mass control presenting the 
greatest self-management challenge to both groups of patients (Item 2, ‘always’). The 
intervention group found coping with their emotions more problematic than managing 
their body weight at the end of the study.  
 
 
 
 
Table 8.16 Adherence to self-management recommendationsa: baseline and post-
baseline 
Item 
 Never 
N (%) 
Sometimes 
N (%) 
Always 
N (%) 
Don’t know 
N (%) 
Baseline 
 
1.“I keep my blood sugar in 
good control” 
 
Control 
Intervention  
p= 0.807
b 
 
0 (0.00) 
0 (0.00) 
 
  8 (33.3)  
11 (42.3) 
 
15 (62.5) 
14 (53.8) 
1 (4.2) 
1 (3.8) 
2.“ I keep my weight under 
control” 
 
Control 
Intervention  
p=0.797
b 
 
4 (16.7) 
3 (11.5) 
 
10 (41.7) 
13 (50.0) 
10 (41.7) 
10 (38.5) 
n/a 
n/a 
 
3.“I do the things I need to do 
for my diabetes (diet etc.).” 
 
Control 
Intervention  
p=0.371
b 
 
0 (0.00) 
1 (3.8) 
 
  9 (37.5) 
13 (50.0) 
15 (62.5) 
12 (46.2) 
n/a 
n/a 
 
4.“I handle my feelings (fear, 
worry, anger) about my 
diabetes fairly well.” 
 
Control 
Intervention  
p=0.649
b 
1(4.2) 
1 (3.8) 
 
  8 (33.3) 
12 (46.2) 
15 (62.5) 
13 (50.0) 
n/a 
n/a 
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8.7.2 Post-baseline health- related beliefs, behaviours and knowledge 
 
The following health-related beliefs, behaviours and knowledge variables were only 
measured post-baseline for both control and intervention patients. 
  
Patient empowerment 
 
The combined scores for ‘somewhat agree’ and ‘agree’ in Table 8.17 (±80% of patients) 
indicate that patients generally believe that they are empowered to provide the care they 
require in order to manage their DM2, with very little difference between the control and 
intervention groups for any of the items. Both groups viewed identifying specific areas of 
dissatisfaction with care (Item 1) as being more problematic than any of the other scale 
items. Patients appeared feeling most empowered about turning diabetes goals into 
action plans (Item 2).  
 
 
 
 
Table 8.16 continued 
Post-baseline 
 
1.“I keep my blood sugar in 
good control” 
Control 
Intervention  
p= 0.618
b 
 
0 (0.00) 
1 (3.3) 
 
 
  9 (34.6) 
  9 (30.0) 
 
 
17 (65.4) 
20 (66.7) 
 
 
0 (0.00) 
0 (0.00) 
 
 
2.“ I keep my weight under 
control” 
 
Control 
Intervention  
p=0.768
b 
 
1 (3.7) 
2 (6.7) 
 
13 (48.1) 
12 (40.0) 
13 (48.1) 
16 (53.3) 
n/a 
n/a 
 
3.“I do the things I need to do 
for my diabetes (diet etc.).” 
 
Control 
Intervention  
p=0.284
b 
 
0 (0.00) 
0 (0.00) 
 
  8 (29.6) 
13 (43.3) 
19 (70.4) 
17 (56.7) 
n/a 
n/a 
 
4.“I handle my feelings (fear, 
worry, anger) about my 
diabetes fairly well.” 
 
Control 
Intervention  
p=0.249
b 
0 (0.00) 
0 (0.00) 
 
13 (48.1) 
19 (63.3) 
14 (51.9) 
11 (36.7) 
n/a 
n/a 
 
a
Attitudes Towards Diabetes Scale
385 
 b
 Chi-squared test 
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Adherence to pharmacotherapy  
 
Self-reported medication adherence data for each of the five items included in Table 
8.18 revealed a degree of non-adherence (i.e.< 100% for the ‘Never’ column)  across all 
items.  
 
 
Table 8.17  Patient empowerment in diabetesa: post-baseline 
Item  Strongly 
disagree 
N (%) 
Somewhat 
disagree   
N (%) 
Neutral          
 
N (%) 
Somewhat 
agree       
N (%) 
Strongly 
agree    
N (%) 
“In general I believe that I:  
 
     
1…know what part(s) of 
taking care of my diabetes 
that  I am dissatisfied with 
 
Control 
Intervention 
p=0.422
b 
1 (3.8) 
4 (14.3) 
 
1 (3.8) 
3 (10.7) 
 
10 (38.5) 
  8 (28.6) 
 
  5 (19.2) 
  7 (25.0) 
 
  9 (34.6) 
  6 (21.4) 
 
2…am able to turn my 
diabetes goals into a 
workable plan 
 
Control 
Intervention 
p=0.990
b 
1 (3.8) 
1 (3.4) 
 
0 (0.0) 
0 (0.0) 
 
  0 (0.0) 
  0 (0.0) 
 
13 (50.0) 
15 (51.7) 
 
12 (46.2) 
13 (44.8) 
 
3…can try out different 
ways of overcoming 
barriers to my diabetes 
goals 
 
Control 
Intervention 
p=0.411
b 
0 (0.0)  
1 (3.4) 
 
0 (0.0)  
2 (6.9) 
 
  1 (3.8) 
  3 (10.3) 
 
18 (69.2) 
16 (55.2) 
 
  7 (26.9) 
  7 (24.1) 
 
4…can find ways to feel 
better about having 
diabetes 
 
Control 
Intervention 
p=0.252
b 
0 (0.0)  
3 (10.3) 
 
1 (3.8) 
1 (3.4) 
 
  5 (19.2) 
  5 (17.2) 
 
13 (50.0) 
  8 (27.6) 
 
  7 (26.9) 
12 (41.4) 
 
5…know the positive ways 
I cope with diabetes-
related stress 
 
Control 
Intervention 
p=0.467
b 
0 (0.0)  
2 (6.9) 
 
2 (8.0) 
2 (6.9) 
 
  6 (24.0) 
  3 (10.3) 
 
12 (48.0) 
14 (48.3) 
 
  5 (20.0) 
  8 (27.6) 
 
6…can ask for support for 
having and caring for my 
diabetes when I need it 
 
Control 
Intervention 
p=0.668
b 
0 (0.0)  
1 (3.4) 
 
2 (7.7) 
1 (3.4) 
 
  1 (3.8) 
  3 (10.3) 
 
10 (38.5) 
  9 (31.0) 
 
13 (50.0) 
15 (51.7) 
 
7…know what helps me 
stay motivated to care for 
my diabetes 
 
Control 
Intervention 
p=0.419
b 
0 (0.0)  
1 (3.4) 
 
0 (0.0)  
1 (3.4) 
 
  1 (3.8) 
  3 (10.3) 
 
13 (50.0) 
  9 (31.0) 
 
12 (46.2) 
15 (51.7) 
 
8…know enough about 
myself as a person to 
make diabetes care 
choices that are right for 
me”. 
Control 
Intervention 
p=0.428
b 
0 (0.0) 
0 (0.0) 
 
 
0 (0.0)  
1 (3.4) 
  1 (3.8) 
  2 (6.9) 
 
14 (53.8) 
10 (34.5) 
 
11 (42.3) 
16 (55.2) 
 
a 
Diabetes Empowerment Scale –Short Form
413 
 b
 Chi-squared test 
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There was a significant difference between the control and intervention groups for Item 
5, “I take less than instructed” (Chi-squared test, p=0.042), but no significant difference 
between the groups for any of the other items. The forgetfulness score (Item 1) for both 
control (53.8%) and intervention patients (60.0%) indicates that this factor was the main 
barrier to medication adherence (Chi-squared test, p=0.975). Overall, patients were least 
likely to use medication intermittently, i.e. “I stop taking them for a while” (Item 3, control 
96.2%, intervention 93.3%, Chi-squared test,  p=0.641). 
 
Depression 
 
Patients were screened for depression-related symptoms using the validated Major 
Depression Inventory428 (not reported in a table) where scores of between 20 and 24 
may indicate mild depression, 25 to 29 moderate depression and over 30 severe 
depression. Patients in the control group achieved a mean total score of 7.5±5.5 and 
Table 8.18 Adherence to pharmacotherapya : post-baseline 
Item 
 
 
Always 
N (%) 
Often 
N (%) 
Sometimes 
N (%) 
Rarely 
N (%) 
Never 
N (%) 
1.“I forget to take them.” 
 
Control 
Intervention  
p= 0.975
b 
1 (3.8) 
1 (3.3) 
0 (0.00) 
0 (0.00) 
 
 
3 (11.5) 
3 (10.0) 
8 (30.8) 
8 (26.7) 
14 (53.8) 
18 (60.0) 
2.“ I alter the dose.” 
 
Control 
Intervention  
p=0.978
b 
 
0 (0.00) 
0 (0.00) 
 
0 (0.00) 
0 (0.00) 
 
3 (11.5) 
3 (10.0) 
4 (15.4) 
5 (16.7) 
19 (73.1) 
22 (73.3) 
3.“I stop taking them for 
a while.” 
 
Control 
Intervention  
p=0.641
b 
 
0 (0.00) 
0 (0.00) 
 
0 (0.00) 
0 (0.00) 
 
0 (0.0) 
1 (3.3) 
1 (3.8) 
1 (3.3) 
25 (96.2) 
28 (93.3) 
4.“I decide to miss out a 
dose.” 
 
Control 
Intervention  
p=0.366
b 
 
0 (0.00) 
0 (0.00) 
 
0 (0.00) 
0 (0.00) 
 
0 (0.0) 
1 (3.3) 
2 (7.7) 
5 (16.7) 
24 (92.3) 
24 (80.0) 
5.“I take less than 
instructed” 
 
Control 
Intervention  
p=0.042
b 
 
0 (0.00) 
0 (0.00) 
 
0 (0.00) 
0 (0.00) 
 
2 (7.7) 
3 (10.0) 
5 (19.2) 
0 (0.0) 
19 (73.1) 
27 (90.0) 
a
 Medication Adherence Report Scale
422 
b
 Chi-squared test 
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those in the intervention group 8.7±9.4, with no significant difference between the two 
groups (independent t-test, p=0.595) 
 
Self-monitoring of blood glucose (SMBG) 
 
There were no significant differences between the two groups in terms of the items 
included in the SMBG scale (Table 8.19). Almost all patients monitored their blood 
glucose levels (Item 1, 92.3% of control and 86.7% of intervention patients, Chi-squared 
test, p=0.496), and over 80% in both groups used these data to inform self-management 
activities (Item 3, Chi-squared test, p=0.623), but fewer patients recorded these data 
(Item 2, 62.5% of control and 73.1% of intervention patients, Chi-squared test,  p=0.423).  
 
Approximately two thirds of patients said that their medical practitioners referred to their 
SMBG values (Item 4, 66.7% of control and 69.2% of intervention patients, Chi-squared 
test, p=0.312), whereas far fewer pharmacists appeared likely to review these data (Item 
5, 16.7% of control and 30.8% of intervention patients, Chi-squared test, p=0.213). Data 
not included in a table revealed that there was no significant difference in HbA1c between 
those patients who said that they monitored their blood glucose regularly and those who 
did not (7.8±1.7, 7.9±2.0, independent t-test, p=0.863). 
 
 
 
Table 8.19  Self-monitoring of blood glucosea: post-baseline 
Item 
 
Control 
N     % 
Intervention 
N    % 
p-value  
Chi-squared test  
1.“Do you test your blood sugar?” 24  (92.3) 26  (86.7) 0.496 
2.“Do you keep a record of your blood sugar results?” 15  (62.5) 19  (73.1) 0.423 
3.“Do you use your blood sugar test results to assist you in        
the management of your diabetes?” 
20  (83.3) 21  (80.8) 0.623 
4.“Does your medical practitioner use your blood sugar test 
results in prescribing your diabetes therapy?” 
16  (66.7) 18  (69.2) 0.312 
5.“Does your pharmacist use your blood sugar test results to 
suggest adjustments to your medication therapy?” 
4  (16.7) 8  (30.8) 0.213 
a
Adapted from the Diabetes Care Profile
385
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Diabetes knowledge 
 
The 14 item Diabetes Knowledge Test436 administered post-baseline (not reported in a 
table) revealed that  there was no significant difference between the groups in terms of 
the mean total scores for the scale, with 26 control patients and 30 intervention patients 
achieving scores (in a range of 0 to 14) of 10.3±2.5  and 10.4±2.2 respectively  
(independent t-test p=0.884).   
 
Self-rated understanding of diabetes  
 
Table 8.20 presents the post-baseline scores for understanding management practices 
in DM2. A greater proportion of patients generally rated their understanding as ‘Good’ or 
‘Excellent’ rather than ‘Poor’, with no important differences between intervention and 
control.  
 
There was a good level of understanding in the key self-management areas of diet and 
glycaemic control, medication use, SMBG and less so with regard to physical exercise. 
There was a significant difference between the groups for the scale item relating to 
understanding the complications of diabetes with the intervention group demonstrating a 
significantly improved self-reported understanding of this aspect (p=0.035). 
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Table 8.20 Self-rated understanding of aspects of diabetesa: post-baseline 
 
 Self-rated understanding of: 
 
 
Poor 
N (%) 
Good 
N (%) 
Excellent 
N (%) 
 
Diet and blood glucose control       
 
Control 
Intervention 
p= 0.550
b 
  2 (7.7) 
  1 (3.4) 
21 (80.8) 
22 (75.9) 
 
  3 (11.5) 
  6 (20.7) 
 
Weight management 
 
Control 
Intervention 
p= 0.075
b
   
 
  7 (26.9) 
  2 (6.7) 
18 (69.2) 
24 (80.0) 
  1 (3.8) 
  4 (13.3) 
 
 
Physical exercise 
 
Control 
Intervention 
p= 0.607
b
    
 
  4 (15.4) 
  5 (17.2) 
21 (80.8) 
21 (72.4) 
  1 (3.8) 
  3 (10.3) 
 
Use of medication  
 
Control 
Intervention 
p= 0.114 
b 
   
  2 (7.7) 
  0 (0.0) 
18 (69.2) 
17 (56.7) 
  6 (23.1) 
 13 (43.3) 
 
Blood glucose testing 
 
Control 
Intervention 
p= 0.896
b
   
 
  1 (3.8) 
  2 (6.7) 
17 (65.4) 
19 (63.3) 
  8 (30.8) 
  9 (30.0) 
 
Foot care   
 
Control 
Intervention 
p= 0.314
b
    
  6 (23.1) 
  3 (10.0) 
16 (61.5) 
19 (63.3) 
 
  4 (15.4) 
  8 (26.7) 
 
Complications of diabetes 
 
Control 
Intervention 
p= 0.035 
b
  
 
  6 (24.0) 
  5 (16.7) 
19 (76.0) 
18 (60.0) 
  0 (0.0) 
  7 (23.3) 
 
Eye care 
 
Control 
Intervention 
p= 0.769b
 
 
  6 (24.0) 
  5 (16.7) 
13 (52.0) 
18 (60.0) 
  6 (24.0) 
  7 (23.3) 
 
Combining diabetes medication with other 
medication 
 
Control 
Intervention 
p= 0.075
b
   
 
10 (38.5) 
  6 (20.0) 
16 (61.5) 
20 (66.7) 
  0 (0.0) 
  4 (13.3) 
 
Alcohol use and diabetes 
 
Control 
Intervention 
p= 0.687
b
    
 
  4 (15.4) 
  6 (20.0) 
16 (61.5) 
15 (50.0) 
  6 (23.1) 
  9 (30.0) 
a 
Understanding Management Practices Scale adapted from the Diabetes Care Profile
385 
b Chi-squared test 
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CHAPTER 9 
DISCUSSION OF RESULTS  
 
9.1 Introduction 
 
Findings at the conclusion of the study indicate no significant differences between the 
control and intervention patients with regard to changes to the primary endpoint of 
HbA1c, nor to any of the secondary biochemical or clinical markers, nor were there any 
significant differences between the two groups in terms of medication adherence and 
adherence to DM2 self-management recommendations. It may be concluded, therefore, 
that the intervention pharmacists showed no demonstrable influence on any of the 
intermediate health outcomes relating to metabolic control or on therapeutic adherence 
in DM2 that was significantly different from that exerted by the control cohort of 
pharmacists.  
 
9.2 The challenge of recruiting pharmacists  
 
The participation of only 16 pharmacists, all of whom were white and mostly female, did 
not adequately represent community pharmacy in South Africa. Recruiting pharmacists 
to the study proved problematic despite efforts to involve pharmacist organisations in the 
recruitment process. While the initial interest expressed by pharmacists was promising, 
many failed to participate for a number of reasons. The spectre of substantially reduced 
revenue and profit margins, which pharmacists believed would accompany the 
introduction of price control on medicines and corporate ownership of pharmacy in South 
Africa, impacted so negatively on community pharmacist sentiment that many in the 
profession questioned the continued viability of community pharmacy practice. This 
negative sentiment was reflected in the closure of some 150 pharmacies between 2004 
and the end of 2006 with further pharmacy closures during 2007 (personal 
communication: Ms Sarah Nyama, Senior Registration Officer, South African Pharmacy 
Council, June 2008).  
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It is probable that the pessimism pervading community pharmacy impacted negatively on 
the study as it became evident during the recruitment process that the voluntary 
commitment of time and resources by pharmacists was by no means assured.  As 
patient and pharmacist attrition levels were difficult to anticipate it was decided to 
canvass for pharmacist participation as broadly as was possible, given the limits 
imposed by available research resources. Similar barriers have been identified by other 
researchers as important impediments to the effective recruitment of pharmacists to 
practice-based research projects.181  
 
It is possible that other factors affected participation including inadequate pharmacy 
infrastructure (e.g. absence of a separate patient counselling area), a perceived lack of 
capacity (i.e. skills, resources, support staff), confidence, and awareness of the purpose 
and value of research.181,529 It was beyond the scope of this study to investigate the 
reasons for pharmacist non-participation, but given the profession’s stated commitment 
to practice-based research, and the professional imperative of using research to inform 
and guide education, training and practice,186  this aspect warrants further investigation.   
 
Pharmacists have often been compensated for participating in research,175,359 and some 
studies note that they have been specifically trained to implement interventions, or that 
they are credentialed to provide care for designated diseases.9,173,175  However, these 
potentially confounding influences are not always acknowledged or discussed when 
outcomes are reported.38 It is probable that more pharmacists would have been recruited 
had there been a promise of compensation. However, it was felt that paying pharmacists 
to participate in intervention research could have introduced an element of bias as 
community pharmacists in South Africa are not generally paid to provide CPS. 
 
The more successful diabetes-related pharmaceutical care interventions noted in the 
literature appear to be associated with specific training of specialist pharmacists and the 
intensive, ongoing support of these pharmacists. 9,173,175  However, this approach does 
not satisfactorily emulate standard community pharmacy practice, as it is associated with 
a more controlled ‘laboratory-style’ research environment. Practising pharmacists may 
be reluctant to participate in research if they question the relevance of studies in the 
context of their own practice.181  
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The lack of face-to-face contact between the researcher and pharmacists may also have 
negatively affected pharmacist recruitment. Initially, a face-to-face recruitment and 
training strategy was mooted but logistical barriers prevented the adoption of such an 
approach mainly because the study was not restricted to any geographical area in South 
Africa and because most pharmacists were constrained by time and human resources 
which prevented attendance at after-hours training.  
 
Recruitment by proxy and the use of a distance-learning training approach appeared to 
offer the next best option, especially since the continuing education programmes for 
pharmacists that are on offer from the Pharmaceutical Society of South Africa most often 
use distance-learning with written material as the method of instruction, and pharmacists 
are therefore familiar with such an approach. Poor communication between researchers 
and pharmacists has been identified as a major barrier to effective research.181  
Reflecting on the recruitment process adopted in this study, far too much reliance was 
placed on the communication media of the various pharmacy organisations during the 
recruitment phase.  
 
9.3 Patient participants 
 
The patients recruited to the study may not have been fully representative of insured 
patients with DM2 in South Africa, as it is possible that there was a disproportionate 
representation of individuals who were already engaged with their care, i.e. there may 
have been little or no representation of those who were medically disengaged from care 
and who for this reason declined to participate. This impacts on the external validity of 
the study. The relatively high levels of adherence reported later in this chapter, in 
contrast to the findings contained in the WHO report on adherence to long-term 
therapies,1 may support such an assumption.  
 
Randomisation of the patient selection sequence reduced the potential for selection bias, 
although it was not possible to audit this process in the pharmacies.35 The stratification 
of pharmacists to improve matching before the randomisation of pharmacists and their 
patients to control and intervention groups at pharmacy level, reduced bias and 
prevented contamination of the groups.35,359 
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Demographically the only significant difference between the intervention and control 
groups was language. Neither group accurately reflected the ethnic composition of the 
South African population,530 although the sample did more closely represent the ethnicity 
of insured healthcare consumers whose prescriptions were filled by community 
pharmacists (personal communication M Willie Council for Medical Schemes 3 
December 2008).  
 
Patient participation may have been influenced by the socioeconomic conditions 
prevailing in South Africa as high levels of unemployment and poverty, especially 
amongst black individuals, prevent many South Africans from being able to access the 
insured healthcare sector.508 Another important barrier to patient use of community 
pharmacy for prescription medicines in this country is the high proportion of medical 
practitioners who dispense medicines to their patients.516 Many black South Africans, 
especially those with few socioeconomic resources, prefer and rely extensively on 
culturally adroit traditional healers and their remedies for a range of physical and 
psychosomatic conditions.331,531,532 This also negatively influences the number of patients 
who receive medicines dispensed by community pharmacists. 
  
As with the demographic data, there were no important differences between the two 
patient groups for other self-reported patient data,359 such as the length of time since first 
diagnosis of DM2 or level of medical care provided, that could have confounded the 
results.   
 
9.4 Co-morbidities and complications  
 
Despite the well-recognised role of glycaemic control in the prevention and arresting of 
diabetes-related complications,4,85 50% of patients did not have their HbA1c levels 
measured every six months, and a further 15% said that they did not  know if this test 
had been done. This finding raises important questions relating to the quality of diabetes 
care, including the method of assessing the effectiveness of therapeutic interventions, if 
intermediate outcomes are not being measured. The old business management adage 
of “if you don’t measure you can’t manage” applies equally to managing glycaemia in 
evidence-based diabetes care.533 
 
 - 154 - 
Hypertension was the most commonly reported co-morbidity and the 60% prevalence in 
both groups  was not significantly different from the 70% reported in the literature.257  
While the vast majority of patients had their blood pressure measured at each diabetes-
related visit (>80% in both groups), less than 25% of all patients were at the SEMDSA 
guideline goal for systolic blood pressure.105 This finding is in line with epidemiological 
data noted in the Hypertension Optimal Treatment (HOT) study,97 and is a particular 
cause for concern as a hypertensive diabetic is particularly at risk for other diseases 
including cardiovascular disease, stroke, nephropathy and retinopathy.4   
 
Cardiovascular disease accounts for between 50% and 80% of all diabetes-related 
deaths.4,41,101 A finding that should be of concern was that despite clear evidence of the 
association between dyslipidaemia, diabetes and cardiovascular disease,534,535 one third 
of all patients reported not having an annual lipogram and over 60% did not have an 
annual ECG. Furthermore, although the correlation between the anthropometric 
variables and cardiovascular risk is well established,49,116 less than 50% of patients 
stated that they were weighed at each diabetes consultation and less than 20% had their 
waist-hip circumference measured. 
 
At the end of the study, 87% of study patients were classified as either overweight or 
obese in terms of the SEMDSA guideline, correlating closely with WHO data which 
shows that approximately 90% of individuals with DM2 are either overweight or obese.49 
One of the most challenging aspects of diabetes self-management relates to the control 
of body mass and a comparison of before and after data, which reveals very little change 
to BMI within or between the groups, bears witness to the difficulty of the problem.361 
However, in other studies, pharmacists have demonstrated an ability to successfully 
counsel patients for weight loss, and they are generally well positioned to provide weight 
reduction support.536,537   
 
 Retinopathy, nephropathy and neuropathy are the most common microvascular 
complications of DM2 and, as a consequence, they make an important contribution to 
the patient’s overall  burden of disease.91,127,538  Approximately 60% of patients reported 
not having an annual eye examination, and although the screening prevalence reported 
in the study compares favourably with data forthcoming from a recent South African 
study where 5.2% of patents had a regular annual fundoscopy,126 it is possible that 
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patients under reported this complication,91 especially as retinopathy often precedes any 
loss of vision. Over 60% of patients did not have an annual kidney function test despite 
raised albuminuria in diabetes being associated with cardiovascular disease and the 
development of nephropathy.103,539,540 This reflects inadequate screening practices, 
especially as other South African data reveals nephropathy prevalence to be significantly 
greater than that reported in this study.541,542  
 
A similar situation exists for neuropathy which may be more prevalent than was reported 
given that approximately 60% of patients did not have an annual foot examination. 
Sexual dysfunction is a common and important complication of diabetes515 but was not 
investigated in this study. This should have been included as pharmacists may be asked 
to counsel individuals on this condition, and as DM2, hypertension, heart disease and 
certain medications used to treat these conditions are associated with the 
complication.544  
  
The overall 11.5% prevalence of depression in this study was lower than the 15%-20% 
reported in the literature.423 This lower prevalence may be due either to under-reporting 
by patients or may reflect the psychological profile of the patients who were willing to 
participate in the research. Concurrent depression has been shown to influence 
glycaemic control and self-management adherence negatively.545 Pharmacists have 
demonstrated that they are able to screen patients for depression using validated 
instruments and to refer identified patients for professional psychological evaluation.546   
 
9.5 Changes to surrogate outcomes (primary and secondary clinical endpoints) 
 
A comparative analysis of all the biochemical and clinical data, with the exception of 
serum creatinine, allows for an immediate visual ‘picture’ of a particular intermediate 
health outcome, for example an HbA1c > 7.0 indicates the absence of glycaemic 
control.105 Pharmacists, having been provided with clinical data at baseline, were 
positioned to easily identify patients not at guideline goal for HbA1c and were therefore 
able to collaboratively tailor individualised remedial interventions.20 The same principle 
holds true for blood lipid values and dyslipidaemia, blood pressure and hypertension and 
BMI and obesity. The serum creatinine value, while not providing an ‘instant picture’ of 
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an intermediate clinical outcome, is an essential element in calculating the glomerular 
filtration rate, which is considered to be the best index of renal function.129  
 
There were no significant differences in any of the clinical variables designated as 
primary and secondary endpoints, either between or within the groups at the end of the 
study.  HbA1c, lipid profiles, serum creatinine, blood pressure and BMI are all accepted 
surrogate markers or intermediate outcomes for the hyperglycaemia associated with 
DM2, dyslipidaemia, chronic kidney disease, hypertension and obesity, 
respectively.173,458  
 
A recent systematic review of pharmacist outpatient interventions in adults with diabetes, 
found that although there were very few RCTs of community pharmacist interventions, 
and despite studies often being limited by design flaws, there was some evidence of 
overall improvement in HbA1c.
458 A systematic review of the literature relating to the 
value of CPS provided in community settings between 1990 and 2002 identified six 
diabetes-related RCTs in which HbA1c was used as a surrogate endpoint.
12 Of these only 
one study was able to show a significant improvement in HbA1c in the intervention group, 
although patients were only followed for four months thus rendering any sustained 
improvement in HbA1c uncertain.
547 A Cochrane review that considered outpatient 
pharmacist impact on patient outcomes concluded that the quality of existing studies 
makes assessment of pharmacist effectiveness difficult.183 
 
9.6 Patients at goal for SEMDSA DM2 guideline 
 
Given the evidence-based nature of the SEMDSA guideline and its role in promoting 
metabolic control in DM2,105 an alternative method of evaluating the DCP intervention 
was to compare the percentage of patients at goal at baseline versus post-baseline. 
There were positive changes in the percentage of patients at goal for some of the lipid 
factors (i.e. total cholesterol and LDL-C) in both groups by the end of the study but there 
were no significant changes in the percentage of patients at goal for any of the other 
clinical variables including HbA1c.  
 
The study did not investigate patient knowledge of guideline recommendations, although 
the intervention pharmacists were provided with copies of the SEMDSA guideline and it 
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was suggested that they discuss the contents with their patients. A recent study relating 
to the prevention of coronary heart disease in DM2 demonstrated the utility of clinical 
practice guidelines in providing a basis for collaboration between pharmacists and 
medical practitioners.  
 
9.7 Prescribed medication  
 
Although there was no significant difference within or between the intervention and 
control groups for glycaemic control, the lower mean HbA1c demonstrated by the control 
group both at baseline (7.3%) and post-baseline (7.6%), compared to the intervention 
group (8.2% at baseline and post-baseline) is a surprising finding given that the control 
patients had been diagnosed with DM2 for considerably longer than the intervention 
group (9 years vs 5 years), and given that DM2 is a progressive disease with insulin 
resistance and β-cell failure increasing over time resulting in an increased HbA1c.
56 The 
control group appeared to have been subjected to more intensive therapy with over 40% 
of the group using insulin either alone or in combination with oral agents, whereas less 
than 20% of the intervention group used insulin and then only in combination with oral 
agents, which may explain the lower mean HbA1c levels reported by the control group.  
 
It is expected that therapy would be intensified with insulin being added to the regimen 
as glycaemic control decreased. This was confirmed in this study which revealed that the 
mean HbA1c in patients using only oral anti-diabetic therapy was lower than for those 
patients on insulin alone or those who used a combination of insulin and oral agents. 
 
Overall insulin utilisation by just over a quarter of study patients appears to be similar to 
that reported previously,549 and is commensurate with South African anecdotal data 
where it is estimated that 26% of DM2 diabetics use insulin (personal communication, 
Young Z, Novo-Nordisk (Pty) Ltd. 20 October 2008). The inadequacy of oral therapy 
occurs over time as a consequence of the progressive nature of DM2, and becomes 
evident once hyperglycaemia persists despite a regimen of two oral agents at maximum 
dose.51 In this study just under two-thirds of all patients using oral anti-diabetic agents 
were taking two agents, with the balance on monotherapy. It was not established if the 
maximum dose of the prescribed medication was being taken and it may be that 
dosages could be further titrated in order to improve glycaemic control.  
 - 158 - 
 
Given that the mean HbA1c of the dual oral therapy group (8.1%) exceeded the IDF 
threshold for initiating insulin therapy (>7.5%),4 it is probable that an additional number of 
patients should have been using insulin as well as oral therapy. The reluctance to use 
insulin both at a provider and a patient level has been described in the literature,550-552 
and may, in part, explain why less than 30% of all patients were at goal for HbA1c at the 
end of the study. Previous research has shown that pharmacists who are prepared to 
develop skills relating to optimising insulin utilisation are able to assist patients and other 
providers in resolving common barriers to this essential therapy.553 
 
The incidence of hypertension and anti-hypertensive medication utilisation reported in 
the study correlated with literature data.89 It is unlikely that the anti-hypertensive 
regimens were optimised given that almost two thirds of patients were on monotherapy, 
whereas the UKPDS and the SEMDSA guideline suggest a two to three agent approach 
in managing hypertension in DM2.104,105  
 
The defined scope of practice of a community pharmacist provides for the appropriate 
monitoring of blood pressure.6 In addition to monitoring and advocating appropriate 
lifestyle and behavioural modifications,554 pharmacists may consider suggesting 
adjustments to antihypertensive therapy where goals are not being met,174 especially 
with regard to the possible inclusion of agents from the ACE inhibitor and ARB classes, 
given the additional renal protection properties of these agents.555 Hypertension 
intervention studies have demonstrated cost-effective outcomes resulting from 
collaborative pharmacist interventions.359,556 
 
The self-reported prevalence of heart disease and dyslipidaemia closely correlated with 
pharmacy prescription data for hipolipidaemic agents. However, the relatively low level of 
statin utilisation indicates possible suboptimal use.  While over a third of patients were 
taking a statin, utilisation was considerably lower than that recommended by the IDF,4 
the Collaborative Atorvastatin Diabetes Study (CARDS)100 and the Heart Protection 
Study99 which suggest that all patients over the age of 40 should be considered for statin 
therapy.  
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The results demonstrating that only 57.7% of control patients and 53.6% of intervention 
patients met the SEMDSA guideline criterion for LDL-C (≤3.0 mmol/l) at the end of the 
study reflect the inadequacy of blood lipid control.105  This result suggests that while it 
may appear that intervention pharmacists did little to influence lipid control, there is 
substantial potential for pharmacists to contribute to both the treatment and the 
prevention of cardiovascular disease via the medication review process. Such 
interventions should include non-pharmacotherapeutic as well as pharmacotherapeutic 
options.557,558     
 
While adjustments to glycaemia-related pharmacotherapy were noted at the end of the 
study, it was, however, not possible to ascertain from the data when the changes 
occurred or if any of the interventions were initiated as a direct result of pharmacist 
recommendations. 
 
9.8 Health-related beliefs, behaviours and diabetes-related knowledge 
 
Results relating to psychosocial variables revealed very little difference in control and 
intervention groups between baseline and the end of the study. 
 
9.8.1 Medication-related beliefs, satisfaction with care and patient empowerment 
 
Patients unequivocally indicated that they believed that the necessity of taking 
medication for DM2 far outweighed any concerns about the perceived adverse effects of 
these medicines. This finding is in line with that of a study that investigated patient 
beliefs concerning the role of medication in chronic disease management, where almost 
90% of patients said that they believed that medication use was a necessary element of 
their care.559 The ‘necessity’ and ‘concerns’ beliefs about medication are closely 
associated with adherence to therapy,272 and the reported positive necessity-concerns 
differential supported the high levels of adherence measured by patient self-report and 
prescription refill frequency data. Neither control nor intervention patients appeared 
overly concerned about the possible harm that medicines in general may do, or about 
the possibility that medical practitioners may overuse medication.272 
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At the end of the study the vast majority of both control and intervention patients (>80%) 
were very satisfied with their recent diabetes care, but substantially fewer (<60%) were 
similarly satisfied with their long-term care. However, it is possible that certain 
expectations arising from participation in the research may have influenced the ‘recent 
care’ scores. While a minority of patients, (22%) considered 12-month care specifically 
provided by their healthcare providers to be ‘poor’ either at baseline or post-baseline, a 
further 20% rated such care as ‘fair’. These findings generally indicate a less than 
satisfactory state of affairs, as patient satisfaction is both a surrogate measure of the 
value patients place on services they receive,560  and is an important driver within the 
adherence dynamic.403  
 
The relatively high level of patient dissatisfaction expressed with regard to longer-term 
care may have been influenced by the intrinsic nature of DM2,561 i.e. it is a progressive 
chronic disease in which the prevalence of complications and associated co-morbidities 
are almost certain to increase over time and patients may experience frustration and a 
sense of powerlessness which may have fuelled their dissatisfaction with long-term 
care.193 In addition, dissatisfaction may be associated with diabetes distress or with the 
embarrassment that some individuals feel about having diabetes.562 Patient 
dissatisfaction with the perceived level of communication between healthcare providers 
speaks to the continued absence, at a systems level, of models of collaborative patient-
centred diabetes care in South Africa.  
 
The percentage of control patients who expressed satisfaction with their pharmacists 
declined by almost 16% during the study, while in the intervention group the percentage 
decline was in the order of 4%. The decline in satisfaction may be a reflection of unmet 
expectations arising from the research process, i.e. patients may have had unrealistic 
expectations relating to the purpose and processes involved in the research. This 
satisfaction differential may be attributed to the increased interaction between 
pharmacists and patients in the intervention group. Patients were particularly dissatisfied 
with the perceived level of communication between pharmacists and medical 
practitioners. Poor levels of communication between healthcare providers has been 
identified as an important barrier to optimising the medication utilisation process.161 
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Encouragingly, at the end of the study approximately 80% of the intervention patients 
continued to believe that pharmacists were equipped to provide diabetes care, while only 
60% of control patients believed similarly. This finding correlates well with the findings of 
a recent systematic review of pharmacist interventions in diabetes, which endorses 
value-added roles for pharmacists in diabetes care,458 and this augurs well for 
pharmacist-delivered diabetes services as it indicates that intervention pharmacists were 
able to positively influence patient perception in this regard. Furthermore, it confirms the 
existence of a foundational basis for the future development of services in line with 
diabetes CPS provided elsewhere.173  
 
There was no significant difference between the control and intervention patients in 
terms of feeling empowered, with over 85% of patients stating that they ‘agreed’ or 
‘strongly agreed’ that they were empowered to manage psychosocial aspects of their 
diabetes. The only areas where patients expressed uncertainty were in being able to 
identify specific aspects of care that caused most dissatisfaction, and in remaining 
positive about coping with diabetes and the stress that having the disease may cause. A 
Swedish diabetes education RCT found no significant difference between the groups in 
terms of patient empowerment,563 although the Asheville Project post-study focus group 
noted that patient diabetes empowerment perception improved as a result of the 
pharmaceutical care intervention.32    
 
9.8.2 Diabetes self-management adherence and depression screening. 
 
Patients were largely adherent to both their prescribed medication therapies and to self-
management recommendations, and no significant differences were identified between 
the control and intervention groups to indicate any intervention effect.  
 
Despite being associated with a possible overestimation of adherence,350 the patient 
adherence self-report is nevertheless a useful tool for identifying barriers to self-
management, which is the cornerstone of effective diabetes care.564,565  The results show 
that approximately 40% of patients said that they always managed to control their body 
mass and that between 50–60% of patients stated that they were adherent at baseline to 
self-management recommendations ranging from glycaemic and emotional control, 
eating appropriately, exercising, monitoring clinical variables, keeping appointments to 
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taking medication. One possible reason that the intervention group was not able to effect 
significant improvements in self-management adherence, when compared with those 
reported by the control group, may be the lack of sufficient emphasis within the DCP 
framework on the importance of adherence. Other reasons may include pharmacist 
uncertainty about what options to explore in developing adherence promoting 
interventions, and that an insufficient number of pharmacists with their patients 
developed and implemented interventions.  
 
Studies of interventions aimed at improving medication adherence in patients with 
chronic diseases have not all demonstrated positive outcomes.324,343 An RCT involving 
16 community pharmacies that compared patient adherence to therapies in two groups, 
one of which received comprehensive pharmaceutical care and the other traditional 
pharmacy services, found that although the intervention group was more satisfied with 
the level of care, adherence was not significantly different from that demonstrated by the 
control patients.405 A Cochrane review of interventions designed to enhance medication 
adherence, found that simple treatment regimens (e.g. a single dose of an agent once a 
day) and complex strategies, which could include comprehensive patient information, 
frequent counselling, follow-up and supervision of self-monitoring, and psychosocial 
support, were more likely to result in improved adherence and treatment outcomes than 
single component interventions. However, the reviewers note even complex strategies 
and interventions appear not be effective in the long term, in spite of the considerable 
time and effort required.330  
 
A common denominator across successful interventions appears to be the improved and 
frequent interaction between provider and patient,330 which supports the nexus of the 
Chronic Care Model,155 i.e. the productive interaction between prepared and proactive 
pharmacist and an informed an informed and activated patient (Section 3.5.3). A 
pharmacist facilitated patient self-management programme described by Garrett and 
Blumi176 was able to demonstrate improved patient adherence to treatment and 
improved clinical, economic and humanistic outcomes through a collaborative process of 
review, coaching and reinforcement. In contrast to this positive finding, a multi-clinic RCT 
of a pharmacist intervention in poorly controlled diabetics by Odegard et al37 did not 
report significantly improved self-reported adherence, glycaemic control or changes in 
medication appropriateness. A systematic review of community pharmacist interventions 
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to improve patient adherence to chronic medication, noted that the paucity of well 
designed studies made it impossible to assess the effectiveness of such interventions.153  
 
The study indicated high levels of post-baseline adherence for all the pharmacological 
categories when assessed from prescription refill data with no significant differences 
between the control and intervention groups. Measuring medication adherence in 
practice remains problematic,380 and as no standard measure of medication adherence 
exists, various categorical cut-off points have been applied in defining the point below 
which the patient is considered to be  non-adherent to a particular regimen. Some 
authors have suggested that patient self-assessment of adherence is most valid when 
non-adherence is defined as anything other than total or optimal adherence.376 
Prescription refill or claims data, which serves as a surrogate measure of medication 
possession, is associated with clinical outcomes and has been used as a proxy measure 
of medication adherence, albeit that possession of medication does not guarantee that it 
is used or that it is used appropriately.348,376,380,566 
 
In addition to the prescription refill data, medication adherence at the end of the study 
was assessed by means of patient self-report using the Medication Adherence Report 
Scale.422 Self-reported medication adherence was very high with an average of 23.5 out 
of a maximum score of 25, and this finding correlated with the prescription refill data 
which revealed a similar high level of adherence. As has been reported in other studies, 
patient self-report slightly overestimated adherence when compared to adherence 
assessed from the prescription refill data.376,567  Adherence levels ranged from a low of 
54% to a high of 96% with both control and intervention patients identifying forgetfulness 
as the main cause of non-adherence, which correlates with findings of other 
studies.343,568,569 Overall adherence results agree with other studies, where adherence to 
oral anti-diabetic therapy was found to range from 36% to 93%.348,566 
 
It is possible that patients who participated in the study were largely adherent to 
pharmacotherapy at baseline and continued in this vein during the study, thus mitigating 
against being able to demonstrate any intervention effect. An RCT designed to improve 
patient medication adherence in DM2 by reducing self-reported adherence barriers 
found that the main reason for the lack of effect was the very high levels of adherence 
and low levels of barriers to adherence reported at baseline.464  
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Ideally the sample should have included patients with lower levels of baseline 
adherence. Paradoxically, it is these patients who may be at greatest risk for increased 
morbidity and are more likely to be disengaged from medical care who may be able to 
best demonstrate a positive intervention effect. However, it is possible that it is their very 
disengagement from care that prevents sustained participation in intervention studies. If 
pharmacists are specifically trained in recruitment techniques, including the way in which 
a study is described to patients, and if they are able to ensure that patients feel secure 
and see value in the research, then it may be possible for samples to be more 
representative of target patient populations.570 
 
Despite the progressive nature of DM2, a number of major studies including UKPDS, 
DCCT and Steno-2 were able demonstrate improvements in hyperglycaemia, 
hypertension and dyslipidaemia using interventions that largely relied on 
pharmacotherapy.92,103,571 The close correlation of prescription refill data and self-
reported medication adherence data indicated high levels of medication adherence, and 
yet only 30% of patients were at goal for the SEMDSA guideline for HbA1c. Given that 
HbA1c, blood pressure and blood lipids are particularly responsive to 
pharmacotherapy,92,103 this anomaly raises the question as to why more patients were 
not at goal at the end of the study. It is possible  that the pharmacotherapy was not 
optimal with  ‘clinical inertia’ being a contributing factor. Clinical inertia, has been 
identified as a critical barrier to the effective control of metabolic risk factors.572,573  
 
An analysis of the prescription data of 54 patients (23 control and 31 intervention) 
revealed that 50% of these patients had changes made to their anti-diabetic medication 
regimens during the 12 month period under review. Unfortunately, the data were 
incomplete in terms of when the changes were made, which prevented any evaluation of 
the impact of these changes on glycaemic control. Nevertheless, further investigation of 
the prevalence of clinical inertia in DM2 for all metabolic risk factors is warranted as the 
implications for patient health outcomes may be significant.573  
 
The utility of pharmacist depression screening in patients with diabetes in a primary care 
setting has been demonstrated,546 although this should be confined to identifying patients 
who may be candidates for escalated psychological care.36 The overall incidence of self-
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reported depression decreased from seven at baseline to four post-baseline. Depression 
is an important co-morbidity in DM2 because it is associated with an increase in diabetic 
complications, reduced adherence to therapy and inadequate levels of self-
management.423  
 
9.8.3 Diabetes-related knowledge, understanding diabetes care and SMBG 
 
At the end of the study, approximately 80% of control and 88% of intervention patients 
indicated that their understanding of key aspects of diabetes care was ‘good’ to 
‘excellent’, with both control and intervention patients demonstrating equally that they 
had good levels of diabetes-related knowledge. Areas of diabetes care in which 
understanding could be improved included the concurrent use of antidiabetic medication 
with other medication, complications commonly associated with diabetes, eye care, foot 
care, body mass control and the use of alcohol in DM2. These more problematic areas 
of understanding diabetes care in some instances correlate with the relatively low 
prevalence of the corresponding SEMDSA guideline tests and examinations. For 
example, 64% of all patients said that had an annual eye examination and 41% an 
annual foot examination, suggesting that improving diabetes understanding of the 
relevance of eye care and foot care may result in increased numbers of patients being 
examined for potential microvascular complications associated with these variables.  
 
Diabetes knowledge has been shown to be associated with improved glycaemic 
control.357,472 although this finding has not been unequivocal.435 Similarly, enhanced 
understanding of the key aspects of diabetes has been associated with improved 
metabolic control.430 Diabetes knowledge and understanding are foundational features of 
patient empowerment and of diabetes self-management education and have been 
associated with the resolution of barriers to care and thus are effective aspects of 
successful problem solving.392,574,575 A study that examined the association between 
patient knowledge of HbA1c and diabetes care attitudes and behaviours found that only a 
quarter of participants knew their HbA1c values. However, although those who knew their 
HbA1c values were better able to assess their level of glycaemic control and had a better 
all-round understanding of diabetes care, this knowledge did not translate into improved 
self-management efficacy.398  
 
 - 166 - 
Approximately 90% of all patients in this study self-monitored their blood glucose levels 
with very little difference in frequency between the intervention and control groups, and 
the results indicated that there was no significant difference in HbA1c between those 
patients who self-monitored and those who did not. A disconcerting finding was that less 
than 20% of patients reported that their pharmacists referred to their SMBG readings 
and made suggestions regarding adjustments to therapy or self-management activities 
based on these data, with no evidence that the intervention pharmacists were more likely 
to engage with their patients than were the control group. The Asheville Project 
demonstrated that patients who engaged with pharmacists about their SMBG not only 
improved glycaemic control, but patient satisfaction with CPS was also enhanced.9  
 
9.9 Study limitations 
 
The study design was informed by The Revised CONSORT Statement for Reporting 
Randomized Trials: Explanation and Elaboration, which was published in 2001. Although 
attention was paid to a checklist of items that the Statement suggested should be 
included in reporting a RCT,35   the study would have benefited had it been informed by 
guidelines specifically developed to assist researchers improve their understanding of 
the difficulties associated with developing and evaluating nonpharmacologic and 
complex interventions as can be found in two recent publications.294,296 The United 
Kingdom Medical Research Council first published a guideline for the development and 
evaluation of complex interventions in 2000 and revised this document with new 
guidance published in 2008.294 As the original CONSORT statement “does not address 
some specific issues that apply to nonpharmacologic trials,”
296 the CONSORT group 
published their guideline for reporting nonpharmacologic RCTs in 2008.   
 
A critical review of the design and methodology of the study, informed by the 
abovementioned reports and other literature relating to the development and evaluation 
of complex interventions, has  identified the following limitations.294,296,576-578 
 
Theory  
The theories and models used to support the pharmacist and patient health behaviour 
change were not adequately explored. The theoretical underpinning of behavioural 
change required additional discussion, especially as key aspects of the  intervention 
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were informed by the 5 A’s model for behavioural change275 and the counselling method 
of Motivational Interviewing,171 which in turn, is informed by behaviour-related theories 
and models including the TTM.579  
 
Modelling.  
The development of the DCP intervention would have been strengthened had there 
been consultation with a sample of pharmacists and DM2 patients, as envisaged by the 
Nominal Group Technique.580 By modelling the intervention in such a manner, essential 
elements such as desired patient outcomes, diabetes self-management needs, the 
relevance and practical implications of the various components of the intervention, as 
well as the training needs of pharmacists could have been better explored and 
addressed. This process may have led to a refining of the components of the 
intervention, and improved understanding of their interaction and the mechanism by 
which they affect outcomes.  
 
Questionnaires and scales 
Although the selection of psychosocial scales and questionnaires was informed by the 
‘Assess’ provision of the 5 A’s model (beliefs, behaviours and knowledge),275 neither 
pharmacists nor patients were consulted about the applicability of these instruments. 
The number and complexity of the questionnaires may have been inappropriate for this 
target patient population. For example, the relevance of the questionnaires could have 
been discussed in focus groups and further tested in a pilot study. 
 
Collaboration and expertise 
This study constituted a complex intervention and it would have benefited from 
collaboration with other investigators, such as a psychologist, sociologist, diabetologist 
and diabetes educator as effective diabetes care is best served by adopting a 
interdisciplinary approach.565 Furthermore, it would have been especially beneficial to 
have collaborated with a healthcare professional with expertise in the design of complex 
interventions. In particular, collaboration with such an expert would have aided the 
researcher in developing strategies to prevent the methodological difficulties which have 
become apparent.  
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Problems associated with the RCT 
The methodological problems routinely associated with RCTs, especially in multisite 
pragmatic trials, may also have constituted limitations in this study.  It was not possible to 
validate pharmacist measurement of the clinical variables and their reporting of 
prescription related data. There may have been an element of selection bias, i.e. only 
participants sufficiently interested in diabetes care may have participated in the study. 
The complex nature of behavioural change, with many possible interacting components, 
made the identification and management of confounding variables (e.g. changes in 
therapy) difficult, especially as this was a multisite trial.  The overall lack of control by the 
researcher with regard to the actual implementation of the DCP in the trial meant that it 
was not possible to identify or assess the efficacy of the individual components of any 
applied intervention. 
      
Details of the intervention and comparator 
In a RCT, the ideal is to be able to precisely describe both the experimental treatment 
and comparator. In this study it was not possible to comprehensively describe the ‘usual’ 
care afforded patients by the control pharmacists as these pharmacists were merely 
requested not to provide their patients with a level of pharmaceutical care that differed 
from that which they traditionally provided. ‘Usual care’ potentially varied widely between 
the control pharmacists. There was no standardisation of the interventions as the DCP 
was intended to be pragmatically adapted by pharmacists for individual practice 
conditions and individualized for patients. While intervention pharmacists were provided 
with a suggested framework for individualized interventions (a DCP manual, Annexure 
6.5), the detail of actual interventions applied was not recorded as the researcher was 
not able to authenticate such data.  
 
Piloting the intervention 
The intervention was not piloted and therefore neither the validity nor feasibility of the 
intervention could be determined prior to its implementation. The lack of an exploratory 
study precluded feedback on the components of the intervention and their subsequent 
refinement (including scales and questionnaires), the assessment of the likelihood of 
being able to recruit pharmacists and patients and their likelihood of adhering to the 
intervention protocol, or if due consideration should be given to an alternate design. 
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Practical considerations mainly relating to available resources mitigated against being 
able to conduct a meaningful exploratory study.  
 
Recruitment and training of pharmacists 
The study may have suffered as a result of the lack of face-to-face contact with the 
pharmacists, both in terms of recruitment and with regard to training for the delivery of 
the intervention. Improved contact and communication with pharmacists may have 
facilitated the resolution of some of the barriers preventing pharmacists from 
participating in practice-based research. It is possible that recruited pharmacists were 
not representative of community pharmacists in general, e.g. possibly only pharmacists 
with an interest in DM2  agreed to  participate in the study, although this aspect was not 
investigated.  
 
Pharmacist training using a distance learning approach is briefly mentioned above as a 
Modeling limitation. The distance learning method adopted in attempting to equip 
pharmacists for the delivery of individualized DCP interventions, did not result in any 
significant interaction between the researcher and the pharmacists, although assistance 
was offered to those who wanted further clarification or information. The development, 
organization and delivery of the training material (the DCP manual) would probably have 
benefited from further pharmacist consultation (e.g. using the Nominal Group 
Technique),580 and from the participation of an expert in the distance learning approach 
to the continuing education of health professionals. Despite distance learning with 
written material being the most common approach to pharmacist continuing education in 
South Africa, it may not be as effective as face-to-face training.581,582   
 
Pharmacist data 
The pharmacist is an important variable in this study that should have been more 
intensively investigated. In particular, investigating pharmacist familiarity with the 
material provided, their confidence in their ability to develop and deliver the DCP, as well 
their actual expertise in delivering the intervention, could have provided valuable insight 
into key aspects of the intervention including the feasibility, validity and interdependence 
of the various components. 
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Blinding 
Although blinding of the assessor (in this case the researcher) is a RCT 
recommendation, practical considerations mitigated against adherence to this item. 
 
Sample size 
The sample size calculation was based on detecting a 0.5% change in HbA1c, whereas 
the literature most often refers to a 1% change as being significant. Had a sample size 
estimate been based on an absolute difference of 1% in HbA1c change between the two 
groups, with a standard deviation of 1%, then a fixed sample size of 20 per group would 
yield a power of 88.54%.517 The relatively small sample size (27 control and 31 
intervention patients) impacted negatively on the quality of the study in terms of being 
able to adequately comment on the effect of the intervention on patient adherence. 
Haynes et al 330 suggests that as a general guide for studies with a single intervention 
group and control group “…at least 60 participants per group are required in order to have at 
least 80% power to detect an absolute difference of 25% in the proportion of patients judged to 
have adequate adherence”. The small sample size exacerbated the problem relating to the 
representativity of both pharmacists and patients.  
 
Pharmacist – medical practitioner collaboration 
The study should have investigated collaboration or information sharing that may have 
taken place between medical practitioners and pharmacists given the emphasis placed 
on multidisciplinary collaboration in diabetes care.19,352,583 
 
Process evaluation 
The lack of effect reported in the study may have been due to failure on the part of the 
pharmacists to implement the DCP adequately and for long enough rather than 
assuming ineffectiveness. The design lacked provision for in-process evaluation and as 
data were only collected at baseline and again post-baseline it was not possible to 
assess intervention fidelity or quality. This important limitation furthermore prevented the 
investigation and reporting of any short-term changes to endpoint variables that may 
have occurred between baseline and post-baseline. 
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Extensive use of self-reported data 
This form of data collection has been associated with overestimation of adherence in 
other studies. It is also possible that patient responses, including those of the control 
patients, may have been influenced by the Hawthorne effect.453 
 
Absence of a validated standard measurement for adherence 
This is possibly the most commonly described limitation relating to adherence 
research.330 
 
Cost-effectiveness evaluation 
While the cost-effectiveness of an intervention is likely to be crucial to those charged 
with deciding whether or not to adopt research in practice, economic modeling and 
evaluation was not feasible given the available resources. 
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CHAPTER 10 
GENERAL DISCUSSION: STUDY DESIGN,  RESEARCH AND PRACTICE  
 
10.1 Introduction 
 
The  study hypothesis was informed by a literature that generally supports extended 
roles for community pharmacists across the disease spectrum, including DM2.38,133,183 
However, systematic reviews of pharmacist-directed interventions, while acknowledging 
the value of CPS interventions, invariably comment negatively on the paucity and 
methodological quality of such studies.133,183,456,584,  
 
The methodological limitations of the DCP trial were discussed previously (Section 9.9). 
In this chapter recommendations for an improved trial design are presented in the hope 
of informing future pharmacy practice research, especially research involving health-
related behaviours. Implications of the study with regard to community pharmacy 
practice are discussed in a separate section, while the conclusion briefly summarises the 
main findings in terms of the research question and study objectives.  
 
10.2 Methodological considerations for an improved DCP intervention 
 
An improved design is discussed below in the context of evidence-based 
recommendations for the development and evaluation of behavioural change 
interventions where “the science of intervention development remains at an early stage.” 585 
Given the complexity of behavioural change interventions, it is strongly recommended 
that from the outset researchers collaborate with experienced others in conducting such 
research.    
 
Three key elements of the process, namely Development, Feasibility/piloting and 
Evaluation (Figure 10.1), are considered.294,313,576,578,586 A fourth element, 
Implementation, which refers to the dissemination of the research for possible adoption 
in practice settings, is not addressed.  
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10.2.1 Development 
 
The research problem, namely: “Are South African community pharmacists able to 
positively influence patient adherence and surrogate health outcomes in DM2?”,  
provides the focus for the literature review which informs the development of the 
intervention by identifying current evidence and appropriate theory.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.1 Key elements of the development and evaluation process294 
 
 
Different levels of evidence may be considered, although systematic reviews are 
recommended. However, identifying appropriate reviews of complex interventions may 
prove problematic as the “methodology of how to find, review and combine data from complex 
intervention studies is not yet fully developed”.
294 
 
Development 
1. Identifying the evidence base 
2. Identifying/developing theory 
3. Modelling process and outcomes 
Feasibility/piloting 
1. Testing procedures 
2. Estimating recruitment/retention 
3. Determining sample size 
Evaluation 
1. Assessing effectiveness 
2. Understanding change process 
3. Assessing cost-effectiveness 
Implementation 
1. Dissemination 
2. Surveillance and monitoring 
3. Long-term follow up 
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  The literature review should identify the diabetes-related risk factors including health 
behaviours, clinical indicators, desired health outcomes and underpinning theory.294 
Soliciting expert opinion prior to and during the literature review may assist the 
researcher in focusing this essential work. Key questions on which the literature review 
is premised are:294  
 Is there clarity about the problem?  
 Do evidence-based interventions exist that appear likely to answer the research 
problem or similar problems?  
 Are the interventions based on sound theory and accepted models of behavioural 
change?  
 What does the literature reveal about pharmacist and patient experience of these 
interventions? 
 Are any identified interventions compatible with the practice of community 
pharmacy in South Africa? 
 Can the interventions be adapted to facilitate acceptance and implementation by 
South African community pharmacists?  
 Are the interventions likely to be accepted by patients?  
 What are the appropriate outcomes measures? 
 
The literature facilitates the theoretical link between the DCP intervention and the 
patient’s health outcome,586 i.e. theory informs the process of defining the changes in 
behaviour likely to impact on the indicators designated as surrogate outcomes.294,313 
Psychological theory identifies the drivers of the targeted behaviours and informs the 
selection of behavioural change methods. Theoretical or conceptual frameworks, such 
as the 5 A’s Behaviour Change Model,275 are important in operationalising the 
intervention as they guide the actions that follow from answers to the questions of when, 
where, how and by whom should what be done?313  
 
Understanding patient diabetes-related needs, and the barriers preventing the patient 
from being able to satisfy these needs is essential for the development of an effective 
DCP intervention. Similarly pharmacists may not effectively deliver the intervention if 
their needs and any barriers to providing diabetes-related CPS are not adequately 
addressed.586  Fundamental to the development process of the intervention is the need 
for the researcher to gain insight with regard to the meaning and importance of the 
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research problem for both patient and pharmacist at an early stage as both the 
pharmacist and the patient will be involved in modifying health-related behaviour.586  
 
Insight into the behaviours requiring change and any barriers to change may be elicited 
by engaging with patients and pharmacists in focus groups such as is envisaged by the 
Nominal Group Technique.580 Focus group discussions may be further informed by the 
findings of supplementary descriptive research.449 Additional qualitative research, i.e. 
conducting a problem and needs analysis by surveying larger numbers of pharmacists 
and patients and then discussing and refining identified issues in focus groups, may be 
required in order to fully explore the diverse and complex needs of pharmacists and 
patients alike as well as their likely response to the intervention.313,587 For example, 
insight into patterns of pharmacy practice as well as the targeting of pharmacist 
education and training to support behavioural change may be elicited using existing 
validated survey instruments adapted for local conditions.587 Such research allows for 
analyses that may be directed at specific aspects of the research problem, thus 
informing the development of each succeeding stage of the intervention. 
 
An analysis of current practice should be conducted to identify interventions currently 
employed by pharmacists in day-to-day or real-life practice313 as pharmacists may 
pragmatically provide CPS associated with diabetes care such as measuring the blood 
pressure of a DM2 patient each time the prescription is refilled.588 These interventions 
may develop by a process involving analytical reasoning and practical experience. Such 
accumulated practice experience may prove invaluable in developing practical 
evidenced-based interventions. 
 
The theory, literature review, and the engagement with patients and pharmacists in focus 
groups establishes a basis for the diabetes self-management education of patients and 
the training of pharmacists to deliver the DCP intervention. Training methods should be 
selected and material prepared with the assistance of an expert in adult education and 
submitted to other experts in the field (e.g. diabetologist, health psychologist and 
diabetes educator) for further comment.175 The material and training protocol may be 
further refined in pharmacist focus group discussions.  
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The individual components of the proposed DCP intervention should be identified and 
their interrelationship as well as their relationship to the selected surrogate outcomes 
defined. Interventions to be applied and which have been described in the literature 
should be prioritized in terms of proven efficacy and, if possible, their cost-
effectiveness,586 The proposed DCP intervention should be critically discussed in the 
modelling phase of the development of the intervention by consulting with experts in the 
field as well as members of the focus groups (both patients and pharmacists) to ensure 
that it meets the requirements of scientific rigour as well as having practical relevance to 
both patients and pharmacists.181  
 
Included in the modelling discussion with experts are matters relating to:294,296, 
 the financial and other resources required to effectively investigate the DCP 
intervention,  
 the length of time of the study,  
 obtaining ethical approval from the Rhodes University Ethics Committee,  
 eligibility criteria for patients and pharmacists, including details of practice 
settings, any resource criteria, as well as qualifications, skill and 
competencies of pharmacists, 
 methods to be used in recruiting patients and pharmacists,   
 the sample size calculation (to be further informed by piloting phase) to 
ensure adequate statistical power, 
 the design of the trial, ensuring RCT wherever possible,  
 randomisation of participants including sequence generation 
 allocation concealment of participants as well as the blinding of the 
researchers, 
 being able to fully describe the intervention, which is based on the 5 A’s 
Behaviour Change Model,275  including identifying the different components 
and, where possible, attempting to gauge the likely cost-effectiveness of the 
intervention, 
 being able to adequately describe  usual or standard care,    
 methods of standardising the intervention,  
 provisions for the recording of any  allowable variation to the protocol, 
 the training of intervention pharmacists, including any ongoing support to be 
provided,  
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 process evaluation, including timelines, assessment of adherence to the 
protocol and precise details of the individualised interventions and of the 
usual care provided,  
 identifying relevant assessment instruments for the designated  primary and 
secondary endpoints,    
 data collection and statistical methods, including the methods to be 
employed, data collections intervals and, as the DCP involves multi-
dimensional outcomes, consideration of the range of statistical options  
available,  
 the overseeing or management of the evaluation, including the independent 
monitoring of data, 
 agreeing on guidelines for the reporting of the trial in an accepted format.  
 
The modelling process together with piloting the intervention furthermore assists in 
identifying weakness in the study design, i.e. areas that may require change or provide 
an indication that the trial is unwarranted.294 
 
10.2.2 Feasibility/piloting 
 
Before implementing the full-scale evaluation, the DCP intervention should be tested in 
practice with a pilot study (or a series of pilot studies) of DM2 patients and pharmacists 
to establish the likelihood of the evaluation being feasible, acceptable and replicable in 
the main trial.294  
  
A pilot study is essential in order to be able address any uncertainties or problems that 
may have surfaced during the development process. Piloting also provides a basis for 
estimating the sample size and the likelihood of being able to recruit and retain 
participants, as well as providing some understanding of the dynamic of fostering 
pharmacist adherence to the protocol. It is imperative that every effort be made to 
evaluate each component as well as the total intervention, thus allowing for component 
as well as overall modification, should this be necessary.313 These changes may be of 
such a nature that further exploratory work may be required before embarking on a full-
scale trial. 294   
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10.2.3 Evaluation 
 
In addition to the precise details of the intervention and comparator, the context and 
environment in which the intervention is investigated should be described.296 In complex 
interventions, such as the DCP intervention, the definition of fidelity is not narrow, as 
interventions may have to be adapted for local conditions and changes may occur over 
time as a result of insight gained during the evaluation. The documentation of any 
variation to the intervention is thus essential in ultimately assessing effectiveness.294  
 
While there are a number of study designs available that may be suitable for evaluating 
complex interventions, randomisation should always be considered because of its ability 
to prevent selection bias.294 Two experimental designs involving the randomisation of 
participants appear particularly suitable for evaluating the DCP intervention. The first is 
an individually randomized parallel group design, and the second a cluster randomized 
trial. The latter design is recommended should there be a likelihood of contamination of 
the comparator group, which could lead to biased estimates of effect size.294  Cluster 
randomized trials require larger sample sizes than parallel group RCTs in order to 
achieve similar statistical power, and they are more complex to design and require more 
complex analysis.455  In this study (the DCP intervention) such contamination is unlikely 
and the design of a randomized parallel group RCT, with pharmacists and their 
associated patients randomized to either control or intervention is an appropriate design.   
 
Evaluation of the components of the intervention is crucial if the study design of a RCT is 
used, as this design allows for the investigation of the effectiveness of an intervention in 
totality. Without adequate insight at a component level “it is not clear if and to what extent 
the individual interventions contribute to the effect”.313 Furthermore, sub-group analyses may 
be required to consider the source of any variation in outcomes.294  
 
Further key aspects of the design of the evaluation include, the choice of outcomes 
measures ( clinical primary and secondary endpoints as well as psychosocial measures), 
the inclusion of process evaluation and, where possible, an assessment of the cost-
effectiveness of the intervention.294,296 The research problem and the evidence base 
together with other aspects of the preceding development work inform the surrogate 
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outcomes selected for the study. Including process evaluation in the trial allows for the 
assessment of pharmacist adherence to the DCP intervention protocol (i.e. assessing 
quality and fidelity),296 and may provide valuable insight as to why an intervention 
succeeds or fails, as well as contextualizing any variations in outcomes.294 Furthermore, 
it is essential for the intervention to be fully described and the procedures tested in order 
to ensure that the intervention may be replicated by others. Evidence of cost-
effectiveness, while not assessed in this DCP intervention, is particularly relevant for 
decision-makers who may consider the implementation of evidence-based disease 
management programmes in the broader practice environment.294  
 
The DCP trial should be reported in a manner that allows for the results to be assessed 
in the context of similar studies, should such evidence exist.294 The CONSORT group35 
recently published a revised checklist of items for reporting non-pharmacologic trials, 
including those involving behavioural change interventions,296 and it is suggested that 
this document be used as a template for reporting the DCP intervention.  
 
While the RCT remains the ‘gold standard’ for reporting intervention trials,35 extensions 
to certain of the methodological parameters governing traditional RCT’s have been 
advocated in order to adequately develop and evaluate complex interventions.294,296,589 
Such trials may be referred to as pragmatic randomized trials. Hotopf M589  in a paper 
detailing key aspects of pragmatic randomised controlled trials makes it clear that the 
traditional approach to conducting a RCT may be criticised “for failing to provide answers to 
relevant clinical problems of everyday practice”.  
 
Some of the key design features of pragmatic RCT’s include:589 
 the need to reflect the heterogeneity of patients  as encountered in clinical 
practice, 
 selection criteria may be not as narrow as in traditional RCT’s, 
 interventions are often complex and therefore greater flexibility in defining the 
interventions is required, 
 “there is tendency to deal with each treatment as a black box – usually the concern is not 
to try to understand specific ingredients within the box”, 
 usual care is difficult to define because it relies implicitly on the knowledge and 
skill of the provider delivering such care, 
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 blinding may not be possible, 
 randomisation at the provider level is permissible, 
 outcomes should reflect the ‘real world’ concerns of patients, providers and 
policy–makers. 
 
10.3 Practice and research opportunities  
 
This section discusses opportunities for community pharmacy practice and some 
potential areas of research arising out of the researcher’s observations during the study, 
reflection on the literature and  personal experience as a community pharmacist. 
 
Community pharmacy practice in South Africa has not been well researched.17 A 
Pubmed search using the term “community pharmacy AND South Africa AND 
pharmaceutical care OR cognitive pharmaceutical services” for the period 1985 to 2007 
produced six articles, none of which were concerned with investigating the provision of 
CPS by community pharmacists.   
 
It has been demonstrated that the most frequent healthcare encounter that a patient with 
diabetes who uses medication obtained from a community pharmacy is likely to have is 
an encounter with a pharmacist,36 and this probably holds true for most other chronic 
diseases that include pharmacotherapy as a treatment option.1,595 The patient-
pharmacist encounter, which is facilitated largely because of the prescription refill 
dynamic,11 presents pharmacists with health promotion and disease monitoring 
opportunities,590 and they should be encouraged to develop care plans and deliver 
appropriate interventions based around these brief but potentially valuable healthcare 
encounters.171,265 
 
Pharmacists in community practice are charged with counselling chronically ill patients 
on the appropriate use of medication and yet they may do so without having access to 
the clinical data that informed the original selection and continued use of a given 
medicine.133,540 Similarly, pharmacists may not routinely assess patients using chronic 
medicines (e.g. by measuring blood pressure, BMI or blood lipids) despite there being 
good evidence to support this aspect of pharmaceutical care.173,470 As pharmacists 
expand their roles in the clinical arena it is incumbent upon them to ensure that their 
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support of patients is informed by appropriate, comprehensive information, including 
clinical data. Access to these data should be considered de rigeur in the practice of 
evidence-based pharmaceutical care.591 Given the increasing ascendancy of patient-
centred care, the effect of the collaborative sharing of appropriate patient data between 
providers requires investigation.155,592   
 
Studies conducted elsewhere have demonstrated that community pharmacists are able 
to engage with DM2 patients in order to measure and collect relevant biochemical and 
other clinical data.178,179 Patients at risk for hypertension or any of the elements of the 
metabolic syndrome should be screened at regular intervals and pharmacists are well 
positioned to play important roles in preventative screening.105 For example, the 
progression of impaired glucose tolerance or impaired fasting glucose to diabetes may 
be forestalled by disease prevention programmes that are well within the scope of 
practice of a community pharmacist.6,561  
 
A large percentage of the SMBG metering devices and associated materials used by 
insured patients are acquired from community pharmacies. This presents community 
pharmacists with opportunities to develop diabetes practices that are anchored by 
SMBG and other elements of clinical monitoring, such as point-of-care cholesterol 
testing and blood pressure monitoring.9   
 
Research indicates that a significant number of community pharmacists in South Africa 
either employ or are associated with registered nurses and this allows pharmacists to 
offer extended clinical services.16 Collaborative models of chronic care based on a 
pharmacist-nurse alliance are able to offer community-based chronic disease self-
management programmes597 and pharmacists should be encouraged to develop 
expertise in this  area.38,155,458 Not only could the pharmacist add value to patients as well 
as to the broader community, but may also contribute to the professionalisation of 
pharmacy practice.163  
 
The role of the pharmacist in patient-centred care and the promotion of chronic disease 
self-management may require the reorientation of pharmacy practice.158,229 Given the 
multidisciplinary approach advocated for the delivery of patient-centred diabetes care,155 
pharmacists should be encouraged to enter into collaborative practice arrangements with 
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medical practitioners and other allied healthcare professionals as there is evidence that 
such initiatives have resulted in improvements to the process of care and to patient 
health outcomes.8,556  Practical and effective strategies to accomplish this objective 
should be investigated. 
 
Research has demonstrated the value of pharmacists in the academic detailing of 
medical practitioners and shown that adherence to clinical practice guidelines by medical 
practitioners significantly improved where pharmacists have been involved in advocacy 
programmes.594  The general acceptance of clinical practice guidelines by the medical 
profession should assist pharmacists contemplating collaborative interventions with 
medical practitioners as guidelines provide common ground for exploring care 
options.105,155   
 
Furthermore, adherence to the provisions of clinical practice guidelines by patients is a 
patient health outcomes factor that may be neglected in pharmacy practice.548,593 A 
common thread in many of the reviews relating to adherence is that despite improved 
adherence being associated with improved health outcomes, successful interventions 
have generally been multifaceted and complex making the sustained delivery of these 
interventions problematic in day-to-day pharmacy practice. 38,330  This problem is further 
compounded by the complex nature of adherence which makes it difficult to identify and 
measure the individual components of interventions that may be effective.38,294,330  
Practical, cost-effective and implementable adherence promoting interventions (i.e. 
pragmatic interventions), which fit seamlessly within day-to-day practice, such as patient 
reminders as well as telephonic and electronic follow-up of patients (email and cellphone 
short message service) appear likely to enjoy pharmacist and patient support,142 and 
should be investigated.330,366 
 
The growing acceptance of patient-centred care and the recognition of the key role of 
health-related behaviour in determining the course of chronic disease is influencing the 
way in which healthcare providers view caring for patients with chronic diseases.155,392 
Consequently, there is increasing acknowledgement that no single component of care in 
diseases such as diabetes is more important than patient self-management.298,596 
Studies have revealed that, with rare exception, chronically ill patients are responsible 
for almost all of the day to day care that they require,229,298 and that underpinning the 
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entire self-management dynamic are complex, interdependent and interacting health 
beliefs and behaviours.275   The practice of pharmaceutical care should therefore not be 
narrowly focused on the biomedical (provider-centred) aspects of care, but broadened to 
include psychosocial support for patient self-management efforts.229,298  
 
At a policy level there is consensus within organised pharmacy that practice research is 
essential for informing both the practice of pharmacy and the education of 
pharmacists.147,181 However, whether this commitment cascades down into community 
pharmacy and is being sufficiently reflected in professional practice activity, requires 
investigation. Wherever possible, practice research should report humanistic, clinical and 
economic outcomes,176 as authors of systematic reviews and meta-analyses frequently 
comment on the dearth of comprehensive outcomes data.183  
 
There are a number of major challenges facing community pharmacists in providing care 
to the chronically ill. These include the development of a greater understanding of health 
behaviour change, together with the acquisition of the necessary skills to appropriately 
influence health behaviours.171,522,598  Further research relating to medicine-taking 
behaviour and other psychosocial imperatives in caring for individuals with chronic 
diseases such is suggested.153,155,599 
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CHAPTER 11 
CONCLUSIONS 
 
This study, which was the first investigation of a South African community pharmacist 
intervention designed to influence patient health-related behaviour and outcomes for 
DM2, demonstrated that community pharmacists did not positively influence patient 
adherence or diabetes-related surrogate health outcomes. Such a finding, however, 
should be tempered by the limitations of the study, which were largely methodological in 
nature. For example, the power of the study would have been enhanced had more 
patients and pharmacists agreed to participate in the research, the educational 
intervention improved by involving an expert in the field of adult education or continuing 
medical education, and the overall design improved by accessing expertise in 
developing and evaluating pragmatic RCT’s.   
 
Both the consumer survey and the diabetes-related study itself demonstrated that a 
good foundational basis exists within the South African patient – community pharmacist 
dyad for the delivery of CPS. This is an important finding as the profession in South 
Africa did not previously have recourse to empirical data in this regard, but relied on 
anecdotal assumptions. 
 
The survey of insured patients revealed that in general they were satisfied with the level 
of medication counselling and disease-related information provided by community 
pharmacists, and valued the CPS they received, although there appeared to be a 
problem related to pharmacist accessibility which requires further investigation. The 
diabetes-related study generally demonstrated patient acceptance and satisfaction with 
the diabetes care provided by pharmacists.  
 
The design of this study, as a RCT, presented many challenges in implementation, and 
problems were encountered in the adaptation of this study design to the complex “real-
world” setting of community pharmacy practice. Perhaps the most important lesson 
learnt in developing and evaluating the intervention was the need for a multidisciplinary 
team approach when attempting a project of this magnitude and complexity. There is no 
doubt that the study would have benefitted had such an approach been taken. 
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A valuable aspect of this study is the critical evaluation and reflection on study design 
that it has demanded, and the consequent insight developed into the methodological 
constraints associated with conducting community pharmacy practice-based research in 
which complex interventions are developed and evaluated. In particular, while the choice 
of a RCT study design is advocated as the ‘gold standard’ for intervention-based 
research, there were considerable constraints associated with this design in its original 
or traditional clinical format.  
 
The traditional RCT, with its narrow, prescriptive and often single component intervention 
focus appears not to offer the best solution for research problems that are complex, and 
where, by definition, there may be a number of interacting and mutually influencing 
components. This has been acknowledged by both CONSORT296 and UKMRC294 in 
guidelines published in 2008, the year in which this DCP study was completed. 
Fortunately for future researchers wishing to investigate non-pharmacologic complex 
interventions using the design of a RCT, there is growing recognition of the need to 
adopt a more pragmatic approach to these trials than with traditional RCTs of 
pharmacologic interventions. For example, the UKMRC guideline suggests that in certain 
circumstances “Fidelity is not straightforward in relation to complex interventions…some 
interventions are deliberately designed to be adapted to local circumstances…Limiting variation in 
treatment may be desirable in an efficacy trial, but in a pragmatic, effectiveness study the 
statistical advantages and gain in ‘internal validity’ need to be weighed against the loss of 
generalisability or ‘external validity’.”
294
   
 
Given that the study was concerned with effectiveness and not efficacy, its value in 
terms of adding to the body of knowledge may, therefore, not lie solely in the empirical 
data produced, which may be of limited value, but rather in serving to inform further 
pragmatic practice-based research, especially that concerned with evolving patterns of 
community pharmacy practice, and in promoting patient health-related behavioural 
change.  
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Annexure 3.2 
 
DIABETES MELLITUS TYPE 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Diagnosis of Type 2 
Address other risk factors 
Lifestyle modification as part of initial management 
Measure HbA1c every 3 months depending on control and changes in therapy 
Target HbA1c should be ≤ 7.0% 
Have lifestyle modifications been successful? 
No Yes 
Consider oral hypoglycaemic agents 
Is there renal and/or cardiac dysfunction? 
Continue to monitor HbA1c 
every 6 months 
Yes No 
Is Patient’s BMI > 25? 
Yes No 
Consider either metformin or a sulphonylurea 
depending on plasma glucose 
Use metformin Consider sulphonylurea 
Adequate control 
No Yes 
Continue to monitor HbA1c and 
blood glucose 3-6 monthly 
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Annexure 3.2 Council for Medical Schemes algorithm for Type 2 diabetes
 
Optimise dose of oral hypoglycaemic agent 
Adequate control 
No Yes 
If patient on metformin consider 
adding a sulphonylurea 
If patient on sulphonylurea and has 
normal renal function and has no 
cardiac dysfunction add metformin. If 
poor renal function consider adding 
thiazolidinedione or insulin 
Is control adequate? 
Yes No 
Monitor HbA1c every 3 to 6 
months 
Consider adding/enhancing 
insulin therapy 
Continue to monitor HbA1c and 
blood glucose 3-6 monthly 
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Community Pharmacist Survey                     Annexure 5.1 
Section 1: Respondent Demographics 
1.1 Gender: 
 
1.2 Ethnic Group: 
 
1.3 Age: 
 
1.4 Medical Aid Membership: 
 
1.5 Occupation Classification: 
 
Section 2: Community Pharmacist related questions 
2.1 Have you received prescription medicines 
 
2.1.1 Do you get your prescription medicines: 
 
2.2 If you get your prescription medicines from a pharmacy, did a pharmacist: 
2.2.1 Counsel you on the use of your prescription medicines: 
 
2.2.2 Provide you with information on your disease or condition: 
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2.3 If you get your prescription medicines from a doctor, did the doctor; 
2.3.1 Counsel you on the use of your prescription medicines 
 
2.3.2 Provide information on your disease or condition 
 
2.4 If you visit a pharmacy; 
2.4.1 How often do you so 
 
2.4.2 What do you purchase 
2.4.2.1 Prescription medicines 
 
2.4.2.2 Over the Counter medicines 
 
2.4.2.3 Other Goods 
 
2.5.1 Does the pharmacy have a clinic  
 
2.5.2 Does the pharmacy have a nurse 
 
2.5.3 Have you had any of the following tests/procedures done in a pharmacy 
2.5.3.1 Blood Pressure Monitoring 
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2.5.3.1.1 If Yes by whom  
 
2.5.3.2 Cholesterol Monitoring 
 
2.5.3.2.1 If Yes by whom 
 
2.5.3.3 Blood Glucose Monitoring 
 
2.5.3.3.1 If Yes by whom  
 
2.5.3.3 Vaccinations (including Influenza) 
 
2.5.3.3.1 If Yes by whom 
 
2.5.3.4 Body Mass Monitored (weighed) 
 
2.5.3.4.1 If Yes by whom 
 
2.5.3.5 Other tests or procedures 
 
2.5.3.5.1 If Yes by whom 
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2.6 Have you ever consulted a pharmacist on health related matters 
 
2.6.1 If Yes, do you think the advice the pharmacist gave you was: 
 
2.6.1 If No, would you ever consider consulting a pharmacist on health related matters 
 
Do you suffer from a chronic illness (a disease such as high blood pressure, diabetes, asthma, 
high cholesterol, epilepsy or any other disease that requires the ongoing use of medicines) 
2.7.1 If Yes - 
2.7.1.1 has a pharmacist given you additional advice on dealing with and controlling your 
condition / disease 
 
2.7.1.2 if a pharmacist has not given you additional advice on dealing with and controlling your 
condition / disease, would you like a pharmacist to do so 
 
2.7.2 If No - and you were to become chronically ill in the future, would you like a pharmacist 
to give you additional advice on dealing with and controlling your condition / disease 
 
2.8 Do you think that pharmacists should be paid for providing professional services, namely: 
"Counseling patients on the correct use of their medicines and giving additional advice on 
dealing with and controlling their conditions / disease" 
 
2.8.1 If Yes - who should pay: 
 
2.9 Is your relationship with your pharmacist; 
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Good 
I know his/her name; he / she knows mine; I trust the health related advice given to me; I feel 
I can speak to him / her at any time about my health problem; I see him /her as 'my' 
pharmacist 
Average 
I know his / her name but I doubt he /s he knows mine; I may or may not trust the health 
related advice given to me depending on the circumstances; I would probably visit the same 
pharmacy most of the time 
Poor 
We don't know each other; I am seldom if ever given health related advice and I may or may 
not trust the advice, I will use the pharmacy most convenient at the time that I need to make a 
purchase 
No relationship 
I never visit a pharmacy nor do I consult with a pharmacist. 
2.10 Which health care professional is most accessible to you; (conveniently situated, readily 
available to talk to, gives free advice or advice that you may be willing to pay for): 
 
 
Submit
 
 
 
Annexure 6.1 
 
 
 
 
 
 
 
 
 
FACULTY OF PHARMACY Tel: (046) 603 8381  Fax: (046) 636 1205 
 
 
Dear Colleague, 
 
Re: Pharmacy Practice Research  
 
I am writing to you to enquire if you would be willing to take part in a community pharmacy 
disease management study. The study is aimed at testing the hypothesis that trained community 
pharmacists are able to positively influence adherence to therapies by patients with Type-2 
diabetes mellitus. Professor Ros Dowse of the faculty of pharmacy at Rhodes University will 
supervise the study. 
 
Research has shown that patient adherence to therapy by the chronically ill falls far short of what 
is considered to be ideal- with less than 50% of patients in the developed world being considered 
adequately adherent to long-term therapies. Therapeutic adherence levels in the developing 
world are considered by the WHO to be far worse than those of the developed world. The impact 
of less than ideal levels of therapeutic adherence by chronically ill patients results in poor 
healthcare outcomes- both from a patient health related quality of life and a health economics 
perspective.   
 
In a report published by the World Health Organisation in January 2003, A.J.M. Hoek, General 
Secretary of the International Pharmaceutical Federation (FIP) had the following to say about the 
role of the pharmacist in improving patient adherence to long-term therapies: 
“ Pharmacists are well positioned to play a primary role in improving adherence to long-term 
therapy because they are the most accessible health care professionals and because they have 
extensive training in pharmaceuticals.” 
 
I understand that some of you may question the appropriateness or need for pharmacy practice 
research at a time when the very existence of community pharmacy in South Africa is under 
threat. I believe that the nature of the threat and the reality of the changed community pharmacy 
environment is cause enough for the profession to explore ways to re-invent itself. The changing 
dynamic supports the premise that we are no longer trading professionals but rather professionals 
who trade. Thus it has become important and urgent that we scientifically prove to healthcare 
stakeholders that we can and do add value to the healthcare chain. 
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The literature reveals that community pharmacists in a number of countries are able to add value 
to healthcare by providing professional cognitive pharmacy services to patients. The position in 
South Africa remains less definite because of a paucity of valid local pharmacy practice research 
to support similar claims to this effect. 
 
In addition to being reimbursed for the act of dispensing medicines, as legislated by the 
Medicines and Related Substances Act (No.101 of 1965) as amended, our right to be reimbursed 
for providing pharmaceutical care to patients is included in the provisions of the suspended 
South African Pharmacy Council Board Notice 94 of 2003. This notice sets out the “rules 
relating to the services for which a pharmacist may levy a fee and guidelines for levying such a 
fee or fees.” In order to unlock the reimbursement potential inherent in the provision of 
pharmaceutical care the profession will have to demonstrate to healthcare stakeholders, 
especially the funders of healthcare, that the provision of pharmaceutical care by community 
pharmacists results in tangible value for patients and funders alike. I believe that the proposed 
study will go someway towards achieving this objective. 
 
The proposed study design is that of a randomised control trial. The pharmacists who will be 
randomised to the intervention cohort will be provided with both type-2 diabetes disease state 
management and adherence promoting intervention training and on-going support. The 
intervention cohort will thus be required to provide their associated type-2 diabetes patients with 
enhanced care. The control cohort will consequently provide their associated type-2 diabetes 
patients with usual care. Key adherence variables and disease risk indicators in both the 
intervention and control cohorts will be measured and studied.  
 
It is hoped that the study will prove the hypothesis that trained community pharmacists are able 
to collaborate with type-2 diabetes patients and assist them to improve their levels of adherence 
to therapies. If the study results in such an outcome, then I believe that valid scientific evidence 
will exist that will support those community pharmacists wishing to establish themselves as 
healthcare providers of value-added professional cognitive pharmacy services. 
 
 
The profession needs your active participation in the study. Those pharmacists who respond 
positively to this request by completing the attached form will be provided with additional 
information on the study including a proposed role-out action plan with time-lines. 
 
I look forward to working with you. Any questions or suggestions then please contact me by 
email at peterhill@intekom.co.za 
 
 
Peter Hill 
PO Box 75 
Molteno 
5500 
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COMMUNITY PHARMACY DISEASE MANAGEMENT STUDY 
 
If you would like to participate in this study, please complete the form and email to me at 
peterhill@intekom.co.za 
 
 
Participating Pharmacist’s Details 
Pharmacy Name:  
Pharmacist’s 
Surname: 
 
Pharmacist’s First 
Name: 
 
Telephone No: Work: Cell: Email: 
 
 
  
  
 
Physical Address: 
 
 
Postal Address: 
 
RAMS/BHF No:    
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 Annexure 6.2 
 
 
 
FACULTY OF PHARMACY 
 
 
 Type 2  Diabetes Mellitus Research 
 
PO Box 275 
Port Alfred 
6170 
 
5 March 2006 
 
 
 
Dear name of pharmacist 
 
Enclosed please find the Patient Study Packs – one for each of the T2DM patients that 
you recruited to the study.  I have written to each recruited patient [see attached] thanking 
them for agreeing to participate in the study and provided some information on the 
process going forward. I suggest that you contact your patients as soon as possible and 
arrange to meet with them to discuss the contents of the enclosed packs. It is crucial that 
patients understand the importance of completing the questionnaires and of having the 
baseline clinical variables measured.  
 
I would appreciate it if these documents could be returned to me in the self-addressed 
postage paid envelopes as soon as possible. The due date for the return of the 
documentation to me is 31 May 2006.  
 
Patient Study Packs 
 
Each pack contains the following: 
 Patient profile [to be completed by the patient and returned to me]. 
 Baseline clinical data form [items 4 - 7 to be completed by you and returned to me. 
Note if the patient has had a Lipogram, HbA1c, or serum creatinine measured within 
60 days you may use those results, in which case please include such values on the 
form]. 
 Ampath form for the required biochemical tests [please complete the form selecting 
the boxes that correspond to the required tests]. 
 Medical practioner information letter [to be completed by you and forwarded to the 
patient’s medical practioner]. 
 Beliefs about medicines questionnaire [to be completed by the patient and returned to 
me]. 
 Patient satisfaction questionnaire [to be completed by the patient and returned to me]. 
 Diabetes care questionnaire [to be completed by the patient and returned to me]. 
 Self-care adherence questionnaire [to be completed by the patient and returned to 
me]. 
 Self-addressed and postage paid envelope. 
 A copy of the International Diabetes Federation’s desktop Guide to Type 2 Diabetes 
[provides you with a type 2 diabetes reference resource]. 
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Language 
We respect the rights of both pharmacists and patients to be addressed in an official 
language of their choice, however, the study is being conducted in English for two main 
reasons: 
• All of the scientifically validated questionnaires and scales that will be used in this 
study have been published in English. Translation of these instruments into other 
languages would not only be time consuming but would require re- validation due to 
the possible effect of bias brought about by translation. Re-validation of these 
instruments is beyond the scope of this research.  
• Although we have a number of official languages in South Africa in addition to 
English, it is the language of use in most of the published literature relating to the 
topic.  
 
 
Thanks once again for your valuable participation and please pass on my thanks and 
appreciation to your patients. 
 
Kind regards 
 
 
 
Peter Hill 
Faculty of Pharmacy 
Rhodes University 
Grahamstown 
046 6243575 
0829285020 
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FACULTY OF PHARMACY 
 
 
 Type 2  Diabetes Mellitus Research 
 
PO Box 275 
Port Alfred 
6170 
 
 
 
Dear  name of patient        
 
Thank you once again for agreeing to participate in the research project aimed at finding 
ways for pharmacists to help people with Type 2 diabetes improve the care and 
management of their condition. 
 
We are now ready to move to the next phase of the research and this is going to require 
you to go into your pharmacy during the months of April and May 2006 to have some 
tests and measurements done.  
 
Certain of the measurements will be done in the pharmacy and others will require a blood 
test. The measurements that are to be done by your pharmacist in the pharmacy are the 
following: 
1. Blood Pressure. 
2. Urine test. 
3. Body Mass Index (weight and height). 
4. Waist and hip measured. 
 
A blood test is required for the following important information about the state of your 
diabetes: 
5. Glycated haemoglobin or HbA1c- this is a measure of the average blood glucose 
level over the past 2-3 months. 
6. Lipogram- a full Cholesterol test. 
7. Creatinine- a kidney function test. 
 
If you have had any of the above blood tests done (tests 5, 6 and 7) within the past 2 
months then you do not have to repeat the tests now- all you have to do is hand copies of 
the results to your pharmacist. Please note that even if you have recently had the 
abovementioned blood tests done, you will still have to have the other 
measurements/tests (tests 1, 2, 3 and 4) done in the pharmacy during April/May 
 
I have arranged with the Ampath pathology group to do the blood tests for you at a 
reduced cost.  
 
The blood tests will have to be done at the beginning (April/May 2006) and again at the 
end of the project (April/May 2007), as will the tests and measurements that will be 
performed by your pharmacist (blood pressure, body mass index, waist-hip and urine test) 
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Some of you may question the need for the tests. The International Diabetes Federation, 
a world authority on diabetes care, stresses the need for regular testing, as mentioned 
above, if diabetes care is to optimised. It is very important that you have the tests done as 
it is impossible to manage diabetes unless certain measurements and tests are regularly 
performed and the results assessed. This research is aimed at finding ways to help you 
improve your diabetes care and the results of your tests will contribute significantly to this 
goal. 
 
I have written to your pharmacist and asked him/her to contact you to make an 
appointment for the measurements and blood test. In addition to the abovementioned set 
of tests, please complete the form entitled ‘Patient Profile’ together with questionnaires 
that your pharmacist will hand to you. These forms have been designed to help us identify 
possible problem areas in your diabetes care.  This information, as is the case with your 
test results, is very important to finding ways of improving diabetes care. When you 
receive the form and questionnaires, please complete them as soon as possible and then 
return them to me in the self-addressed postage paid envelope that I will provide. 
 
If you have any questions or suggestions, please do not hesitate to contact your 
pharmacist. 
 
Your contribution to improving diabetes care is invaluable and very much appreciated. 
 
kind regards 
 
 
 
 
Peter Hill 
Faculty of Pharmacy 
Rhodes University 
Grahamstown 
046 6243575 
0829285020 
Type 2 Diabetes Mellitus  Research Project Annexure 6.2
NB Please print clearly
Name of your pharmacy : 
Your surname and initial:                                                                                         
Your  diabetes research identity number:                                                                                     
Patient Profile -please tick the box corresponding to your answer
Gender M F
Age (years)
Ethnic group Black White Coloured Asian
Marital status ( M=married or living with a partner; S = single living alone) M S
Education-highest level of education completed Primary Secondary Tertiary No School
Home language isiZulu isiXhosa Afrikaans Sepedi English Setswana Sesotho Other
Duration of diabetes-how long since you were first diagnosed with Type 2 diabetes (years)
Medical care-how often do you see your doctor about your diabetes? (times a year)
                     -and do you see your GP or a specialist (endocrinologist or diabetologist)? GP Specialist
Family history of diabetes-is there a family history of diabetes? Y N Not sure
Diabetes education-have you ever received diabetes education? Y N
Diet-has a dietician ever advised you on meal planning? Y N
      -do you follow a diabetes friendly meal plan? Y N
Exercise-has your doctor or any other health care professional advised you to exercise? Y N
              -do you exercise regularly (3-5 times a week) Y N
Social support-do you receive support from family and or friends in managing your diabetes? Y N
Medicines for diabetes-do you take medicine and/or use insulin to treat your diabetes? Y N
                                         -are your diabetes medicines  taken orally, injected (insulin) or both? Oral Injected Both
Other chronic conditions-do you have any of the following conditions?
                                            -do you have heart disease? Y N
                                            -have you had a stroke? Y N
                                            -do you have high blood pressure? Y N
                                            -do you have high cholesterol? Y N
                                            -are you depressed (diagnosed by a doctor)? Y N
                                            -do you have kidney disease? Y N
                                            -do you have blood circulation problems? ('Diabetic foot') Y N
                                            -do you have eyesight problems related to diabetes? Y N
Medicines for other chronic conditions-do you take prescription medicines for the following chronic conditions
                                                                  -heart disease? Y N
                                                                  -high blood pressure? Y N
                                                                  -high cholesterol? Y N
                                                                  -any form of depression? Y N
  Do you have any of the following tests and examinations?
  -do you have your HbA1c ( glycated haemoglobin) monitored at least once every 6 months ? Y N Not sure
  -do you self-monitor your blood glucose ? Y N
   -if yes, then how often ? Daily Weekly Monthly
   -do you have your cholesterol monitored at least once a year? Y N
   -do you have your blood pressure monitored at every diabetes consultation**? Y N
  -do you have your kidney function monitored at least once a year? Y N
  -do you have your weight monitored at every diabetes consultation**? Y N
  -do you have your waist and hip measured regularly? Y N
  -do you have you feet examined at least once a year? Y N
  -do you have an eye examination at least once a year? Y N
  -do you have a yearly ECG? Y N
Complementary Medicines-do you use homeopathic or herbal medicines to treat your diabetes? Y N
Tobacco use-do you smoke tobacco? Every day Occasionally Never
Alcohol use -do you consume alcohol? Y N
                         -if yes, and you have a drink every day-how many drinks do you have each day?
                         -if yes, and you do not  have a drink every day-how many drinks do you have each week?
** consultation= whenever you consult a doctor, nurse, pharmacist about your diabetes
This information will be treated as confidential and is for research purposes only

                     Annexure 6.2   
 
 
Type 2 Diabetes Mellitus Research    
 
Baseline Clinical Data Form 
 
 
Name of Pharmacy…………………………………………..                                                                                                                    
 
 
Laboratory:  Ampath    Other laboratory               Pharmacy laboratory 
 
 
 
 Patient Surname…………………………………Initials…………………. Research ID No…… 
 
Test Result Date 
1. Glycated haemoglobin – HbA1c ( %)   
2. Lipogram ( mmol/l)   
2.1 Total Cholesterol   
2.3 HDL Cholesterol   
2.4 LDL Cholesterol   
2.5 Triglycerides   
3. Serum Creatinine (mmol/l)   
4. Proteinuria (urine dipstick-positive[+ve] or negative [-ve] )   
5. Blood Pressure (mmHg)   
4.1 Systolic blood pressure   
4.2 Diastolic blood pressure   
6. Body Mass Index-BMI (mass in kg/ height in m2)   
7. Waist-Hip Ratio    
 
All patient information provided in the course of this research will remain confidential.  
 
 
 
Please fax the completed form to Peter Hill at  046 6243575 
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Dear Doctor 
 
Re: Pharmacy Practice Research 
 
 Improving Patient Adherence to Self-care Recommendations in Type 2 
Diabetes Mellitus: a  Community Pharmacist Randomised Controlled Cluster 
Trial 
 
This letter serves to advise you that name of participating patient                                        
has agreed to participate in a Rhodes University, Faculty of Pharmacy endorsed 
research project aimed at testing the hypothesis that community pharmacists are 
able to assist patients with Type 2 diabetes mellitus improve their adherence to long-
term therapies and other diabetes self-care recommendations. 
 
Project Overview 
 
Patient Adherence to Long-term Therapies. 
The World Health Organisation (WHO) published a report in January 2003 entitled 
“Adherence to long-term therapies: evidence for action”.1 The report is an extensive 
review of the published literature on patient adherence to long-term therapies. 
Research has shown that there continues to be an epidemiological shift along the 
disease continuum from acute to chronic. Furthermore, therapeutic adherence 
amongst the chronically ill has been shown to fall far short of what is considered to 
be ideal with the level of adherence to long-term therapies being no better than 50% 
in developed countries and certainly less than 50% in developing countries.1 The 
result is that so-called ‘ therapeutic failure’ is not an uncommon phenomenon, 
especially amongst patients in the developing world 2  
 
The WHO report endorses the view held by Hayes, an internationally acknowledged 
researcher on adherence, that “increasing the effectiveness of adherence 
interventions may have a far greater impact on the health of the population than any 
improvement in specific medical treatments”5  
 
Studies referred to in the report show that poor levels of therapeutic adherence by 
chronically ill patients result in poor health outcomes, both from a patient health-
related quality of life and a health economics perspective.1  
  
 
Type 2 Diabetes Mellitus 
Diabetes mellitus is a group of highly prevalent diseases affecting approximately 150 
million people worldwide and this number is predicted to double within the next 22 
years. It is estimated that by 2025, 75% of patients with diabetes will be living in 
developing countries.3 Type 2 diabetes mellitus accounts for about 90% of all 
diagnosed cases of the diabetes mellitus.1 It is an insidious condition as it has been 
shown to be associated with the silent downstream development of serious co-
morbidities especially coronary heart disease, hypertension and hyperlipidemia.4  
 
 
 2 
 
It follows, therefore, that therapeutic adherence by patients with Type 2 diabetes 
mellitus is of crucial importance not only in managing the primary condition but also 
in preventing or arresting the development of very important microvascular and 
macrovascular complications. The 1991 United Kingdom Prospective Diabetes Study 
revealed that around 50% of patients had already developed certain of the 
complications associated with diabetes mellitus by the time they were first diagnosed 
with Type 2 diabetes .6 
 
The Role of the Community Pharmacist 
The WHO and other authorities have identified the community pharmacist as one of 
the health care professionals ideally positioned to impact positively on patient 
adherence to long-term therapies.1,5,7. Worldwide, the profession is increasingly 
emphasizing the importance of providing pharmaceutical care to patients.8, 9 SA 
legislation too has recognized the changing dynamic as evidenced by the publishing 
by the SA Pharmacy Council of mandatory Rules governing Good Pharmacy 
Practice.10  
 
Study Design 
The study is a national  multi-centre Randomised Controlled Trial designed to test the 
hypothesis that the intervention cohort of community pharmacists are able to 
positively influence Type 2 diabetic patient adherence to therapies and key self-care 
recommendations.  
 
Each participating pharmacist will recruit 10 Type 2 diabetic patients randomly 
selected from the pharmacy’s prescription database. We will measure all participants 
for identified clinical indicators and psychosocial variables at baseline then 
randomise the pharmacists and their associated patients to control (usual care) and 
intervention (enhanced care) and again measure the variables 12 months post 
baseline. The intervention pharmacists will be provided with a diabetes care plan 
framework after randomisation. The primary endpoint is HbA1c which, in addition to 
being an intermediate health outcome, serves as a surrogate marker for adherence. 
Other clinical and psychosocial indicators will be secondary endpoints.  
 
Dr Ros Dowse, Associate Professor in the Faculty of Pharmacy, Rhodes University, 
Grahamstown, is supervising the research. Professor Dowse may be contacted at 
telephone 046 603 8399 or email r.dowse@ru.ac.za.  
 
Patient Information letter 
Prospective participating patients have been provided with study information letters 
and consent forms which set out that: 
• the reason for the research programme is to determine if pharmacists can assist 
diabetic patients improve their adherence to diabetes self-care recommendations; 
• improved adherence to self-care recommendations in Type 2 diabetes helps to 
prevent the development of diabetes-related complications which, in turn, 
translates into improved health-related quality of life; 
• the programme supports and does not interfere with treatment prescribed by their 
doctor or any other health care professional; 
• all they have to do is complete short questionnaires and to have certain clinical 
indicators measured at the beginning of the programme ( baseline), again after 
12 months; 
• all information provided will be treated confidentially; 
• their right to discontinue participation in the study at any time and without 
prejudice is recognised. 
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Patient-centred care 
In keeping with the collaborative patient-centred approach to health care that is 
increasingly finding favour with health care consumers and progressive health care 
professionals around the world, it is the intention of the research to support the 
relationship between pharmacist and medical practioner as this is a key component 
of collaborative patient-centred care.  
 
Accordingly we affirm that: 
•  the study supports accepted national and international treatment guidelines for 
Type 2 diabetes;  
•  it is not our intention to interfere with prescribed therapy but rather to support the 
practice of evidence-based care in type 2 diabetes; 
•  all adherence promoting interventions applied in the intervention cohort are 
based on evidence contained in the literature; 
• patients participate in the study of their own free will and may discontinue their 
participation at any time and without prejudice; 
• the Ethics Committee of Rhodes University has approved the research in terms 
of the Medical Research Council’s guidelines for human subject research  
 
  
We value your support of the research and welcome any contribution that you might 
care to offer. 
 
kind regards 
 
                                                                                             
   
Name of -Study Pharmacist                                          Peter Hill-Researcher 
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FACULTY OF PHARMACY  
 
Type 2 Diabetes Mellitus Research Project Questionnaire* No. 1 
* Reproduced with the permission of Professor Robert Horne, University of Brighton 
 
Your research identity number: 
 
 
Your views about medicines prescribed for you 
 
 We would like to ask you about your personal views about all the medicines 
prescribed for you. 
 These are statements other people have made about their medicines.  
 For each of the statements, please tick the box that is closest to your opinion 
. 
 
There are no right or wrong answers. We are interested in your personal views 
 
 Views about medicines 
prescribed for you: 
 
Strongly 
agree 
Agree Uncertain Disagree Strongly 
disagree 
1 My health at present, depends 
on my medicines 
     
2 Having to take medicines worries 
me  
     
3 My life would be impossible 
without my medicines 
     
4 I sometimes worry about the 
long-term effects of my 
medicines 
     
5 Without my medicines I would be 
very ill 
     
6 My medicines are a mystery to 
me 
 
     
7 My health in future will depend 
on my medicines 
     
8 My medicines disrupt my life 
 
     
9 I sometimes worry about 
becoming too dependant on my 
medicines 
     
10 My medicines protect me from 
becoming worse 
     
11 These medicines give me 
unpleasant side effects 
     
 
 
 
 
 2 
Your views about medicines in general 
 
 These are statements other people have made about medicines in general.  
 For each of the statements, please tick the box that is closest to your opinion 
. 
 
 Views about medicines in general Strongly 
agree 
Agree Uncertain Disagree Strongly 
disagree 
1 Doctors use too many medicines 
 
     
2 People who take too many 
medicines should stop their 
treatment for a while every now 
and again 
     
3 Most medicines are addictive 
 
     
4 Natural remedies are safer that 
medicines 
     
5 Medicines do more harm than 
good 
 
     
6 Most medicines are poisons 
 
     
7 Doctors place too much trust in 
medicines 
     
8 If doctors had more time with 
patients they would prescribe 
fewer medicines 
     
 
Please return the completed questionnaire in the self-addressed postage paid 
envelope provided. 
 
Thank you for completing the questionnaire 
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FACULTY OF PHARMACY  
 
 
Type 2 Diabetes Mellitus Research Project Questionnaire* No.2 
* Reproduced with the permission of the University of Michigan Diabetes Research and Training Center 
 
 
Your research identity number: 
 
 
 
These statements reflect on the diabetes care you have received recently. For each 
of the statements, please tick the box that is closest to your opinion . 
 
 
 
Q1 
Strongly 
Disagree 
 
Disagree 
Not 
Sure 
 
Agree 
Strongly 
Agree 
 
A. I’m very satisfied with the diabetes care that  
I receive 
 
     
 
B. Most people receive diabetes care that could 
be better 
 
     
 
C.  The diabetes care that I have received in the 
last few years is just about perfect 
     
 
D.  There are things about the diabetes care       
I receive that could be better 
     
 
               
    
Q2. Who currently provides your main diabetes health care?  (Tick only one box) 
 
   Generalist (your GP, or a nurse,) 
 
 Specialist (a diabetologist, endocrinologist, or nurse working with a   
diabetologist or endocrinologist) 
 
   Other (please specify): 
 
 No one- I do not have a regular health care provider who provides my 
diabetes care 
 
 
                                  
 
 2 
 
 
Q3. Thinking back over the past 12 months, how would you rate the diabetes care 
you have received with regard to:  
  
(Tick only one box in each line)  
Poor 
 
Fair 
 
Good 
Very 
Good 
 
Excellent 
 
A. Keeping you informed about what the next step 
in your care would be. 
 
     
 
B. Different health care providers being up-to-date 
on your current treatments and recent test 
results 
 
     
 
C. Communication between different health care 
providers caring for you 
 
     
 
D. Knowing who to ask when you had questions 
about your health 
 
     
 
                           
 
Please return the completed questionnaire in the self-addressed postage paid 
envelope provided. 
 
Thank you for completing the questionnaire 
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FACULTY OF PHARMACY  
 
 
Type 2 Diabetes Mellitus Research Project Questionnaire No. 3 
 
 
Your research identity number: 
 
 
 
 
Q1 Have you set diabetes-related goals for yourself? 
 
Yes No 
            
  Yes No Not 
Sure 
Q2 Do you have a diabetes care plan? 
 
   
Q3 Did a health care professional (e.g. doctor, nurse, or 
pharmacist) assist you with the development of a diabetes 
care plan? 
 
   
Q4 Does your diabetes care  include the regular monitoring 
by a health care professional of the following, your: 
 
   
 a.  self monitored blood glucose test results    
 b. HbA1c ( Glycosylated haemoglobin) levels    
 c. weight    
 d. exercise programme    
 e. medication use    
 f. blood pressure     
 g. cholesterol levels    
 h. kidney function    
 i. eye sight    
 j. blood circulation ( ‘diabetic foot’)    
 k. use of alcohol*   n/a 
 l. use of tobacco*    n/a 
 m. diabetes-related stress    
 n. family or social support    
 
*Note: If you do not use alcohol or tobacco  please tick the n/a  blocks 
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These statements consider the role of your pharmacist in your diabetes care plan.  
 
For each of the statements, please tick the box that is closest to your opinion . 
 
 
Q5 
Strongly 
Disagree 
 
Disagree 
Not 
Sure 
 
Agree 
Strongly 
Agree 
 
a. My pharmacist provides me with a good 
level of diabetes care  
     
 
b. I would like my pharmacist to do more to 
help me manage my diabetes 
     
 
c. I think that my pharmacist is equipped to 
provide me with diabetes care 
     
 
d. My pharmacist and doctor work together 
to provide me with diabetes care 
     
 
 
 
 
Please return the completed questionnaire in the self-addressed postage paid 
envelope provided. 
 
 
Thank you for completing the questionnaire 
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FACULTY OF PHARMACY  
 
 
Type 2 Diabetes Mellitus Research Project Questionnaire* No. 4 
* Reproduced with the permission of the University of Michigan Diabetes Research and Training Center 
 
Your research identity number: 
 
 
For each of the statements, please tick the box that is closest to your opinion . 
 
 
                                                              Never       Sometimes        Always         Don’t know 
 
                                                              Never        Sometimes           Always      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please return the completed questionnaire in the self-addressed postage paid 
envelope provided. 
 
Thank you for completing the questionnaire 
 
 
 
 
 
Q1 
 
I keep my blood sugar in good 
control 
    
 
Q2 
 
I keep my weight under control 
   
 
Q3 
 
I do the things I need to do for 
my diabetes (diet, medicine, 
exercise, etc.) 
   
 
Q4 
 
I handle the feelings (fear, 
worry, anger) about my diabetes 
fairly well 
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Preface
A desktop guide
In 1989 the European NIDDM Policy Group published its first Desktop Guide for the
management of Non-insulin-dependent ( Type 2 ) Diabetes, and in 1993 that document
was revised on behalf of the St Vincent Declaration Initiative.
The current Desktop Guide builds on those guidelines, in the light of newer
understandings, and attempts to provide a more direct and more accessible format.  Our
aim here is to provide Guidelines which can offer easy access to high quality and better
integrated care, while reducing health inequalities.
The greater emphasis on arterial risk factor management, rather than just good blood
glucose control, is given particular prominence.
Furthermore, this time language that can be followed by the educated person with
diabetes has been used, remembering that “the primary resource for diabetes care is the
person with diabetes themselves, supported by enthusiastic and well-trained
professionals”.
Evidence
In an attempt to maintain clarity, accessibility and usefulness, the current Desktop Guide
remains didactic in its approach.  However, a source document to be published later will
go further than the previous guidelines in referencing the evidence and strength of the
recommendations given here.
Aims of diabetes care
The aim of these Guidelines is to enable people with diabetes to have a life of normal
length and fulfilment through :
x
 provision of skills to adapt life-style to ensure optimum health;
x
 development of understanding to allow coping with new challenges, and to give
maximum flexibility;
x
 control of risk factors for arterial disease, and for eye, kidney and nerve damage;
x
 early detection and management of any existing vascular damage.
A way forward
The 1998-1999 European Diabetes Policy Group has worked on both the major types of
diabetes – the sister publication on Type 1 diabetes appeared last year.  The working
group came from richer and poorer nations throughout Europe, and included people with
diabetes, as well as members of multi-disciplinary teams.
European Diabetes Policy Group, 1999
Correspondence:
Correspondence to :  Professor George Alberti, Department of Medicine, Framlington Place,
Newcastle upon Tyne, NE2 4HH, UK.  E-mail : george.alberti@newcastle.ac.uk
Electronic file :  Download as Word 97 document, or HTML ( web browser ) files from :
http://www.staff.newcastle.ac.uk/philip.home/guidelines
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1 Diagnosis of Hyperglycaemic States
Management classification  –  hyperglycaemic states
Diagnostic background
The purpose of diagnosis is to identify those at risk of developing the complications of diabetes,
both arterial ( macrovascular ) and microvascular, as well as to deal with any symptoms
The levels of blood glucose vary for these different risks, and determine management
1. Symptomatic ( biochemically confirmed ) Ö "Diabetes"
2. At risk of arterial and microvascular damage Ö "Diabetes"
3. At risk of arterial damage from hyperglycaemia  "Impaired Glucose Tolerance ( IGT )"
Ö
and of progression to diabetes "Impaired Fasting Glycaemia ( IFG )"
Diagnostic algorithm
1. Symptomatic or glycosuria or incidental hyperglycaemia
Ö Check random venous plasma glucose ( see below for capillary / venous equivalents )
If >11.0 mmol/l ( t200 mg/dl ) Ö "Diabetes"
If  >5.5 mmol/l ( t100 mg/dl ) then proceed to next step (2.)
( and review cause of symptoms )
2. Random or fasting screening glucose >5.5 mmol/l ( t100 mg/dl )
Ö Check fasting venous plasma glucose
If t7.0 mmol/l ( >125 mg/dl ), repeat and if confirmed Ö "Diabetes"
If >6.0 mmol/l ( t110 mg/dl ) do oral glucose tolerance test ( OGTT )
If >5.0 mmol/l ( >90 mg/dl ), consider yearly reassessment of arterial risk factors,
including plasma glucose
OGTT ( venous plasma glucose ) :
If 2-h >11.0 mmol/l ( t200 mg/dl ) Ö "Diabetes"
If 2-h d11.0 mmol/l ( <200 mg/dl ) and t7.8 mmol/l ( t140 mg/dl ) Ö "IGT"
If fasting >6.0 mmol/l ( t110 mg/dl ) and 2-h <7.8 mmol/l ( <140 mg/dl ) Ö "IFG"
Diagnostic equivalents for plasma and blood
Plasma glucose* Whole blood glucose
Venous* Capillary Venous Capillary
mmol/l mg/dl mmol/l mg/dl mmol/l mg/dl mmol/l mg/dl
Fasting
"Diabetes" t  7.0 >125 t  7.0 >125 >  6.0 t110 >  6.0 t110
"IFG" >  6.0 t110 >  6.0 t110 >  5.5 t100 >  5.5 t100
OGTT 2-h
"Diabetes" >11.0 t200 t12.2 t220 t10.0 t180 >11.0 t200
"IGT" t  7.8 t140 t  8.9 t160 t  6.7 t120 t  7.8 t140
* preferred measure
OGTT: 75 g glucose in 300 ml water over 3-5 min
See cautions on next page
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Diagnostic aids and cautions
1. Fasting glucose estimations require a certainty of no previous calorie intake
¾
 
be suspicious if HbA1c not consistently elevated
¾
 
if suspicious repeat after 2-h supervision, or consider OGTT
¾
 
diagnosis cannot be based on a single abnormal glucose estimation in the absence of
symptoms
2. Venous plasma glucose estimation is preferred
¾
 
for convenience, equivalents for whole blood and capillary glucose estimations are
given on previous page
3. HbA1c ( glycated haemoglobin ) can be useful in clinical diagnosis
¾
 
provided that confirmatory venous plasma glucose estimations are obtained
¾
 
provided the assay is DCCT standardized, an HPLC chromatogram is reviewed for
presence of abnormal haemoglobins, and erythrocyte turnover is not abnormal
¾
 
approximately, HbA1c >7.5 %  |  fasting plasma glucose t7.0 mmol/l ( >125 mg/dl )
>6.5 %  |  fasting plasma glucose >6.0 mmol/l ( t110 mg/dl )
4. Diagnostic procedures should not be performed :
¾
 
in the presence of acute illness or after trauma or surgery
¾
 
during short courses of blood glucose raising drugs
5. Diagnostic tests should be interpreted with reservation :
¾
 
in people on long-term blood glucose raising drugs
¾
 
in people with reversible endocrine conditions
¾
 
in pregnant women ( see section 20 )
6. If suspicion or high risk of diabetes, but fasting glucose normal, do OGTT, particularly in the
elderly
7. The above procedures are not applicable to people with hepatic cirrhosis or other extreme
forms of peripheral insulin resistance
¾
 
in people with normal fasting but elevated post-prandial glucose levels, diagnose
according to 2-h OGTT criteria
DELIVERY OF CARE
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2 Framework of Diabetes Care
A framework for quality diabetes care
Ensure  provision of the following :
¾
 
A diabetes team
 ( professionals ) with up-to-date skills, including :
x doctors
x diabetes nurse specialists/assistants and educators
x nutritionists ( dieticians )
x podiatrists ( chiropodists )
¾
 
A solid infrastructure
x easy access for people with diabetes
x protocols for diabetes care
x facilities for education and foot care
x information for people with diabetes
x structured records
x recall system for Annual Review / eye surveillance
x access to quality-assured laboratory facilities
x database / software for quality monitoring and development
x continuing education for professional staff
¾
 
A range of services
x for regular review ( often 3-monthly )
x for Annual Review
x for education
x for foot care
x for eye surveillance
x emergency advice line
x access to heart, renal, eye, vascular specialists
x joint obstetric service
¾
 
A system of quality development
x feedback from people with diabetes on service performance
x regular review of service performance ( see section 5 )
DIABETES CONSULTATION
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3 The Diabetes Consultation
Consultation infrastructure
Consultation process
Annual Review
Include the following :
Ö Welcome
Friendly greeting and early establishment of rapport
Ö Problems review
Identification of : ¾ recent life-events / new symptoms
¾ new difficulties in self-management of diabetes
Review of : ¾ self-monitored results;  discussion of their meaning
¾ dietary behaviours, physical activity, smoking
¾ diabetes education, skills, and foot care
¾ blood glucose, lipid and blood pressure therapy and results
¾ other medical conditions and therapy affecting diabetes
Management of : ¾ arterial / foot risk factors identified at Annual Review
¾ complications and other problems identified at Annual Review
Ö Analysis and planning
Agreement on : ¾ main points covered
¾ targets for coming months
¾ changes in therapy
¾ interval to next consultation
Ö Recording
Completion of : ¾ structured record / patient-held record
Make available for consultations the following :
¾
 
diabetes team members
¾
 
time and space
¾
 
printed information for the individual with diabetes
¾
 
records and means of communication to other health professionals
Include additionally, at Annual Review, surveillance of the following :
Symptoms
 ischaemic heart disease, peripheral vascular disease
neuropathy, erectile dysfunction ( see section 19 )
Feet footwear, deformity / joint rigidity, poor skin condition, ischaemia,
ulceration, absent pulses, sensory impairment ( see section 18 )
Eyes visual acuity and retinal review ( see section 17 )
Kidney damage albumin excretion and serum creatinine ( see section 16 )
Arterial risk blood glucose, blood pressure, blood lipids, and smoking
( see section 8 )
Attendance podiatry / ophthalmology / other, as indicated
CLINICAL MONITORING
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4 Organization of Clinical Monitoring
Schedule for clinical monitoring at different types of visit
* not required if proteinuria
Social history / life-style review
Complications history / symptoms
Long-term / recent diabetes history
Regular
review
Annual
Review
Initial
review /
referral
Background history
Other medical history / systems
Family history diabetes / arterial disease
Drug history / current drugs
Current skills / well-being
Diabetes self-management
Self-monitoring skills / results
Vascular risk factors
HbA1c ( glycated haemoglobin )
Lipid profile
Blood pressure
Smoking
*Urine albumin excretion
Examination / complications
General examination
If problem
If problem
If problem
If problem
If problem
If problem
Weight / body mass index
If problem
Foot examination
Eye / vision examination
Urine protein
Serum creatinine
Review topics
QUALITY DEVELOPMENT
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5 Monitoring Quality of Care
Protocol for quality development and monitoring of performance
Examples of indicators for quality development and monitoring
Aggregate the data gathered at Annual Review onto a database
Choose indicators ( see below ) to reflect outcome as well as process of care
Analyse data in line with published recommendations
Compare performance with pre-determined standards or other providers of diabetes care
Review performance at regular meetings of your diabetes team
performance of education programmes
Act to design and implement action plans for improvement
Measure : Calculate :
Intermediate outcomes
HbA1c Percent with HbA1c >7.5 and >6.5 %
Albumin excretion Percent with abnormal albumin excretion
Eye damage Percent with retinal damage
True outcomes
Amputation above ankle Incidence
Myocardial infarction Incidence
Stroke Incidence
Foot ulceration Incidence
Risk factor control
        Hypertension Percent with blood pressure t140/85 mmHg
        Smoking Percent people still smoking
Process of care
        Eyes screened Percent people examined in year
Education performed Percent people seeing nurse educator in year
Feet examined Percent people examined in year
These are examples; many other indicators are possible
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6 Patient Education
Patient education  –  Taking responsibility
Patient education  –  Assessment
Assess whether the person with diabetes :
¾
 
has the knowledge and behavioural skills necessary for optimum self-care
¾
 
makes early and effective responses to everyday problems
¾
 
has the confidence to obtain the best input from the diabetes health-care team
Ensure that empowerment is :
¾
 
a primary objective of your consultations and education programme
¾
 
supported by availability of diabetes publications and other information sources
¾
 
the active policy of your diabetes service
Provide :
¾
 
positive encouraging responses to requests for information and understanding
¾
 
a copy of the European Patients’ Charter
or a similar national or local statement of rights and roles
¾
 
a copy of the person’s diabetes health-care record
¾
 
information on the results and meaning of all investigations
Consider :
¾
 
need for assisted self-care for those with cognitive or physical impairment
It is the responsibility of the diabetes team to ensure that the person with diabetes can
follow the life-style of their educated choice, achieved through the three elements of
empowerment: knowledge, behavioural skills, and self-responsibility
Use :
¾
 
review of diabetes skills ( self-monitoring, food identification )
¾
 
biomedical measures ( changes in body weight, glycated haemoglobin )
¾
 
evidence of appropriate behaviours
( footwear, physical activity, smoking cessation, membership of diabetes associations )
¾
 
assessment of life-style, emotional adjustment, and perceptions of barriers to life-style
activities and self-care
¾
 
perceptions of desired short-term goals ( glucose control, weight ), and long-term
vulnerability ( to arterial disease )
¾
 
knowledge ( as a basic measure )
¾
 
diabetes-specific well-being and health profile assessments ( as global measures )
Perform assessment :
¾
 
as part of routine care visits, by direct enquiry
¾
 
more formally, as part of Annual Review, or on first contact
PATIENT EDUCATION
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Patient education  –  Goals
Patient education  –  Provision
Aim to optimize :
¾
 
knowledge of diabetes, its progressive nature, and the aims of its management
¾
 
ability to define personal health-care targets
¾
 
motivation and attitudes to self-care
¾
 
behaviours which interact with diabetes management
¾
 
empowerment in using the skills of health-care and other professionals
Aim to provide skills to :
¾ manage nutrition and physical activity ¾ monitor and use the results of therapy
¾ understand and agree health-care targets, ¾ avoid self-destructive behaviours and deal
and develop strategies for meeting them adequately with stress
¾ manage complications of therapy including ¾ ensure appropriate use of glucose-lowering
hypoglycaemia therapies
¾ use the professional members of the ¾ empower self-management during
diabetes care team effectively intercurrent illness
¾ respond to new problems in diabetes care ¾ cope appropriately with the late tissue
damage of diabetes
Integrate education into regular clinical care by providing your own curriculum and programme
Ensure that the diabetes team has personnel adequately trained in patient education
Assess special needs of each individual ( see above )
Be aware of needs of special groups ( language problems, physical / mental disabilities )
Provide education within three time frames :
¾
 
At and shortly after diagnosis :
x basic information on healthy eating, physical exercise, and smoking cessation
x supportive information on the nature and outcomes of diabetes
x the minimum skills to obtain control over the new situation
¾
 
In the months following diagnosis :
x a comprehensive coverage
x topics covered previously, plus
x targets of therapy, eating at home and away
x complications of diabetes, arterial risk factors, foot care
x employment, insurance, driving and travel
¾
 
In the long term :
x reinforcement periodically after annual evaluation ( see previous page )
Include carers and family members as appropriate
Use group education to uncover problems and provide solutions and behavioural change
through peer example
Review, evaluate, and improve the impact of your education programmes regularly
PATIENT EDUCATION
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Patient education  –  Life-style issues
Assessment
Topics
Ask regularly about diabetes interfering with :
¾
 
employment
¾
 
social and leisure activities
¾
 
travel
Employment
Provide :
¾
 
individualized advice
¾
 
counselling and contacts for those affected by a change to insulin therapy
Insurance and driving licences
Be aware of where appropriate and up-to-date premiums can be obtained
Provide :
¾
 
advice to patients wishing to enter into insurance contracts
¾
 
rapid and appropriate reports on request
¾
 
informed comment and advice on legal restrictions on licences
Travelling
Provide advice :
¾
 
on the need for valid travel insurance
¾
 
on special health risks in visited countries
¾
 
as appropriate for those using insulin ( see Desktop Guide to Type 1 Diabetes, 1998 )
Review  coping skills for acute illness, especially gastroenteritis, and hypoglycaemia
The aims of patient education and training are to provide information
in an acceptable form, in order that people with diabetes develop the
knowledge to self-manage their diabetes and to empower them to
make informed choices in their lives
SELF-MONITORING
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7 Self-monitoring of Blood Glucose Control
Use and assessment of self-monitoring
Achieving effective self-monitoring
Advise use of self-monitoring for :
¾
 
education on effects of diet and physical activity on blood glucose
¾
 
assurance of satisfactory blood glucose control
¾
 
coping with illness and new situations
¾
 
insulin dose adjustment and hypoglycaemia management where relevant
Assess skills ( and meters if used ) yearly or if problems with self-monitoring
Evaluate reliability of self-test results ( if indicated ) by :
Ö consistency with the results of glycated haemoglobin estimation
Ö comparison with acute results obtained at consultation
Ö review of the quality of self-test record diaries
Use :
¾
 
for all people with Type 2 diabetes
¾
 
blood reagent strips / meters, or self-urinalysis according to individual need
Provide appropriate training and regular review of technique
Recommend :
Ö results are recorded ( with date and time )
Ö different patterns of testing according to need :
x urine glucose post-prandially 1-7 times a week if results consistently negative and
glucose control targets met ( see section 8 )
x blood glucose 1-4 times a day according to need if glucose control is deteriorating
or if using insulin therapy ( see Desktop Guide to Type 1 Diabetes, 1998 )
x blood glucose 4-8 times a day during illness, life-style changes, in pregnancy
Ö tests 1-2 h after meals and not just pre-prandially
Ö testing to cope with variations in eating or activity
Ö urine glucose testing if blood glucose monitoring is indicated but not possible, or if the
patient does not wish to continue with it
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8 Assessing Blood Glucose, Blood Lipid, and Blood Pressure Control
Using assessment levels to set targets
Assessment of blood glucose, blood lipid, and blood pressure control
Use the assessment levels ( next page ) for glucose, lipids, and blood pressure :
¾
 
as an integral part of diabetes care  –  do not manage diabetes on symptoms alone
¾
 
to indicate need for further intervention
¾
 
as the basis for short-term and longer-term individualized targets
¾
 
as an educational tool to help the person with diabetes
Ask yourself the following at consultations :
Ö Is it possible for the individual to approach each target more closely, without a counter-
balancing deterioration in quality of life?
Be concerned about targets :
Ö Failure to attempt to reach agreed targets is inadequate care, unless this would lead to
deterioration in quality of life
Measure :
Ö glycated haemoglobin 2-6 monthly
Ö the blood lipid profile ( total, LDL, and HDL cholesterol, and triglycerides ) 2-6 monthly if
previously above assessment levels ( see next page ), otherwise annually
Ö blood pressure at each consultation unless known to be below assessment levels
Use the assessment levels ( next page ) to set individual blood glucose, blood lipid and blood
pressure targets, depending on overall risk and what it may be possible to achieve within a
foreseeable time period
Modify individual targets at least yearly in the light of past success, and if any change in clinical
circumstances
Smoking target :  Stop, or reduce to as low as possible
Identify smoking habits :
¾
 
at diagnosis / referral and Annual Review
Emphasize importance :
¾
 
at diagnosis and if critical events occur
¾
 
at every appropriate opportunity
Provide information on :
¾
 
health risks and benefits of stopping / reducing
¾
 
techniques for reducing tobacco consumption
¾
 
use of pharmacological substitutes
¾
 
formal smoking cessation programmes
VASCULAR RISK ASSESSMENT LEVELS
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Blood glucose control assessment levels  
Fasting capillary blood glucose is around 1.0 mmol/l ( 18 mg/dl ) lower than venous plasma;
post-prandial capillary blood glucose is the same as venous plasma
Blood lipid control assessment levels
Blood pressure control assessment level
             Low risk                  At risk                High risk
Serum total cholesterol
mmol/l
mg/dl
Serum LDL cholesterol
mmol/l
mg/dl
Serum HDL cholesterol
mmol/l
mg/dl
Serum triglycerides
mmol/l
mg/dl
<4.8
<185
<3.0
<115
>1.2
>46
<1.7
<150
4.8-6.0
185-230
3.0-4.0
115-155
1.0-1.2
39-46
1.7-2.2
150-200
>6.0
>230
>4.0
>155
<1.0
<39
>2.2
>200
HbA1c (DCCT standardized)
%Hb
Venous plasma glucose
Fasting/pre-prandial
mmol/l
mg/dl         
Self-monitored blood glucose
Fasting/pre-prandial
mmol/l
mg/dl
Post-prandial (peak)
mmol/l
mg/dl
   Low risk                 Arterial risk  Microvascular
 risk
d6.5
d6.0
<110
d5.5
<100
<7.5
<135
>6.5
>6.0
t110
>5.5
t100
t7.5
t135
>7.5
t7.0
>125
>6.0
t110
>9.0
>160
Low risk  ( mmHg )    <140/85
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9 Providing Nutritional Advice
Reviewing dietary management
Healthy eating
Review dietary management regularly :
Ö Is healthy eating ( see box ) a normal part of life-style?
Ö Is calorie intake appropriate to desired body weight?
Ö Is alcohol intake moderate?  Could it be exacerbating hypertension or
hypertriglyceridaemia?  Could it be contributing to early or late hypoglycaemia?  Is this
understood by the person with diabetes?
Ö Is money being spent unnecessarily on special 'diabetes' food products?
Ö Does calorie distribution reflect the patient's life-style and preferences, as well as
glucose lowering therapy and regional eating habits?
Ö Do raised blood pressure or kidney damage suggest a benefit from special
recommendations ( protein intake <0.8 g/kg, salt intake <6 g/day, respectively )?
Make recommendations and review eating :
¾
 
at diagnosis
¾
 
at each consultation if overweight or vascular risk factor control sub-optimal
¾
 
formally every other year as a routine, or more often as required
¾
 
on beginning insulin therapy
¾
 
on request
Advise carbohydrate intake should be higher, and fat intake lower than that of most Europeans,
but not different from recommendations for the population in general :
¾
 
Saturated fat : <10 % of calories
¾
 
Polyunsaturated fat : <10 % of calories
¾
 
Carbohydrate : use foods containing soluble fibre in a carbohydrate rich diet
¾
 
Simple sugars : need not be rigorously excluded from the diet, but should be limited
¾
 
Protein : <15 % of calories
¾
 
Monounsaturated fat : use to maintain palatability and balance calorie intake
¾
 
Total calories : as required for normal body mass index
¾
 
Fresh fruit / vegetables : encouraged as part of meal-time calorie intake
¾
 
Alcohol : if desired, as part of total daily calorie intake
Individualize intake to match needs, preferences and culture
Nutritional management is an integral part of initial and continuing education programmes
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10 Physical Exercise
Assessment of physical activity
Management
Advise that physical exercise :
¾
 
can benefit insulin sensitivity, blood pressure, and blood lipid control
¾
 
should be taken at least every 2-3 days for optimum effect
¾
 
may increase the risk of acute and delayed hypoglycaemia
Manage physical exercise using :
Ö formal recording of levels of physical activity
Ö identification of new exercise opportunities ( see box above ), and encouragement to
develop these
Ö appropriate self-monitoring, additional carbohydrate, and dose adjustment of glucose
lowering therapy for those using insulin or insulin secretagogues
Ö warnings :
x about delayed hypoglycaemia, especially with more prolonged, severe, or unusual
exercise for those using insulin therapy
x that alcohol may exacerbate the risk of hypoglycaemia after exercise
x about risks of foot damage from exercise
x need to consider ischaemic heart disease in those beginning new exercise
programmes
Review :
¾
 
activity at work, and in getting to and from the workplace
¾
 
physical activity practice and opportunities in domestic activities and hobbies
¾
 
the possibility of formal physical exercise on a regular basis
Examples :
Ö brisk walking 30 min per day
Ö active swimming for 1 h three times a week
Dietary management, physical activity, and drug therapies
 are partners in the battle to achieve and maintain low risk
blood glucose, blood lipid and blood pressure levels
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11 Therapy for High Blood Glucose Concentrations
Using oral glucose-lowering drugs  ( for insulin therapy see next page )
Life-style management of raised blood glucose levels should be given a
good trial before beginning glucose lowering drugs
Ö Patient education : see section   6, page 11
Ö Self-monitoring : see section   7, page 14
Ö Blood glucose targets : see section   8, page 16
Ö Dietary management : see section   9, page 17
Ö Physical exercise : see section 10, page 18
Begin oral agent therapy when :
¾
 
an adequate trial of life-style intervention / education has been given
¾
 
either ( usually ) :
HbA1c >6.5 %, fasting venous plasma glucose >6.0 mmol/l ( t110 mg/dl )
¾
 
or ( occasionally ) if thin and no other arterial risk factor :
HbA1c >7.5 %, fasting venous plasma glucose t7.0 mmol/l ( >125 mg/dl )
Use :
¾
 
metformin
¾
 
insulin secretagogues ( sulphonylureas and repaglinide )
¾
 
D-glucosidase inhibitors
¾
 
thiazolidinediones and related PPARJ-agonists
Choice of agents
Metformin :  strong evidence base in the overweight, lowers LDL cholesterol, but gastro-
intestinal side effects in some patients; dose titration may help tolerance

 
contraindicated ( risk of lactic acidosis )  if renal impairment, overt liver disease, or
severe cardiac failure; monitor renal function at least yearly
Sulphonylureas :  good evidence base, provided patient has useful islet B-cell function

 
hypoglycaemia a significant problem  glibenclamide > glipizide { chlorpropamide >
gliclazide > tolbutamide ( some other agents lack data );  avoid glibenclamide /
chlorpropamide particularly if renal impairment or in the thin insulin-sensitive
patient ( especially if elderly )
Repaglinide :  new rapid-acting insulin secretagogue; possible advantage in
hypoglycaemia avoidance and control of post-prandial glucose excursions
D-Glucosidase inhibitors :  effective control of post-prandial hyperglycaemia, but poorly
tolerated by many patients; dose titration may help tolerance
PPARJ-agonists : new agents, offering effective glucose-lowering particularly in
combination with insulin and insulin secretagogues

 
contraindicated if any history of liver disease, and require organized monitoring of
liver function tests until hepatic safety assured
A number of new drugs are currently entering clinical practice;  we anticipate the need to
modify the above advice as the role of such drugs becomes better understood
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Maintaining good blood glucose control with oral glucose-lowering drugs
Insulin therapy in Type 2 diabetes
Monitor  ( see section 4, Clinical monitoring  –  page 9 ) :
¾
 
dietary quality and quantity, physical exercise level
¾
 
HbA1c ( or fasting venous plasma glucose ), and self-test results
¾
 
body weight
¾
 
other vascular risk factors ( blood lipids, blood pressure )
Adjust therapy :
Ö Increase dose of individual agent at each visit up to maximum tolerated / effective
dose, if targets are not met
Ö Decrease dose of individual agent, if therapy-related problems arise, or if glucose
control well into the non-diabetic range
Combination therapy   
Ö Add another agent of therapy when maximum dose of current drugs reached
Ö Use triple therapy when control targets cannot be reached on maximum tolerated
doses of two agents
( For combination therapy with insulin see next box )
Expect :
Ö continuous deterioration of glucose control with time
Ö a need to increase therapy and add new agents with time
Ö insulin therapy to be needed in many patients after a variable number of years
Begin  when HbA1c has deteriorated to >7.5 % after maximum attention to dietary control and
oral glucose-lowering therapy ( unless poor life-expectancy and asymptomatic )
Ö Arrange dietary review when starting insulin therapy
Ö Review ( or start ) self-monitoring of blood glucose before starting insulin
Ö Continue therapy with metformin / insulin secretagogues / PPARJ-agonists
Use :
¾
 
NPH insulin at night with oral glucose-lowering drugs in people with good insulin
secretory reserve
¾
 
pre-mixed insulin twice daily in the majority of people
¾
 
twice daily NPH insulin in people with high pre-breakfast blood glucose concentrations
relative to their HbA1c
Adjust therapy :
¾
 
frequently at first, using self-monitored results, until insulin dose is adequate to reach
blood glucose targets ( see section 8 ), or hypoglycaemia becomes a risk
Ö Consider more intensive insulin regimens
x in the more active patient if control remains sub-optimal
x if control remains sub-optimal due to hypoglycaemia ( but not if due to insulin
insensitivity )
x to assist achievement of more flexible life-styles
See Desktop Guide to Type 1 Diabetes, 1998
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12 Therapy for Abnormal Blood Lipid Concentrations
Using blood lipid lowering drugs
Life-style management of abnormal blood lipid profiles should be given a
good trial before beginning lipid lowering drugs
Ö Patient education : see section   6, page 11
Ö Blood lipid targets : see section   8, page 16
Ö Dietary management : see section   9, page 17
Ö Physical exercise : see section 10, page 18
Monitor ( see section 4, Clinical monitoring  –  page 9 ) :
¾
 
dietary quality and quantity ( including alcohol )
¾
 
physical exercise level
¾
 
body weight
¾
 
blood glucose control
¾
 
lipid profile including triglycerides and LDL cholesterol
Begin :
Ö Optimize blood glucose control as far as is possible
Ö Establish lipid profile before beginning a trial of therapy
Use :
¾
 
a statin if : LDL cholesterol t3.0 mmol/l ( t115 mg/dl )
( >4.0 mmol/l ( >155 mg/dl ) if low risk including thin elderly )
¾
 
a fibrate if : triglyceride >2.2 mmol/l ( >200 mg/dl )
and LDL cholesterol <3.0 mmol/l ( <115 mg/dl )
¾
 
a fibrate first if triglyceride markedly elevated ( >6.8 mmol/l ( >600 mg/dl ) ); check
thyroid, renal, and liver function ( and apoE genotype if available ); consider
combination therapy with a statin if LDL cholesterol remains elevated
¾
 
combination therapy beginning with statin for high LDL cholesterol and triglyceride
Choice of agents
Statin : choice will usually be determined by relative cost-effectiveness locally
Fibrates :  ciprofibrate and fenofibrate are probably more effective than bezafibrate in
lowering triglycerides
Other drugs :  in general not recommended, unless severe hyperlipidaemia and
intolerance to statins and/or fibrates
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13 Therapy for Raised Blood Pressure
Using anti-hypertensive drugs
Life-style management of raised blood pressure should be given a good
trial before beginning anti-hypertensive drugs
Ö Patient education : see section   6, page 11
Ö Blood pressure targets : see section   8, page 16
Ö Dietary management : see section   9, page 17
Ö Physical exercise : see section 10, page 18
Monitor ( see section 4, Clinical monitoring  –  page 9 ) :
¾
 
dietary quality and quantity ( including alcohol ), physical exercise, body weight
¾
 
sitting blood pressure ( after 5 min rest, 1st and 5th phase )
Ö Use : family doctor / occupational health services to obtain monthly records
patient-held record card to provide cumulative record of progress
self-monitoring devices if available
Use :
¾
 
single agent therapy at rising doses until target achieved ( or intolerance )
¾
 
multiple therapy if targets not reached on maximum doses of single agents
¾
 
once daily drug administration regimens
Available drug classes
ACE-inhibitors : good evidence base in diabetes, advancing renal disease, cardiac failure

 
monitor renal function / K+  ( risk of renal artery stenosis with arterial disease )  
E-Adrenergic blockers : good evidence base in diabetes and useful where angina or
previous myocardial infarction

 
avoid combination with thiazides ( metabolic deterioration ), and if peripheral
vascular disease.  Ask about tiredness and impotence
Calcium channel antagonists : some evidence base in diabetes and in advancing renal
disease

 
use only long-acting preparations

 
fluid retention a problem with some agents ( avoid if history of foot ulceration )
Thiazides : some evidence base in diabetes

 
use low doses only and avoid combination with E-adrenergic blockers ( metabolic
deterioration ).  Ask about impotence
Loop diuretics : useful synergistic action with ACE-inhibitors
D-Adrenergic blockers :  effective blood pressure lowering and metabolically beneficial

 
use only long-acting drugs ( postural hypotension )
Angiotensin II receptor blockers : no special advantages
Choice of agents – summary
Multiple therapy is often required; add loop diuretic to ACE-inhibitor, and avoid thiazides
with E-adrenergic blocker; otherwise most combinations neutral
Many older and less expensive agents are as effective as newer agents
If abnormal albumin excretion, particularly if progressive, begin with ACE-inhibitor, or
calcium channel antagonist if ACE-inhibitor not tolerated
If ischaemic heart disease, consider E-adrenergic blocker first
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14 Managing Arterial Risk Factors
Integrated management of arterial risk
Review arterial risk factors :
 blood glucose  blood lipids    blood pressure 
 smoking  body weight / abdominal adiposity
 family history  albumin excretion rate  arterial / heart symptoms
¾
 
at diagnosis
¾
 
yearly
¾
 
more frequently if abnormal or treated
Define risk level as :
Ö Average risk : any one arterial risk factor
or High risk : established disease, or any two arterial risk factors
or Very high risk : established disease + any arterial risk factor
or any three arterial risk factors
Manage as follows :
If High risk  manage blood glucose, blood lipids, blood pressure to assessment
levels
If Very high risk  manage blood glucose, blood lipids, blood pressure to lowest
possible risk levels
If Smoking manage problem aggressively ( see box, section 8 )
Educate people :
Ö about the risks of heart disease / stroke from the time of diagnosis
Ö about not smoking and smoking cessation programmes ( see box, section 8 )
Ö about healthy eating ( see box, section 9 )
Prescribe :
Ö a programme of regular physical exercise ( see section 10 )
Ö glucose, lipid, and blood pressure lowering therapy as indicated
Ö low-dose aspirin for those in the High risk or Very high risk categories
Ö selective E-adrenergic blockers if known ischaemic heart disease
Consider :
Ö hormone replacement therapy post-menopausally ( if agreed )
Diagnose :
Ö silent myocardial ischaemia in higher risk patients ( see section 15 )
Arterial damage is the major cause of death and disability in people with Type 2 diabetes
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15 Ischaemic Heart Disease
Assessment and diagnosis
Management
Investigate if :
¾
 
classical angina or suspicious symptoms
¾
 
unexplained breathlessness
¾
 
cardiac failure, cardiomegaly, or cardiac rhythm disorder
¾
 
arterial thrombotic event
The threshold for investigation is lower if albumin excretion rate is abnormal
Investigate by :
¾
 
standard 12-lead ECG and chest X-ray
¾
 
cardiac ultrasound scan
¾
 
exercise stress ECG
¾
 
angiography / stress echo if indicated
Ischaemic heart disease develops in over three-quarters of people with Type 2
diabetes, and kills half of them.
It is often silent, often accompanied by cardiac failure, and is less amenable to
surgical intervention than usual
Intensify :
¾
 
management of arterial risk factors ( see section 14 )
¾
 
education on life-style management including smoking ( see sections 6, 8-10 )
Review :
¾
 
choice of blood pressure lowering drugs ( indication for E-adrenergic blockers )
¾
 
use of aspirin / other anti-thrombotic therapy ( all patients )
¾
 
use of cardiac failure drugs ( indication for ACE-inhibitors )
Advise :
¾
 
early coronary bypass therapy / angioplasty / stenting if indicated
Use :
¾
 
intravenous insulin to control blood glucose levels after admission for myocardial
infarction
Consider :
¾
 
hormone replacement therapy in post-menopausal women ( if agreed )
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16 Kidney Damage
Detection and surveillance
Management if raised albumin excretion rate
Check for proteinuria yearly using reagent strips
Measure urinary albumin excretion yearly ( if not proteinuric ) using :
¾
 
pre-breakfast albumin:creatinine ratio, or
¾
 
pre-breakfast urinary albumin concentration
Ö If ratio >2.5 mg/mmol ( >30 mg/g ) in men or >3.5 mg/mmol ( >40 mg/g ) in women
or concentration >20 mg/l :
x repeat to confirm
x monitor any progression of kidney damage by more frequent measurement
Check for infection and consider other renal disease if proteinuria positive
Ö exclude infection with leucocyte/nitrate strips and microscopy / culture if positive
Measure serum creatinine yearly ( more often if abnormal, or if rising and metformin-treated )
Measure blood pressure yearly for surveillance purposes ( sitting, after 5 min rest, 1st/5th phase )
Raised albumin excretion rate in Type 2 diabetes is often a sign of general vascular
damage rather than specific renal damage.   It is a useful arterial risk marker
Abnormal serum creatinine in Type 2 diabetes is often due to renal arterial disease and/or
diuretic therapy for cardiac failure rather than to diabetic nephropathy
Detection and surveillance of specific kidney problems therefore depends on identifying
progression of albumin excretion rate and serum creatinine, in the absence of other causes
If serum creatinine normal :
Ö monitor albumin excretion rate yearly to detect progression suggestive of specific
diabetic kidney damage
Ö intensify management of modifiable arterial risk factors ( glucose, lipids, blood pressure )
If serum creatinine abnormal :
Ö review other possible causes of renal impairment ( recurrent infection, renal arterial /
hypertensive damage, loop diuretic therapy / cardiac failure, glomerulonephritis )
Ö monitor albumin excretion and serum creatinine more frequently to detect progression of
renal damage
If specific diabetic kidney damage ( diabetic nephropathy ) suspected :
Ö treat blood pressure aggressively with a target of <130/80 mmHg
Ö reduce salt intake
Ö use ACE-inhibitors as first-line drug therapy
Ö add loop diuretics, other agents if necessary
Ö reduce protein intake with target of <0.8 g/kg
Ö maintain good blood glucose control and tight arterial risk factor control ( see above )
Ö treat urinary infections aggressively;  consider papillary necrosis if recurrent
Ö arrange evaluation by a nephrologist before creatinine rises to 250 µmol/l ( 3.0 mg/dl )
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17 Eye Damage
Detection and surveillance
Eye disease management
Organize a recall system to ensure it occurs regularly for every individual
Measure or assess yearly :
¾
 
visual acuity ( glasses or pinhole )
¾
 
the lens and vitreous ( ophthalmoscopy )
¾
 
the retina ( dilated pupils, retinal photography or skilled ophthalmoscopy )
¾
 
related factors ( smoking / blood pressure )
Reassess after shorter interval ( 3-6 mo ) if :
¾
 
pregnant ( see section 20 )
¾
 
new or progressive early or moderate non-proliferative retinopathy
¾
 
blood glucose control recently improved in people with retinopathy
Refer to ophthalmologist if :
¾
 
severe non-proliferative retinopathy
¾
 
proliferative retinopathy
¾
 
macular oedema or exudative maculopathy
¾
 
visual disability from cataract
¾
 
unexplained deterioration of visual acuity
¾
 
other eye disease of visual significance
¾
 
unrecognized eye lesions
Review and intensify management of :
¾
 
diabetic kidney disease
¾
 
blood pressure ( target <140/85 mmHg )
¾
 
blood glucose control
¾
 
blood lipid control ( if hard exudates )
¾
 
smoking
Attend to the psychological and social aspects of visual impairment where it develops
The primary management of diabetic eye disease
is by careful attention to blood glucose control
targets from the time of diagnosis
Detection and surveillance of eye problems are a routine part of Annual Review
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18 Foot Problems
Detection and surveillance
Foot management  –  preventative
Organize a recall system to ensure it occurs regularly for every individual
Examine yearly :
¾
 
foot shape, deformity, joint rigidity, and shoes
¾
 
foot skin condition ( fragility, cracking, oedema, callus, ulceration )
¾
 
foot and ankle pulses
¾
 
sensitivity to monofilament or vibration, and pin prick
Assess yearly :
¾
 
history of foot problems since last review
¾
 
visual and mobility problems preventing self-care of feet
¾
 
self-care behaviours and knowledge of foot care ( including carer if appropriate )
Categorize as :
Ö Foot ulcer : active foot ulceration
or High risk : neuropathy  or  vascular disease  or  previous ulcer  or  Charcot foot
or At risk : deformity  or  self-care problem  or  simple skin problem
or Low current risk
Monitor related factors ( blood glucose control, claudication, drug therapy, smoking )
High risk foot
Involve a specialist in diabetes foot care
Provide :
¾
 
regular foot assessment
¾
 
local preventative attention to callus
¾
 
relief of pressure using foam spacers, made-to-order shoes, customized insoles
¾
 
regular foot care education  –  the commandments of foot care
¾
 
vascular referral if symptoms or critical arterial supply
At risk foot
Provide :
¾
 
routine foot care according to need 
¾
 
advice on appropriate footwear 
¾
 
foot care education at routine visits
¾
 
advice to carers
Detection and surveillance of foot problems are a routine part of Annual Review
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Foot management  –  advanced disease
Foot ulceration is usually preventable
Amputation, even if foot ulceration occurs, is nearly always preventable
Established foot ulceration / infection
Involve your local diabetes foot team without delay
Use local measures including :
¾ debridement and trimming of callus ¾ foot casts to relieve pressure
¾ dressings to absorb exudate
 
¾ surgical drainage
Use systemic and proximal measures including :
¾
 
intravenous or oral antibiotic therapy – usually staphylococcal coverage, plus wider
spectrum, anaerobes, or streptococcal as specifically indicated
¾
 
vascular referral, investigation, and reconstruction / angioplasty if indicated
Reserve amputation for :
¾
 
uncontrolled pain ( secondary to vascular disease )
¾
 
debilitating, long-term, non-healing ulceration
¾
 
a useless and disabling infected or Charcot foot
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19 Nerve Damage
 for Foot problems see previous section
Detection and surveillance
Management of painful neuropathy
Management of autonomic neuropathy
Enquire yearly for :
¾
 
painful and other symptomatic neuropathy
¾
 
erectile impotence in men
Enquire for other manifestations of autonomic neuropathy if :
¾
 
other complications ( especially kidney )
¾
 
before anaesthesia
¾
 
erratic blood glucose control
Counsel for the depressing and disabling nature of the condition
Consider initially :
Ö bed foot cradles for night-time problems
Ö simple analgesia taken in advance of diurnal symptoms
Ö contact dressings
Consider therapeutic trials of :
Ö tricyclic drugs ( amitriptyline )
Ö carbamazepine at high doses ( 600-1200 mg/day )
Erectile impotence
Ö sildenafil may be helpful if not contraindicated ( beware of nitrate therapy )
Ö intracavernosal / intraurethral alprostadil can be useful in some men
Ö referral to professionals with specialist expertise can be useful for :
x advice on vacuum devices, or mechanical or surgical prostheses
x vascular investigation and reconstruction
x psychological assistance
Gastroparesis
Ö investigation using radiological or radioisotope methods may help in diagnosis
Ö investigation of cardiovascular autonomic neuropathy may help diagnosis
Ö cisapride and domperidone are worth a trial
Diabetic nocturnal diarrhoea
Ö investigation must exclude other causes of intestinal upset
Ö may be helped by high doses of codeine, loperamide or diphenoxylate, or by
erythromycin / tetracycline
Gustatory sweating
Ö explanation and counselling are often required
Ö try topical or oral anticholinergic agents
Detection and surveillance of nerve damage are a routine part of Annual Review
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20 Pregnancy and Contraception in Women with Type 2 Diabetes
Contraception / pre-pregnancy management
Enquire :
¾
 
as to need for contraceptive advice if pregnancy not intended
¾
 
as part of Annual Review as to pregnancy intentions
Advise :
¾
 
on barrier methods, or low-dose oral contraceptives if low arterial risk ( see above )
¾
 
not to discontinue contraception until adequate metabolic control achieved
¾
 
repeatedly the need for pregnancy planning
¾
 
on the intensity of diabetic pregnancy management, and the risks to the fetus
If pregnancy is intended :
Ö start folic acid
Ö stop oral glucose-lowering drugs ( consider insulin therapy )
Ö stop statins
Ö optimize blood glucose control :
x self-monitoring targets : pre-prandial 3.5-5.5 mmol/l ( 65-100 mg/dl )
post-prandial 5.0-8.0 mmol/l ( 90-145 mg/dl )
Ö assess and normalize ( <130/80 mmHg ) blood pressure :
Ö replace ACE-inhibitors with methyldopa / nifedipine / labetalol
Ö assess retina and treat as indicated
Ö review education and repeat as needed
Ö urge to stop smoking
Women of child-bearing age with Type 2 diabetes are almost invariably overweight
and have a high relative risk of arterial damage / thrombotic problems
Women who develop diabetes in pregnancy and revert to normal after delivery
 ( gestational diabetes ) are at high risk of developing Type 2 diabetes in later life
Diagnosis of diabetes in pregnancy
If venous plasma glucose >6.0 mmol/l ( t110 mg/dl ) at any time :
Ö perform 75 g oral glucose tolerance test
Ö manage as diabetes :
if fasting plasma glucose t7.0 mmol/l ( >125 mg/dl )
or 2-h plasma glucose t7.8 mmol/l ( t140 mg/dl )
PREGNANCY AND PRE-PREGNANCY
DIABETES TYPE 2 DESKTOP GUIDELINES      31
Pregnancy care
Organize joint obstetric care in a designated centre
¾
 
include a diabetologist, a diabetes teaching nurse, a dietician, an obstetrician, a
midwife, and a neonatologist
Provide support for continuing good blood glucose control :
Ö frequent review ( every 1-2 weeks )
Ö appropriate educational support
Ö regular self-monitoring of blood glucose with reliable system
Ö target blood glucose as close to normal as possible, while avoiding hypoglycaemia
x self-monitored blood glucose fasting : 3.5-5.5 mmol/l ( 65-100 mg/dl )
post-prandial : 5.0-7.5 mmol/l ( 90-135 mg/dl )
x glycated haemoglobin close to the upper limit of normal
Ö food intake
x weight controlling but adequate to maintain maternal and fetal nutrition
x frequent small meals may facilitate improved blood glucose control
Ö insulin therapy if blood glucose control remains above targets
Examine eyes each trimester
Provide regular obstetric care :
Ö ultrasound examination early and repeated for dates and fetal malformation
Ö fetal monitoring in later stages
Ö frequent antenatal review
Provide a normal safe delivery :
Ö deliver at term unless obstetric or diabetes risk
Ö deliver vaginally unless obstetric or diabetes risk
Ö provide optimal neonatal care :
x access to specialized neonatal intensive care
x neonatologists warned of expected delivery
Ö good blood glucose control during / after labour
Ö IV infusion of glucose and insulin if necessary with frequent blood glucose
measurement
Ö cessation of insulin therapy at delivery if started during pregnancy ( and no suspicion of
Type 1 diabetes )
If diabetes before pregnancy provide advice for post-pregnancy blood glucose control
If diabetes diagnosed in pregnancy :
Ö confirm remission at post-natal follow-up
Ö advise patient / family doctor of need for regular arterial risk factor review for rest of life
Evaluate quality of care
Ö monitor outcomes of pregnancy of women with diabetes
Ö compare outcomes with other diabetes services
Ö review any need for improvements in pregnancy care
SURGERY
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21 Management of Diabetes during Surgery
Organization
Management
Surgical glucose-insulin-potassium (GIK) regimens
Ö Use 500 ml 10 % ( 100 g/l ) glucose ( dextrose ) containing :
x unmodified ( soluble, regular ) human insulin 16 U
x potassium chloride 10 mmol
Infuse at 80 ml/h from a volumetric pump
Ö Consider higher dose ( 20 U ) if obese, or initial blood glucose high
Ö Consider lower dose ( 12 U ) if very thin, or usual insulin dose low
Ö Decrease dose by 4 U if glucose falling and normal or low
Ö Increase dose by 4 U if glucose rising or high
Ö Continue the GIK infusion until 30-60 min after first meal
Ö Use higher strength glucose solutions if water volume a problem
Ö Check for dilutional hyponatraemia daily
Optimize blood glucose control pre-operatively ( see section 8 )
Delay major surgery if possible when :
¾
 
HbA1c >9.0 %, or
¾
 
fasting blood glucose >10.0 mmol/l ( >180 mg/dl ), or
¾
 
post-prandial >13.0 mmol/l ( >230 mg/dl )
Screen for complications which may affect surgery risk; alert the surgical team :
¾
 
heart or kidney problems
¾
 
autonomic or peripheral nerve damage
¾
 
proliferative retinopathy
Manage blood glucose :
Ö If  diet / oral agents  and  good blood glucose control  and  minor surgery :
Ö omit therapy on morning of surgery
Ö restart when eating normally ( metformin only after renal function check )
Ö avoid glucose-containing IV infusions
Ö If  insulin therapy  or  unsatisfactory blood glucose control  or  major surgery :
Ö use IV glucose-insulin-potassium infusion ( GIK )
Ö start at 0800 h and continue until eating normally
Ö monitor blood glucose before, during, and after ( 1-4 hourly ) surgery
x use a quality-assured method
Ö aim for blood glucose levels of 6.0-10.0 mmol/l ( 110-180 mg/dl )
Encourage supervised self-management while in hospital
Prepare a local care protocol
Disseminate the protocol to relevant professionals
LOCAL NOTES
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 FACULTY OF PHARMACY  
 
 
   
Diabetes Care Research Programme- Patient Information 
 
I am happy to announce that Name of Pharmacy and researchers from the Faculty of Pharmacy at 
Rhodes University will be working together on a research programme aimed at assisting Type 2 diabetic 
patients improve their diabetes management.  
 
As you are probably aware diabetes is very often associated with other serious conditions such as 
coronary heart disease, high blood pressure, high cholesterol, eye and foot problems and kidney failure. 
Diabetes specialists worldwide agree that doing everything possible to prevent or slow down the 
development of these serious conditions is very important. Our diabetes research programme is designed 
to help patients with Type 2 diabetes improve the management of their condition. We will work with 
patients, their doctors and other health care professionals to identify and address important diabetes-
related issues in order to ensure that patients are able to maximize the benefits of their treatment. 
 
Our programme will run for 12 months and during this period participating patients will be required, 
from time to time, to have their body mass index (weight to height ratio), waist-hip, blood glucose, 
blood pressure and total cholesterol measured. Patients will also be asked to complete questionnaires 
that will help the researchers measure other important aspects of their treatment. All the information 
provided, together with the results of the tests will be regarded as confidential.  
 
I hope that you will agree to take part in this programme. I want to help you manage your condition and 
I know that by working together as a team we can go a long way towards getting the best out of your 
treatment. If you would like to take part in this research then please complete and sign the attached 
Patient Consent form and hand it back to me.  
 
Please note that your participation in this programme is voluntary and that you may withdraw from this 
programme at any time. 
 
 
 
 
 
  
    Name of Pharmacist          
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Pharmacy Stamp 
   
 
  
 
 
Diabetes Care Research Programme- Patient Consent Form     
 
Patient’s Surname: 
 
Initials: 
Postal Address: 
 
 
 
 
Postal code: 
Telephone (daytime):                                          Code: 
                                          
Fax:                                                                       Code:  
Cellphone number: 
Email: 
 
ID Number: 
 
Gender:    Male                         Female 
Age: 
 
Patient 
 
I,                                                                                     being the abovementioned patient, hereby  
agree to  participate in this research programme on the understanding that any and all personal 
information provided by me or my pharmacist or medical practioner to the researcher will be 
provided in the interests of furthering this research and will remain confidential. Furthermore, I 
understand that I may withdraw from the research programme without prejudice at any time. 
 
Signature                                                              Date 
 
              
Witness                                                                                
 
Pharmacist 
 
I,                                                         being the registered pharmacist agree that any and all 
patient information provided to me in the course of this research will remain confidential. 
 
 
Signature      Date 
 
Researcher 
 
I, Peter William Hill being the researcher approved by the Faculty of Pharmacy of Rhodes 
University Grahamstown, agree that any and all patient information provided to me in the 
course of this research will remain confidential. 
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Signature Date 
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FACULTY OF PHARMACY 
 
Patient adherence in type 2 diabetes mellitus: a South African community 
pharmacist diabetes care intervention. 
8 November 2006, 
 
 
Dear name of pharmacist 
 
Further to my email of 6 August 2006, I would like to confirm that you and your associated 
patients have been randomised to the intervention arm of the study.  
 
As you are no doubt aware, practice conditions vary from pharmacy to pharmacy, and 
both pharmacists and patients, as individuals, are unlikely to approach adherence or any 
aspect of diabetes care on a “one-size-fits-all” basis. Furthermore, your rights and 
obligations as a registered healthcare professional are recognised. Therefore, I have not 
prescribed precise stage-specific diabetes care interventions, but rather wish to 
encourage you to collaborate with your patients in developing interventions to suit 
individual patient needs within the reality of your specific practice situation. 
 
 An intervention framework in the form of a manual will be sent to you by registered mail 
during the first week of December 2006. The intervention document, IDF guidelines and 
any published article or paper I send you are resource material and provide a framework 
or guide for individualized diabetes care plans that I trust you will develop with each of 
your patients. But, and this is important, it’s up to you to decide on how you go about 
working with and assisting your patients.   
 
 The intervention is an individualized pharmacist-directed diabetes care plan [DCP]. In 
essence, the DCP requires you to: 
• Conduct medication reviews to assist in the identification of actual or potential 
medication related problems. 
• Assess patient diabetes-related needs and goals. 
• Discuss and agree strategies to address the needs and goals [within your scope of 
practice as a pharmacist]. 
• Implement any agreed interventions [you are to use your initiative and professional 
judgment in deciding on the actual interventions]. 
• Monitor patient diabetes-related clinical and psychosocial indicators. 
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• Discuss the findings with your patients and agree remedial action [including referral to 
other healthcare professionals]. 
• Regular review and appropriately modify the DCP. 
 
The DCP is comprised of two main elements: 
• a clinical intervention and  
• a patient education and counseling intervention [PEC].  
 
The Clinical Intervention 
The clinical intervention requires that you pay particular attention to the issue of 
medication-related problems. In this regard I suggest that you refer to the ASHP 
Guidelines on Pharmacist-Conducted Patient Education and Counseling 2001, a copy of 
which is included in the manual. Also please refer to your copy of the IDF‘s A Desktop 
Guide to Type 2 Diabetes Mellitus, which I previously sent you. Included too you will find 
copies of the Revised SEMDSA Guidelines for the diagnosis and management of type 2 
diabetes mellitus for primary health care in 2002, The South African Council for Medical 
Scheme’s Algorithm for Diabetes Mellitus Type 2. Please don’t forget to refer to your copy 
of the South African Pharmacy Council’s publication, Good Pharmacy Practice in South 
Africa, as this publication deals with the statutory requirement of providing pharmaceutical 
care. I suggest that you refer to the SEMDSA and IDF guidelines to inform your 
discussions about diabetes-related goals, tests and examinations, monitoring indicators 
and general self-care recommendations.  Remember it’s really important to monitor 
because the cliché: “if you can’t measure you can’t manage”, most certainly applies to 
diabetes care.  
 
The PEC Intervention 
The patient education and counseling (PEC) intervention is an important component of 
the DCP for two reasons: 
• The potential for PEC is not limited to structured appointments only as pharmacist-
patient dialogue can take place in a range of circumstances using various methods of 
communication.  
• It is the intervention concerned with reinforcing the pre-eminent role of patient self-
care in Type 2 diabetes. 
 
The PEC intervention is based on the counselling model of Motivational Interviewing   and 
adapted for use in community pharmacy.  I understand that community pharmacists in 
practice do not have much time to spend with each patient and so I have suggested an 
MI design that is brief. However, I assume that you will use your professional judgment in 
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deciding how much time you will need to spend with each patient.  As mentioned above, I 
will be posting you a fairly detailed framework for the diabetes care plan and I will also let 
you have published literature to augment the main document. If however, you feel you 
need help in a particular area then please don’t hesitate to contact me and I will make 
every effort to assist you. 
 
Remember the research hypothesis is that community pharmacists are able to assist 
patients with Type 2 diabetes improve their adherence to therapies and self-care 
recommendations and, by inference, improve patient health outcomes. As previously 
mentioned individual pharmacists working with other individuals [patients] suggests that 
there can be no one-size-fits-all solution to the problem of adherence. There are, 
however, a number of true-north principles underpinning therapeutic adherence: 
 Patients must have access to an appropriate healthcare system [including healthcare 
professionals and affordable medicines]. 
 They need to have a basic understanding of their disease and how to use their 
medicines correctly. 
 They need to be able to motivate themselves to follow agreed therapy and self-care 
recommendations. 
 They need to convert motivation into behaviours that include medicine taking and 
lifestyle modifications, and then they need to sustain the changed behaviour. 
 They should be encouraged to accept that through self-care they alone hold the key 
to successful chronic care. 
 Healthcare providers should support chronic care models that recognise the pre-
eminent and defining role of patient self-care. 
 
Given the realities of working in a busy practice, I suggest you use the patient interaction 
opportunity created by the script refill encounter to review pharmacotherapy [check for 
any medication related problems], monitor key indicators [measure blood pressure, body 
mass, waist-hip, check on their SMBG values etc.] and discuss findings. This is also an 
ideal time to re-enforce self-care behaviours. Telephonic follow-up between pharmacy 
visits has been shown to be very useful in promoting adherence and in building 
relationships with patients.   
 
The study will run for 12 months post-baseline (May 2006 to May 2007) and the 
intervention during the 6-month period December 2006 to May 2007. During May 2007 
identified clinical and disease-risk indicators together with other qualitative variables will 
be measured for patients in both the intervention and control groups.  
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Thank you once again for your very valuable contribution to this research.  
 
Kind professional regards 
 
 
 
 
Peter Hill 
Faculty of Pharmacy 
Rhodes University 
Grahamstown 
 
 
       PO Box 275 Port Alfred 6170 Tel 046 6243575   Cell 0829285020   email peterhill@intekom.co.za 
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FACULTY OF PHARMACY 
 
 
 
The South African Community Pharmacist and Type 2 Diabetes Mellitus: A 
Pharmaceutical Care Intervention. 
EXECUTIVE SUMMARY 
1. The intervention is a pharmacist scope of practice patient-centred Diabetes Care 
Plan (DCP) involves the documented processes of:  
Assessment:  identify diabetes-related needs, goals and problems. 
Planning:  patient  and pharmacist (and other health care providers) collaborate 
to develop strategies and interventions required to address the needs, goals and  
problems. 
Implementation: patient and pharmacist implement  agreed interventions. 
Monitoring: pharmacist and patient monitor  key variables underpinning patient 
goals.  
Review: pharmacist and patient review monitoring results and other data  at 
agreed intervals. Adjustments to therapy and onward referral based on evaluation 
of  the data forthcoming from the monitoring and review process. 
2. The DCP consists of two main elements : 
 a Patient Education & Counselling intervention (PEC) ( page 12 – 19).   
 a Clinical intervention (page 20 – 23 ). 
 
 
3. The patient education & counselling intervention involves: 
  3 
 Diabetes-related education designed to improve patient knowledge and 
understanding of key aspects of Type 2 diabetes (DM2) as per the 
International Diabetes Federation (IDF) Global guidelines for Type 2 Diabetes.  
 Counselling for patient self-management based on the Motivational 
Interviewing model.  
4. The clinical intervention essentially involves : (i) medication review, (ii) self-
management assessment,  (iii) agreeing diabetes-related goals (iv) monitoring of 
key clinical and disease-risk variables, (v) evaluation of data. 
4.1 Medication review   
 Conduct medication review informed by American Society of Health-System 
Pharmacists (ASHP) guidelines on pharmacist-conducted patient education 
and counseling,  revised Society for Endocrinology Diabetes and Metabolism 
of South Africa (SEMDSA) guidelines for diagnosis and management of type 
2 diabetes mellitus for primary health in 2002,  and The Council for Medical 
Schemes diabetes mellitus type 2 algorithm. 
 Measure medication adherence by reviewing prescription refill data.   
 Measure patient self-reported adherence using Medication Adherence Report 
Scale. 
 Identify  and resolve/refer any other medication related problems. 
 Refer to medical practioner for adjustment to pharmacotherapy where 
required. 
 Identify and resolve/refer  medication access problems. 
 Conduct medication appropriateness evaluation for self-medication (OTC’s). 
4.2 Self-management assessment  
 Using the  questionnaires provided establish baseline values for psychosocial 
variables. 
 Use the clinical and disease-risk indicator data collected to establish baseline 
values. 
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4.3 Establish desired and realistic diabetes-related goals informed by  SEMDSA 
guidelines for : 
 Blood Glucose – to achieve and maintain guideline glycaemic levels.  
 Blood Pressure – to achieve and maintain guideline blood pressure levels. 
 Lipid profile – to achieve and maintain guideline lipid levels.  
 Body Mass Index – to achieve and maintain guideline BMI. 
 Any other scope of practice diabetes-related goals the patient may identify. 
4.5 Intervention 
 Provide appropriate diabetes education to ensure adequate knowledge base. 
 Identify and enlist patient's social support structures (family, friends). 
 Discuss, agree  and plan interventions required for the realisation of patient 
diabetes-related goals.  
 Identify  and attempt to resolve barriers to patient self-management.  
 Refer appropriately to other health care providers (including for psychosocial 
investigation). 
 Agree date and times for follow-up consultations (more frequently for high-risk 
patients e.g. elderly, multiple co-morbidities, poor glycaemic control). 
4.4 Monitoring of the clinical and disease-risk indicators and other variables 
 Refer to the monitoring schedule (page  21-23 ).  
 Follow-up telephonically between face-to-face consultations.   
4.5 Evaluation  
 Review the patient’s health status. 
 Refer to results of the monitoring process and  discuss and agree to modify 
strategies and interventions and escalate the diabetes care ( refer to other 
healthcare professionals) where necessary.  
 Review and reinforce self-management activities. 
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 Reward achievement and encourage where there has been regression. 
The following documents are included in the manual in support of the DCP intervention :                  
Patient Education & Counselling  
Intervention 
Content 
Motivational Interviewing Motivational interviewing helps patients confront change.  
Berger B US Pharmacist 
Assessing and interviewing patients for meaningful 
behavioral change.  Part 1 Berger B The Case Manager 
Assessing and interviewing patients for meaningful 
behavioral change.  Part 2 Berger B The Case Manager 
Motivational interviewing in health settings: a review. Britt E 
et at. Patient Education an Counseling  
Communication Persuasive communication. Part 1 Berger B US Pharmacist 
Persuasive communication. Part 2 Berger B US Pharmacist 
Change Change is a multistep process. Berger B Us Pharmacist 
Helping patients face change. Berger B US Pharmacist 
Clinical Intervention  
Diabetes education Education: IDF global guidelines for type 2 diabetes. IDF 
Guideline and medicine review Revised SEMDSA guidelines for diagnosis and management 
of type 2 diabetes mellitus for primary health in 2002 
Council for medical schemes algorithm for diabetes mellitus 
type 2 
ASHP guidelines on pharmacist conducted patient education 
and counseling. American Journal of Health-System 
Pharmacists 
Self-management adherence Improving adherence to diabetes self-management 
recommendations. Schechter CB and Walker EA. Diabetes 
Spectrum  
Diabetes-related knowledge Diabetes knowledge questionnaire: assesses patient’s day-
to-day knowledge of diabetes 
Self-management: SMBG Self-monitoring of blood glucose questionnaire: assesses 
SMBG practices 
Self-efficacy Diabetes empowerment (DES-SF) questionnaire : assesses 
patient self-efficacy 
Self-management: understanding Understanding self-management questionnaire: assesses 
patient’s understanding of self-management practises 
Self-management: medication 
adherence 
Medication Adherence Report Scale (MARS): assesses 
patient adherence to medication therapy 
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Depression Major depression inventory (MDI): a depression assessment 
tool (for possible referral) 
 
 
Note: In addition to the abovementioned please refer to the copies of the following which 
were completed by each of your patient’s at baseline and which I forwarded to you: 
 Patient Profile  
 Clinical Data Form 
 Beliefs about Medicines Questionnaire 
 Patient Satisfaction Questionnaire 
 Diabetes Care Plan Questionnaire 
 Self-care Adherence Scale 
 
In addition it is recommended that pharmacists consult the excellent and comprehensive 
resource, IDF Global Guideline for type 2 Diabetes available free-of-charges on-line at                                      
www.idf.org/webdata/docs/IDF%20GGT2D.pdf  
 
Conclusion 
The DCP is designed to provide pharmacists participating in the study with resource 
material and a  suggested framework on which to base  individualised diabetes care 
plans. Pharmacists are not compelled to use any specific intervention and are free to use 
their professional judgement (as you do in day-to-day practice) in deciding on the 
interventions to be used and how they are to be applied. However, in keeping with good 
pharmaceutical care practice it is suggested that pharmacists record any such 
interventions and the clinical and other data in a manner that allows for easy referral.   
The intervention will run for 6 months starting in January 2007 and ending in June 2007. 
Please remind your patients that we will need to re-measure them for the clinical and 
disease-risk indicators that we measured at baseline in April/May 2006 (HbA1c, Lipogram, 
Serum creatinine, Waist-Hip, BMI, and BP ) in June 2007. At the end of the study period I 
will ask you to forward all outstanding patient data to me. 
Please contact your patients as soon as possible to arrange for the initial interview which 
should ideally take place at your earliest convenience during December/January. I 
suggest that you have your patients complete the questionnaires in the pharmacy during 
the initial interview. Please score questionnaires once they are completed, make copies 
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for your file and then post the originals to me using the self-addressed postage paid 
envelopes provided.  
Once again, thank you for your participation and I look forward to working with you during 
this intervention phase. Do not hesitate to contact me  by email if you need clarification on 
any issue.  
I would also like to wish you a merry and Blessed Christmas and a Happy New Year. 
Kind regards 
 
 
Peter Hill 
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Overview 
 
Introduction 
The pharmacist intervention for the study takes the form of an agreed (between patient 
and pharmacist), evidence-based DCP appropriate to the scope of practice of a 
pharmacist.  The DCP has been developed from the literature and from own past 
experience as a community pharmacist.  
 
A role for the patient in diabetes care  
The patient is not a passive recipient of diabetes care but is actively involved in all aspects 
of the DCP, including defining diabetes-related needs, discussing and agreeing strategy, 
implementing interventions and monitoring outcomes. This collaborative approach is 
founded on the pre-eminent role that self-management plays in chronic care.  
Self-management in DM2 is based on the following true-north principles: 
 that the day-to-day therapeutic (e.g. take medicine), lifestyle (e.g. exercise) and 
behavioural (e.g. self-monitor blood glucose) decisions are made by the person with 
diabetes; 
 that self-management can never be practiced in isolation and that collaborative 
support  that  allows patients to make  the best possible decisions about their care is 
a patient right; 
 that almost all of the barriers to self-management can only ever be resolved by 
motivated and empowered patients themselves; 
 that the consequences of diabetes care, i.e. patient outcomes, are born by the 
patients and their immediate social circle and not by healthcare providers. 
 
A role for the pharmacist in diabetes care  
The DCP embodies the following principles of care delivery identified by the IDF as 
essential for the provision of quality, patient-centred and evidence-based care to people 
with DM2. 
i. Offer care, with sensitivity to cultural wishes and desires, to people with DM2. 
ii. Organise care around the person with diabetes.  
iii. Encourage a collaborative relationship by actively involving the person with 
diabetes in the development of the DCP and, at each consultation, create 
opportunities for them to ask questions and express concerns. Ensure that issues 
important to the person with diabetes are addressed. 
 
iv. Agree and document an individualised DCP with each person: 
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 Use diabetes care interventions that are protocol and guideline-driven to deliver 
the DCP. 
 Review key elements of the DCP at agreed fixed date and time intervals 
(‘appointments’) based on patient-risk evaluation, cost and convenience.   
 Modify the DCP according to changes in findings,  wishes & circumstances. 
 Review the entire DCP at  six monthly intervals. 
v. Offer surveillance, appropriate to the scope of practice of a pharmacist, of all 
aspects of diabetes control and complications to people with DM2 . These 
aspects include: 
 Self-management knowledge and beliefs 
 Lifestyle adaptation and wishes (including nutrition, exercise, smoking) 
 Body weight trends 
 Psychological status ( e.g. depression/diabetes distress)   
 Cardiovascular risk 
 Self-monitoring skills and equipment  
 Medication review 
 Blood glucose control 
 Blood pressure control 
 Blood lipid control 
 Kidney function 
 Vision ( eye) 
 ‘Diabetic foot’ 
 Erectile dysfunction 
vi. Refer, where required, to members of a multidisciplinary care team with specific 
diabetes-related expertise.           
vii. As a minimum, ensure that at each prescription refill diabetes care  is reinforced. 
viii. Provide urgent access to diabetes healthcare advice for unforeseen problems. 
ix. Consider  how people with diabetes, acting as expert patients, and knowing their 
limitations,  together with other interested parties might be involved in supporting 
the pharmacist-directed care delivery. 
x. Access decision support systems and resources to enhance care delivery. 
xi. Follow up by maintaining contact with patients between appointments and other 
unscheduled encounters and use the data gathered in routine care to support 
quality assurance and intervention-related activities. 
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The main thrust of the DCP lies in providing patients with appropriate information and 
support in an effort to enable them to achieve their diabetes-related healthcare goals.  
The process of diabetes care in its entirety is complex and requires a collaborative 
multifaceted approach beyond the scope of practice of a pharmacist alone. However, 
pharmacists because of the frequency of contact with their DM2 patients, most of whom 
rely on pharmacotherapy, are positioned to significantly contribute to the overall objective 
of improved patient outcomes. 
 
The proposed DCP consists of two interrelated interventions, one of which is  
predominately psychosocial in nature and the other biomedical or clinical. The 
psychosocial intervention is a patient education and counselling intervention, (see the 
following section entitled “Patient Education & Counselling”). The biomedical or clinical 
intervention is described in the section entitled “Clinical” which follows the patient 
education and counselling section of this document. Although the patient education and 
counselling intervention and the clinical intervention are referred to separately in this 
manual the two are interdependent with many of the clinical activities being subject to 
psychosocial drivers and vice versa.  
 
Patient Education & Counselling intervention (pages 12 – 19) 
The patient education and counselling intervention consists of two components namely, 
‘education’ and ‘counseling’ that are distinct in purpose but interdependent. Patient 
education is aimed at addressing deficiencies in patient knowledge about DM2, any co-
morbidity, and any other issue that may impact on the management of diabetes, in order 
to ensure that the patient has a clinical foundation adequate for the effective self-
management of the disease. Patient counseling differs from patient education in that, 
while education is more biomedically focused, counseling takes a psychosocial approach 
to aspects of diabetes care. In this context, counseling has a broader reach than 
education as it is less concerned about the transfer of empirical knowledge between 
pharmacist and patient and more focused on encouraging the patient to make informed 
decisions about self-management behaviour.  
Patient counseling by the pharmacist has a number of secondary outcomes designed to 
support the main objective of informed decision-making and these include: 
 fostering of caring patient relationships through concordant alignment of vision, 
expectation, contribution and commitment; 
 elucidating and discussing patient needs, diabetes-related goals and desired health 
outcomes;  
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 empowering patients to take ownership of their diabetes care and at the same time 
reassuring them of continued pharmacist support;   
 reinforcing the appropriate use of medication, nutrition and exercise therapies, 
given patient health and medication beliefs and the effect of cultural imperatives on 
patient choice of therapies and lifestyle practices; 
 encouraging adverse medication event reporting; 
 identifying possible diabetes-relate distress or depression with possible referral for 
professional psychological evaluation and support; 
 resolving, where possible, issues relating to patient access to the healthcare 
system and, where needed and possible, providing assistance through a referral 
process; 
 involving spouse, partner or close family member in diabetes care; 
 where required, facilitating patient enrolment in smoking cessation programmes; 
 improving patient adherence to therapies and self-management recommendations 
by suggesting mechanisms to overcome barriers to adherence, encouraging the 
use of adherence promoting aids, and the use of patient self-report tools to self-
monitor adherence to   therapies. 
  
Clinical intervention (pages 20-23) 
Monitoring is a key aspect of the clinical intervention in diabetes care. The management 
maxim of “If you can’t measure it, you can’t manage it” certainly applies to diabetes care. 
The pharmacist is able to measure many of the key clinical and disease-risk variables 
associated with diabetes care (HbA1c, blood pressure, blood lipids, aspects of renal 
function, BMI, medication adherence) and qualitatively measure certain important 
psychosocial variables, such as patient satisfaction, self-management adherence and 
diabetes empowerment using validated scales. Data such as these when viewed in 
conjunction with evidence-based disease management protocols and accepted 
guidelines for the treatment of DM2, could be used to inform both the overall diabetes 
care plan and, most importantly, the patient’s self-management plan. In broad terms the 
monitoring intervention involves the following: 
 Collection, interpretation and discussion of the data.  
 Evaluation of the effectiveness of the DCP interventions by benchmarking the results 
obtained against accepted guidelines and the patient’s own goals. 
 Referring patients where necessary and with their approval, to other healthcare providers for 
further evaluation and possible intervention. 
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Patient Education and Counselling  Intervention 
 
The PEC intervention is based is the model of Motivational Interviewing (MI) developed 
by Miller and Rollnick underpinned by the South African Pharmacy Council’s Good 
Pharmacy Practice Standards and the SEMDSA and IDF guidelines. MI was developed 
as a patient-centred counselling tool for use with patients suffering from addictions but 
has subsequently been adapted for use in other healthcare settings, including chronic 
disease care. Additional resource material in the mainly in the guise of  ‘practical’ articles 
by Professor Bruce Berger are attached to the executive summary of this manual.  
 
Acute care vs. Chronic care 
The acute care or biomedical model presupposes a dynamic in which the expert 
healthcare provider interacts with the naïve patient. The chronic care model  first 
proposed by Wagner1  recognised that a  different approach to caring for people with 
chronic diseases was required as “patients and families struggling with chronic illness have 
different needs, and these needs are unlikely to be met by an acute care organisation and culture”  
Wagner proposed that chronically ill patients required, inter alia: 
 planned and regular contact with their healthcare professionals in order to 
systematically and continually assess progress in terms of accepted treatment 
guidelines; 
 interventions focused on addressing exacerbations and complications of their 
diseases; 
 behavioural support for their role as self-managers of their disease; 
 regular and continuous follow-up;  
 that the entire chronic care process  should be documented using a clinically 
appropriate information system. 
Implicit in the model is the recognition of the key role of patient self-care or self-
management, and that the healthcare provider in the context of chronic care is the entity 
created by the collaborative partnership between the patient and healthcare professional. 
 
Patient self-management 
Patient self-management has a pre-eminent role to play in the treatment and 
management of DM22.  Patients who do not achieve desired health outcomes do so 
largely because their therapeutic goals have not been achieved, and not because of 
incorrect diagnosis or therapy. The self-management recommendations that will drive 
HbA1c and other disease-risk and clinical indicators to  levels that meet national or 
international guideline targets for DM2include: 
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 lifestyle modifications ( smoking cessation, diet and exercise); 
 self-monitoring of blood glucose;  
 adherence to prescribed therapies;  
 regular attendance at appointments with healthcare professionals;  
 having essential tests and examinations  done as per guideline recommendations. 
 
Patient behaviour: readiness to change 
Patient behaviour is the main driver underpinning self-management in DM22. Resistance 
to change or having mixed feelings (ambivalence) about the necessity to change 
behaviour can only be resolved by the patient and never by the healthcare professional. 
Resolving resistance to change or ambivalence requires motivation to change on the part 
of the patient, and motivation in the context of MI is viewed as readiness to change rather 
than as a personality trait3. This, in effect, means that motivation is not ‘fixed’ but is rather 
a state that is open to change. 
 
The pharmacist in applying the principles of MI acts as a facilitator of behavioural change 
by helping patients to recognise and resolve their resistance to change or ambivalence3. 
This is very different from the traditional view of pharmacist counselling which is based on 
giving advice or providing information in the hope that patients will change health 
behaviours.  While this approach may work with some patients, research shows that only 
about 5-10% of patients will undertake behavioural change as a result of such an 
intervention3.  Many patients do not want to be given advice in a way that may seem 
prescriptive especially if the healthcare provider only emphasises the benefits of change 
without taking into consideration the personal cost to the patient of the behavioural 
change. Such an approach is likely to increase resistance to change or ambivalence 
rather than to lead to the removing of any barriers to change.  To illustrate this point, 
telling an obese patient to loose weight without attempting to address the psychosocial 
drivers behind the patients obesity is probably futile and may well increase patient 
resistance or even be perceived as confrontational by the patient.  
 
Motivational Interviewing 
Motivational Interviewing employs a counselling style that is “quiet and facilitative, and where 
the relationship is more like a partnership or companionship than an expert/recipient one.” 3 The 
strategy used in the application of MI has 3 core elements,4 and for each of the core 
elements 5 clinical principles apply 3  
The 3 core elements are: 
(i) Elicitation 
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This is asking the patient to provide information about the issue under discussion by using 
open-ended questions that do not allow for ‘Yes’ or ‘No’ answers. In other words, the 
patient is encouraged to identify both a need and the barrier(s) that prevents the need 
from being met (the cause of the resistance to change or the nature of the ambivalence). 
For example, if discussing non-adherence to pharmacotherapy with a patient, the 
pharmacist could ask the patient a question along the lines of, “You say that you do not 
always take you medicines as prescribed-why do you think this happens?” The patient has 
identified the problem – does not take medication regularly- but has not yet identified the 
reason  for the behaviour. The pharmacist in asking the question, “why do you think this 
happens?” is directing the patient to identify the reason for the resistance or ambivalence, 
and so it is important that the pharmacist have a clear goal in mind when exploring a 
patient’s ambivalence. 
 
(ii) Provision 
The pharmacist must accept that resistance to change or ambivalence with regard to 
therapy is a ‘normal’ behaviour. Research has shown that patients weigh up the pros and 
cons of pharmacotherapy by considering their need to take medicines versus their 
concerns about any perceived negative aspect of the therapy5 . Having listened to what 
the patient has had to say, the pharmacist should use the opportunity to provide 
information and answer questions in a manner that is directional but without being 
dictatorial. For example, continuing with the non adherence theme, the patient may have 
said that he finds taking a once-a-day dose before breakfast makes him nauseous and so 
he consciously does not  take the medicine every day. This is an adverse-effect issue and 
the pharmacist might suggest that the patient try taking the medicine last thing at night as 
a way of overcoming this barrier to adherence. In doing so the pharmacist accepts the 
patient’s ambivalence and then is directive in suggesting the change in the timing of the 
dosage.  
 
(iii) Elicitation 
The pharmacist restates the problem and the  patient’s agreed solution or decision and 
then asks if there are any other issues that require clarification. As a result of providing 
information and answering questions it is possible that other concerns may surface in the 
patient’s mind and so it is important that patient’s be encouraged to raise any further 
issues. 
 
An important technique used in providing information in MI is to seek the patient’s 
permission before offering advice, especially if the information could be construed as 
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dictatorial ‘advice’. In the abovementioned example, the pharmacist in changing the 
timing of the dose from morning to night might be drawing on past experience either with 
other patients or from information contained in the literature. In this case it may be helpful 
to say something like, “If I may, I’d like to share something of my experience with others patients 
who had a similar problem?” before going on to suggest the change. Seeking the patient’s 
permission to provide solutions to a problem demonstrates the pharmacist’s willingness  
to  collaborate  and  encourages the patient to make decisions. 
 
The 5 clinical principles of Motivational Interviewing 
In applying the MI strategy of Elicitation- Provision- Elicitation,  five principles or skills are 
used to effect behavioural change through a process of self-motivation. These principles 
are: 
 
(i) Roll with resistance 
 If a patient seems ambivalent or is resisting any aspect of their therapy then instead of 
confronting the patient’s resistance head-on, use the central theme of the resistance or 
ambivalent statement to support the provision of information and create what is referred to 
as dissonance (or clashing of ideas) in the patient’s mind3.  
 
Consider the following hypothetical example of a patient who smokes and who has 
previously been counselled on the health issues relating to smoking. The interview 
reveals that the patient is aware that smoking causes lung cancer and that it plays a role 
in the development of other serious diseases. This realisation, even if unspoken, creates 
dissonance (current health-related behaviour [smoking] versus other behaviour [not 
smoking] required to achieve the patient’s desired health outcomes). It is believed that 
dissonance motivates the patient to change behaviour. The pharmacist must work with or 
exploit the dissonance that the patient self-realises in order to encourage the patient to 
shift perception. 
 
Advice that the patient may perceive as confrontational may simply reinforce resistance to 
change. For example, if the patient was defensive about smoking and said something 
like, “I enjoy smoking and besides I am concerned about putting on weight if I stop”. An answer 
along the lines of “ Well being fat is better than being dead from lung cancer” is likely to be 
viewed as confrontational and increase resistance.  
 
Rolling with resistance would mean a  comment by the pharmacist that would recognise 
the patient’s concern about gaining weight, “I can understand that you are reluctant to stop 
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smoking because of the possibility of gaining a few kilos”,  offer encouragement,  “but in my 
experience this does not always happen and in any event I am able to help you  if this should 
happen”, and  at the same time  raise the possibility of a more serious health outcome if 
they continue to smoke, “I would like to suggest, however, that if you decide to keep smoking, it 
might be an idea to have your lungs and heart checked out more frequently because as you know 
there are very real health risks associated with smoking”. Finally, the pharmacist should 
recognise the patient’s right to make their own decisions about their health care6, “I’d like to 
add  that I  respect your right to make your own decision about whether or not you stop smoking.”  
 
(ii) Express empathy   
This is a sincere attitude born out of the acceptance on the part of the pharmacist of the 
reality that self-management is the primary determinant of patient health outcomes in 
DM2.  Being able to express empathy is a very important MI skill as it demonstrates the 
pharmacist’s capacity for care. Furthermore, it supports the development of trust, and 
both underpins the patient-pharmacist relationship and facilitates behavioural change by 
the patient. Being empathic also means being non-judgemental and empathy shows the 
patient that although the pharmacist may not have diabetes there exists an acceptance 
and understanding of the problems associated with the day-to-day issues of living with 
this chronic disease. Referring to the smoking example above, the comment, “ well being 
fat is better than being dead from lung cancer” does not reflect empathy whereas, “I can 
understand that you are reluctant to stop smoking because of the possibility of gaining a few kilos, 
but in my experience this does not always happen and in any event I am able to help you  if this 
should  happen”, is an empathic reply. 
 
(iii) Avoid arguments 
 If in trying to breakdown resistance or resolve ambivalence and an argument between 
the patient and pharmacist develops then the patient is likely to become defensive and 
resistance to change may become entrenched.  Avoiding arguments signals to the patient 
that the pharmacist is on the patient’s side. That is not to say that MI is non-
confrontational, to the contrary the model allows patients to be confronted about their 
aberrant  behaviour but in a manner that is not argumentative.  
 
Consider an example of a female hypertensive patient whose blood pressure remains 
uncontrolled despite being prescribed medication known to be effective in controlling the 
condition. A review of the patient’s medication history reveals that the patient has been 
having her prescription refilled every 45 days instead of every 30 days or so. The 
pharmacist in counselling the patient on non-adherence says the following, “ I see that you 
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have missed quite a number of  doses of your Renitec over the past two months. You realise that 
you are acting irresponsibly by putting yourself at risk for a stroke or heart attack”. Such a 
statement by the pharmacist  may well be considered to be argumentative. The following 
alternative approach, while still confronting the patient about the possible serious 
consequences of her non-adherence does not invite argument.  “ From my records it looks 
as though you are not taking your Renitec every day. As you know keeping your blood pressure 
under control is essential if you are to minimise the chances of a stroke or heart attack and this 
means taking your medicine every day. If you would like to tell me why you have missed doses 
then perhaps we can work together and find a solution so that you are able to minimise the risk of 
something serious happening to you”. This statement is empathic, non-judgemental, seeks to 
understand why the patient is not being adherent and offers meaningful help to overcome 
the problem.  
 
(iv) Develop Discrepancy 
This principle creates dissonance as a result of the misalignment of the patient’s current 
health-related  behaviour and their desired health outcomes. Simply put if, for example, a 
patient has a stated health-related goal of meeting an acceptable blood pressure target 
but does not take the antihypertensive medication as prescribed, and the non-adherence 
is raised appropriately, then the patient is likely to realise that a discrepancy exists 
between what they desire from a blood pressure perspective and what they are doing to 
support this goal. Motivation that is effective and sustainable must be self created. Put 
another way, motivation must arise from within the patient and this is what dissonance 
does – it fosters readiness to change.   
 
Again considering the non-adherent antihypertensive patient, the pharmacist might 
facilitate dissonance by saying something along the lines of, “I notice that you have missed 
some doses of your Renitec since your last repeat. What are you thoughts on how this might affect 
your risk of suffering  a stroke or a heart attack?”   The pharmacist can facilitate the creation of 
dissonance in two ways: Firstly, by eliciting information about the patient’s hypertension-
related goals, for example “The ideal blood pressure for someone of your age is around 130 
over 80. What would you like to aim for?  Secondly, having established a blood pressure goal 
the following question should focus on the behavioural changes needed to realise the 
patient’s stated goal “Taking your Renitec regularly every day will certainly help you reach your 
blood pressure goal, so what do you think you need to do to help you ensure  that you don’t miss a 
dose?”    
 
(v) Support Self-Efficacy 
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 Patients not only have to believe that their therapy will improve their chances of 
preventing the downstream development of diabetes-related complications but, 
importantly, that they are also capable of effecting the required changes in behaviour. 
Pharmacists should notice and encourage not only the actual changes in behaviour but 
also any contemplated changes. For example should a patient say, “ I have been giving 
some thought to stopping smoking”  then an appropriate response by the pharmacist would 
be something along the lines of, “That’s really good news. If you don’t mind telling me, how do 
you plan to stop?”   
 
Changes in behaviour that lead to the realisation of diabetes-related goals should be 
rewarded with praise, “Great- your blood pressure is spot on this month. You obviously have 
been taking your meds every day and cutting back on the salt. Well done and keep it up!”  Patients 
must be encouraged when targets are missed, “ Don’t worry, I know that you can do this. 
What do you think you need to change to get there?”  Pharmacists should think innovatively 
and access outside expertise where needed, provided the patient is in agreement. 
 
Conclusion 
Chronic diseases, with interrelated and sometime conflicting biomedical, psychological 
and social drivers, are by nature complex7. It follows, therefore, that the solutions to 
managing these diseases must be complex. DM2 presents a special set of challenges 
because it is a disease where treatment and care are largely reliant on patient self-
management behaviour. Furthermore, it is a disease very often clustered with other 
serious chronic disease states which require focused  self-management. Pharmacists are 
encouraged to reflect on how best to influence patient health-related behaviour within the 
scope of practice of a pharmacist. Motivational Interviewing, while not a universal 
panacea for poor patient health-related behaviour, is an approach well worth considering. 
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The Clinical Intervention 
 
The review and monitoring of diabetes-related variables is key to optimising diabetes care 
and thus a very important part of the DCP. Diabetes care is founded essentially on patient 
self-management of lifestyle ( mainly diet and exercise) and pharmacotherapy, as 
approximately 95% of the care required by a diabetic is provided by themselves or 
members of their family. Eating correctly, exercising adequately and taking medication 
appropriately are all behavioural activities. Measuring and monitoring these activities adds 
a  crucial clinical dimension as it is difficult to conceive of managing without measuring.    
 
Monitoring therapy and clinical and disease-risk indicators and other variables allows the 
patient and pharmacist to confirm that the therapy and self-management behaviours, that 
are aimed at optimising patent economic, clinical and humanistic outcomes, are having 
the desired effect. If patient outcomes are being compromised then monitoring provides 
the basis – the evidence – for the initiation of remedial action. 
 
Monitoring need not be time consuming, and an ideal time to undertake some of the 
more frequent monitoring activities (e.g. BP, SMBG review, BMI, medication adherence) 
is during the prescription refill encounter.  Furthermore, simplifying regimens, providing 
prescription refill reminders and telephonic follow-up between patient visits to the 
pharmacy have been shown to be very effective adherence promoting and monitoring 
interventions. 
 
The monitoring schedule below is informed by the clinical monitoring schedule contained 
in the IDF’s  Desktop Guide to Type 2 Diabetes Mellitus  which was provided to study 
pharmacists earlier in the year.  It is suggested that pharmacists refer to this resource and 
to other guidelines [ IDF’s Global guidelines for Type 2 Diabetes, National Institute for 
Health and Clinical Excellence’s Type 2 diabetes clinical guideline (www.nice.org.uk), 
American Diabetes Association’s Standards of Medical Care in Diabetes 2006. Diabetes 
Care 2006; 29(suppl 1):S4 – 42 ] 
 
The schedule summarises suggested monitoring activities for Type 2 diabetes patients 
participating in the study. The frequency with which the various elements of a monitoring 
programme are implemented are dependant on the risk profile of the patient (patients 
whose disease-risk indicators indicate that they are well  controlled will require fewer  
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monitoring encounters than those who are not well controlled) and  the time available to  
the patient and pharmacist. It is suggested that pharmacists structure fixed time 
appointments for the initial visit and for subsequent planned encounters (more frequently 
in the case of those patients who are particularly at risk – e.g. the elderly, multiple co-
morbidities, polypharmacy). Pharmacists should discuss and agree an individualised 
monitoring schedule with each patient.  
 
Monitoring Schedule 
 
Domains Baseline 
evaluation 
Interim 
evaluation 
12 month 
evaluation 
Background history and medication review    
Social history/lifestyle review √   
Social support status: family/friend involvement √ If required  
Lifestyle practices:  current exercise, diet, smoking 
status 
√ √  
Long-term and recent diabetes history √   
Complications: history and symptoms √ If required  
Medical history ( refer Patient Profile)
 
 √   
Medication review of prescribed therapy: 
• Appropriateness evaluation as per national 
algorithm 
• Pharmacotherapy, names of medicines, dosages 
and side-effects 
• Medication related problems including adverse 
effects  
• OTC and CAM use 
√ If required  
 
 
 
 
 
Diabetes knowledge and self-management    
Diabetes disease and therapy related knowledge  
• Basic pathophysiology 
• Complications, and co-morbidities 
• Disease-risk  and clinical indicators 
• Self-care recommendations 
• General diabetes-related knowledge  
√ If required  
Self-monitoring skills/results especially: 
• Self-monitored blood glucose  
• Blood pressure   
• Cholesterol 
• Body mass index (BMI) 
• Waist-hip ratio 
√ If required  
Self-care recommendations
 
awareness of the need for: 
• Lifestyle modification especially diet, exercise, 
smoking  
• Foot care  
• Medication adherence  
• Attendance at regular examinations  
• Measurement of clinical indicators  
√ If required  
Key clinical indicators    
 Review and refer in terms of SEMDSA guidelines for :    
• Glycated haemoglobin ( HbA1c ) √  √ 
• Lipid profile √  √ 
• Blood pressure √ √ √ 
• Proteinuria √  √ 
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• BMI and waist-hip ratio √ √ √ 
Provider referral    
General examination by medical practioner and referral 
to diabetologist/endocrinologist for at-risk patients 
√ If required  
Foot examination- podiatrist referral   √ If required  
Eye- ophthalmologist referral  √   
ECG- physician referral  √   
Behavioural indicators √   
Smoking √ If required  
Alcohol consumption √ If required  
The Beliefs about Medicines Questionnaire
 √  √ 
The Satisfaction with Diabetes Scale
 √  √ 
Diabetes Care Plan Questionnaire √  √ 
The Self-care Adherence Scale
 √  √ 
The Brief Diabetes Knowledge Test
 
  √ 
The Self Monitoring Blood Glucose Scale
 
  √ 
The Diabetes Empowerment Scale Short Form
 
  √ 
The Understanding Self-care Practices Scale
 
  √ 
The Medication Adherence Report Scale
 
  √ 
The Major Depression Inventory
 
  √ 
 
 
Notes to the monitoring schedule: 
 
 “If required”,  indicates that the pharmacist may want to revisit those aspects 
identified during the initial consultation and which may require follow-up.  
 The medical history is contained in a Patient Profile self-report completed by each 
patient at baseline.  
 The practice of pharmaceutical care demands that the pharmacist (as the ‘medicine 
expert’ on the diabetes healthcare team) pay particular attention to assisting the 
patient to resolve any medicine related problems.   
 Research shows that while diabetes related knowledge is seldom enough to 
guarantee good patient outcomes it is an important aspect of diabetes care. 
 There is a strong correlation between regular self-monitoring, especially self-
monitored blood glucose (SMBG) and the optimisation of  therapy. Adjustments to 
dosages, food intake and exercise require accurate blood glucose levels. Patient’s 
must monitor blood glucose regularly and use the values to aid in their decision 
making. The same holds true for other important indicators. 
 The most important aspect of diabetes care is patient self-management. 
 Patients and pharmacist should know what the guidelines suggest in terms of  key 
clinical and disease-risk indicators (Society for Endocrinology Metabolism and 
Diabetes of SA  guidelines for Type 2 diabetes). 
 The UKPDS ( United Kingdom Prospective Diabetes Study) Risk Engine is a  
cardiovascular and stroke risk assessment web-based tool developed by the 
Diabetes Trials Unit at Oxford University to risk rate Type 2 diabetes patients for non-
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fatal and fatal coronary heart disease and stroke.  Pharmacists wishing to use the 
tool can do so by copying the following website address to their Internet browsers 
http://www.dtu.ox.ac.uk/index.php?maindoc=/riskengine/index.php  and then  select 
‘download’ following the links. Patient data is entered in the specified fields and the 
relative risk is calculated. The tool is useful both as a referral indicator and in 
assisting patients understand their possible risk of experiencing a cardiovascular 
event and or stroke.  
 The IDF and SEMSDA guidelines for Type 2 diabetes suggest certain medical 
examinations be done at specified intervals.  
………………… 
 
Motivational Interviewing Helps Patients Confront 
Change 
Bruce Berger, Ph.D. 
Professor, School of Pharmacy, Auburn University, Auburn, AL 
 
This last article in the series on change considers motivational interviewing. Motivational 
interviewing was originally developed by Miller and Rollnick
1
 as a complementary 
process to the Transtheoretical Model of Change (see U.S. Pharmacist, October 1999). It 
was first targeted toward people with addictive behaviors, but with the development of 
brief motivational interviewing, it is now being used to assist healthcare providers in 
managing patients with other illnesses.
2
  
 
Motivational interviewing was developed as a strategy for assisting patients in making a 
commitment to change. It combines Rogers’ client-centered approach
3
 to therapy and 
more directive approaches for helping people to make changes. The basic idea behind 
motivational interviewing is that for any number of reasons patients are often ambivalent 
about change. They may not be aware that a change is truly needed. Or, patients may 
have misinterpreted the seriousness of the condition. Alternatively, patients may 
understand the treatment regimen, but cannot see any way to carry it out without great 
difficulty. As a result, they’re not sure they have “what it takes” to control their illness. 
 
Ambivalence affects motivation and readiness to change and inhibits a patient’s ability to 
adapt coping strategies for change. An important aspect of motivational interviewing is to 
start with an assessment of the patient’s readiness to change. Knowing what stage a 
patient is in will assist a practitioner in defining coping strategies to promote change. For 
example, individuals in the precontemplation stage may not be aware that there is a 
problem. They need objective, nonjudgmental information. On the other hand, people in 
the action stage are ready for change. For these individuals, the pharmacist may want to 
check the accuracy of the information so that coping strategies are appropriate. In 
addition, these patients have made a commitment to change and therefore, 
encouragement and assisting in defining strategies work well.  
 
Motivational interviewing is extremely useful because it teaches the healthcare provider 
to explore the patient’s understanding and concerns. It focuses its attention on dealing 
with resistance and on helping patients to move through the stages of change. 
 
The Menu of Strategies  
 
The following menu of strategies is the process the pharmacist may use to identify the 
stage of readiness of the patient and create a climate for change. It is modified from the 
work of Rollnick and colleagues.
2
 A skilled provider can use the entire menu in no more 
than 5–15 minutes with a patient. Each patient may require some or all of the items, 
depending on where the patient is in the process. Each time the patient is seen, some or 
all of the strategies will be employed. After the menu of strategies is discussed, specific 
skills will be addressed. 
 
1. Opening strategy—lifestyle: This strategy involves talking in general about the 
patient’s lifestyle from his or her own perspective. Does the patient view it as healthy or 
unhealthy? What does he or she like or dislike about it? Are there aspects that need to 
change? This opening strategy is to give the pharmacist a general picture of the patient’s 
health habits (or lack of them) and desire to change unhealthy habits or take on new 
behaviors. 
 
2. A typical day: Knowing what a typical day is like for the patient allows the 
pharmacist to do a better job of realistically tailoring medication regimens (or exercise, 
etc.) to fit the patient’s daily routines. Tailoring can greatly improve treatment adherence 
since patients can attach medication taking to a behavior or activity they are used to 
doing. Also, knowing how the patient’s day is structured can help with better planning. 
There is no need to tell a patient to monitor her blood glucose at three in the afternoon 
when that is a busy time for her each day. This strategy also helps to build rapport with 
the patient. 
 
3. The good things and less good things: Here the pharmacist continues to build rapport 
and explores how a patient represents his or her illness and its treatment. Patients with 
misconceptions about an illness or its treatment may treat the illness inappropriately. By 
asking questions such as, “What does having diabetes mean to you?” the pharmacist is 
able to determine which beliefs are accurate and which need to be corrected. In 
discussing the good things and less good things, the pharmacist can also ask patients 
about what they perceive as barriers and facilitators to treating their illness. All of this 
gives the pharmacist the opportunity to listen to the patient and demonstrate 
understanding by empathic responding. Identifying barriers and facilitators of behavior 
change will also allow the pharmacist to more accurately determine the patient’s stage of 
readiness. Barriers to change are much more prominent in earlier stages of readiness. 
Finally, knowing the good things and less good things gives the pharmacist the 
opportunity to develop discrepancies between old, unwanted behaviors and new, desired 
behaviors. This is an effective skill for moving patients forward. 
 
4. Providing information: This strategy is really aimed at exchanging further 
information. This is an important point. First, the pharmacist should ask if the patient 
wants additional information about the illness and its treatment (or, e.g., smoking 
cessation). If the patient is not ready for more information, it is wise to note this and 
provide a leaflet only. It does not make sense to try to tell patients more when they are 
not ready to hear it. If the patient is ready for additional information, it should be 
provided in an unbiased, nonjudgmental manner. The information provided should assist 
patients in taking their medications appropriately. The point is that patients should leave 
the pharmacy with a clear understanding of what to expect and what to do if the expected 
doesn’t occur. For a thorough discussion of the kind of information to be provided, see 
U.S. Pharmacist, February 1999, pp. 64–73.  
 5. The future and the present: The intention of this strategy is to allow patients to 
discuss what they want to have happen as a result of treating the illness (taking 
medication, losing weight, etc.). Usually, any concerns or dissatisfaction on the part of 
the patient will come out here and should be addressed in a compassionate, 
nonjudgmental manner. 
 
6. Helping with decision-making: Lastly, the pharmacist should assist patients in 
making decisions about managing their illnesses. Patients should be asked questions such 
as, “What are you thoughts about managing your diabetes” or “Where does this leave you 
now?”
2
 These are neutral, nonjudgmental questions. It is very important for the 
pharmacist to be patient during this time of questioning. Patients may vacillate between 
changing and staying the same. 
 
The Five Principles 
 
Five general principles are used to support the menu of strategies.
1
 
1. Express empathy 
2. Develop discrepancy 
3. Avoid argumentation 
4. Roll with resistance 
5. Support self-efficacy 
 
What follows is a rationale for each principle. A dialogue between a pharmacist and a 
patient is also presented which will incorporate these five general principles. 
Express empathy: Practitioners who are judgmental, perceive the patient as lazy or 
uncooperative, or are impatient, are likely to fail in assisting a patient with change. The 
pharmacist who sees the patient as one who is struggling with the process of change and 
respects the patient and the struggle, will be far more successful. What you are observing 
with a patient who seems uncooperative, uninterested, or resistant is that patient’s way of 
coping with the situation. It may not be productive, but it is the only way that the patient 
knows how to cope at the time. One of the roles of the HCP is to identify and understand 
the reasons for the resistance from the patient’s perspective. Only then can other, more 
productive ways of coping be identified. The tools successful therapists use to initially 
assess a patient are open-ended questions, reflective listening and empathic responding. 
For a more thorough discussion of this topic, see U.S. Pharmacist, October 1998, pp. 69–
76. 
 
Develop discrepancy: Because patients are often ambivalent about change, initiatives 
must be taken to begin to move the patient in the direction of the desired change. While 
persuasive strategies may work very well for patients in the later stages of change, they 
generally fail miserably when patients are in the precontemplation or contemplation 
stages. Generally, persuasive strategies are met with resistance in these early stages. So, 
what does one do? It has already been suggested that expressing empathy is critical early 
on. The next step is to develop discrepancies between a patient’s present behavior and the 
behaviors desired. People are much more highly motivated to change when discrepancies 
exist between current behavior and desired personal goals.
2
  
 
Motivational interviewing attempts to create these discrepancies without making the 
patient feel threatened or pressured. Through effective questioning, the skilled 
interviewer attempts to identify discrepancies that already exist within the patient, rather 
than impose external pressures. If done properly, it will be the patient who will come up 
with the reasons that the change is necessary. 
 
Avoid argumentation: As stated by Miller and Rollnick, “Motivational interviewing is 
confrontational in its purpose: to increase awareness of problems and the need to do 
something about them.”
1
 However, this kind of confrontation is different than arguing 
with the patient, trying to convince patients they have a problem when they are not ready 
to accept this, or labeling patients (overweight, diabetic, hypertensive, anorexic, 
uncooperative) in order to promote change. Arguing tends to increase resistance rather 
than increasing motivation to change.
1
  
 
Roll with resistance: When dealing with patients who do not want to change, are 
overwhelmed, or won’t take their illnesses seriously, there is a tendency to become 
frustrated or angry. This frustration or anger often leads to increased efforts at trying to 
persuade patients that they have a problem, they should take it seriously, and make a 
more committed effort to adhere to instructions (“to get with the program”). When 
patients make statements that indicate resistance (“But I just can’t remember to take it 
three times a day,” “Yeah, it’s easy for you to say...you don’t have high blood pressure,” 
“I just don’t understand what the big deal is...I feel fine”), they are providing valuable 
insight into where the problems lie. For example, a less complicated regimen, 
identification of low-salt foods that can be eaten, or clarification of information may be 
solutions to the identified problems. Nonetheless, communication that expresses 
understanding of the problems that the patient encounters will go much further than 
brow-beating or arguing. Ultimately, it will be the patient’s job (with your support and 
assistance) to solve the problems presented. You may be able to decrease the complexity 
of the regimen, but the patient will still have to take the medication. You may be able to 
suggest foods that do not contain sodium, but the patient will still have to avoid high-
sodium foods. 
 
Support self-efficacy: Patients have to believe that they have the knowledge and skills or 
abilities to carry out the treatment plan. The pharmacist can greatly assist the patient in 
developing self-efficacy about carry out the treatment plan. Pharmacists can help by: 1) 
providing and clarifying information; 2) offering realistic hope and expressing confidence 
in the patient’s ability to succeed; 3) noticing successful attempts at adherence, even if 
they are short-lived; 4) praising ideas from the patient to solve problems; and 5) 
continuing to emphasize and support the responsibilities that both the patient and 
provider have in improving treatment adherence and treatment outcomes.4 
 
Conclusion 
 
Motivational interviewing and the stages of change are useful concepts and processes for 
meeting patients where they are in their readiness to manage their illnesses. They provide 
pharmacists with stage-specific skills and strategies for assisting patients with change. 
This approach requires that the pharmacist view his or her job as serving the needs of the 
patients, not vice versa. When this can be achieved, better outcomes are more likely to 
occur. 
A PHARMACIST-PATIENT DIALOGUE 
This dialogue involves a pharmacist who has been trained in motivational 
interviewing and a patient who is having a difficult time accepting that she has 
asthma. Mrs. Jones has been diagnosed with asthma and has brought in several 
prescriptions. 
 
Mrs. Jones: “Here.” 
Pharmacist: “You seem a little down today, Mrs. Jones” (expressing empathy). 
Mrs. Jones: “Well, look at these prescriptions.” 
Pharmacist: “Looks like you have asthma.” 
Mrs. Jones: “So now you know why I’m so down.”  
Pharmacist: “You are down because you just found out and it came unexpectedly” 
(expressing empathy). 
Mrs. Jones: “Well, yes. I mean, I get winded sometimes but I didn’t know I had 
asthma.” 
Pharmacist: “Asthma sounds bad to you” (expressing empathy). 
Mrs. Jones: “Sure. You have to take medicine for it. I have to stop smoking. I found 
out my cat’s hair might be a problem. That doesn’t sound bad to you?” 
Pharmacist: “It sounds like a lot of change at one time” (expressing empathy and 
avoiding argumentation). 
Mrs. Jones: “You’re darn right. I might quit smoking, but I’ve had my little Chubbers 
for seven years and I’m not giving her up. I love that cat.” 
Pharmacist: “It sounds like you have a lot of difficult decisions to make” (expressing 
empathy). “What did the doctor tell you about asthma?” 
Mrs. Jones: “Not much—he just said that I need to use these medicines, stop 
smoking and get rid of the cat. He’s got some nerve—get rid of the cat!” 
Pharmacist: “You didn’t like his advice” (expressing empathy, rolling with resistance 
and avoiding argumentation). 
Mrs. Jones: “Not one bit.” 
Pharmacist: “I know that you don’t want to get rid  
of your cat, Chubbers. What do you think about quitting smoking?”  
Mrs. Jones: “I don’t know. It relaxes me a lot, but Dr. Carroll says it’s bad for my 
asthma. Is that true?” 
Pharmacist: “Smoking does make asthma worse. It does increase your risks 
associated with asthma.”  
Mrs. Jones: “That’s what Dr. Carroll said, too. I guess it’s true.” 
Pharmacist: “So, on the one hand you’re telling me that smoking relaxes you, but 
you also seem to be saying that you realize that smoking will make your asthma 
worse” (developing discrepancy). 
Mrs. Jones: “Yeah, I guess so. I need to go home and sort all of this out. Just fill my 
prescriptions.” 
Pharmacist: “It must seem somewhat overwhelming right now” (expressing 
empathy). 
Mrs. Jones: “Yes.” 
Pharmacist: “I’ll get these prescriptions filled and then we’ll talk about how to use 
these properly so you will get the most benefit from them.” 
Mrs. Jones: “All right.” 
Pharmacist: “Has Dr. Carroll talked to you about a peak flow meter?” 
Mrs. Jones: “A what?” 
Pharmacist: “A peak flow meter to tell how your breathing is doing?” 
Mrs. Jones: “Look, I can’t handle anything else right now. Could you just get my 
prescriptions filled?” 
Pharmacist: “Sure, we can talk about the peak flow meter another time” (rolling with 
resistance, expressing empathy).  
ANALYSIS 
It seems clear from this dialogue that Mrs. Jones is not ready to accept her asthma 
and the things she may need to do to get it under control. The pharmacist is patient 
and caring and does not try to push the patient too fast. The pharmacist does not 
insist on talking to the patient about peak flow because she is not ready to hear 
about this yet. She is ambivalent about what to do and needs some time to sort 
things out. The pharmacist uses many of the principles of motivational interviewing 
in this dialogue. A key point is this: Even though everything did not get covered and 
all of the steps of the menu of strategies were not employed, no bridges were 
burned and no added resistance occurred because the pharmacist did not rush 
things. The pharmacist realized that this is a process, and other opportunities to 
talk to Mrs. Jones about her asthma  
will arise. 
 
1. Miller, WR. and Rollnick S. Motivational Interviewing, The Guilford Press, New York, New York 1991. 
2. Rollnick S, Heather, N, and Bell A. Negotiating behavior change in medical settings: the development of brief motivational 
interviewing. J Mental Health 1992:1:25-37. 
3. Rogers CR. The necessary and sufficient conditions for therapeutic personality change. J Cons Psych 1957:21:95. 
4. Berger BA. Readiness for Change: Improving Treatment Adherence, a monograph published by Glaxo Wellcome Inc, 1997. 
 
TCM 46 September/October 2004
Each year millions of people suffer from
drug-related morbidity and mortality as
a result of noncompliance. Especially
when it comes to taking medication and
lifestyle changes, noncompliance can
result in increased health care costs. For
example, noncompliance with medica-
tion regimens and the needed lifestyle
changes for diabetes patients can result
in gangrene, neuropathies, even death.
Not only does this underutilization of
medication decrease pharmacy rev-
enues, it also increases overall health
care costs, because an estimated 11% to
20% of hospital admissions, emergency
room visits, and repeat doctor visits may
be results of noncompliance.3,4
Compliance Interventions
Because noncompliance is complex, mul-
tiple approaches to improving compli-
ance may be necessary. A patient taking
more than one drug may have trouble
remembering to take one and may not
believe in the efﬁcacy of the other.
Therefore, patient-speciﬁc approaches
urse case managers are in a unique
position to help patients move
toward healthy behaviors and out-
comes. Compliance is the extent to
which patients follow advice given
to them by health care providers, whether the
advice concerns taking medications, making
lifestyle changes, or other interventions. While
some studies estimate that 50% to 60% of
patients are noncompliant with their medication
regimens, compliance with lifestyle changes is
even lower, at 30%.1 “Of all patients, 30% to 40%
fail to follow preventive regimens, and 20% to
30% fail to follow curative (relief of symptoms)
medication regimens. Moreover, when long-term
medication is prescribed, 50% fail to adhere.”2
N
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are needed. Please keep in mind that
different compliance studies use differ-
ent measures and methods so that rates
are not always the same or comparable.
The following steps have been proven
to increase compliance by:5
• Assessing the patient’s understanding
and then educating about the disease
state and the treatment regimen
• Tying the medication-taking process
to other daily routines (tailoring)
• Using compliance aids, such as medi-
cation organizers or charts
• Simplifying medication regimens
• Providing human support within the
health care team (listening and
empathic understanding from the
health care providers are essential)
• Recognizing poor coping skills and
other sociobehavioral issues within
the patient
• Developing a client-centered
approach
Why have rates of noncompliance
remained so high, despite years of
research and convenient daily and week-
ly drug therapy? While there has been
an increasing emphasis on patient coun-
seling in the health professions, counsel-
ing has been confused with the simple
provision of information. Although infor-
mation provision is a prerequisite, it has
not been shown to predict compliance,
because often the information is provid-
ed in ways that are ambiguous or don’t
allow the opportunity for the patient to
ask questions and to express concerns.
Information provision is a provider-cen-
tered approach rather than a client- or
patient-centered approach to improving
compliance. Client-centered approaches
have been found to be more effective in
promoting compliance. A client
approach is “one where the client collab-
orates with the provider in helping to
identify treatment goals, choose treat-
ment options, monitor symptoms, and
evaluate and revise regimens if prob-
lems occur.”6
Failing to take appropriate medications
correctly is a complex process that goes
beyond patients simply forgetting to
take their drugs. Several conditions
must exist to increase the probability
that the patient will be compliant. Com-
pliance requires that a patient:
• Understand and believe the diagnosis
• Be interested in his/her health
• Correctly assess the impact of the
diagnosis
• Believe in the efﬁcacy of the pre-
scribed treatment
• Know exactly how to take the medica-
tion and the duration of therapy
• Know how long it will take for the
medication to start working and how
to know it is working
• Find ways to incorporate the medica-
tion regimen into his/her daily routine
to minimize the negative impacts on
his/her life
• Value the outcome of treatment more
than the “cost” of treatment
• Believe that he/she can exert some
degree of control over the illness by
carrying out the treatment plan
• Believe that the health care practition-
ers involved in the treatment process
truly care about him/her as a person
and do not just view the patient as a
disease to be treated7
• Be assessed for the readiness to man-
age the illness and take the medica-
tion8
In a client-centered approach, these fac-
tors are assessed by the nurse case man-
ager. For example, the nurse case man-
ager asks the patient to state in her own
words her understanding of the illness
and what the medicine will (or won’t)
do relative to the illness. In addition,
efforts are made to address the patient’s
questions or concerns. What barriers
does the patient foresee? Does the
patient believe the medicine will work
(if not, why not, and what would the
patient need to know to be more conﬁ-
dent) and what value does the medicine
have for the patient?
Counseling is an exchange of informa-
tion so that clear treatment goals and
expectations are explored. Information
provision is unidirectional and does not
allow for this interaction. For example,
what does “Take 1 tablet twice a day”
mean to the patient? If the patient is
supposed to take it every 12 hours, is
that time frame communicated clearly to
him? Does he know how long it will
take for the medicine to work? Can he
work the medicine into his daily rou-
tine? Because of the visibility and the
accessibility of nurse case managers,
they have the potential to play a major
role in improving patient compliance or
persistence with drug therapies. The
ability to do so requires an understand-
ing of why noncompliance occurs and
the communication skills to interact
with patients so that problems may be
identiﬁed and resolved.
In the psychology literature, the terms
“therapeutic alliance,” “working
alliance,” or “helping alliance” have
been used to describe the necessary
relationship that must exist between a
counselor or a psychotherapist and a
client (nurse case manager and patient)
for positive therapeutic change to take
place. Speciﬁcally, a therapeutic alliance
is deﬁned as “the observable ability of
the therapist and the patient to work
together in a realistic, collaborative rela-
tionship based on mutual respect, liking,
trust, and commitment to the work of
treatment.9 Some researchers have gone
so far as to say that the therapeutic
alliance is the collaboration exhibited by
the patient.10 The quality of the alliance
is a function of the extent to which the
patient and the therapist agree about
the goals and tasks of psychotherapy.
As one can see, this agreement would
also be critical to pharmaceutical care
because effective pharmacotherapeutic
goals and outcomes, and the behaviors
needed to carry them out, must be nego-
tiated between the nurse case manager
and the patient if treatment has any
chance of being effective. Therefore,
compliance requires a partnership. While
it is ultimately up to the patient to decide
if he or she is going to be compliant with
a medication regimen, the relationship or
collaborative alliance between the nurse
case manager and the patient is the key
predictor of success.11
Motivational Interviewing
Managing an illness, particularly a
chronic illness, is complex. Changes in
many behaviors may be involved. Some
habituated behaviors may have to be
given up (smoking), whereas other new
behaviors may need to be added. Medi-
cation regimens must be worked into
daily routines. Sometimes regimens
don’t ﬁt very well into an individual’s
lifestyle, but taking medication must
become habituated along with other
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routines. Often changes in lifestyle must
occur—weight must be lost and kept off,
or diets must be changed. Exercise may
have to be initiated or increased.
While health care providers can certain-
ly describe for the patient what needs to
be done, ultimately, it is the patient who
must manage her own illness. The best
that health care providers can do is to
make an accurate diagnosis, prescribe
the appropriate treatment, give proper
information, answer questions, and cre-
ate a nurturing environment in which
patients feel safe enough to discuss their
concerns (more on this later). And while
these things are vitally important, it is
still patients who must decide if they
want to or can regulate their illnesses.
This point is critical to understand.
It is unfortunate that providers often
use single strategies to address problems
of patient adherence to medication regi-
mens. They assume that patients who
ﬁll prescriptions are ready to take their
medication properly and to manage
their illnesses. However, research exam-
ining changes in health behaviors indi-
cates that only 30% of all patients with a
new chronic illness may be ready to take
their medicine properly and to manage
their illness.12 In fact, different interper-
sonal skills and strategies need to be
used, depending on how ready patients
are to take action to take their medicines
and to regulate their illnesses.13 For
example, patients who resist taking their
medication properly and/or managing
their illness require different communi-
cation strategies and interventions than
patients who try to maintain healthy
behaviors.
Last year in the United States, we spent
more than $1 trillion for health care.
According to the World Health Organi-
zation, approximately 51% of these costs
were behavioral in nature; that is, these
costs required patients to engage in a
behavior (such as taking medication) or
ceasing a behavior (such as smoking).
Our current way of talking to patients
only affected 2% of these costs. The esti-
mated cost of drug-related morbidity
and mortality—this is for legitimate
drug therapy—is nearly $100 billion.
These costs include avoidable hospital-
izations, emergency room visits, and
physician visits. All of these costs
accrued because patients did not prop-
erly use their prescribed therapy (if at
all). Simply put, for every dollar we
spend on the drug itself, we have to
spend another dollar to deal with the
health-related problems resulting from
improper use of that drug. Something is
terribly wrong, and current approaches
are not nearly effective enough.
Motivational interviewing is a psychoso-
cial or sociobehavioral approach to
patient care that contrasts with the tradi-
tional biomedical approach shown in
Table 1. This process was developed to
help health care providers assess a
patient’s readiness to comply with a treat-
ment regimen. The biomedical approach
has not been successful in assisting
patients with sustained behavior change.
Note the major differences in these mod-
els. The biomedical model is practitioner
centered, whereas the psychosocial
model is patient centered. The psychoso-
cial model stresses that the patient’s
needs and concerns must be appropriate-
ly addressed; otherwise, noncompliance
may occur. Asking what questions or con-
cerns the patient may have about the ill-
ness or treatment is a proactive way of
assessing this possibility.
While the biomedical model has the
health care expert telling the patient
what to do, the psychosocial model
views an encounter between patient
and health care provider as a meeting of
experts. The nurse case manager may be
an expert in helping the patient with
disease management, but patients are
experts on themselves and how they are
affected by the proposed changes in
their lives. In the psychosocial model,
our job is to assist patients in saving
themselves. It is their decision (with our
input) to choose healthy or unhealthy
behaviors. Remember, patients manage
their illness, not us. However, we can
create an environment through caring,
sufﬁcient information, and understand-
ing to improve the chance that the
patient will manage the illness.
Behaviors need to be negotiated, not
dictated. In the psychosocial model,
adherence implies that both the health
care provider and patient take responsi-
bility for improved outcomes. Failure is
not just the patient’s to take on. We are
there to serve, within reason, the needs
and the concerns of the patient, not vice
versa. We do not motivate patients; we
assess their motivation and then apply
the appropriate skills and strategies to
address their readiness. This point is
critical. Patients vary in their readiness
to take their medicines, make lifestyle
changes, etc., so they must be assessed
to determine how prepared they are to
do what is needed. How important do
they think the changes are? Are they
ready to make them? Are they conﬁdent
they can do so? Will they need help? Do
they understand the beneﬁts? What bar-
riers do they perceive? How will they
reduce them?
Based on this assessment, different skills
and strategies will be needed to assist
Biomedical Psychosocial
Practitioner centered Patient centered
Information giving Information exchange
“Save” the patient Patient “saves” self
Dictate behavior Negotiate behavior
Compliance Adherence
Authoritarian (parent to child) Servant 
Motivate the patient Assess and explore motivation
Persuade, manipulate Understand, accept
Resistance is bad Resistance is information
Argue Confront
Respect is expected Respect is earned
TABLE 1. THE BIOMEDICAL MODEL OF CARE VERSUS THE
PSYCHOSOCIAL MODEL OF CARE
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patients in identifying and implement-
ing their change processes. This is the
heart of motivational interviewing. Our
job is to understand and to accept the
patients’ needs and concerns, not to try
to talk them out of these things. In this
approach, resistance is seen as informa-
tion, not as something bad. Resistance is
simply the patient’s way of expressing
that something is wrong or uncomfort-
able. More on this idea later.
Consequently, we don’t argue with
patients; we address and explore their
concerns. There is a difference
between chastising the patient by say-
ing, “Mrs. Jones, how many times
have I told you how important it is to
take your medicine every day?” versus
addressing the problem by saying,
“Mrs. Jones, I notice that you haven’t
been taking your blood pressure
medicine every day. Can you tell me if
there is a problem?” The former is
argumentative and judgmental and
will not allow the patient to express
the reasons for noncompliance with-
out defensiveness. The latter is non-
judgmental and invites the patient to
openly express the reasons for her
noncompliance. The former closes
down any talk about noncompliance;
the latter opens up productive talk
about the problem that may lead the
patient to a solution for her problem.
Finally, in the psychosocial model,
respect is earned, not expected. The
health care provider needs to earn the
respect and the trust of the patient by
being competent and caring.
Change and Resistance
Change and resistance are opposite
sides of the same coin. Change often
evokes resistance because change inher-
ently questions our motivation and abil-
ity to do what is needed. Resistance is a
person’s way of saying, “I don’t like the
proposed change,” or “I don’t know if I
can handle the proposed change.”
Resistance behavior is the person’s sig-
nal of a disturbance in the relation-
ship—it is a disturbance in rapport. This
is not necessarily a bad thing. When
people resist change, they feel out of kil-
ter. This is when they are most likely to
do something if they perceive that the
beneﬁts of the change outweigh the
downside of the change. People have an
internal “decisional balance” about any
change under their control. If the pros
of the change outweigh the cons, they
make the change. A skilled health care
provider can help “tilt” the pros in favor
of the change and help the patient over-
come the cons.
On the other hand, ambivalence kills
change. When people are ambivalent,
they do nothing. The pros and cons of
the change seem the same. For example,
when they are unclear about what to do
or if they doubt they have the necessary
skills, patients often choose to do noth-
ing. The same is true if patients doubt
that the medicine will actually work.
Resistance is a person’s way of saying, “I
need to explore this and see if it works
for me.” Understanding is needed in
response to resistance, not persuasion
nor criticism.
Resistance behavior can take many
forms. Patients can negate things you
say by blaming, disagreeing, excusing,
minimizing, etc. They may argue with
you by challenging you, discounting
what you say, or becoming hostile or
agitated. They may resist by interrupt-
ing frequently or ignoring things you
say. The point is that sensitive health
care providers listen for resistance,
which is a signal that there is a distur-
bance in rapport that needs to be
addressed and explored, not squashed.
A change is needed in the way we are
communicating with the patient. When
the patient says, “I just don’t know if I
can do this,” rather than saying, “Sure
you can. It’s not so hard,” we could say
instead, “Tell me what makes it seem so
difﬁcult for you,” or “What would make
you feel more conﬁdent that you could
do this?” These latter responses explore
the patient’s concerns and reveal infor-
mation that can be used to help the
patient overcome barriers.
“Yes, but” communication and argumen-
tative tactics are not the solution to
resistance. A common trap is to respond
to your patient in the following way:
Patient: “I just don’t like taking
medicine.”
Case manager: “Yes, but you want
to get your cholesterol under con-
trol, don’t you?” or, “Don’t you
think it’s important to stay
healthy so you can see your kids
graduate?”
Neither of these responses explores the
problem the patient presents. Both
responses ensure more resistance.
Understanding, exploration, and
patience are the keys to managing
resistance. If we try to move people too
quickly toward a behavior, they will
dig in and resist even more. A better
response to the patient saying she
doesn’t like taking medicine would
have been, “What bothers you the
most about taking this medicine?” This
way the patient can explain herself,
and you can speciﬁcally address the
concern.
Motivational interviewing is a patient-
centered, directive method of commu-
nicating for enhancing a person’s
intrinsic (internal) motivation to change
by exploring and resolving ambivalence
and resistance. This means that we use
our communication to stimulate the
patient’s internal processes of motiva-
tion. We do not motivate. We assess
motivation and stimulate the patient’s
internal processes to increase their own
intrinsic motivation. Because the pro-
cess is directive, it takes less time than
simply allowing patients to talk about
anything.
Simply put, for every dollar we spend on the drug
itself, we have to spend another dollar to deal with the
health-related problems resulting from improper use of
that drug. Something is terribly wrong, and current
approaches are not nearly effective enough.
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Before talking about dissonance, a dis-
tinction between ambivalence and
resistance is needed. When someone is
ambivalent about doing something, he
may not know what to do, how to do
it, understand why it needs to be done,
does not yet believe it needs to be
done, or doubts his own ability to carry
out what is needed. Ambivalence shuts
down motivation for change and,
therefore, needs to be addressed. Resis-
tance occurs because the person does
not like the proposed changes, is
unwilling to make the necessary
changes, etc. A person may be resistant
because he does not accept the pro-
posed changes as being needed. How-
ever, resistance is a more active choice
about staying the same than ambiva-
lence. In either case, the ambivalence or
resistance must be explored if behavior
is to change.
Dissonance
Motivational interviewing is used to cre-
ate dissonance in a person. Dissonance,
an inconsistency between two behav-
iors, attitudes, values, etc., creates dis-
comfort that is motivating. For example,
if a person’s attitudes are inconsistent
with his behaviors, dissonance occurs,
and the person is likely to try to reduce
it because it is uncomfortable. A person
may say that he is generous but will
experience dissonance if it is pointed out
that he frequently turns down giving to
charitable organizations.
For our purposes, we want to create dis-
sonance about noncompliant behavior.
We want our patients who don’t take
their medicines as they should to feel
dissonance between their goals and
their noncompliant behaviors. We want
them to resolve this dissonance by iden-
tifying future behaviors that are more
beneﬁcial than their present noncompli-
ant behaviors.
The spirit of motivational interviewing
is collaboration, evocation, and autono-
my. That is, we desire a relationship
with the patient in which we collaborate
on mutually agreed goals. We ask ques-
tions to understand the patient’s resis-
tance or ambivalence; the patient knows
the answers, not us. And ﬁnally, we
believe that patients must make
informed choices. It is not enough to
simply provide information. We need to
make sure that the patient understands
the information, knows how to use it,
and feels conﬁdent in his ability to do
what is needed. This includes assessing
the patient’s understanding of the ill-
ness and its treatment.
Motivational interviewing was devel-
oped by psychologists William Miller
and Stephen Rollnick to assess a
patient’s readiness for change (take their
medications; make a lifestyle change,
etc.). Patients vary in their readiness to
carry out a treatment plan. If we assess
their degree of readiness, we can choose
speciﬁc communication skills and
appropriate strategies. We will discuss
this in more detail later. Motivational
interviewing is used to create a favor-
able climate for change—problems are
attacked, not people—and it is nonjudg-
mental. As stated previously, motiva-
tional interviewing addresses ambiva-
lence and resistance. It is designed to
take 3-5 minutes per session with the
patient.
So how does motivational interviewing
work? Motivational interviewing uses
the general process of elicit–provide–
elicit. That is, we elicit information from
patients to better understand them and
what they already understand (what do
they already know about the illness and
its treatment); then we provide the nec-
essary information (and interventions)
to assist our patients in moving forward
with the treatment plan; then we elicit
information again to check for concerns
or questions that new information may
have brought up.
Speciﬁcally, motivational interviewing
uses a menu (or a sequence) of strate-
gies and a set of speciﬁc skills to accom-
plish its goals. The menu is the speciﬁc
process used to elicit and to provide
information. The 5 principles that follow
the menu of strategies are speciﬁc skills
used to support the menu and to allow
us to address ambivalence and to resis-
tance and to create dissonance as the
basis for change. Along with the princi-
ples are speciﬁc assessments called
readiness rulers and the envelope,
which are used to assess a patient’s
readiness to manage a behavior (take a
drug, lose weight) and to identify barri-
ers impeding them from doing so. We
will discuss these items in the second
article. ❑
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The Opening Strategy
The opening strategy with a new patient
is to elicit information. This strategy builds
rapport and helps to relax the patient. The
information gathered is often very useful
when tailoring taking of medication to the
patient’s daily routines. Tailoring has been
shown to increase compliance. The open-
ing strategy simply asks the patient to talk
about his or her lifestyle—eating habits,
nutrition, exercise, for example. This infor-
mation can be incorporated into counsel-
ing that involves changes in eating habits,
exercise, and so forth. It is good to start
with an understanding of the patient’s
perspective. Ask the patient:
• How do you view the changes we have
discussed? What are your thoughts?
• Tell me about your eating habits.
et’s look at the menu of strategies
in motivational interviewing. The
menu is the speciﬁc process used
to elicit and provide information.
Keep in mind that not all of the
steps are needed with each patient; only
certain steps may be needed, depending
on how well you already know the patient.
Let’s start by assuming that we have a new
patient with a new prescription for high
blood pressure.
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Editor’s note: This article is the second in a two-part series on motivational interviewing to effect change in patients to improve their health. The ﬁrst
dynamic article emphasized that the spirit of motivational interviewing is collaboration, evocation, and autonomy. That is, we, as case managers, desire
a relationship with the patient in which we collaborate on mutually agreed goals. We ask questions to understand the patient’s resistance or ambiva-
lence. And ﬁnally, we believe that the patient must be allowed to make his or her own choices but must be given sufﬁcient information to do so. Fur-
thermore, we need to make sure that the patient understands the information, knows how to use it, and feels conﬁdent in his ability to do what is need-
ed. This includes assessing his understanding of the illness and its treatment. This article outlines strategies for achieving these goals.
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• Tell me about how much you exercise.
Do you think you get as much exer-
cise as you need?
A Typical Day
Next ask the patient about a typical day:
• Tell me about your daily routine.
• Do you eat 3 meals a day? When?
• When do you get up? When do you
go to sleep?
This information could be extremely
important to scheduling medication
doses around or with activities the
patient already does, which can improve
compliance. Moreover, it does not make
sense to tell a patient to take a dose in
the morning if he or she works the night
shift and is asleep during that time.
The Good Things and Less Good Things
Assuming that a diagnosis has been
made and that medication is being pre-
scribed, the next step is to elicit the
patient’s thoughts on the illness and its
treatment. At this point, ask the patient
to state in his own words what the con-
dition means to him.
• What is your understanding of the
consequences of not treating your
high blood pressure?
• Do you believe the medicine pre-
scribed will help you?
• Do you believe the diagnosis?
• Can you do what is being asked? What
will get in the way? What will help?
• What are the positive aspects of treat-
ing the illness? Negative aspects?
• What is your overall goal in using this
medicine? What do you want to see
happen?
This is a time to let the patient speak and
for you to really listen. If he cannot see
anything positive to what is happening,
say, “May I tell you what other patients
have said? What do you think of that?”
Concerns need to be explored through
evocative, open-ended questions. It is
especially important to listen to discrep-
ancies in what the patient says. For exam-
ple, we should ask patients what their
goals are as a result of treating their con-
dition. What do they want to happen?
One patient may say that, as a result of
lowering cholesterol, he wants to reduce
his risk of a heart attack as a goal. How-
ever, when asked about the downside of
treatment, he says, “I just don’t like tak-
ing medicines. Besides, I feel ﬁne.” It is
important to point out this apparent
contradiction in a matter-of-fact way by
saying, “On the one hand you want to
reduce your risk of heart attack by low-
ering your cholesterol, but you don’t
like the idea of taking medicine and you
feel ﬁne.” Follow this with, “I am con-
cerned that if you don’t take this medi-
cine, your cholesterol will remain elevat-
ed, and you will be at greater risk for a
heart attack. This worries me.”
Pointing out the discrepancy and
demonstrating caring creates dissonance
for the patient. Dissonance is motivat-
ing. It throws the patient’s system out of
kilter. No one likes to be seen as irra-
tional or inconsistent.
What if the patient does not believe the
diagnosis or does not feel conﬁdent the
medicine will work? Instead of trying to
convince the patient, simply ask, “What
would you need to know to feel conﬁdent
that the doctor made an appropriate diag-
nosis?” or “What makes you doubt the
diagnosis?” or “What information would
you like to have to feel conﬁdent that this
medicine will work?” We deal with resis-
tance by asking evocative questions, not
through persuasion or trying to squash it.
It is critical to make sure that the patient
understands the beneﬁts of medication.
This is done simply by asking, “What do
you see as the beneﬁts of using this
medicine?” The patient’s positive
answers should be praised or encour-
aged. If the patient cannot articulate any
beneﬁts or does not mention several
important aspects, ask, “May I tell you
some other beneﬁts that my other
patients have mentioned?” It is impor-
tant to ask permission to allow for
respect and patient autonomy. Next, ask
what barriers the patient anticipates in
taking the medicine. Then ask what he
plans to do to reduce or eliminate them.
If the patient does not know, say, “May I
tell you what other patients have done
to overcome this barrier?”
Remember, it is vital to make sure that
the patient’s decisional balance tilts
toward healthy behavior by making
sure the beneﬁts outweigh the risks.
This is done by emphasizing the bene-
ﬁts and discussing how to reduce the
risks.
Providing Information
After eliciting information from the
patient, the next step is to provide infor-
mation about the drug therapy, including
the name of the drug, dosing informa-
tion, onset of action, what effects the
patient can expect, and some unwanted
side effects and how to treat them. Dos-
ing information should not be taken for
granted. One tablet twice a day may not
mean approximately every 12 hours to
the patient. This timeframe needs to be
made explicit. Also, the onset of action is
critical information. How long will it take
for the drug to have an effect, and what
is that effect? The patient will not be able
to feel lowered blood pressure, so it may
be wise for him to purchase a blood pres-
sure cuff and learn how to use it.
Finally, the patient should be alerted to
the two or three most common side
effects and how to minimize them. If
they will go away in time, the patient
should be told what to expect, whether
1 week, 2 weeks, or more. If side effects
do not go away or if they become both-
ersome, patients should be told to con-
tact their doctor or nurse case manager.
If the side effects can be reduced by cer-
tain actions (take medicine on a full
stomach), the patient should be told.
Rechecking for Concerns
After information has been provided,
new concerns that it may raise should
be addressed. These new questions can
be elicited by asking:
• What are your thoughts now about
managing your high blood pressure?
• Where does this leave you now in
managing your diabetes?
• Do you anticipate needing any help?
The overall process in motivational
interviewing is elicit–provide–elicit. First,
ask patients about themselves and their
initial concerns, then provide new
information, then recheck for new con-
cerns.
The Five Principles
Throughout the menu of strategies,
motivational interviewing uses ﬁve prin-
ciples or major skills to assess and create
motivation within the patient.
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• Roll with resistance
• Express empathy
• Avoid arguments
• Develop discrepancy
• Support self-efﬁcacy
The ﬁrst letter of each skill forms the
acronym READS to help you remember
the ﬁve principles. Let’s look at each
skill in more detail.
Roll with Resistance
Rolling with resistance is a matter of
ignoring any antagonistic elements in
the patient’s comments to focus on the
important underlying issues. In this
sense, rolling follows the central direc-
tion of the patient’s resistance. For
example, the patient says, “Look, I
haven’t had any real problems with my
smoking so far, so don’t worry about it.”
Instead of rejecting this comment by
saying, “If you continue smoking, I can
assure you that you will suffer some
major consequences,” the health care
provider can roll with the expressed
resistance by saying, “I hope your health
continues to stay that way. I would like
you to consider getting your lungs
checked because early stages of cancer
and lung disease may not have symp-
toms. That way, you can make a better
decision about whether you want to
keep smoking. I am worried that your
smoking is going to make your heart dis-
ease much worse in the future. However,
the decision to smoke or quit smoking is
yours.” Here the provider has not only
followed the direction set by the patient
but has extended the issue to create a
discrepancy. This response respects the
patient, creates some dissonance, and
allows the patient to hear information
without being chastised.
Express Empathy
Probably the most important skill in
motivational interviewing is expressing
empathy, because it is the primary skill
for demonstrating caring and under-
standing. The deﬁnition of empathy is
an objective identiﬁcation with the
affective state of another (not his or her
experience). We identify with the
patient’s affect (emotions), not with the
experience. We need not have high
blood pressure to identify the fear some
patients may have about a chronic ill-
ness. Empathy is objective; we do not
pass judgment on people’s feelings. We
attempt to understand them instead.
Empathy is shown throughout the moti-
vational interviewing process to identify
and to understand resistance and rea-
sons for unhealthy behaviors (for exam-
ple, noncompliance). It is nonjudgmen-
tal and creates a climate for change
through trust. Here is an example. One
of your patients smokes, and you want
him to quit. You ask him what he likes
about smoking, and he says it relaxes
him. Instead of creating defensiveness
by asking, “Can’t you think of some-
thing else to relax you?” you state
empathically, “It would be difﬁcult to
give up something that was relaxing.”
As a result, the patient is now in a much
better position to hear what you have to
say next. The patient sees you as an
advocate, not someone who is going to
beat him up about his smoking.
Advice giving, probing, and warning
may be necessary at times. For example,
it may be completely appropriate to
warn our patients or give advice, praise
their behavior, or point out unhealthy
habits. However, these responses are not
listening or empathic responses. If a
patient says, “I just can’t believe that my
cholesterol is that high!” responding
with, “Well, you need to take this
medicine as prescribed, regardless” does
not address her concern. While the
directive may be true, it does not pro-
mote the relationship.
A more appropriate response might be,
“You are having some difﬁculty accept-
ing that your cholesterol is high. What
concerns you the most?” This response
acknowledges the concern and explores
it further. This response may be fol-
lowed by, “I really do want you to get
your cholesterol under control by taking
this medicine as prescribed,” but only
after the patient has had her concern
addressed.
Avoid Arguments
Avoiding arguments is a powerful skill,
because we do not add to a person’s
resistance by forcing the patient to
defend the behavior we are trying to
change. By avoiding arguments, the
patient is more likely to see us as being
on her side. It is important to note that
motivational interviewing is confronta-
tional, however. It is acceptable to say,
“Mrs. Jones, I see that you have been
getting your reﬁlls about every 40 days
or so, but you receive only a 30-day sup-
ply. Can you tell me what happened?”
or “Mrs. Smith, I have noticed that you
get your reﬁlls like clockwork. I am
happy to see that you are taking your
medicine regularly to get your choles-
terol under control.” Both statements
confront the patient. Neither is argu-
mentative or judgmental.
Finally, it should be noted that feelings
that a patient may express (for example,
fear, concern) are not arguable. They are
real for the patient. Here is an example
of avoiding arguments about a patient’s
feelings. The patient says, “Taking
medicine for depression makes me feel
like I can’t even control my own prob-
lems.” The health care provider
responds, “You feel like you have to
depend on a medicine instead of your-
self to feel better. I hope you come to see
the medicine as something that will
allow you to do that. What are your
thoughts?” Notice that this response is
empathic, addresses the patient’s con-
cern, and asks for more input.
Develop Discrepancy
An extremely important skill in motiva-
tional interviewing is developing dis-
crepancy. This skill, more than any
other, is used to create dissonance and
can be achieved in two major ways.
First, ask the patient about the good
things and the less good things or the
pros and the cons about the changes
that are needed and then listen carefully
for discrepancies that allow for the cre-
ation of dissonance. Remember, disso-
nance is motivating. We develop dis-
crepancies by repeating back the pros
and the cons stated by the patient.
Second, we develop discrepancies by
asking the patient to discuss his or her
goals relative to the treatment. For
example, we say, “What do you want to
happen as a result of taking this
medicine for your blood pressure?”
Establishing this goal is critical. It not
only gives taking medicine a speciﬁc,
deﬁnable purpose, it also allows us to
ask patients about behaviors that do not
support the goal.
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For example, you notice that Mr. Jones
does not take his blood pressure
medicine daily as prescribed. You say,
“Mr. Jones, I have noticed that you skip
doses of your blood pressure medicine.
What are your thoughts on how this
might affect your goal of reducing your
risk of stroke or heart attack?” Notice
that the question is nonjudgmental and
allows the patient to draw his own con-
clusions. Nevertheless, asking the ques-
tion creates dissonance. It is important
to ask the patient to elaborate on dis-
crepancies between stated goals and
behaviors that contradict them. Change
is motivated by a perceived discrepancy
between present behavior and impor-
tant personal goals or values.
Case Study
Try to identify how the case manager’s com-
ments in the ﬁrst scenario close down the
dialogue by inadvertently encouraging
defensiveness in the patient. See if you can
ﬁgure out how the strategy and the princi-
ples of motivational interviewing could open
up the dialogue and could prompt the
patient to consider whether his behavior is
consistent with his values and goals.
Richard Stallings is a 57-year-old man who
smokes close to a pack of cigarettes each
day and who has high blood pressure.
While he is not overweight, he does not
exercise because “he gets winded easily.”
He has received a prescription drug to treat
his high blood pressure. His case manager
calls him to ﬁnd out how he is doing.
Case manager: Mr. Stallings. Hi, this is
Nancy. I’m calling back to see how you are
doing on your blood pressure medicine.
Mr. Stallings: Doing just ﬁne. Taking it every
day.
Case manager: Good. Are you taking your
blood pressure like we discussed?
Mr. Stallings: Now and then.
Case manager: Mr. Stallings, we talked
about this last time—what’s the point in hav-
ing a blood pressure cuff if you aren’t going
to measure your blood pressure?
Mr. Stallings: Don’t worry, I’m doing ﬁne. I
take the medicine every day.
Case manager: Yes, but you need to see if
the medicine is lowering your blood pres-
sure. Have you thought any more about
what we talked about last time concerning
your smoking?
Mr. Stallings: Nope. Not ready to quit.
Case manager: Mr. Stallings . . .
Mr. Stallings (interrupts): OK, stop right
there. I am not ready to quit smoking. I take
my blood pressure medicine every day.
Leave it alone.
Case manager: Well, all right. It’s your life.
Mr. Stallings: That’s right, it’s my life.
Case manager: OK, well, I really wish you
would think about quitting, that’s all. It’s not
good for you.
Mr. Stallings: (sarcastically) Whatever you
say.
Case manager: It’s gonna make your high
blood pressure worse, but it’s your decision.
Mr. Stallings: Right. OK, are we done?
Case manager: Yes. Keep taking your
medicine.
Mr. Stallings: Got it!
Discussion
Mr. Stallings is not ready to conform to this
case manager’s idea of what a “good
patient” should be. She is very parental in
her approach—she does not explore Mr.
Stallings resistance to taking his blood
pressure or to quitting smoking. She does
not praise his compliance with his blood
pressure medication regimen; she only
admonishes the patient for what he is not
doing. She uses “yes, but” communication
and tries to “ﬁx” or to save the patient
instead of demonstrating any patience or
understanding. The only thing she demon-
strates is her intolerance. What is sad is that
she thinks she is trying to help this patient,
when in reality she is alienating him
because she is so ﬁxated on pushing her
agenda (and her needs) instead of trying to
better understand this patient. Let’s look at
a dialogue that incorporates motivational
interviewing.
Case manager: Mr. Stallings. Hi, this is
Nancy. I’m calling back to see how you are
doing on your blood pressure medicine.
Mr. Stallings: Doing just ﬁne. Taking it every
day.
Case manager: Great, that’s terriﬁc! I wish
more of my patients were as conscientious
as you. How are you doing on taking your
blood pressure?
Mr. Stallings: Taking it now and then.
Case manager: How often is that?
Mr. Stallings: Oh, about once a week.
Case manager: And how is it doing?
Mr. Stallings: Last time I took it, it was 150
over 95.
Case manager: I see. That’s still a little high.
Have you thought about taking it more often
to see if it ﬂuctuates during the week?
Mr. Stallings: Not really.
Case manager: I would like you to consider
taking it more often so we can get a better
picture of how your blood pressure is doing
during the week. Would you consider doing
that?
Mr. Stallings: I don’t know. I’m not sure.
Case manager: What would make you
decide to take your blood pressure more
often?
Mr. Stallings: I’m not sure.
Case manager: Okay. Well, I would really
like for you to consider taking your blood
pressure every day so we can get a better
picture of how your medicine is working.
Mr. Stallings: I’ll think about it.
Case manager: Good, that’s all I can ask.
Have you thought any more about quitting
smoking?
Mr. Stallings: Not much.
Case manager: Smoking is your decision. I
am concerned that your smoking is going to
make your high blood pressure worse. You
told me last time we talked that your goal is
to get your blood pressure down to normal
to reduce your risk of stroke or heart attack.
Smoking increases that risk. What are your
thoughts on that?
Mr. Stallings: I don’t know. I’m just not ready
to quit. I’ll take the medicine, and I’ll think
about taking my blood pressure more often,
but I’m not ready to quit. It relaxes me.
Case manager: It would be very difﬁcult to
give up something that is relaxing. You have
been asked to make a lot of changes at one
time. If you get to the point where you think
you may want to quit, I would like to help. I
am worried about your smoking and heart
disease.
Mr. Stallings: I hear ya. I’ll let you know.
Case manager: Good. Well, keep up the
good work on taking your medicine. I will
check back on you soon. If you have any
questions, don’t hesitate to call.
Mr. Stallings: OK, goodbye.
Discussion
The case manager’s communication in this
scenario is patient and caring. How is car-
ing communicated? The case manager lis-
tens to Mr. Stallings without judging him or
his decisions. She lets him know that she
understands that he is being asked to do a
lot at once and that quitting is not easy. She
does confront the patient and create disso-
nance by bringing up an established goal
and the conﬂict between that goal and his
smoking. She lets him draw his own conclu-
sion and does not rush to a decision. She
realizes that change is a process that must
not be forced. As a result, the patient stays
open to change. While the patient has not
yet decided to quit smoking, the case man-
ager’s communication did not force him to
defend his behavior. This leaves the patient
open to change.
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Support Self-Efﬁcacy
A person’s belief in the possibility of
change is an important motivator. Sup-
porting self-efﬁcacy is a key skill. Health
care providers need to support, to
notice, and to encourage thoughts and
behaviors that indicate that the patient
not only wants to move toward the tar-
get behavior (such as taking a medicine
correctly) but also believes that she can
accomplish this change. It is important
to notice not only actual changes in
behavior but also contemplated changes
expressed in positive statements, such
as, “I have been thinking more about my
diet and lowering my cholesterol.” Let
the person know you have noticed. Say
something like, “That’s great. Tell me
more about what you have been think-
ing.” For the patient who gets her medi-
cations ﬁlled on time, you could say,
“Mrs. Smith, I think it’s terriﬁc that you
take your blood pressure medicine each
day the way we discussed. Keep it up!”
Remember, the patient, not the health
care provider, is responsible for choos-
ing and carrying out change. In addi-
tion, the provider’s own belief in the
patient’s ability to change becomes a
self-fulﬁlling prophecy. Let clients know
how you feel. Praise the behavior, not
the person, and continue to support
self-efﬁcacy throughout the process.
Here’s another example, “I really like it
that you have been seriously thinking
about lowering your cholesterol.” To
support self-efﬁcacy, you have to look
for opportunities to praise the change
efforts of your patients.
Readiness Rulers
Before summarizing motivational inter-
viewing, I would like to discuss readiness
rulers. They are used along with the ﬁve
principles to elicit change talk and are
especially useful when you encounter
resistance. They are a quick and an effec-
tive way for eliciting change talk from
your patients and for determining what
else needs to happen for the patient to
make a greater commitment to change.
Readiness rulers measure two concepts:
how important the change (e.g., taking
the medicine) is to the patient and how
conﬁdent the patient is that he or she can
do what is needed.
If you sense some ambivalence or resis-
tance on the part of your patients about
taking medicines, here is what you do.
Look at the patient and say, “On a scale
from 1 to 7, where 1 is not at all impor-
tant and 7 is extremely important, how
important is it for you to take your
______ (drug name) each day as we have
discussed?” Let’s say the patient
responds, “3.” Instead of asking, “Why 3,
not 7?” (this response would cause
patients to talk about why they cannot
take the medicine), say, “Why 3, not 1?”
This question elicits positive change talk;
it allows patients to state reasons why
they think taking the drug is important.
Reﬂect back on what you have heard,
then say, “Other patients have also stat-
ed these reasons . . . Do these ﬁt you?”
Again, let the patient respond, then say,
“What would have to happen for you to
say 4 or 5?” This asks the patient to
think about incremental change. We do
not want to ask about “7” because that
moves the patient too fast from the ini-
tial response. Even if the patient cannot
come up with something right now, ask
him to think about it and to let you
know. You are planting the seeds of dis-
sonance to create change.
Do the same thing with the readiness ruler
for conﬁdence about taking the drug. With
a few readiness ruler questions, you can
elicit a great deal of information.
We also have a method called the enve-
lope, which can be used to gather infor-
mation. Here is how it works. A patient
states, “I don’t know. I just don’t want
to quit smoking.” You say, “If I were to
hand you an envelope, what would the
message inside have to say for you to
think more about quitting?” Listen care-
fully to the patient’s answer. Usually she
will give you some hook to grab onto. In
addition, the exercise gets the patient
thinking. This method is very effective.
What happens if you use the envelope
query and the patient says, “There is
nothing in that envelope that would
make me want to quit smoking”?
Remember, the decision to use medicine,
to quit smoking, to start exercising, and
so forth, is the patient’s decision. If you
have given the patient objective infor-
mation about the behavior change and
you still meet with resistance, do not
argue. Simply say, “Mr. Jones, it sounds
like you are not ready to quit smoking. If
you decide to quit, let me know because
I have some things that can help. I do
want you to know that I am going to be
concerned about you. I do believe that
the smoking will make your heart dis-
ease worse, much sooner. It is your deci-
sion, though. I would recommend that
you get your lungs checked if you have
not done so to be sure you are okay.”
Even if the patient does not respond,
you have created dissonance.
Conclusion
In summary, motivational interviewing
is a process to address resistance and
ambivalence and to create dissonance.
We use evocative questions to elicit
change talk and to explore concerns and
the pros and the cons of change. We
encourage patients to elaborate on their
concerns and what they see as the bene-
ﬁts of the change. We elicit information
from the patient, then provide informa-
tion, then recheck for new concerns or
questions. We are directive insofar as we
keep the dialogue centered on exploring
how the goals and the values of the
patient relate to the treatment and the
patient’s behaviors.
We do all of this with empathy and
understanding to allow the patient to
feel safe and cared for in the relation-
ship. Skillful and caring case managers
may be able to assist their patients in
making dramatic improvements in their
health. It is hoped that this will be satis-
fying and rewarding for both patients
and case managers. ❑
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Abstract
There is evidence that patient-centred approaches to health care consultations may have better outcomes than traditional advice giving,
especially when lifestyle change is involved. Motivational interviewing (MI) is a patient-centred approach that is gathering increased
interest in health settings. It provides a way of working with patients who may not seem ready to make the behaviour changes that are
considered necessary by the health practitioner. The current paper provides an overview of MI, with particular reference to its application
to health problems.
© 2003 Elsevier Ireland Ltd. All rights reserved.
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1. Introduction
Many health problems are related to lifestyle factors such
as diet, exercise, and smoking. Changing such behaviours
is difficult, requiring time, considerable effort and motiva-
tion. Furthermore, ambivalence about behaviour change is a
common problem in health care consultations [1].
Traditionally, health practitioners have encouraged pa-
tients to make such changes through the provision of ad-
vice (i.e. information giving with direct persuasion) about
behaviour change [2]. While this works with some patients
[3], the evidence of the effectiveness of advice giving about
lifestyle change is not strong [4], with success rates of only
5–10% [5,6].
Furthermore, there is evidence that patients do not nec-
essarily want advice if it is provided in a style that is per-
ceived as being “told what to do” [7]. Additionally, advice
giving can develop into non-constructive disagreement, with
the health practitioner placing emphasis on the benefits of
change while undervaluing the personal costs, and the pa-
tient looking closely at the personal implications of change
and the immediate costs while minimising future benefits
[2]. The risk of such an encounter is that the patient be-
comes resistant to change or resistance, if already present,
is increased [8].
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In contrast, there is evidence that more patient-centred
approaches produce better outcomes [9–11]. The essential
features of these patient-centred approaches are that the pa-
tient does most of the talking, and that there is a ‘meet-
ing between experts’ [2], with the concept of reciprocity in
the consultation [12]. However, patient-centred counselling
has not been developed into a replicable method specifically
geared towards negotiating behaviour change in health con-
sultations [13].
Motivational interviewing (MI), which evolved from
Miller’s experience with the treatment of problem drinkers
[14], and was later elaborated by Miller and Rollnick [8], is
a patient-centred approach that has been gathering increased
interest in health settings [13]. Miller conceptualises mo-
tivation as a state of readiness for change, rather than a
personality trait [14]. As a state, motivation may fluctuate
over time or from one situation to another, and can be
influenced to change in a particular direction [15]. Thus,
lack of motivation (or resistance to change) is not seen as
inherent within the patient but rather something that is open
to change. The main focus of MI is facilitating behaviour
change by helping patients to explore and resolve their
ambivalence about the behaviour change [16].
This conceptualisation of motivation as a state which is
open to change is a sharp contrast to traditional approaches
which view motivation as an attribute of personality, and
denial or resistance as something to be dealt with through
aggressive confrontation [17–20]. In fact, Miller and Roll-
nick suggest that adopting an aggressive and/or confronta-
tional style (as in traditional approaches) is likely to produce
0738-3991/$ – see front matter © 2003 Elsevier Ireland Ltd. All rights reserved.
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responses from the patient (such as arguing) which may then
be interpreted by the practitioner as denial or resistance [8],
thus creating a “self-fulfilling prophecy” (p. 10).
While MI is patient-centred in that it focuses on the pa-
tients wants, thinks and feels, and it is the patient that does
most of the talking, MI differs from other patient-centred
approaches in that it is directive. That is, in MI there is the
clear goal of exploring the patient’s ambivalence in such
a way that the patient is more likely to choose to change
his or her behaviour in the desired direction, and systematic
strategies are used in order achieve this [8].
2. MI principles and techniques
Rollnick and Miller distinguish between the “spirit”
(p. 326) of MI and specific MI techniques [16]. Within the
spirit of MI, readiness to change is not seen as a patient
trait, but a “fluctuating product of interpersonal interaction”
(p. 327), and motivation to change is viewed as something
which is evoked in the patient, rather than imposed [16]. It
is the patient’s task (not the practitioner’s) to articulate and
resolve his or her own ambivalence. It is the practitioner’s
task to expect and recognise ambivalence, and to be di-
rective in helping the patient to examine and resolve the
ambivalence.
Miller and Rollnick suggest the following clinical prin-
ciples upon which MI is based: express empathy, develop
discrepancy, avoid argumentation, roll with resistance, and
support self-efficacy [8].
An empathic style is seen as fundamental to MI. The
underlying attitude must be one of acceptance, and belief
that ambivalence is normal. Within this empathic style it is
the practitioner’s task to create and amplify any discrepancy
between the patient’s present behaviour and important goals,
so that the patient presents the argument(s) for change.
Argumentation or direct persuasion is considered coun-
terproductive and is to be avoided, as it is likely to produce
defensiveness or resistance. Instead, the style is generally
quiet and facilitative, and the relationship is more like a part-
nership or companionship than an expert/recipient one.
Resistance, on the other hand, is seen as a signal to change
strategy. It is not opposed, but rather acknowledged and
explored, with the view to shifting the patient’s perceptions.
In supporting self-efficacy, the patient is seen as a valuable
resource in finding solutions to problems. The patient is
seen as responsible for choosing and carrying out personal
change, but at the same time he or she must have a belief in
his or her ability to change.
Rollnick and Miller describe specific, trainable tech-
niques, which are characteristic of a MI style [16]. Seeking
to understand the patient’s frame of reference, particularly
via reflective listening, and expressing acceptance and af-
firmation are techniques of MI borrowed from Rogers’
non-directive patient-centred therapy [21,22]. MI tech-
niques of evoking and selectively reinforcing the patient’s
own self-motivational statements, monitoring the patient’s
readiness to change, ensuring that resistance is not gen-
erated by jumping ahead of the patient, and affirming the
patient’s freedom of choice and self-determination, are
techniques which distinguish MI from other patient-centred
approaches [8].
The techniques of MI are applied within the context of
the ingredients for effective brief interventions, using the
acronym FRAMES [8,23], namely Feedback, Responsibil-
ity for change lies within the individual, Advice giving,
Menu of change options, Empathic style, and Self-efficacy
is enhanced. In MI, however, advice is not given without
the patient’s permission, and when given, is accompanied
by actively encouraging the patient to make his or her own
choices.
MI therefore is not being practised when the practitioner
argues that the patient has a problem and needs to change,
or offers direct advice, or prescribes solutions to the prob-
lem without the patient’s permission or without actively
encouraging the patient to make their his or her choices.
MI is also not being offered if the practitioner takes an
authoritative/expert stance, leaving the patient in a passive
role, or functions as a unidirectional information delivery
system. The MI practitioner should not do most of the talk-
ing, impose a diagnostic label, or behave in a punitive or
coercive manner towards the patient.
Within MI, there are a number of strategies that may be
used to help build and strengthen motivation for change.
They should be used flexibly to fit with each patient’s situa-
tion and state of change and are discussed in order according
to degree of readiness to change.
The patient is encouraged to talk about their typical day,
and thereby talk about their current behaviour in detail within
a non-pathological framework. For example, “can we spend
the next 5–10 min going through a typical day from begin-
ning to end. What happened, how did you feel, and where
did your diabetes fit in?”
The patient is encouraged to make decisions about where
to take the consultation by the use of agenda setting, used to
structure the initial discussion. This may take the form of an
agenda setting chart, with diagrams or words representing
key areas which may be useful to explore (e.g. smoking
exercise, alcohol, weight, etc.), and can be introduced as:
“These are some of the things which we could talk about.
What about you today? Would you like to talk about any of
these, or do you have something else (pointing to the blank
spaces) you would prefer to talk about?”
The personal dissonance strategy aims to create disso-
nance between the patients’ positive image of themselves as
a person on the one hand and a negative image of themselves
on the other. A suggested line of questioning is: “Give me
some words that describe your positive points as a person.
Now give me some words that describe you as you have
been with your drinking. How do these two fit together?”
The patient is invited to outline the positive things about
continuing as they are and then conversely the negative
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things. Some suggested questions are: “What are the good
things about smoking. Let’s flip the coin. Tell me about the
not so good things about smoking.”
The patient is encouraged to talk about specific individ-
ualised problems and concerns they have about their be-
haviour. A suggested line of questioning is: “What problems
are you experiencing because of your weight? What con-
cerns do you have about your weight? What else, what other
concerns, do you have?” This strategy ends with a summary
which highlights not only these problems and concerns, but
also the positive benefits of continuing as they are currently
(i.e. not changing).
Patients are encouraged to think about their current sat-
isfaction with life and what the future looks like both if
they continue as they are and if they change their behaviour.
Suggested questions are: “How have things changed for you
because of your high blood pressure? What will happen if
you continue as you are now? If things are to improve, what
needs to be different?”
The patient is invited to weigh up the pros and cons
of changing his or her behaviour. Suggested questions are:
“What would be some of the costs of changing? What would
be the benefits of changing?”
The patient is encouraged to construct decisional bal-
ances, which involves generating the pros and cons of change
options generated as a result of earlier questioning. These
may be written down in the form of balance sheets and given
to the patient, and should include: reasons to continue as
before and reasons to change; short- and long-term positive
and negative consequences of changing or staying the same;
positive and negative consequences for self and for others,
and self-approval rating for self and from others. In each of
these balances the factors which support change are to be
emphasised over those that may maintain the status quo.
When the patient indicates some desire to make a decision
to change, the practitioner can help with decision making
by the following: “Where does that leave you now?”, which
can then be followed up by questions which elicit, rather
than impose, possible solutions/targets for behaviour change,
such as: “There is no one solution to this problem, but many.
I can tell you about what has worked for others, but in the
end, you will be the best guide of what is going to work for
you. Shall we look at some of the options together? What
might work for you?”
These strategies should not be used in isolation. Rather,
they should be used within the context of the ingredients for
effective brief intervention and alongside the MI techniques
mentioned earlier, with particular reference to the patient’s
readiness for change.
3. Theoretical basis
MI was not based on any specific theory. Rather, Miller
drew from social psychology [14], applying processes
such as attribution [24], cognitive dissonance [25], and
self-efficacy [26,27], and empathic processes from the
methods of Rogers [21,22].
Despite the lack of empirical data, considerable interest
in MI was shown, mostly within the addictions field, after
Miller’s initial article [14]. Because of this interest, Miller
began to research the processes and outcomes of MI, and as
result, his initial model was elaborated and further developed
by Miller and Rollnick [8,16].
A major development was to link MI to the transtheoreti-
cal model of change [28,29], with the transtheoretical model
providing a framework for understanding the change process
itself, and MI providing a means of facilitating this change
process [30]. Within this framework readiness for change
is seen as the extent to which the patient has contemplated
the need for change, having considered the pros and cons
of change. Lack of motivation can therefore be viewed as a
“perceptual” (p. 115) problem, in which the patient sees no
(or insufficient) need to change, whereas others (e.g. health
professionals) do perceive a problem and a need for change
[14].
MI aims to alter how the patient sees, feels about, and
means to respond to the problematic behaviour. Ambivalence
is seen as the key to this. It is resolved by focusing on the
patient’s wants, expectations, beliefs, fears and hopes, with
particular emphasis on the inconsistencies between these and
the problematic behaviour.
The concept of readiness to change might help explain
why simple advice giving is limited in effectiveness [4], as
the patient may not be ready to change, and so any ad-
vice given is unlikely to be acted upon. Concrete behaviour
change should not be the only goal. Instead, the practitioner
might aim to increase the patient’s readiness for change
through the use of MI. The concept of readiness to change
also provides the possibility of tailoring interventions to suit
the degree of readiness for change of the patient, which
should ensure greater parity between the agendas of the prac-
titioner and the patient, and therefore minimise resistance
and improve the effectiveness of intervention.
The principles of MI have been related to the principles
of cognitive dissonance [31]. That is, MI’s emphasis on
resolving ambivalence by focusing on inconsistencies is
creating dissonance. The techniques of MI (e.g. reflections,
summarising) function to arouse cognitive dissonance. MI,
then, is seen as producing a dissonant state (by focusing
on ambivalence or inconsistencies) and then controlling the
direction chosen for the dissonance resolution through the
skilful use of MI techniques.
MI appears consistent with a number of models of health
behaviour, such as Locus of Control [32], Theory of Rea-
soned Action [33], Social Cognitive Theory [34], Decisional
Balance [35], Health Belief Model (HBM) [36], Health Ac-
tion Process Model [37], Self-determination Theory [38] and
Self-regulatory Model [39]. All of these models, despite dif-
ferences in their terms and emphasis, share three common
constructs [40], which are the focus of MI. These are the
patient’s expectations about the consequences of engaging
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in the behaviour, the influence of the patient’s perception
of, or beliefs about, personal control over the behaviour, and
the social context of the behaviour.
The Health Belief Model, for example, suggests that
health behaviour change depends on the simultaneous oc-
currence of: first, the belief that one is susceptible to a
health threat or the medical or social consequences of the
health threat; second, sufficient health concern to make the
issues relevant; and third, the belief that a particular health
recommendation would be beneficial in reducing the per-
ceived threat at an acceptable cost [41]. MI appears to be a
process by which the preceding three factors for health be-
haviour change, as postulated by the HBM, can be created
or enhanced in the patient by the health practitioner.
Additionally, it has been suggested that the HBM could
be improved by drawing upon Bandura’s self-efficacy the-
ory [26,42]. According to this theory, the degree to which
an individual develops the expectancy that they will be able
to perform desired behaviours (i.e. self-efficacy) is an im-
portant factor in behaviour change [26].
Self-efficacy has been used to predict health behaviours
such as smoking cessation, weight reduction, exercise,
and cardiac rehabilitation [43]. As mentioned earlier,
self-efficacy is an important aspect to MI, with MI attempt-
ing to increase the patient’s belief in his or her ability to
change his or her behaviour (self-efficacy).
4. Specific interventions
The principles of MI have been incorporated into a brief
intervention (called the Drinker’s Check-up or DCU) for
problem drinkers [44,45]. This is an assessment based strat-
egy, involving a comprehensive assessment of the patient’s
drinking and related behaviours, followed by systematic
feedback to the patient of findings using a MI communica-
tion style.
Motivational Enhancement Therapy or MET [46] is a four
session adaptation of the Drinker’s Check-up, which was
developed as one of three interventions for alcohol abuse
and dependence evaluated in Project MATCH [47]. It aims
to motivate patients to make changes rather than provide
detailed step-by-step advice about behaviour change, using
a MI style.
Brief motivational interviewing (BMI) [1] consists of a set
(or menu) of techniques, which follow the spirit and practice
of motivational interviewing. It was designed for use in a
single 40 min session in primary health care settings, with
non-help-seeking problem drinkers.
Studies are evaluating whether the spirit of MI can be cap-
tured in even briefer (e.g. 5–10 min) encounters [48]. Roll-
nick et al. present a method focused on behaviour change in
health settings, designed for brief consultations [49]. This
comprises readily teachable brief strategies that follow the
main goals of MI, but are more suited to health care prac-
titioners, who have less time to acquire listening skills re-
quired for MI and who often have limited time with patients.
While Rollnick et al. caution that the method they present
should not be equated with MI [49], the method draws
heavily from MI and the transtheoretical model of change.
MI has been provided by telephone consultation [50] and
in a group format [51–53]. However, a group format, while
more efficient, may compromise the effectiveness of MI
as the intervention will not be able to be targeted at each
individual’s specific need as it is likely that different mem-
bers of the group will be at different stages of change, at
different times during the group. Studies are also currently
underway exploring other formats for MI, such as comput-
erised or paper self-help manuals.
MI in its various forms (MI style, DCU, MET, and BMI)
has been applied both as a stand-alone intervention and as
a preparation for treatment, and in a range of settings. This
includes health settings such as the general hospital ward
[54], emergency department [55], and general medical prac-
tice [48,56,57].
5. Efficacy of MI
Many studies reporting on the outcome of MI do not
provide adequate information on what the intervention in-
volved, or how it may have been modified for the particular
target problem or client population, which makes it difficult
to draw conclusions or make comparisons. However, there
have been studies, particularly within the alcohol abuse field,
which have utilised a specific MI intervention, such as the
DCU or MET, and which have made attempts to ensure that
the therapists adhere to the intervention protocol by evalu-
ating the therapist’s behaviour as well as client outcome.
The greatest support for MI comes from the treatment of
problem drinkers, particularly Project MATCH [47]. This
study represented the first test of MI as a stand-alone treat-
ment for alcohol problems in a clinical population. In this
comprehensive randomised controlled trial (RCT), 1726
alcohol-dependent participants were randomly assigned to
one of three outpatient treatments: MET, Twelve Step Fa-
cilitation, or Cognitive Behavioural Coping Skills Training.
On all measures (self-report, collateral, and biochemistry)
MET was found to be more effective than the two longer
(12 sessions) outpatient treatments.
Similarly, Sellman et al. compared MET with a similar
brief intervention, Person Centred Therapy (PCT), and found
MET to be more effective [58]. In this study, 122 participants
with mild to moderate alcohol dependence were randomly
assigned to one of three groups: MET, PCT, or a control
group who received no further counselling. The MET group
showed significantly less heavy drinking at 6 weeks and 6
months follow-up than the other two groups.
Furthermore, in a re-analysis of the Project MATCH data,
MET was found to be most effective for those individuals
with a higher level of anger [59]. Additionally, Heather et al.,
in a study of 123 heavy drinkers randomly assigned to one of
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three groups: brief MI, skills-based brief counselling, or no
intervention, found that MI was most effective for individ-
uals who were least motivated, as measured by self-report
and collateral measures of alcohol consumption [54]. These
findings, then, provide evidence that MET may be most ef-
fective for patients who may be perceived as most resistant
to change.
In a slightly different study, Handmaker et al. [57] eval-
uated the efficacy of MI as an intervention for pregnant
drinkers in order to reduce the risk of fetal alcohol effects.
In this pilot study, 42 pregnant drinkers were randomly
assigned to receive written information about the effects
of drinking during pregnancy (control group) or a 1 h MI
session. Results indicate that women who reported the
highest blood alcohol concentration (BAC) levels in early
pregnancy showed significantly greater reduction in their
estimated BAC later in pregnancy if assigned to the MI
group rather than the control group.
Pilot studies suggest that MI can be successfully used with
other substance abuse problems, such as heroin [60–62], co-
caine [63] and marijuana [64], as well as with substance
abusers with dual diagnoses [65]. However, the conclusions
that can be drawn about the generalisability of MI from al-
cohol abuse to other substance abuse problems, or substance
abusers with dual diagnoses, are limited as these studies
are either single case reports, have combined MI with some
other intervention, or the exact nature of the MI intervention
utilised is unclear.
It has been suggested that MI could usefully be applied
to health problems [66] and health promotion [67]. Further-
more, it has been suggested that MI might be particularly
useful in the management of chronic illness [68] such as pain
management [69], cardiac rehabilitation [70], diabetes [71],
weight loss [72], and HIV risk behaviour [73,74]. However,
there are few studies investigating the efficacy of MI applied
to health problems.
The greatest support for the efficacy of MI applied to
health behaviour change is from smoking cessation studies.
For example, Stotts et al. examined the efficacy of MI as
a late pregnancy smoking cessation intervention for resis-
tant pregnant smokers [75]. In this study, 269 women who
were still smoking at 28 weeks gestation were randomised
to either an experimental group who received MI adapted
from MET, or to a control group who received no further
intervention apart from usual pregnancy care. MI was con-
ducted in two sessions over the telephone, with a person-
alised feedback letter mailed following the first call. The
results suggest that 43% of the women who received the
full MI intervention (n = 175) were not smoking (i.e. no
cotinine in urine samples) at the 34th week of gestation
compared to 34% of the control group, and that 6 weeks
post-partum 27.1% of the full intervention group reported
to be either abstinent or light smokers, compared to only
14.6% of the control group. Similar support for the efficacy
of MI in maternal smoking cessation is provided by Vala-
nis et al. [76] using a quasi-experimental prospective cohort
design, with regression analysis showing statistically signif-
icant quit rates during pregnancy and smoking abstinence
6–12 months post-partum for the intervention women, al-
though they relied entirely on self-reported smoking.
In another RCT (n = 291), Emmons et al. [77] evaluated
the efficacy of MI (based on MET) for smoking parents of
young children (under 3 years of age) in reducing house-
hold passive smoke exposure. Participants in the MI con-
dition received one MI session in their home, followed by
four follow-up telephone calls, whereas participants in the
self-help group received information on quitting smoking in
the mail. The results again lend support to the efficacy of
MI, with 6-month nicotine levels significantly lower in the
MI households compared to the self-help households.
There has also been increasing interest in the use of MI in
the treatment of anorexia nervosa and bulimia nervosa, with
the recognition that ambivalence about treatment is common
with eating disorders [77–82]. However, there are few stud-
ies evaluating the efficacy of MI applied to the treatment of
eating disorders.
Treasure et al. [83] in an RCT, in which 125 female pa-
tients with bulimia nervosa received four sessions of either
MET or cognitive behavioural therapy (CBT), found MET
to be as effective in the short-term (i.e. over 4 weeks) as
CBT in reducing symptoms of binge eating, vomiting and
laxative abuse. However, because patients were randomised
to treatment blind of stage of change, some of the power of
MET may have been lost, as MET might be expected to be
particularly effective with patients in the precontemplation
and comtemplation stages of change.
Further, preliminary evidence that MET could be a
useful treatment for eating disorders comes from a pilot
study in which 19 patients with eating disorders received a
group form of MET [84], with results suggesting that the
participants’ motivation to change increased following the
intervention, along with decreases in depressive symptoma-
tology and an increase in self-esteem. The results of these
two studies suggest that further research into MET applied
to the treatment of eating disorders in warranted.
MI has been receiving increased interest as a means of
promoting treatment adherence in diabetes [48,71,85]. Smith
et al. [72], in a pilot study, investigated whether the addition
of three motivational interviewing sessions (conducted by
psychologists) to a standard (16 weeks) behavioural weight
reduction program for 22 obese women with Type 2 diabetes
would increase adherence to treatment and improve glucose
control. The MI group demonstrated better adherence to the
program, as evidenced by higher attendance, more diaries
turned in, and more frequent monitoring of their blood glu-
cose levels. Furthermore, both groups reduced their average
weight to a significant degree, but the MI group also achieved
better glucose control. While the relatively short follow-up
(4 months) and small sample size limit the conclusions
that can be drawn, the results suggest that MI may con-
tribute to increased efficacy of behavioural weight control
programs.
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Stott et al. [71] in an RCT with 200 patients with Type
2 diabetes with general practice doctors and nurses being
trained in MI report that the general practice doctors and
nurses were keen to learn new techniques, and found the
MI techniques acceptable and useful, particularly the agenda
setting chart, with over 70% of the health care practitioners
reporting to frequently use it. However, patient outcome data
were not reported.
Another area of treatment adherence in which it has been
suggested that MI may be useful is psychiatric patient com-
pliance with treatment [86], given that one of the main barri-
ers to effective care of the long-term mentally ill is the poor
compliance of many patients with recommended treatment,
including compliance with prescribed medication regimes
[87]. However, again, there are few empirical studies inves-
tigating this application of MI.
Swanson et al. in a study that randomised 121 psychiatric
inpatients to either standard treatment (ST), which included
pharmacotherapy, individual and group psychotherapy, ac-
tivities therapy, milieu therapy and discharge planning, or
to ST plus MI, found that significantly more patients who
received ST plus MI attended their first outpatient appoint-
ment [87]. In another pilot study, Hayward et al. compared
MI focused on medication self-management, for 21 patients
with non-organic psychotic illnesses, to a control group, and
found that the MI group showed positive changes in their at-
titude towards medication and insight into their illness, but
the difference between the two groups was not statistically
significant [87].
There are isolated studies which apply MI to other health
behaviour, such as physical activity and dietary change. An
RCT in which patients with hypertension were randomised
to one of three groups: control, or low level or high level
(MI) counselling conducted by nurse counsellors in a gen-
eral practice setting, found that the MI group produced sig-
nificant decreases in both weight and blood pressure over
18 weeks [88].
In another RCT, Harland et al. [89] examined the effec-
tiveness of MI in promoting physical activity among adults
aged 40–64 years attending a general medical practice. Par-
ticipants (n = 523) were randomised to one of four groups
or a control group: brief (one session) or intensive (six ses-
sions over 12 weeks) MI, with or without financial incentive
(vouchers for free access to leisure facilities). Although the
results rely on self-report (exercise in the previous 4 weeks)
they indicate that the intensive MI intervention (six sessions
plus vouchers) was the most effective for promoting the
adoption of exercise at 12 weeks, but that no intervention
promoted long-term (12 months) adherence to exercise.
A form of BMI (three telephone counselling calls) was
used to promote fruit and vegetable intake among African
American church goers after they received an educational
package focused on the 5 A Day message [90]. Participants
receiving the MI calls had the largest increase in fruit and
vegetable intake, with group× time effects significantly dif-
ferent from group 1 who received the educational package
alone or group 2 who received the educational pack, plus one
telephone call to cue the use of the material presented. How-
ever, in addition to the study relying solely on self-reported
fruit and vegetable intake, it is unclear whether the MI per
se resulted in the dietary changes, or whether the effect was
simply due to the increased number of telephone calls.
One of the main issues when considering MI for use in
health settings is the amount of training that might be re-
quired for health professionals to use MI and whether MI can
fit within the demands of busy health settings. As mentioned
earlier, Rollnick et al. [49] have begun to address this issue
through the development of readily teachable brief strate-
gies that follow the main goals of MI, which are suited to
health care practitioners, who may have less time to acquire
the skills required for MI and who often have limited time
with patients. Additionally, there are reports of MI applied
to health settings, which suggest that it may be feasible and
relevant to health behaviour change [91–94], and that the
techniques may be considered acceptable by health practi-
tioners [71]. However, it is unclear how much training is
required for competent use of MI. It seems that developing
the attitude and knowledge necessary may not be too time
consuming, but that the skills required for effective MI may
take longer to develop, depending on the type of MI to be
practised (e.g. BMI or MET) [92,95].
6. Conclusions
MI appears to hold substantial promise for health be-
haviour change. It is consistent with the call (from pa-
tients, and health researchers and practitioners) for more
patient-centred approaches in health care in which the
health practitioner–patient relationship is seen as a partner-
ship, rather than an expert–recipient one. MI also provides
health practitioners with a means of tailoring their interven-
tions to suit the patient’s degree of readiness for change. In
particular, it provides practitioners with an effective means
of working with patients who are ambivalent about, or not
ready for, change.
Despite the promise which MI holds for promoting heath
behaviour change, there are few controlled studies evaluat-
ing the efficacy of MI with health problems, with clinical
innovation remaining ahead of scientific evaluation [13].
Continued outcome research into MI applied to health
behaviour change is required.
Additionally, it remains unclear as to how MI has its effect
and what elements of MI are essential [96]. Further research
needs to establish the process of MI and its key components.
For example, little is known about what is the best way
to structure sessions, or which are the optimal methods for
responding to resistance.
It is also unclear which patients would benefit most from
MI and which specific motivational intervention (i.e. DCU,
MET, BMI or even briefer motivational consultations) would
be of most benefit for which patients. For example, it is
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unclear how a patient’s level of motivation and other char-
acteristics may influence the effectiveness of MI.
The challenge is to develop MI interventions that are use-
able in health consultations (which tend to be brief), are
teachable, and are sufficiently specific to enable proper eval-
uation [4]. With such interventions, patients are likely to
feel listened to and understood by their health practitioner.
Health practitioners, on the other hand, are likely to gain
a greater sense of achievement from recognising change in
patients’ readiness as important progress, rather than see-
ing concrete behaviour change as the only goal. Thus, MI
interventions are likely to contribute to a greater sense of
satisfaction for patients and practitioners, as well as helping
promote health behaviour change.
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At one time or another all of us have probably tried to persuade someone to do 
something. And, most likely, we have all met with varying degrees of success. For 
persuasive communication to be effective, certain principles must be followed or the 
attempt can backfire and cause more resistance to engaging in the target behavior. Much 
research has been done on persuasive communication. In the next two articles in this 
series, persuasive strategies will be discussed and illustrated to help improve 
pharmacists’ “powers of persuasion.” 
 
What is Persuasive Communication? 
 
Communication that is persuasive is directed toward changing or altering another 
person’s beliefs, attitudes, and, ultimately, behaviors. Generally speaking, attitudes are 
composed of three components:  
(1)    cognitive—the manner in which the attitude object is perceived,  
(2)    affective—feelings of like or dislike toward the object, and  
(3)    behavioral—action tendencies toward the attitude object.1 The cognitive component 
is the person’s belief about the attitude object. The idea is that beliefs affect attitudes, 
which affect behaviors. Change a person’s beliefs or attitudes, and you change their 
behaviors. However, while there are relationships between beliefs, attitudes and 
behaviors, these relationships are not always straightforward. A few examples will help 
clarify this. 
 
Example 1 
 
Mrs. Jones is 80 years old. She knows that many people take medicines and that they are 
helped by them. However, she doesn’t like to put any kind of medicine in her body. She 
believes that medicine can help other people, but she does not like (affective component) 
medicines; therefore, she won’t take them.  
 
Example 2 
 
Mr. Smith thinks that Mercedes makes a great car (belief), and he really likes the way 
they look and perform (affective component); however, he isn’t going to buy one because 
he can’t afford it.  
 
 
Example 3 
 
Mr. Taylor, age 20, believes that medicines can really help people, has taken medicine for 
illnesses, but because of his busy schedule he has compliance problems.  
 
Each of the people mentioned above is positive in his beliefs about medicine, but their 
attitudes and behaviors are different. Positive beliefs don’t necessarily produce positive 
behaviors and resulting action. For Mr. Smith, an intervening variable (money) precluded 
him from purchasing (the behavior) a Mercedes, even though he believes they are good 
cars and he likes them. Therefore, different strategies are needed to change behavior. One 
size does not fit all. 
 
While influence and persuasion are often used interchangeably, there is a distinction 
between the two. When someone is influenced by another, there is often a change in the 
person’s beliefs, attitudes or behavior. This sounds a lot like persuasion. However, we 
can influence people without consciously attempting to do so.
2 
For example, a parent 
could positively (or negatively) influence the behavior of his or her child by the way the 
parent interacts with others. The parent may not be consciously aware that the child is 
watching and learning, but the influence is there nonetheless. Persuasion, on the other 
hand, is a conscious, volitional attempt to influence someone else. 
 
Influences on Persuasive Messages 
 
Many factors determine the effectiveness of a persuasive message. Four major factors 
are: 1) the message source, 2) believability of the message, 3) environmental factors, and 
4) comprehension and retention of the message. It should be noted that these factors 
overlap a great deal.  
 
Message Source 
 
For a persuasive message to have its intended impact, the message source (the 
pharmacist) must be seen as credible. Credibility involves recognized expertise, a desire 
to do what is right, a desire to serve the patient, and to be warm and fair. Therefore, 
expertise is not enough. The patient must perceive that the pharmacist’s expert power is 
being used not to manipulate or control, but to do what is best for the patient. Of course, 
this involves finding out from the patient’s perspective what he/she thinks is best, too. It 
is important to note that expertise is not simply ascribed to a pharmacist because of a 
societal role. It must be demonstrated and done so in a way that supports the patient. 
Expertise that “puts the patient in his place” is not generally persuasive. A few examples 
will illustrate this point. Mrs. Jones enters the pharmacy to have her antihypertensive 
medication refilled.  
 
Example 1 
 
Pharmacist: Hello, Mrs. Jones, how are you today? 
Mrs. Jones: Just fine. Couldn’t be better. 
Pharmacist: Great! I’ll go refill your prescription. 
Pharmacist: (a few moments later) Mrs. Jones, I noticed that your blood pressure 
medicine should have run out several weeks ago. Are you taking your medicine the way 
you’re supposed to take it? 
Mrs. Jones: Oh sure, every time I get a headache. 
Pharmacist: That doesn’t make any sense. How often is that? 
Mrs. Jones: Oh, maybe once a week. 
Pharmacist: Mrs. Jones, that’s not how you’re supposed to take it at all. Where did you 
get such an idea? Didn’t you read the label instructions? It says take it every day.  
Mrs. Jones: What’s your problem? Just give me my medicine! (Grabs the bag.) Put it on 
my account (she exits the pharmacy). 
Pharmacist: But you’re not taking it the right way. 
 
The pharmacist is in no position to have influence here because of the approach taken. He 
will probably have to call Mrs. Jones later and get this situation straightened out. Rather 
than taking a calm approach, he berates Mrs. Jones. She is unwilling to listen and leaves 
without finding out what the problem is. Let’s see an alternative approach. 
 
Example 2 
 
Pharmacist: Hello, Mrs. Jones, how are you today? 
Mrs. Jones: Just fine. Couldn’t be better. 
Pharmacist: Great! I’ll go refill your prescription. 
Pharmacist: (a few moments later) Mrs. Jones,  
I noticed that your blood pressure medicine should have run out several weeks ago. Can 
you tell me how you’re taking it? 
Mrs. Jones: Oh sure, every time I get a headache. 
Pharmacist (calmly): So you take it when you get a headache because you believe that 
you have headaches when your blood pressure is up? 
Mrs. Jones: Exactly! 
Pharmacist: That makes sense. However, we should have done a better job of explaining 
to you how to take this medicine. 
Mrs. Jones: What do you mean? 
Pharmacist: While it is certainly true that people with high blood pressure sometimes 
get headaches, it is usually stress, not your high blood pressure that is causing them. It is 
really very difficult, if not impossible, to tell when your blood pressure is up without 
measuring it. The medicine should be taken once a day for you to get the most benefit 
from it.  
Mrs. Jones: Once a day? I didn’t realize that.  
Pharmacist: Well, let’s have you start taking it once a day from now on, even if you 
don’t have a headache. I want to make sure your blood pressure stays controlled. 
Mrs. Jones: So do I. I never knew. 
Pharmacist: I know. Again, I sure can understand the confusion. 
 
This pharmacist took responsibility and because he did not blame or berate the patient, 
she was willing to listen. She was able to be influenced because she felt understood. The 
pharmacist’s communication was directed toward solving a problem, not ascribing blame. 
Even though he knew the label directions were not being followed, he felt no need to 
point this out and risk her embarrassment. 
 
Believability of the Message 
 
The believability of the message is very much related to the credibility of the message 
source. Also, does the message fit with the patient’s belief system? Some patients may 
find it very hard to believe (and understand) different concepts that pharmacists take for 
granted. For example, potency is often a difficult concept for patients. A patient may 
have been taking a tablet for pain relief. This tablet was taken twice a day and was quite 
large, but the patient got no relief despite the fact that he was taking it properly. The 
physician prescribes another medication that is more potent, is taken less often and is 
much smaller in size. It may be difficult for some patients to accept that this smaller 
tablet is going to help if the larger one taken twice as often did not help. As a result, the 
patient may not even try the new medicine unless he is persuaded by the pharmacist. To 
be persuasive, the pharmacist will first have to acknowledge and objectively reflect back 
an accurate understanding of the patient’s beliefs. Then, factual information about 
potency will have to be given that makes sense to the patient. Analogies may need to be 
used to allow the patient to understand the concept of potency. One such analogy that 
might make sense to a patient is that of black pepper versus cayenne pepper. The idea 
being that smaller amounts of cayenne pepper are more potent in their effects in the 
mouth than larger amounts 
of black pepper.  
Gender Differences 
There is a great deal of literature on male and female 
differences in persuasive communication. While there is 
literature to support the idea that men and women use 
different persuasive strategies, the literature is inconsistent in 
trying to identify exactly what those strategies are or whether 
they result from gender differences or differences in roles. 
For example, some literature reports that women use a more 
democratic and participative leadership style to have 
influence while men tend to be more autocratic and 
directive.
3
 However, other research attributes these 
differences more to role in the organization than to gender 
differences. That is, as women move higher in the 
organization, their communication tends to be more 
autocratic and directive. 
 
Gilligan found that “men employ a ‘justice’ orientation in 
reasoning about moral choices by emphasizing the 
importance of rights, respect, and impartiality, while women 
employ a ‘care’ orientation in their moral reasoning by 
emphasizing mutual participation, cooperation, and attention 
to individuals’ feelings and needs.”
4
 Men are most likely to 
influence by focusing on rights and responsibilities, while 
women are likely to influence emphasizing issues relating to 
Another issue patients may 
have difficulty grasping is 
that many drugs have 
multiple indications at 
various dosing schedules. 
For example, diazepam can 
be used for anxiety, 
epilepsy, and muscle 
relaxation. It is often very 
difficult for patients to 
understand how this can 
occur. Therefore, when a patient asks, “What’s this medicine for?” the best answer is, 
“Could you tell me what caused you to see the doctor?” rather than, “It’s for numerous 
things, like anxiety, epilepsy and muscle relaxation.”  
 
Environmental Factors 
 
In a pharmacy, environmental factors are related to issues of privacy, noises, 
interruptions, and distractions that can affect whether a message is heard and understood. 
It is especially important when attempting to deliver a persuasive message that it be done 
in an environment free from (as much as possible) noises, distractions and interruptions. 
Each time these events occur, the likelihood of message comprehension and retention 
decreases. Therefore, the pharmacist should do as much as possible to create private areas 
to talk to patients. If this is not possible, then attempts to pull patients away from sources 
of noises, interruptions, and distractions should be made. 
 
Comprehension and Retention 
 
Obviously, for a persuasive message to be effective it must be understood and recalled. 
Another key factor that affects comprehension of the message is the language level of the 
message. Is the message conveyed in language that is understood by the receiver of the 
message? Too often in health care, providers use jargon that is common to medicine and 
pharmacy, but not to patients. For example, a 67-year-old woman came into a pharmacy 
and asked a pharmacist how her methyldopa lowered her blood pressure. She was told 
that it was a dopa decarboxylase inhibitor. The woman looked confused, but said, “Oh, 
OK,” and then left the pharmacy. She most likely found the message believable. 
However, she may not have understood a word the pharmacist said. It is vitally important 
to use language the patient can understand. It is better to say “high blood pressure” than 
“hypertension.” 
 
Another problem regarding comprehension of the message has to do with the receiver 
interpreting the meaning of the message. Sometimes, a pharmacist’s communication with 
patients seems clear to him or her, but is open to interpretation by the patient. For 
example, when the pharmacist tells a patient to “take one tablet twice a day” he or she 
means that the patient should take a tablet approximately every 12 hours. But, if this 
meaning is not made explicit, problems may occur. Similarly, how are the directions, 
feelings and caring.
5
 These influence foci are not right or 
wrong, they are simply the way many men and women 
attempt to influence others. The key point is that these 
strategies do work, but only for individuals who orient in the 
same way. Both men and women need to be flexible enough 
to realize that “appeals to justice” also work for many women 
and “appeals to emotions and caring” also work for many 
men. 
 
A flexible set of influence strategies is needed.  
 
“Take one tablet after meals and at bedtime” interpreted? It largely depends on how many 
meals you eat a day. A patient with diabetes may eat 6–7 mini-meals each day and take 
7–8 tablets. If this response is not correct, then pharmacists need to be much more 
explicit in their directions. 
 
Finally, the only way to know if a message is understood and can be recalled is for the 
pharmacist to ask patients to repeat back their understanding of the message.  
 
1. Engel JF, Kollat DT, Blackwell RD. Consumer Behavior, Dryduen Press, 2nd ed, Hinsdale, IL, 1973.  
2. McCroskey JC, Richmond VP, Stewart RA. One on One: The Foundations of Interpersonal Communication, Prentice-
Hall, Englewood Cliffs, NJ, 1986.  
3. Baker MA. Gender and verbal communication in professional settings: A review of research. Management 
Communication Quarterly. 1991;5:36-63.  
4. Gilligan C and Attanucci J. Two moral orientations: Gender differences and similarities. Merrill-Palmer Quarterly. 
1988;34:223-237.  
5. Kline SL. Gender issues in persuasive messages practices. Women’s Studies in Communication. 1998;4:68-88.  
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The pharmacist may use direct or indirect persuasive strategies when trying to 
influence a patient’s behavior.  
The previous article on persuasive communication noted that persuasion was a conscious 
effort to influence the belief, attitudes, and ultimately, the behaviors of another person. It 
also covered factors affecting persuasive communication, such as message source and 
believability of the message. In this article, direct and indirect persuasive strategies will 
be discussed. 
 
Direct Strategies 
 
Consciousness-raising: One direct strategy is consciousness-raising. With respect to the 
pharmacist-patient relationship, this involves (1) providing information about the 
patient’s illness and treatment in a straightforward, objective way or (2) helping the 
patient become more aware of healthy or unhealthy behaviors (or beliefs or attitudes) in 
which they are currently engaged. In either case, exerting influence is the objective. 
While providing information seems straightforward, the way in which pharmacists 
communicate information may either result in clarity or cause confusion. Therefore, the 
language used must be clear and easy to understand. Helping the patient become more 
aware of healthy or unhealthy behaviors is less straightforward.  
 
Example 
Pharmacist: Mr. Johnson, I am concerned about the fact that you continue to smoke 
even though you have asthma. 
Patient: I feel O.K.  
Pharmacist: That’s great. I hope you do. Over time, cigarette smoking will continue to 
compromise your lungs, and your breathing will become more and more difficult. I 
would hate for you to have to go to the emergency room or be hospitalized. Also, 
smoking puts you more at risk for other illnesses. 
Patient: I just didn’t know that asthma was that serious. 
Pharmacist: It can be if it’s not controlled, and it’s almost impossible to control if you 
continue to smoke. That concerns me a great deal. 
Patient: I need to give this some serious thought.  
Pharmacist: I know of several products and smoking cessation programs that are 
helpful. Give me a call when you’re ready. 
This pharmacist confronted this patient about his smoking and used consciousness-raising 
to address the problem directly. The pharmacist was able to have influence on this 
patient’s beliefs because he was objective and demonstrated caring. 
 
Messages that Arouse Fear: Research supports the view that a message can be 
persuasive if it arouses fear. The idea is that avoiding problems is rewarding. Messages 
that arouse fear can promote a change in health behavior if they meet the following 
conditions: (1) the message provides a strong argument that the recipient will suffer a 
negative consequence if the recommendations are not accepted; and (2) the message 
provides strong assurance that adoption of the recommendations will eliminate the 
negative consequences.1 Two studies evaluated the effects of fear-arousing health 
messages in women. One involved cancer in general, and the other, breast cancer and 
breast self-examination. The fear-arousal messages did increase participation in 
preventive measures.1 The key is that after hearing the fear-arousal message, the patient 
must believe that his/her actions will lead to a reduction of the threat.  
 
Example 
Pharmacist: Mrs. Ackerman, I am quite concerned that you are only taking about 30% 
of your doses for your high blood pressure. Given that your blood pressure is 170/110, I 
am very concerned about you having a stroke or heart attack. 
Patient: Don’t you think you’re overreacting? I feel just fine. 
Pharmacist: That’s part of the problem. People can’t tell when their blood pressure is up 
by how they feel. Most patients feel just fine even when their blood pressure is 
dangerously high. You are still putting a strain on your heart. It is very important that you 
take your medicine every day, as prescribed, to get your blood pressure down and reduce 
your risk of a stroke or a heart attack.  
Patient: Can you guarantee that that will keep me from having a heart attack? 
Pharmacist: I can guarantee that you will greatly reduce your risks and that you are 
asking for trouble if you don’t take your medicine as prescribed, each day. Is 
remembering to take it once a day a problem for you? 
Patient: Not really—I just didn’t know I was at such high risk. 
Pharmacist: This is really very important. 
Patient: O.K. 
Pharmacist: Please let me know if you have any problems. 
 
This pharmacist used a fear-arousing appeal. It worked because the pharmacist expressed 
caring and concern. The patient finally understood that she really was at risk, and now 
believes that she can do what is necessary to reduce the risk. 
 
Use of Vivid Information: Particularly in fear-arousal appeals, research supports the use 
of vivid information versus abstract information.2 Vivid information uses emotional 
appeals and examples that the patient can relate to. These could be examples of other 
people the patient’s age (famous or otherwise), etc. It is the use of any kind of concrete 
example that helps the patient take abstract information and make it more real to them. In 
the above example of the patient with hypertension, if the pharmacist could have pointed 
out another patient who recently had a stroke because of uncontrolled blood pressure 
(without mentioning the patient’s name), this could help this patient understand the 
problem more clearly. 
 
In general, the research on negatively framed appeals (fear-arousal) versus positively 
framed appeals has supported negative appeals in promoting health behaviors to avoid 
risk (e.g., of cancer, osteoporosis).1 More research is needed to evaluate these findings. 
Moreover, telling patients the benefits of taking their medicine properly and of their 
engaging in healthy behaviors is also vitally important.  
 
Linguistic Binds: One last category of direct persuasive appeals requires caution. 
Linguistic binds are discussed in the persuasion literature and could have relevance to 
pharmacy practice. However, there is an element of deception in the use of linguistic 
binds. Binds create the illusion of choice by using language that appears to offer a choice; 
however, either choice the listener chooses, he or she is still going along with what the 
speaker wants.3 Linguistic binds cause one to walk a fine line between influence and 
manipulation. 
 
Example 
Pharmacist: Mrs. Smith, I note from this new prescription that you are newly diagnosed 
with high blood pressure. 
Patient: Yes, I just came from the doctor. 
Pharmacist: The medicine the doctor prescribed is very effective if taken correctly. 
Patient: Oh, believe me—I’ll take it correctly. I don’t want to have a stroke. 
Pharmacist: Great! Dr. Stevens probably told you that the only way that we can really 
know if your blood pressure is being controlled is to take regular readings using a blood 
pressure cuff. 
Patient: Yes, he did say I should take my medicine even if I feel fine. 
Pharmacist: Good. Since you will only be seeing Dr. Stevens every 3 months, I would 
like to either show you a blood pressure cuff for home use or I have a monitoring service 
that costs $30 per month for unlimited readings that I will fax to your doctor every 2 
weeks. Which would you prefer? 
Patient: Uh, I guess I would rather have the monitoring service. 
Pharmacist: Great. Would you like to go ahead and set up your first appointment now, 
or, when is a good time for you to meet to take your blood pressure? (pharmacist has pen 
in hand to jot down a time) 
Patient: I guess Friday mornings. 
Pharmacist: Good, 10 a.m. this Friday? 
Patient: O.K. 
Several issues need to be discussed here. First, offering to sell a patient a blood pressure 
cuff or providing a monitoring service certainly is appropriate for any patient with high 
blood pressure. If patients with high blood pressure had their blood pressure regularly 
monitored, far fewer strokes or heart attacks would probably occur. When the pharmacist 
uses the linguistic bind both times, the “illusion?of choice is presented. In the first bind, 
the pharmacist wants to sell a product or a service, either of which would benefit the 
patient and the pharmacist. The choice that is left out is to buy neither. In the second 
bind, the illusion of choice is setting up the first appointment. It is hard to argue against 
monitoring of high blood pressure. It is a good thing for the patient to do. However, what 
concerns some people about linguistic binds is the element of confusion or deception 
created. It seems to be not quite honest. The expert authority the pharmacist has is being 
used to “force?a choice. Here, linguistic binds are being used to benefit the patient and 
the pharmacist. Binds that only benefit the pharmacist at the expense of the patient are 
not appropriate and are ethically questionable. 
 
Indirect Persuasive Attempts  
 
Despite following all of the above guidelines, there are times when persuasive strategies 
don’t work or aren’t very effective. Generally speaking, when people strongly resist 
change, direct persuasive strategies are very ineffective. These direct strategies often take 
the form of advice giving or “yes, but?communication.  
 
Example 
Pharmacist: Mr. Johnson, you really need to quit smoking because of your asthma. 
Mr. Johnson: (yes, but) I’m really not ready to quit. I like it too much. It relaxes me. 
Pharmacist: (yes, but) Don’t you think your health is important? 
Mr. Johnson: (yes, but) Why don’t you let me worry about that? 
Pharmacist: (yes, but) I don’t think you understand how serious this is. 
Mr. Johnson: (yes, but) I don’t think YOU understand how serious I am! 
 
This could go on and on, and usually does. The “yes, buts?the pharmacist is using 
actually force the patient to defend the very behavior the pharmacist is trying to change. 
Remember, persuasion involves a conscious attempt to influence, not an attempt to 
coerce or convince. To influence people, it is especially important that they feel they are 
not being coerced or manipulated and that they have choices. Otherwise, especially for 
resistant people, they dig in further. The work of Miller and Rollnick4 and Prochaska and 
colleagues5 has added much to our understanding of patient resistance. Ambivalence is 
often the cause of such resistance.4 When people are ambivalent they tend to do nothing. 
Therefore, one approach is to provide objective, nonjudgmental information. If patients 
are informed, but not ready to change because they are ambivalent about their ability to 
make the necessary changes, different strategies are needed. 
 
One strategy involves attempting to see the world as the patient sees it and then clearly 
defining the choices that need to be made.  
 
Example 
Pharmacist: I’m very concerned that you are continuing to smoke, because of your 
asthma. 
Patient: I’m just not ready to quit. It really relaxes me. 
Pharmacist: It would be hard to give up something that was relaxing. 
Patient: Yeah, no kidding. You ever tried to quit smoking? 
Pharmacist: No, but I know that it is very hard for most people. I wanted you to know 
that I am concerned because smoking can make your asthma much worse. I do have some 
smoking cessation products that could help when you are ready to quit. The choice really 
is up to you.  
Patient: I appreciate that. I’m just not ready. 
Pharmacist: I understand. If you haven’t had a chest x-ray lately, you might consider 
that just to make sure everything is O.K. At least it would give you additional 
information to make an informed decision. Let me go ahead and show you how this 
asthma inhaler works. 
 
This pharmacist was informative, but did not try to coerce this patient into quitting. We 
cannot make people change their behavior. The pharmacist opened a door for future 
conversation and keeps it open by nonjudgmentally directing his communication at what 
is appropriate for this patient. 
 
Self-persuasion and Cognitive Dissonance: Another strategy that often works for 
resistant patients involves self-persuasion and the use of cognitive dissonance. Cognitive 
dissonance theory states that a feeling of dissonance or distress occurs in people when 
they do or say something that runs in direct opposition to their beliefs or self-concept. To 
reduce the dissonance produced, people will try to reduce the disparity.6 It has been 
found that dissonance is very self-motivating. Therefore, if pharmacists can create 
dissonance in communicating with patients, this will stimulate patients to persuade 
themselves to do something to reduce the dissonance.  
 
Example 1 
Patient: I’m just not ready to quit smoking. I find it very relaxing. 
Pharmacist: What would you tell your teenage daughter, Sara, about smoking? 
Patient: I’d tell her not to do it. 
Pharmacist: Because? 
Patient: For obvious health reasons, cost, and  
the like. 
Pharmacist: Your smoking and the advice you would give seem a little inconsistent. 
Patient: I suppose they are. 
 
Example 2 
Patient: I’m just not ready to quit smoking. I find it very relaxing. 
Pharmacist: It would be hard to give up something you find relaxing. What else do you 
like about smoking? 
Patient: It gives me something to do with my hands and I especially like lighting up after 
a meal. It’s very relaxing. It also helps me keep weight off. 
Pharmacist: Those things are important. Do you see any downside to smoking? 
Patient: Oh sure, the usual health reasons, plus my wife says my breath and clothes 
smell. And it’s become more and more expensive. 
Pharmacist: So on the one hand, smoking relaxes you, gives you something to do with 
your hands, and keeps you from gaining weight, but on the other hand you realize that it 
is very bad for your health, your wife says your breath and clothes smell, and it’s 
expensive. 
Patient: Right. 
Pharmacist: I did want you to know that I am concerned about your smoking, but I 
won’t bug you about it. I do have some things that can help you stop if you get to that 
point. 
 
In example 1, the pharmacist creates dissonance by creating a discrepancy between the 
patient’s beliefs or values and what he actually does. In example 2, the dissonance is 
created by repeating back what the patient says is positive and negative about smoking. 
The dissonance becomes the stimulus for change. It is important to note that in both 
examples, the pharmacist is nonjudgmental and does not attempt to move the patient 
along too quickly. This would only create more resistance (see U.S. Pharmacist, October 
1999, “Change is a Multi-Step Process?. 
 
Conclusion 
 
Whether using direct or indirect forms of persuasive communication, the emphasis in 
either case has been on using influence strategies that benefit the patient and enhance 
patient care. Pharmacists are encouraged to try out several of these strategies, because 
patients will respond differently to different forms of influence. 
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The first article of this three-part series examined people’s emotional reactions to change 
and why they have these reactions. This article will examine change from the perspective 
of the patient’s readiness to change in order to manage an illness, particularly a chronic 
illness. Managing an illness often requires changes in multiple behaviors. For example, 
patients with diabetes will need to use their medicine(s) correctly, exercise, change their 
diet, and monitor their blood glucose. They will not necessarily engage in each of these 
behaviors equally well, nor are they likely to engage in each of the behaviors with the 
same degree of motivation or commitment. This article will examine a model of change 
and discuss how pharmacists and other healthcare providers can assist patients in 
managing their illnesses.  
 
The Transtheoretical Model of Change (TMC) 
During the 1970s and 1980s Prochaska and colleagues carried out an exhaustive 
examination of the literature on change.
1,2
 They looked at why and how people change in 
psychotherapy, why they did not change, and why and how they changed outside of 
therapy. The objective was to develop a comprehensive model of change that could be 
used to predict how ready an individual was for change and how to intervene to assist the 
individual in making the change.  
 
As a result of their extensive research, Prochaska and colleagues developed the 
Transtheoretical Model of Change. They identified five stages of readiness for change 
(see Table 1) and ten processes of change (see Table 2) that individuals use to move from 
one stage of readiness to the next. In other words, change is not an either/or process.
3,4
 
People often cycle through five stages of change (or readiness) before the change is 
internalized and habituated. The first three stages are cognitive—that is, people think 
about the change and weigh the pros and cons of making the change. They also make 
decisions about whether they think they have the skills and/or resources to make the 
necessary changes (self-efficacy).   
 
 
 
Table 1 
Stages of Change and Pharmacist Support 
STAGE  CHARACTERISTICS    SKILLS/INTERVENTIONS BY 
PHARMACIST 
Precontemplation Unaware, unwilling, too 
discouraged, have not tried 
anything, cons outweigh 
pros, not ready to try 
anything within next six 
months 
Listening and empathic 
responding, effective 
questioning, identifying barriers 
to change, nonjudgmental 
approach needed. Persuasive 
strategies are generally 
ineffective. Avoid argumentation 
in all stages    
Contemplation     Open to information, 
education, thinking about  
trying something within six 
months, low self-efficacy, 
high perceived temptations 
to stay  the same 
Listening and empathic 
responding, educa-Listening and 
empathic responding, 
educational interventions, 
emotional support, social 
support, effective questioning, 
discussion of strategies to 
remove barriers, developing 
discrepancies  
Preparation  Ready to engage in 
behavior(s) in the next 
month, have made at least 
one prior attempt in the 
past year, beginning to set 
goals and “psyche”  
themselves up 
Listening/empathy. Praise for 
their readiness to manage 
illness, help to set goals, discuss 
their plan of action with them,  
identify possible pitfalls, ask if 
they have the support of others 
Action  Taking steps, fighting 
“coercive forces,” engaging 
will power, developing a 
sense of autonomy, 
improved self-efficacy, but 
may also experience guilt, 
failure, limits of personal 
freedom; very stressful 
stage  
Listening/empathy. Reinforce 
self-efficaciousbehavior, 
encouragement, continued 
emotional support is important, 
especially if relapse occurs; 
identify reasons for relapse. 
Confrontation may be necessary. 
Avoid argumentation 
Maintenance  Has been engaged in new 
behaviors for at least  six 
months, person senses that 
“I am becoming more like 
the person I want to be.” Is 
able to more clearly identify 
situations and self-
defeating behaviors that 
encourage relapse     
Listening/empathy. Open 
assessment of situations likely to 
produce relapse, continue to 
apply counter-conditioningand 
stimulus control, continue 
supportive  role and provide 
positive reinforcement 
Within each stage of readiness people use different internal processes (Table 2) to move to 
the next stage of readiness. It is the healthcare provider’s task to assess the patient’s 
readiness to manage the target behaviors. Next, the healthcare provider should use stage-
specific skills and strategies to stimulate the internal processes needed to motivate change 
and help the patient move to the next stage of readiness. Notice that the task is not 
necessarily to move the patient directly to action; it is to assist the patient in moving to 
the next stage. One internal process is consciousness raising. It is the most-used process 
of change. For example, increasing the information available to the patient can help the 
patient make better choices. In order for patients with diabetes to manage their illness 
they must first know enough about the illness and how to control it to be successful. 
Therefore, their understanding of the illness and its treatment must be assessed and then 
appropriate information communicated. While education does not predict adherence, it is 
vital that patients assimilate accurate information so that they have a reasonable chance to 
succeed. Education can stimulate the internal process—consciousness raising—in the 
patient.   
Table 2 
Characteristics of the Processes of Change 
PROCESS  PEAK STAGE 
Social liberation 
Noticing that others with a similar condition in their 
environment are changing behaviors    
Contemplation and 
 preparation 
Dramatic relief 
Becoming upset or emotional in response to information 
about the hazards of  not changing  
Precontemplation and 
contemplation 
Helping relationships 
The existence of meaningful others who provide support 
for one’s efforts to change  
Prepar., action, and 
maint. 
Consciousness-raising 
Gaining and thinking about information that is relevant to 
one’s health maintenance behaviors 
Precontemp., 
contemp. 
Environmental reevaluation 
Recognizing the harmful effects of not taking care of one’s 
physical and social needs 
Contemplation 
Reinforcement management 
Rewarding oneself or being rewarded by others for healthy 
behaviors 
Action and 
maintenance 
Self-reevaluation 
Cognitively evaluating one’s attitudes toward healthy and 
unhealthy behaviors 
Contemplation 
Stimulus control 
Altering or manipulating the environment to remove cues 
that trigger relapses in behaviors, and introducing cues to 
facilitate healthy behaviors 
Action and 
maintenance 
Counterconditioning 
Developing and engaging in new behaviors to take the 
place of old, unhealthy ones,  e.g., overeating 
Action and 
maintenance 
Self-liberation 
Realizing that one is capable of successfully engaging in 
healthy behaviors if he or she chooses to 
Preparation 
This model is very powerful, yet sometimes it presents difficulties for healthcare 
providers who have a strong need for control or who believe that they manage the 
patient’s illness. In reality, we cannot control, motivate or save the patient. 
 
Nor do healthcare providers manage an illness. Patients manage illnesses—or they don’t. 
What healthcare providers can do is offer sufficient, understandable information in a 
caring, trusting context in which patients feel safe enough and free enough to discuss 
their successes and problems in managing their illnesses. In addition, providers can use 
patient-specific skills and strategies to assist patients in moving towards healthy 
behaviors. Table 3 contrasts the Biomedical (Paternalistic) Model of care with a Socio-
Behavioral Model of Care. The Biomedical Model is one in which the healthcare 
provider is in “control,” whereas the Socio-Behavioral Model places the patient and 
provider as partners who negotiate care. The Biomedical Model works in settings in 
which the patient is nonambulatory (for example, hospitals, nursing homes). However, it 
does not work well at all when the patient is ambulatory and can choose whether to 
follow a treatment regimen or not. This is where Socio-Behavioral Models work best. 
The Transtheoretical Model is a Socio-Behavioral Model of care.  
Table 3 
Traditional versus Empowerment Model of Care 
BIOMEDICAL MODEL (PATERNALISTIC)    SOCIO-BEHAVIORAL MODEL 
Practitioner-centered      Patient centered 
Information giving   Information exchange 
Practitioner must “save” the patient     Patients must save themselves 
Dictate behavior     Negotiate behavior 
Compliance      Adherence 
Authoritarian (parent-child) relationship     Servant 
Motivate the patient     Assess the patient’s motivation 
Persuade, manipulate     Understand, accept 
Resistance is bad     Resistance is information 
Argue      Confront 
Respect expected     Mutual respect is assumed 
Some Important Contrasts 
Before examining the stages of change, some important contrasts need to be considered 
(see Table 4). When people are faced with change, initially, the change may seem foreign 
to them. This is especially true when they are told they have a chronic illness to manage. 
They may say, “It is not happening to me” or “It is not really that serious.” In other 
words, they do not accept what is happening to them. Until the change or illness is 
internalized or integrated, becoming part of the person’s sense of self, the change is 
unlikely to take place. Through empathy, understanding and education, the process of 
internalization can be assisted. 
 
Ambivalence is a major reason why people don’t change. If they do not know what to do, 
how to do it, or do not believe they have the skills or resources to do what is necessary, 
change usually does not occur. Therefore, interventions that help people understand what 
is needed and the resultant benefits are often useful. In addition, creating dissonance is a 
powerful tool to promote change. If people believe that staying the same will create more 
problems than changing, they will be more likely to change. Dissonance stimulates the 
process of self-reevaulation. In other words, in order to change, the patient must decide 
that he will like himself more as a result of the changes. People are less likely to change 
if they feel coerced or as if their freedom is being impinged on; they are more likely to 
change when they believe that the decision to do so is theirs. The ability to make good 
decisions is aided by accurate, nonjudgmental information, empathic understanding, and 
stressing the positives of making the change. 
 
Finally, helping relationships are far more likely to move people toward change than will 
treating patients like children. Helping relationships do the following: they involve the 
patient in the decision-making, thay respect that this change is only part of what is 
occurring in their lives, and they allow the patient to express fears, doubts or concerns. 
Helping relationships serve to stimulate, among other processes, self-liberation, in which 
patients feel free to make better choices. Having said all of this, there are patients who 
want to be told exactly what to do and when. However, even this is a choice the patient—
not the healthcare provider—is making. 
 
The Stages of Change 
Precontemplation: Individuals approach change with varying degrees of readiness. 
Precontemplation is considered the first stage of readiness. Individuals in this stage are 
either unaware, unwilling, or too discouraged to change. For the precontemplator who is 
unaware, the best strategy is education. For example, people with diabetes cannot 
effectively manage their illness if they do not understand the illness or its treatment.  
 
For patients who are aware of negative consequences but are unwilling to change, a 
different approach is needed. Many smokers are aware of the dangers of smoking, but 
continue to do so for other reasons. Here, the strategy is to ask the smoker what he/she 
likes about smoking. If the smoker says, “It relaxes me,” a helpful response is, “It would 
be hard to give up something that is relaxing.” This response does not put the patient on 
the defensive and in fact, demonstrates nonjudgmental understanding. After asking what 
else the smoker likes about smoking, asks what he/she sees as the downside of smoking. 
Summarize all that you have heard. Saying, “So, on the one hand you like smoking 
because....while on the other hand, you see the downside of smoking as...” This is called 
developing discrepancies. Saying the pros and cons of a behavior out loud creates 
dissonance, and the dissonance creates motivation for change. To assess just how 
resistant to change the patient is, the “envelope” method is recommended. Using our 
smoking example, you would say, “Mr. Smith, if I were to hand you an envelope, what 
message would have to be inside of it for you to consider quitting?” Very resistant 
precontemplators will tell you, “There isn’t any message that could get me to quit.” Some 
patients will have no intention of changing in our lifetime. We cannot save them. To 
them we would say, “Mr. Smith, it sounds like you’re not ready to quit smoking. I am 
concerned that your smoking increases your chances for a stroke or heart attack because 
of your high blood pressure, but it really is up to you if you want to quit. If you get to the 
point where you are considering quitting, let me know and I would be glad to help you 
with some methods for doing so.”  
 
On the other hand, when asked about the envelope, some patients might say, “I guess I 
would consider quitting if I found out that I had early warning signs of problems.” Now 
you have an opening to ask the patient to consider getting his or her lungs checked so he 
or she can make a better decision about whether to consider quitting. 
 
For the patient who is too discouraged to attempt to change, identifying any successes 
they have had in past attempts at change is very helpful. Often identifying what worked, 
if even for a short period of time, helps the patient repeat these actions for longer periods. 
 
Contemplation: In this stage, patients are more open to information and want to learn 
more. They are thinking of changing within the next six months. Providing objective, 
nonjudgmental information is very important in this stage. Noticing the patient’s 
statements, indicating a shift in his/her stage of readiness, is also important. Asking the 
patient what he/she anticipates will be the greatest obstacles to overcome and what the 
patient perceives as the benefits of the change is very useful. 
Preparation: In the preparation stage, the patient is getting ready to try something within 
the next 30 days. It is not until this stage that any action-oriented strategies are 
considered. Setting small goals and removing barriers to change are very important in this 
stage. Discussing the patient’s plan for action and praising the patient’s readiness are very 
important. 
 
Action: The action stage is critical. A great deal of effort is being made. The patient has 
now engaged in the behavior(s), but for less than six months. Often, once the patient 
engages in action, healthcare providers think their work is done. However, it is really just 
beginning. Patients need to be noticed and the new behaviors need to be reinforced. Some 
encouragement and social support is essential. It is unfortunate that major improvements 
may go unnoticed because healthcare providers and family may say, “Why should I 
praise them for doing what they’re supposed to be doing?” The answer is simple: you 
want them to keep doing it. Statements such as, “Mr. Jones, I noticed that you were right 
on time for your blood pressure medicine this month. That’s great. How have you been 
able to get yourself on track? I’d like to be able to pass this on to other patients” are very 
helpful.    
Table 4 
Important Contrasts in the Process of Change 
Foreign____________________________________Internalization 
Ambivalence________________________________Dissonance 
Coercion___________________________________Decision-making 
Paternalism_________________________________Helping relationship 
Maintenance: In the maintenance stage, the patient has been engaged in the target 
behavior(s) for at least six months. Again, noticing these positive changes is very 
important. Preventing relapse is an important focus of this stage. At some time or 
another, patients may relapse: the smoker may smoke, the patient with diabetes will go 
off his diet, etc. The key is to stay focused on targeting problems, not people. For 
example, the pharmacist may inquire about the relapse in a tactful, respectful manner: 
 
Pharmacist: “Mrs. Jones, what happened to cause your blood glucose to go up?” 
Mrs. Jones: “Seems like we had a rash of birthdays at work—you know, cake, ice 
cream, the works. I overindulged.” 
Pharmacist: “O.K., that happens now and then. Since you were doing a great job of 
keeping your diabetes under control, I know that you’ll get back on track. What is your 
plan?” 
Mrs. Jones: “I plan to eat a smaller piece of cake, and no ice cream next time.” 
 
Summary 
The Transtheoretical Model of Change helps to convey that change is a process and that 
each stage of the process requires different skills and strategies to effectively help the 
patient. At all times, the pharmacist’s communication is supportive, encouraging and 
nonjudgmental. 
 
Editors’ Note: We welcome your feedback. You can e-mail the author at 
uspharmacist@jobson.com. 
 
1. Prochaska JO. Systems of psychotherapy: a transtheoretical approach. Homewood,IL: Dorsey Press; 1979. 
2. Prochaska JO, DiClemente CC. The transtheoretical approach: crossing traditional boundaries of therapy. Homewood, IL: Dow 
Jones-Irwin; 1984a. 3. DiClemente CC, Prochaska JO, Fairhurst SK, et al. The process of smoking cessation: An analysis of 
precontemplation, contemplation, and preparation stages of change. Journal of Consulting and Clinical Psychology. 1991;59:295-
304. 4. DiClemente CC, Prochaska JO, Gibertini M.Self-efficacy and the stages of self-change of smoking. Cognitive Therapy and 
Research. 1985;9:181-200. 
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Helping Patients Face Change 
Bruce Berger, Ph.D. 
Professor, School of Pharmacy, Auburn University, Auburn, AL 
 
Change is one of the few constants in life. Yet, most of us are not completely comfortable 
with change. Individuals differ in their comfort and tolerance level toward change, with 
different kinds of changes producing different responses. John Galbraith once stated that 
when people are given a choice between changing and proving that change is not 
necessary, most get busy with the proof. Given their current level and response to stress 
(change), people use their best problem-solving strategies to get their needs met, even if 
these strategies are dysfunctional. People do what they know until they learn something 
new. Managing an illness requires behavior change. For example, to manage diabetes, 
patients must take their medicine properly, monitor their blood glucose, often change 
their eating habits, and get sufficient exercise. These changes are not easy. In the face of 
such changes, people often avoid the critical choices they need to make. 
 
Massive changes are taking place in healthcare and in pharmacy. Changes are required of 
patients when they have to manage an illness. Given these realities, this column will 
explore issues surrounding change. This and future articles will discuss the emotional 
responses people have to change, the behavioral responses, the internal processes people 
use to change, the stages of change that people go through, how we can assist people with 
change, how to assess a person’s readiness for change, how to choose appropriate skills 
and intervention strategies to match a person’s readiness to change, and, lastly, a process 
for improving patient readiness to manage their illness. 
Emotional Responses to Change 
Table 1 summarizes the different emotional reactions people have to change. Table 2 
summarizes reasons for these reactions. Let’s examine each reaction and their reasons, 
and note effective responses. 
Table 1 
Intrapersonal Aspects of Change:  
Why Change is So Difficult 
FEELINGS 
Fear, anxiety, ambivalence 
Anger, blaming, scapegoating 
Going numb, avoidance 
Excitement, joy, relief 
Frustration 
Depression - both existential and clinical  
Out of control 
Shame/guilt 
Being alone in the world 
 
Table 2 
Intrapersonal Aspects of Change: 
Why Change is So Difficult 
REASONS 
Lack of confidence in ability to make the transition  
(“Do I have the skills?” “Can I really do this?”) 
 
Lack of understanding (vision) of what is needed 
 
Lack of involvement 
 
Cannot see personal or professional benefits of  
the change 
 
“What’s wrong with the way things are?” 
 
“Have I done something wrong?” 
 
“I’m too old for this.”  
Fear, Anxiety, Ambivalence: When faced with the need to change, some people become 
anxious or frightened. Change calls into question our capacity and ability to make 
changes. A person faced with change may wonder: Do I have the necessary skills? Do I 
know what is required of me? Is the change really going to be beneficial to me? Will 
training be available if I need it? Will others think I’m stupid (inept, clumsy, etc.) if I 
have difficulties at first? All these issues can cause us to feel fearful or anxious. In fact, if 
these questions are not adequately answered, people experience ambivalence. 
Ambivalence is the primary reason people will not make a change or engage in a change. 
They do not know what to do, how to do it, or are not sure if they have the capacity to do 
it. Ambivalence shuts people down, causing them to proceed with great caution, or not at 
all. When people are ambivalent, they often maintain old behaviors because of 
familiarity. Therefore, anyone interested in helping someone to change must help the 
person address these issues for that person to move forward. Listening and empathic 
responding are very important (see U.S. Pharmacist, October 1998). People’s fears and 
concerns must be taken seriously and responded to in a respectful way. Fear or anxiety 
need to be honored (“So, you are concerned that you may not have all of the resources 
that you need to make the necessary changes”), not obliterated. Attempting to minimize 
the fear (“Oh come on, it’s not so bad”) is not effective in gaining trust. Comparing the 
person to others (“Other patients haven’t had difficulties with this”) is also not effective.  
Anger, Blaming, Scapegoating: It is not unusual for people to become angry or 
defensive when faced with change, particularly if they have not been involved in the 
decision-making process. Therefore, participation and feedback are essential. In addition, 
anger is an emotion that is often used to mask another emotion, such as fear, anxiety, or 
frustration (see U.S. Pharmacist, March 1999). Rather than admit they feel afraid in 
confronting change, people often convert that fear to anger, because anger feels more 
powerful. What sometimes follows this angry response is blaming, scapegoating or some 
form of discounting. People begin to blame someone or something for why the change is 
silly and/or unnecessary, why they cannot make the change, or why it will not work. 
They may discount the importance of the change so that they do not have to act. The key 
is to understand that these responses indicate that people feel threatened and anxious 
about the change. Therefore, perceived threats need to be explored and understood rather 
than minimized. Individuals need to be respectfully confronted with statements such as: 
“From what you have said, you don’t believe the change is necessary. Tell me why. I’d 
like your input,” or “Given the problem we are having, what would you propose 
instead?” The key is to make the person responsible for his/her statements and behavior 
without being punitive or shaming. 
Going Numb: One response to change is to simply avoid it altogether, to go numb, act 
like nothing is different. The thought behind this is, “If I don’t think about it, it will go 
away.” Most of us would agree that this approach is unhealthy, but it is still a way to cope 
when feeling threatened. Going numb can also mean deciding to do nothing rather than 
enact a change, for others have also done nothing, even though all involved know that 
this decision may be harmful to themselves or others. 
Excitement, Joy, Relief: Some patients may experience these emotions when diagnosed 
with an illness. For example, the patient who finds out she has diabetes may experience 
relief at finally knowing why she has felt so badly for so long. Knowing that the illness is 
controllable, she experiences relief and a sense of being in charge of her life again. For 
many people, change can be exciting if it clearly represents something better for them, 
whether that be working conditions, technology, health, etc. 
Positive reactions to change should also be noticed. If a patient is doing a particularly 
good job of managing his/her illness, this should be acknowledged (“I like that you are 
refilling your medicine on time and regularly monitoring your blood pressure”) so that 
desired behaviors are repeated. It is unfortunate that we often focus on what people do 
that we do not like, rather than seeing the things they do that we like. We sometimes have 
the mentality, “Why should I praise someone for doing what they’re supposed to be 
doing?” The answer is simple: We want them to keep doing it. All of us like to be 
recognized for our accomplishments. 
Frustration: This is a common response to change. For reasons similar to those 
describing anger, change can be very frustrating when people affected by the change are 
not involved in the decision-making process and have not been solicited for feedback. 
Again, the reasons for the frustration need to be explored rather than minimized. 
Depression (existential and clinical): This sometimes occurs when people are faced 
with change, even if they can see its benefits. This is particularly true when people find 
out they have a chronic illness that will have to be treated for life. Many times, the 
chronic illness is a harsh reminder that they are not immortal or that they are growing 
older. This is difficult for most of us to accept immediately. It is unfortunate that when 
patients begin to express this sense of loss, which is healthy, too many healthcare 
providers and others often try to fix the problem rather than being emotionally available 
to the person. This fixing results in statements such as: “Cheer up, at least you know what 
it is,” “It’s not so bad, millions of people have diabetes (high blood pressure, asthma, 
etc.) and it’s treatable,” etc. These statements minimize the importance of the patient’s 
present feelings about the illness. Listening to the patient and showing understanding 
would be far more powerful. 
A distinction needs to be made between existential depression and clinical depression. 
Existential means that the feeling moves the patient forward. It promotes existence. When 
faced with change, even if it is positive, we must give up a part of what we used to be to 
become something new. This creates a sense of loss that can be experienced as 
depression. If one has ever been in a funk for a day or two and could not explain why, 
chances are very good that some important change was taking place in that person’s life. 
Clinical depression is much more severe. Clinical depression can result from major 
changes in a person’s life. It needs to be taken seriously by healthcare providers and 
treated by a therapist and/or drug therapy. 
Out of Control: When faced with change, particularly sudden or chaotic change, people 
often feel out of control. In order to feel more in control, they revert back to familiar 
behaviors, numb out, blame someone, discount the change, or, hopefully, make the 
change. To encourage the person to make the change, understand the person’s reasons for 
feeling out of control and examine ways he or she might feel more in control of what is 
happening. 
Shame/Guilt: Some people feel ashamed or guilty when faced with change. If the change 
is threatening, such as a chronic illness or a modification in job description, some feel the 
change is a result of past sinful behavior. They believe they deserve the punishment being 
inflicted on them. This is unfortunate, because these thoughts are irrational and cannot be 
dealt with through reasoning. Listening and empathy are important. Staying focused on 
the task at hand is also vital. For example, Mrs. Jones states, “I just know I got diabetes 
because I ate too many sweets as a kid.” The helpful pharmacist replies, “Let’s see what 
we can do to get your diabetes under control so that you can live a long, healthy life,” 
rather than, “Oh, Mrs. Jones, I’m sure that has nothing to do with this.” 
Being Alone in the World: Even when people realize they need to change, it can feel 
very lonely. Our primary fear is being alone in the world. One of the most powerful 
things pharmacists can do to help patients make necessary changes is to be emotionally 
available and reflect back their understanding. If a problem can be understood, it can be 
solved. This provides hope. Hope provides energy for change. If the change ultimately 
must be made, the person’s resistance to the change should be explored to determine how 
he or she can be helped to change. 
 
http://www.uspharmacist.com/oldformat.asp?url=newlook/files/phar/acf268.htm 
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There is now extensive evidence on the optimal management 
of diabetes, offering the opportunity of improving the 
immediate and long-term quality of life of those with the 
condition.  
Unfortunately such optimal management is not reaching 
many, perhaps the majority, of the people who could beneﬁ t. 
Reasons include the size and complexity of the evidence-
base, and the complexity of diabetes care itself. One result 
is a lack of proven cost-effective resources for diabetes care. 
Another result is diversity of standards of clinical practice. 
Guidelines are one part of a process that seeks to 
address those problems. Many guidelines have appeared 
internationally, nationally, and more locally in recent years, 
but most of these have not used the rigorous new guideline 
methodologies for identiﬁ cation and analysis of the evidence. 
Increasingly, national organizations have sought to use these 
new approaches, which are described in the IDF publication 
Guide for Guidelines. It was noted in that document that 
many countries around the world do not have the resources, 
either in expertise or ﬁ nancially, that are needed to promote 
formal guideline development. In any case, such a repetitive 
approach would be enormously inefﬁ cient. 
Accordingly the International Diabetes Federation (IDF) has 
developed a global guideline. For reasons of efﬁ ciency the 
current initiative has chosen to use the evidence analyses 
of prior national and local efforts. This should also help to 
ensure a balance of views and interpretation.
A global guideline presents a unique challenge. Many 
national guidelines address one group of people with 
diabetes in the context of one health-care system, with one 
level of national and health-care resources. This is not true in 
the global context where, although every health-care system 
seems to be short of resources, the funding and expertise 
available for health care vary widely between countries and 
even between localities. 
Published national guidelines come from relatively resource-
rich countries, and may be of limited practical use in less 
well resourced countries. Accordingly we have also tried to 
develop a guideline that is sensitive to resource and cost-
effectiveness issues. Despite the challenges, we hope to 
be found to have been at least partially successful in that 
endeavour, which has used an approach that we have termed 
‘Levels of care’ (see next page). 
Funding is essential to an activity of this kind. IDF is grateful 
to a diversity of commercial partners for provision of 
unrestricted educational grants. 
Preface
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n Standard care
Standard care is evidence-based care which is cost-effective 
in most nations with a well developed service base, and with 
health-care funding systems consuming a signiﬁ cant part of 
national wealth.
Standard care should be available to all people with diabetes 
and the aim of any health-care system should be to achieve 
this level of care. However, in recognition of the considerable 
variations in resources throughout the world, other levels of 
care are described which acknowledge low and high resource 
situations. 
n Minimal care
Minimal care is the lowest level of care that anyone with 
diabetes should receive. It acknowledges that standard 
medical resources and fully-trained health professionals 
are often unavailable in poorly funded health-care systems. 
Nevertheless this level of care aims to achieve with limited 
and cost-effective resources a high proportion of what can 
be achieved by Standard care. Only low cost or high cost-
effectiveness interventions are included at this level.
n Comprehensive care 
Comprehensive care includes the most up-to-date and 
complete range of health technologies that can be offered to 
people with diabetes, with the aim of achieving best possible 
outcomes. However the evidence-base supporting the use of 
some of these expensive or new technologies is relatively weak. 
Summary of the Levels of Care 
structure
Standard care
Evidence-based care, cost-effective in 
most nations with a well developed service 
base and with health-care funding systems 
consuming a signiﬁ cant part of their national 
wealth.
Minimal care
Care that seeks to achieve the major 
objectives of diabetes management, but 
is provided in health-care settings with 
very limited resources – drugs, personnel, 
technologies and procedures. 
Comprehensive care
Care with some evidence-base that is 
provided in health-care settings with 
considerable resources.  
All people with diabetes should have access to cost-effective 
evidence-based care. It is recognized that in many parts 
of the world the implementation of particular standards of 
care is limited by lack of resources. This guideline provides a 
practical approach to promote the implementation of cost-
effective evidence-based care in settings between which 
resources vary widely. 
The approach adopted has been to advise
on three levels of care: 
Levels of care
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ß  The process involved a broadly based group of 
people, including people with diabetes, health-care 
professionals from diverse disciplines, and people from 
non-governmental organizations (see Members of the 
Guidelines Group).
ß  Within the Group, a number of people had considerable 
experience of guideline development and health 
economics, and of health-care administration, as well as 
of health-care development and delivery, and of living 
with diabetes.
ß  Geographical representation was from all the IDF 
regions, and from countries in very different states of 
economic development (see Members of the Guidelines 
Group).
ß  In general the evidence analyses used were published 
evidence-based reviews and guidelines from the last 5 
years; those used are referenced within each section. 
However, members of the Group were asked to identify 
any more recent publications relevant to the section of 
the guideline allotted to them, and encouraged to review 
details of papers referred to in the published guidelines. 
Key evidence-based reviews and meta-analyses are also 
referenced.
ß  The whole Group met to hear the synthesis of the 
evidence for each section of diabetes care, to address 
what recommendations should be made, and to make 
recommendations over what should be in each Level of 
care for each section.
ß  The results from the meeting were synthesized into 
written English by a scientiﬁ c writer with a knowledge of 
diabetes, with the assistance of the initiative’s chairmen; 
those drafts were then reviewed by the members of 
the Group who originally worked on each section, and 
amendments made according to their suggestions.
ß  The whole draft guideline was sent out for wider 
consultation to IDF member associations, IDF elected 
representatives globally and regionally, interested 
professionals, industry sponsors (of the guideline and of 
IDF generally), and others on IDF contact lists, a total of 
378 invitations. Each comment received was reviewed by 
the two chairmen and the scientiﬁ c writer, and changes 
were made where the evidence-base conﬁ rmed these to 
be appropriate.
ß  The revised and ﬁ nal guideline is being made available 
in paper form, and on the IDF website. The evidence 
resources used (or links to them) will also be made 
available. Versions are also being made available in 
descriptive form (in Diabetes Voice), and in language 
made accessible to people without technical medical 
training. 
ß  Past experience of international diabetes guidelines is 
that they have a useful lifespan exceeding 5 years. IDF 
will consider the need for review of this guideline after 
3-5 years.
The methodology used in the development of this guideline 
is not described in detail here, as it broadly follows the 
principles described in Guide for Guidelines. 
In summary:
Methodology 
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Recommendations
n Standard care
SD1  Each health service should decide whether to have a programme to detect 
people with undiagnosed diabetes. 
   ß   This decision should be based on the prevalence of undiagnosed diabetes 
and on the resources available to conduct the detection programme and 
treat those who are detected.   
  ß  Universal screening for undiagnosed diabetes is not recommended.
    ß   Detection programmes should target high-risk people identiﬁ ed by 
assessment of risk factors.
SD2  Detection programmes should use measurement of plasma glucose, 
preferably fasting.
  
   For diagnosis, an oral glucose tolerance test (OGTT) should be performed 
in people with a fasting plasma glucose ≥5.6 mmol/l (≥100 mg/dl) and 
<7.0 mmol/l (<126 mg/dl).
SD3  Where a random plasma glucose level ≥5.6 mmol/l (≥100 mg/dl) and 
<11.1 mmol/l (<200 mg/dl) is detected on opportunistic screening, it 
should be repeated fasting, or an OGTT performed.
SD4  The WHO 1999 criteria [1] should be used to diagnose diabetes; these include 
the importance of not diagnosing diabetes on the basis of a single laboratory 
measurement in the absence of symptoms.
SD5  People with screen-detected diabetes should be offered treatment and care.
This guideline does not deal with lesser degrees of hyperglycaemia detected on 
screening.
01
Rationale
Screening for Type 2 diabetes has important implications 
for individual health, day-to-day clinical practice, and public 
health policy. While the early detection and treatment of 
diabetes seems logical in terms of minimizing complications, 
there is currently no direct evidence as to whether or not 
this is beneﬁ cial to individuals. Despite this lack of direct 
evidence, early detection through screening is taking 
place and is recommended by a number of organizations 
throughout the world. 
The decision about conducting a detection programme 
should be based on the following considerations [2]:
ß  epidemiological - prevalence of undiagnosed Type 2 
diabetes
ß  health systems - capacity to carry out the screening, 
provide care for those who screen positive, and implement 
prevention programmes in those at high risk of future 
development of diabetes
ß  population - acceptability and likely uptake of the 
screening programme
ß economic - cost of early detection to the health system 
and to the individual, and relative cost-effectiveness of 
early detection compared with improving care for people 
with known diabetes.
Evidence-base
Diabetes is associated with a range of serious complications 
which result in reduced quality of life and premature 
mortality. Early detection and treatment is one strategy 
proposed for reducing this burden. 
Screening / early detection
Type 2 diabetes has a long asymptomatic pre-clinical phase 
which frequently goes undetected. At the time of diagnosis, 
over half have one or more diabetes complications [3]. 
Retinopathy rates at the time of diagnosis range from 20 % 
to 40 % [4,5]. Since the development of retinopathy is related 
to duration of diabetes, it has been estimated that Type 2 
diabetes may have its onset up to 12 years before its clinical 
diagnosis [4].
Of people with Type 2 diabetes, the proportion who are 
undiagnosed ranges from 30 % to 90 %. Overall, data 
from countries as diverse as Mongolia [6] and Australia [7] 
demonstrate that for every person with diagnosed diabetes 
there is another who has undiagnosed diabetes. Other 
countries have even higher rates of undiagnosed diabetes 
– 80 % in Tonga [8] and 60-90 % in Africa [9-11]. However, in 
the USA only 30 % are undiagnosed [12].  
Although there is considerable evidence supporting the 
beneﬁ ts of improved blood glucose, blood pressure and 
blood lipid control in Type 2 diabetes, no randomized 
controlled studies have assessed the potential beneﬁ ts of 
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n Comprehensive care
SDC1  Resources should be available for diabetes detection programmes.
SDC2  Investigations to classify type of diabetes (e.g. islet-cell related antibodies, 
C-peptide, genotyping) should be available.
n Minimal care
SDM1  Detection programmes should be opportunistic and limited to high-risk 
individuals.
SDM2  Diagnosis should be based on fasting laboratory plasma glucose (preferred) 
or capillary plasma glucose. 
SDM3  If blood glucose testing is not available, the presence of glycosuria, 
especially with classical symptoms, may be used to diagnose diabetes. 
early diagnosis on outcomes in screen-detected diabetes. 
Therefore there is only limited indirect evidence suggesting 
that early detection may be beneﬁ cial. 
Schneider et al. [13] performed an analysis of a mass-
screening programme based on urinary glucose levels, 
conducted in the former East Germany in the 1960s and 
1970s. It suggested that people found to have diabetes by 
screening had an improved outcome compared with those 
presenting spontaneously with diabetes. 
Fasting plasma glucose (FPG) at diagnosis might serve 
as a surrogate for the duration of diabetes. A post-hoc 
analysis of UKPDS showed that the frequency of subsequent 
complications was related to FPG at study entry [14]. The 
group with an initial FPG <7.8 mmol/l (<140 mg/dl) had 
signiﬁ cantly lower rates of all major end-points compared 
with the ≥10.0 mmol/l (≥180 mg/dl) group and also had 
signiﬁ cantly lower diabetes-related death rates and 
myocardial infarction rates compared with the 7.8 to 
<10.0 mmol/l (140 to <180 mg/dl) group. These ﬁ ndings 
suggest a beneﬁ t of intervening either at lower FPG levels 
or earlier in the natural history of diabetes, and may be 
consistent with a beneﬁ t derived from early detection. 
Studies in progress which may contribute to the knowledge-
base on early detection of diabetes are the ‘Inter99’ study in 
Copenhagen county, Denmark [15] and the (Anglo-Danish-
Dutch) ADDITION study [16]. 
Screening for diabetes will also identify individuals with 
lesser degrees of hyperglycaemia who may beneﬁ t from 
interventions to prevent or delay progression to diabetes, 
and to prevent cardiovascular disease.
Screening strategies
There are several options for strategies to screen for 
undiagnosed diabetes. The ultimate choice is based on 
available resources and a trade-off between sensitivity (the 
proportion of people with diabetes who test positive on the 
screening test), speciﬁ city (the proportion of people who 
do not have diabetes who test negative on the screening 
test), and the proportion of the population with a positive 
screening test which needs to proceed to diagnostic testing. 
Most screening strategies include risk assessment and 
measurement of plasma glucose, performed either 
sequentially or simultaneously. Screening tests are followed 
by diagnostic tests (fasting plasma glucose (FPG) and/or an 
oral glucose tolerance test (OGTT)) in order to make the 
diagnosis. References 2 and 17 provide a detailed review of 
screening options. Combined screening strategies have a 
sensitivity and speciﬁ city in the order of 75 %, and 25 % of 
the population require diagnostic testing. People who screen 
negative will need re-testing after 3-5 years. These people 
should also be offered lifestyle advice to minimize their risk 
of developing diabetes.
Although the usefulness of urine glucose as a screening test 
for undiagnosed diabetes is limited because of low sensitivity 
(21-64 %) [17], speciﬁ city is high (>98 %), so it may have a 
place in low-resource settings where other procedures are 
not available.
Diagnosis
Following a positive screening test, diagnostic testing is 
required. This may either be a conﬁ rmatory FPG (≥7.0 mmol/l,
 >125 mg/dl) or an OGTT. The diagnostic criteria for diabetes 
adopted by the WHO [1] and American Diabetes Association 
(ADA) [18] are accepted internationally. 
Consideration
The place of screening for undiagnosed diabetes as part of 
an overall strategy to reduce the health burden of diabetes 
is not established. However, many organizations recommend 
it. The choice of whether to screen or not, and the screening 
strategy, must be made locally taking into account local 
considerations. 
Implementation
A clear and transparent decision should be made about 
whether or not to endorse a screening strategy. If the 
decision is in favour of screening, this should be supported 
by local protocols and guidelines, and public and health-care 
professional education campaigns. 
Evaluation
Number of health-care professionals and services performing 
screening, proportion of the population being screened, 
and detection rate of undiagnosed diabetes should be 
ascertained. Percentage of diagnosed people entering and 
continuing in care should be measured. 
Screening and diagnosis
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Recommendations
n Standard care
CD1  Offer care to all people with diabetes, with sensitivity to cultural wishes and 
desires. 
CD2  Encourage a collaborative relationship, by actively involving the person with 
diabetes in the consultation, and creating opportunities for them to ask 
questions and express concerns. Ensure that issues important to the person 
with diabetes are addressed. 
CD3  Offer annual surveillance of all aspects of diabetes control and complications 
to all people with Type 2 diabetes (see Table CD1).
CD4  Agree a care plan with each person with diabetes 
  ß  review this annually or more often if appropriate
  ß  modify it according to changes in wishes, circumstances and medical 
ﬁ ndings. 
CD5  Use protocol-driven diabetes care to deliver the care plan between annual 
reviews, at booked routine reviews. 
CD6  Provide urgent access to diabetes health-care advice for unforeseen problems.
CD7  Organize care around the person with diabetes. 
CD8  Use a multidisciplinary care team with speciﬁ c diabetes expertise maintained 
by continuing professional education. 
CD9  Ensure that each person with diabetes is recorded on a list of people with 
diabetes, to facilitate recall for annual complications surveillance. 
CD10  Provide telephone contact between clinic visits. 
CD11  Consider how people with diabetes, acting as expert patients, and knowing 
their limitations, together with local/regional/national associations, might be 
involved in supporting the care delivery of their local health-care team. 
CD12  Use data gathered in routine care to support quality assurance and 
development activities. 
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n Comprehensive care
CDC1 In general this would be as Standard care.
CDC2  The person with diabetes will have access to their own electronic medical 
record via secure technology from remote sites. They will be able to give 
permission for any health-care professional to access that record.
CDC3  Decision support systems might be available to the health-care professional, 
and perhaps to the person with diabetes.
n Minimal care
CDM1  Offer annual surveillance, agree care plans, deliver protocol-driven care, and 
ensure that each person with diabetes is recorded on a local list of people 
with diabetes, as for Standard care.
CDM2  Organize care around the person living with diabetes, using an appropriately 
trained health-care professional to deliver the diverse aspects of that care. 
Table CD1
A summary of the assessments to be performed at Annual Review (or annually) for each person 
with Type 2 diabetes 
Assessment topic
Self-care knowledge and beliefs
Lifestyle adaptation and wishes (including 
nutrition, physical activity, smoking) 
Psychological status
Self-monitoring skills and equipment
Body weight trends
Blood glucose control
Blood pressure control
Blood lipid control
Cardiovascular risk
Erectile dysfunction, neuropathy
Foot condition
Eyes
Kidneys
Pre-pregnancy advice (need for)
Medication review
Guideline section
Education
Lifestyle management 
Psychological care
Self-monitoring
Lifestyle management
Glucose control; Clinical monitoring
Blood pressure control 
Cardiovascular risk protection
Cardiovascular risk protection
Nerve damage
Foot care
Eye screening
Kidney damage
Pregnancy
 —
Rationale
The person diagnosed with Type 2 diabetes requires access 
to immediate and ongoing care. Who provides this care, and 
where and when, will depend on local circumstances, but it 
needs to be organized in a systematic way. General principles 
include: annual review of control and complications; an 
agreed and continually updated diabetes care plan; and 
involvement of the multidisciplinary team in delivering that 
plan, centred around the person with diabetes.
Evidence-base
Systems underlying structured organization of care for 
people with diabetes do not easily lend themselves to 
comparison by randomized controlled trials (RCTs). Much of 
the literature in this area is descriptive and interventions are 
often multifaceted. Some aspects of care organization that 
do not have a strong evidence-base have been adopted as 
good practice by a wide range of diabetes services across the 
world. Systematic review of the evidence was undertaken by 
the Canadian guideline [1] and the UK National Institute for 
Clinical Excellence (NICE) guideline on Type 1 diabetes [2]. 
Both guidelines found support for the multidisciplinary 
approach, with the Canadian guideline citing a systematic 
review by Renders et al [3]. Involvement of nurses with 
training in teaching skills and adult education in a number 
of aspects of diabetes education, and of formally trained 
dietitians and podiatrists within the speciﬁ cally relevant areas 
of diabetes care, was highlighted [2]. Although there is no 
RCT evidence for annual review of control and complications, 
this has become the basis for many quality control structures 
for diabetes care [2,4]. Some of the rationale for annual 
surveillance in different areas of care is given in individual 
sections of the current guideline.
The Canadian guideline advocates organizational 
interventions that have been shown to improve health-
care efﬁ ciencies, such as databases to provide patient and 
physician reminders and transfer of information [1,5], while 
NICE considers a database-driven recall system to be implicit 
in recommendations for annual surveillance [2]. Evidence for 
the usefulness of telemedicine (ranging from the telephone 
to technology for transmission of images) was reviewed by 
NICE, who recommended its use to improve process and 
outcomes [2,6], and drew attention to its potential in rural 
and remote situations.
Protocol-driven care is not speciﬁ cally addressed by the 
guidelines, but Davidson has reviewed studies, including 
RCTs, in which nurses or pharmacists delivered diabetes 
care following agreed protocols, and found they achieved 
improved process and outcomes compared with ‘usual care’ 
within the US health-care system [7,8].
The literature on care plans and patient-held/accessed 
records is as yet only descriptive, without useful analysis 
of patient-related outcomes, but the UK National Service 
Framework ﬁ nds that these can help to empower people 
with diabetes [9].
Consideration
Given the diversity of health-care systems around the world, 
recommendations in this part of the guideline are presented 
in very general terms. Flexibility and adaptability would seem 
to be important principles. Redeployment of underused 
resources (such as leprosy clinics) may offer opportunities 
for improved care in some areas. Where databases are not 
feasible, lists of people with diabetes can be established in 
simple book form. Telemedicine can encompass anything 
from telephones allowing access to health-care professional 
advice to sophisticated data transfer, but any advance 
in communications technology, or access to it, may offer 
opportunities for improved organization of care. Empowering 
patients to ﬁ nd their way in the system through access to 
their own data and perhaps through use of decision-support 
tools would seem to be a logical development. 
Implementation
Organization of care to deliver the above recommendations 
is largely concerned with:
ß     putting registration, recall and record systems in place to 
ensure care delivery occurs for all people with diabetes, 
and
ß  having the health-care professionals trained and available 
to provide the appropriate advice. 
Simple communications technologies, and personnel 
support for those, need to be in place. More sophisticated 
telemedicine and other IT approaches require not just 
appropriate software and hardware, but again appropriately 
trained staff, and continuing maintenance. 
Evaluation
Evaluation will show evidence of structured records being 
appropriately completed as part of recall and appointment 
systems driven from a list of people with diabetes. Evaluation 
of proportions of the managed population receiving 
deﬁ ned components of care (such as glucose control, eye 
screening or blood pressure checks) within a 12-month 
Care delivery
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period should be made regularly. The staff providing the 
service should be identiﬁ ed, together with evidence of 
their continued professional training. The existence of 
appropriate communications equipment and protocols,  
and arrangements for their use, can be reviewed. 
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Education
Recommendations
n Standard care
ED1  Make structured patient education an integral part of the management of 
all people with Type 2 diabetes:
  ß from around the time of diagnosis
  ß  on an ongoing basis, based on annual assessment of need
  ß on request.
ED2  Use an appropriately trained multidisciplinary team to provide education to 
groups of people with diabetes, or individually if group work is considered 
unsuitable. Where desired, include a family member or friend.
ED3  Include in education teams a health-care professional with specialist 
training in diabetes and delivery of education for people with diabetes. 
ED4  Ensure that education is accessible to all people with diabetes, taking 
account of culture, ethnicity, psychosocial, and disability issues, perhaps 
delivering education in the community or at a local diabetes centre, and in 
different languages.
ED5  Use techniques of active learning (engagement in the process of learning 
and with content related to personal experience), adapted to personal 
choices and learning styles. 
ED6  Use modern communications technologies to advance the methods of 
delivery of diabetes education. 
n Comprehensive care
EDC1  This would be as for Standard care but would also include the availability 
on demand of individual advice, through a named key contact. 
n Minimal care
EDM1  This would be as for Standard care but education would be provided by an 
appropriately skilled individual rather than a team.
EDM2  Consider how available technologies can best be used to deliver education.
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Education
Rationale
Education in the broadest sense underpins diabetes care, 
at every contact between the person with diabetes and 
the health-care team. This has made it difﬁ cult to isolate 
those aspects of education which best contribute to its 
effectiveness. Recognition that 95 % of diabetes care is 
provided by people with diabetes themselves, and their 
families, is reﬂ ected in the current terminology of ‘diabetes 
self-management education’ (DSME) programmes. With the 
understanding that knowledge itself is not enough to enable 
people to change behaviour and improve outcomes [1,2], 
new approaches emphasizing active learning have been 
introduced and continue to be developed.
Evidence-base
Systematic reviews of the evidence are generally critical 
of the quality of reporting and methodology in many of 
the studies in this ﬁ eld, and point out the need for further 
research, and possible strategies for this [3-7]. In the 
technology report informing its guidance on the use of 
patient-education models, NICE provided a review, rather 
than formal meta-analysis, due to differences in design, 
duration, outcome measures and reporting of studies [4].
NICE excluded foot self-care education but otherwise 
reviewed the evidence on both general and focused self-
management education in Type 2 diabetes. The evidence 
from eight trials (6 RCTs, 2 CCTs) suggested that general 
self-management education has a limited impact on clinical 
outcomes, although few long-term data were available. The 
evidence from eight trials (7 RCTs, 1 CCT) of focused self-
management education (focused on one or two aspects of 
self-management) suggested that this may have some effect 
in reducing or maintaining HbA1c levels, although there was 
little evidence of impact on other clinical outcomes, partly 
because of short study durations. Also reviewed were four 
trials (3 RCTs, 1 CCT) that included people with Type 1 
or Type 2 diabetes, where there was some evidence that 
education may improve glycaemic control and quality of 
life, but little evidence about the longer-term beneﬁ ts of 
education. The other reviews painted a similar picture of 
educational interventions producing modest improvements 
in glycaemic control [5-7]. The NICE review commented that 
generally those studies reporting signiﬁ cant results used 
group interventions [4].
NICE found that costs depended on the type of programme 
offered, starting with a diabetes centre-based teaching 
programme spread over three afternoons. Although there 
is very little evidence regarding the cost-effectiveness of 
patient education in general, it was concluded that, given 
the relatively small costs associated with educational 
programmes, only small improvements in terms of morbidity 
or health-related quality of life were needed to make 
educational interventions cost effective [4]. 
Consideration
Despite the patchy evidence, certain common principles 
emerge and are reﬂ ected in the recommendations. 
Assessment of needs is fundamental to tailoring education 
to the perspective of the person with diabetes, while 
identiﬁ ed needs of the population served will determine 
the curriculum. Delivery of advice on nutrition (see Lifestyle 
management) or foot-care (see Foot care) or any other 
aspect of diabetes care would apply the same underlying 
educational principles outlined in these recommendations. 
It is noted that diabetes education was an integral part of 
intensiﬁ cation of care in the DCCT (in Type 1 diabetes), 
and that nutritional advice made a signiﬁ cant impact in the 
UKPDS cohort prior to randomization. Accordingly diabetes 
education is taken as an essential part of diabetes care. 
Implementation
Major components of implementing these recommendations 
are the recruitment of personnel and their training in the 
principles of both diabetes education and behaviour change 
strategies. These staff then need to develop structured 
education programmes for people with diabetes, supported 
by suitable education materials matched to the culture 
of the community served. Attention needs to be given to 
provision of space in an accessible location, and access to 
communication tools such as telephones. Levels of literacy 
and understanding need to be considered.
Evaluation
NICE suggests measures that could be used, for instance, to 
audit education for people newly diagnosed with diabetes [4]. 
These will include the presence of the multidisciplinary 
team, space and education resources, together with a local 
curriculum. There will be an entry within individual records 
of the offering and provision of education around the time 
of diagnosis, of annual assessment of educational need 
subsequently, and of provision of such education when the 
need is identiﬁ ed. 
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Other useful resources
Diabetes patient education is a large topic, and many health-
care professionals are unfamiliar with modern educational 
principles. The following documents are chosen as helpful 
resources for those wishing to develop materials (curriculum) 
and skills in this area.
ß IDF Consultative Section on Diabetes Education. 
International Curriculum for Diabetes Health Professional 
Education. Brussels: IDF, 2002. www.idf.org
  This comprehensive document deals with education of 
the diabetes health-care professionals, and is directed 
towards (though not solely applicable to) the diabetes 
educator.  
ß  European Diabetes Policy Group 1999. A Desktop Guide 
to Type 2 Diabetes Mellitus. Diabet Med 1999; 16: 716-30. 
www.staff.ncl.ac.uk/philip.home/guidelines
  This formal consensus guideline succinctly covers in three 
pages the appropriate approach to the education of 
someone with diabetes (initial and ongoing), and some of 
the content and issues which need to be addressed.  
ß  Diabetes Education Study Group of the European 
Association for the Study of Diabetes. Basic Curriculum for 
Health Professionals on Diabetes Therapeutic Education. 
2001. www.desg.org
  This approachable booklet sets out step by step to 
address the issues and skills which need to be understood 
and acquired by anyone seeking to deploy educational 
techniques in helping people with diabetes.  
ß WHO Working Group Report. Therapeutic Patient Education: 
Continuing education programmes for healthcare providers 
in the ﬁ eld of prevention of chronic diseases. Copenhagen: 
WHO Regional Ofﬁ ce for Europe, 1998.  
 This document again addresses the competencies needed 
by those delivering ‘therapeutic patient education’, and 
in so doing addresses to some extent the detail of areas 
to be covered in delivering a comprehensive education 
programme. 
Education
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Recommendations
n Standard care
PS1  In communicating with a person with diabetes, adopt a whole-person approach 
and respect that person’s central role in their care (see also Education, Lifestyle 
management).
 
   Communicate non-judgementally and independently of attitudes and beliefs.
PS2  Explore the social situation, attitudes, beliefs and worries related to diabetes 
and self-care issues.
  
   Assess well-being and psychological status (including cognitive dysfunction), 
periodically, by questioning or validated measures (e.g. WHO-5 [1]).  
   Discuss the outcomes and clinical implications with the person with diabetes, 
and communicate ﬁ ndings to other team members where appropriate.
PS3  Counsel the person with diabetes in the context of ongoing diabetes education 
and care.
PS4  Refer to a mental health-care professional with a knowledge of diabetes when 
indicated. Indications may include: adjustment disorder, major depression, 
anxiety disorder, personality disorder, addiction, cognitive dysfunction.
n Comprehensive care
PSC1  Principles of communication will be as for Standard care. 
PSC2  A mental health specialist (psychologist) would be included in the 
multidisciplinary diabetes care team.
PSC3  Periodic assessment and subsequent discussion would be as for Standard care, 
but could use additional measures [2-4] and computer-based automated scoring 
systems. The mental health specialist in the team would be able to provide a 
more comprehensive (neuro)psychological assessment, if indicated.
PSC4  Counselling would be as for Standard care, but the mental health specialist in the 
team would be available to offer psychological counselling, to participate in team 
meetings, and to advise other team members regarding behavioural issues.
Psychological care
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Rationale
Psychological well-being is itself an important goal of 
medical care, and psychosocial factors are relevant to nearly 
all aspects of diabetes management. Being diagnosed with 
diabetes imposes a life-long psychological burden on the 
person and his/her family. Having diabetes can be seen as an 
additional risk factor for developing psychological problems, 
and the prevalence of mental health problems in individuals 
with diabetes is therefore likely to exceed that found in the 
general population. Poor psychological functioning causes 
suffering, can seriously interfere with daily diabetes self-
management, and is associated with poor medical outcomes 
and high costs [5-7]. More serious psychological disorders 
need to be identiﬁ ed, and referral to a mental health 
specialist for diagnosis and treatment considered.
Ways in which health-care professionals can directly or 
indirectly help resolve behavioural and psychological 
issues, with the aim to protect and promote emotional 
well-being (quality of life) can be considered in terms 
of: 1. communication with the patient; 2. assessment or 
monitoring; and 3. counselling.
Evidence-base
Psychosocial aspects of diabetes care are included (to 
varying extents) in the guidelines from the CDA [8], SIGN [9], 
NICE (Type 1) [10] and ICSI [11] and, for the ﬁ rst time in 
2005, in the ADA standards of care [12]. NICE examined 
evidence from studies including people with Type 2 diabetes, 
particularly in the area of depression, which is the only topic 
addressed by ICSI and (for adults) by SIGN. Depression has 
been found to be twice as prevalent in people with diabetes 
compared with the general population [13] and is often 
under-detected [14].
Evidence-based guidelines for psychosocial care in adults 
with diabetes have been published under the auspices of 
the German Diabetes Association (DDG), indicating the 
level of evidence for psychological interventions in different 
problem areas [15].
There is RCT support for efﬁ cacy of antidepressant treatment 
(in a mixed group of Type 1 and Type 2 diabetes with 
major depressive disorder), and for cognitive behaviour 
therapy (in Type 2 diabetes with major depression) [8,14]. 
There is growing evidence that psychological counselling 
can contribute to improved adherence and psychological 
outcomes in people with diabetes [16]. A systematic review 
and meta-analysis has shown that, overall, psychological 
interventions are effective in improving glycaemic control in 
Type 2 diabetes [17].
Consideration
People coping with diabetes are more likely to be affected 
by mental health problems, and self-management is likely to 
be more difﬁ cult in the presence of such disorders. Detection 
of emotional problems in relatively brief consultations with 
diabetes professionals is likely to be problematic without 
a formal or structured approach. Lastly there is a clear 
need for some basic training for diabetes professionals in 
management issues in this area, and for appropriate referral 
pathways to mental health specialists with a knowledge of 
diabetes for people more seriously affected.
If followed by adequate treatment or referral, screening 
for mental health problems as part of routine diabetes care 
can help to improve patient satisfaction and psychological 
outcomes. 
Implementation
Agreement on the importance of psychological factors, and 
the underpinning philosophy of empowerment of people 
with diabetes, implies agreement within the care team on 
the relevance of psychological issues in diabetes. There is 
then a need for training of diabetes care team members 
in communication/interview skills, motivational techniques 
n Minimal care
PSM1  Principles of communication will be as for Standard care.
PSM2  Be alert to signs of cognitive, emotional, behavioural and social problems which may 
be complicating self-care, particularly where diabetes outcomes are sub-optimal.
PSM3  Refer for mental health specialist advice according to local availability of such 
professionals. 
Psychological care
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and counselling. Training of health-care professionals in the 
recognition of psychological problems will also be needed. 
Where resources allow, psychological assessment tools 
should be made available to diabetes teams, and health-care 
professionals should be trained in applying assessment/
monitoring procedures. Collaboration with mental health 
specialists who already have an interest in diabetes can help 
to extend the education/training of other mental health 
specialists in relation to diabetes.
Evaluation
Evaluate by number of psychological assessments in a 
given time-period, level of well-being and satisfaction in 
the managed population over a period of time (overall and 
by subgroups), and by number of referrals to mental health 
specialists, indications and outcomes. The training, and 
continuing education, of diabetes health-care team members 
can also be evaluated.
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Lifestyle management
Recommendations
n Standard care
LS1  Advise people with Type 2 diabetes that lifestyle modiﬁ cation, by changing 
patterns of eating and physical activity, can be effective in controlling many 
of the adverse risk factors found in the condition.
LS2  Provide access to a dietitian (nutritionist) or other health-care professional 
trained in the principles of nutrition, at or around the time of diagnosis, 
offering one initial consultation with two or three follow-up sessions, 
individually or in groups. 
LS3  Provide ongoing counselling and assessment yearly as a routine, or more 
often as required or requested, and when changes in medication are made.
LS4  Individualize advice on food/meals to match needs, preferences, and culture.
LS5   Advise control of foods with high amounts of sugars, fats or alcohol. 
LS6   Integrate drug therapy, where needed, into the individual’s chosen lifestyle. 
LS7   For people choosing to use ﬁ xed insulin regimens, advise consistent 
carbohydrate intake at meals. For these people, as well as those on ﬂ exible 
meal-time + basal insulin regimens, offer education on assessment of 
carbohydrate content of different types of foods. 
LS8   Provide advice on the use of foods in the prevention and management of 
hypoglycaemia where appropriate. 
LS9   Introduce physical activity gradually, based on the individual’s willingness 
and ability, and setting individualized and speciﬁ c goals. 
LS10   Encourage increased duration and frequency of physical activity (where 
needed), up to 30-45 minutes on 3-5 days per week, or an accumulation of 
150 minutes of physical activity per week. 
LS11   Provide guidelines for adjusting medications (insulin) and/or adding 
carbohydrate for physical activity. 
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Lifestyle management
Rationale
People with Type 2 diabetes often have lifestyles (eating 
and physical activity) which contribute to their problem. It is 
essential they receive help soon after diagnosis to consider 
how they may modify lifestyle in ways which enable them to 
take control of their blood glucose, blood lipid and blood 
pressure abnormalities, even if they also require drug therapy 
in the short or longer term (see Glucose control: therapy).
Evidence-base
Evidence supports the effectiveness of nutrition therapy 
and physical activity in the prevention and management of 
Type 2 diabetes [1-4]. This is reﬂ ected in the current ADA 
standards of medical care [5] (which draw on a detailed 
evidence-based technical review on nutrition [6] and a more 
recent review on physical activity [2]) and in the Canadian 
guideline [7]. An earlier UK guideline [8] pointed out that 
LS12  Both nutrition therapy and physical activity training should be incorporated 
into more broadly based diabetes self-management training programmes 
(see Education). 
LS13  For weight reduction in people with Type 2 diabetes who are obese, it may 
sometimes be appropriate to consider weight loss medications as adjunct therapy. 
n Comprehensive care
LSC1  Advice on lifestyle management will in general be as for Standard care. 
LSC2  Education might also be provided as a routine for special topics such as label 
reading, restaurant eating, special occasions. 
LSC3  Intensive personal counselling might be offered on a regular basis with a 
health-care professional speciﬁ cally trained in the principles of nutrition, to 
facilitate maintenance of lifestyle modiﬁ cations and support weight loss or 
weight maintenance.
LSC4  Exercise testing could be available for those considering programmes of 
physical activity. 
LSC5  Aerobic and resistance training sessions might be available, with individualized 
testing and education by exercise specialists, and continued support from them. 
n Minimal care
LSM1  The principles of lifestyle management are as for Standard care.
LSM2  Offer basic nutrition guidelines (healthy food choices) for improved glycaemic 
control.
LSM3  Advise on ways to reduce energy intake (carbohydrate, fat, alcohol as 
appropriate).
LSM4  Provide nutritional counselling from someone with training in nutrition 
therapy, around the time of diagnosis, then as assessed as being necessary, 
or more often as required or requested. 
LSM5  Advise and encourage participation in regular physical activity. 
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involvement in a lifestyle study, even in the control group, 
can be beneﬁ cial, but that lifestyle modiﬁ cation can be 
difﬁ cult to achieve and maintain. That guideline expressed 
some concern over methodological problems in trials of 
complex and multifactorial interventions. Most studies have 
been short-term (a problem currently being addressed in a 
US trial), and we do not yet know the ongoing contribution 
of lifestyle measures once medication has been introduced, 
or what kind of support is required on a continuing basis. It 
may be noted that in the UKPDS initial dietary education was 
very effective in lowering blood glucose after diagnosis, and 
that some people were then able to maintain target glucose 
control for many years by diet modiﬁ cation alone [9,10].
Randomized controlled trials and outcome studies of medical 
nutrition therapy (MNT) in the management of Type 2 diabetes 
have reported improved glycaemic outcomes (HbA1c decreases 
of 1.0-2.0 %, depending on the duration of diabetes). MNT in 
these studies was provided by dietitians (nutritionists) as MNT 
only or as MNT in combination with diabetes self-management 
training. Interventions included reduced energy intake and/
or reduced carbohydrate/fat intake, and basic nutrition and 
healthy food choices for improved glycaemic control. Outcomes 
of the interventions were measurable by 3 months [6,7,11-15].
In a meta-analysis of non-diabetic people, MNT restricting 
saturated fats to 7-10 % of daily energy and dietary cholesterol 
to 200-300 mg daily resulted in a 10-13 % decrease in total 
cholesterol, 12-16 % decrease in LDL cholesterol and 8 % 
decrease in triglycerides [16]. An expert committee of the 
American Heart Association documented that MNT typically 
reduced LDL cholesterol 0.40-0.65 mmol/l (15-25 mg/dl) [17]. 
Pharmacological therapy should be considered if goals are not 
achieved between 3 and 6 months after initiating MNT. 
A meta-analysis of studies of non-diabetic people reported 
that reductions in sodium intake to ≤2.4 g/day decreased 
blood pressure by 5/2 mmHg in hypertensive subjects. Meta-
analyses, clinical trials and expert committees support the 
role of reduced sodium intake, modest weight loss (4.5 kg), 
increased physical activity, a low-fat diet that includes fruits, 
vegetables and low-fat dairy products, and moderate alcohol 
intake, in reducing blood pressure [18]. 
A meta-analysis of exercise (aerobic and resistance training) 
reported an HbA1c reduction of 0.66 %, independent of 
changes in body weight, in people with Type 2 diabetes [19]. 
In long-term prospective cohort studies of people with Type 2 
diabetes, higher physical activity levels predicted lower long-
term morbidity and mortality and increases in insulin sensitivity. 
Interventions included both aerobic exercise (such as walking) 
and resistance exercise (such as weight-lifting) [2,20,21].
The Canadian guideline has a section on the management 
of obesity in Type 2 diabetes, which addresses lifestyle 
measures and also drug and surgical options [7]. 
Consideration
It is noted that in general costs of educational initiatives 
to change lifestyle are low, because unlike drug therapy 
they are provided on an intermittent rather than continuing 
basis. From a health-provider perspective many of the 
costs fall outside their budget, healthier foods and exercise 
programmes and equipment generally being a cost met 
directly by the person with diabetes. For these reasons, 
and because, for glucose control, the gain from lifestyle 
modiﬁ cation is greater than that from any individual 
therapy, lifestyle measures are heavily promoted. Lifestyle 
modiﬁ cation is, however, sometimes difﬁ cult for the 
individual to maintain in the long term, or to develop further 
after early changes have been made. Where professional 
nutritionists are unavailable, it was noted that other health-
care professionals should be trained in basic nutritional and 
other lifestyle education. 
Implementation
Recognition of the importance and cost-effectiveness 
of lifestyle interventions should drive allocation of 
resources required for care and self-management training. 
Implementation demands knowledgeable and competent 
personnel, and dietitians/nutritionists and other health-care 
professionals may require training to be effective providers 
of lifestyle interventions. Consistency of approach to lifestyle 
issues across the diabetes care team is an important principle 
here. A process is needed to enable people to gain access to 
services as required.
Self-management counselling in nutrition (for individuals or 
groups) has four components: 1. assessment; 2. identiﬁ cation 
of the nutrition problem; 3. intervention that integrates 
nutrition therapy into overall diabetes management and 
implementation of self-management training; and 4. nutrition 
monitoring and evaluation of outcomes. A similar approach 
needs to be taken for physical activity. Development of 
educational materials, or adaptation of them from elsewhere, 
is needed.
Evaluation
Services should be able to show the availability of 
appropriately trained personnel, and records that individuals 
with diabetes have contact with them around the time of 
diagnosis and at regular intervals thereafter. Educational 
Lifestyle management
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support materials should also be demonstrable. Outcomes 
can be assessed in terms of improvement in appropriate 
food choices and amounts, and responses to questioning 
about physical activity levels and, where appropriate, alcohol 
consumption. Metabolic measures are, however, likely to be 
confounded by changes in drug therapies. 
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Glucose control levels
Recommendations 
n Standard care
TT1  Advise people with diabetes that maintaining a DCCT-aligned HbA1c below 
6.5 % should minimize their risk of developing complications. 
TT2  Provide lifestyle and education support, and titrate therapies, to enable 
people with diabetes to achieve a DCCT-aligned HbA1c below 6.5 % (where 
feasible and desired), or lower if easily attained.
TT3  Advise those in whom target HbA1c levels cannot be reached that any 
improvement is beneﬁ cial.
TT4  Sometimes raise targets for people on insulin or sulfonylurea therapy in 
whom attainment of tighter targets may increase the risk of hypoglycaemic 
episodes, which may present particular problems for people with other 
physical or mental impairment.
TT5  Equivalent target levels for capillary plasma glucose levels are <6.0 mmol/l 
(<110 mg/dl) before meals, and <8.0 mmol/l (<145 mg/dl) 1-2 h after meals.  
 
n Comprehensive care
TTC1  The intervention levels are as for Standard care, but it may be possible to 
devote more resources to achieving lower target levels without adverse 
impact on health.
n Minimal care
TTM1  The intervention levels are as for Standard care, but may need to be based 
on measurement of plasma glucose levels alone.
Plasma glucose is the preferred measure of most modern laboratories. Whole 
blood gives lower readings due to the volume occupied by haemoglobin. Capillary 
blood glucose strips measure the glucose in the plasma of the capillary blood 
sample, but may be calibrated to give results either as plasma or whole blood 
glucose (check meter instructions). 
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Rationale
The UKPDS established the importance of glucose control 
in prevention of vascular complications in people with 
Type 2 diabetes. The issue then arises as to the desirable 
level of glucose control to be achieved. In an ideal world 
this would be ‘normal’, but if the available lifestyle and 
pharmaceutical therapies are less than optimal in terms of 
efﬁ cacy and adverse effects on quality of life, or if these 
therapies are expensive, then some compromise (varying 
between individuals and health-care systems) will be needed. 
The chosen measures of glucose control (HbA1c and self-
monitoring) are discussed elsewhere (see Clinical monitoring, 
Self-monitoring) – this section deals with target levels. 
The concept of targets is open to criticism – they may be 
unattainable, they may limit what could be attained, and 
they may be uneconomic to attain. However, without some 
form of targeted control of an asymptomatic condition it 
becomes difﬁ cult to promote care at all. Targets are often 
better thought of as ‘assessment levels’ and ‘intervention 
levels’. 
Evidence-base
The evidence for a target level of control is rarely the subject 
of an RCT. However, the epidemiological analyses of the 
UKPDS [1] can be informative in setting targets. Other 
evidence will usually come from cohort and cross-sectional 
epidemiological studies [2,3]. While target levels have been 
set by a number of organizations (including the ADA [4,5] 
and IDF (Europe) [6]) and in the NICE Type 2 diabetes [7] 
and Canadian guidelines [8], they are rarely supported by 
any kind of formal discussion of literature. There is however 
a high degree of conformity of the recommendations. The 
NICE Type 1 diabetes guideline does attempt to derive its 
recommendations with more rigour, and while this is largely 
directed to microvascular prevention, the argument relating 
to prevention of arterial disease in people with Type 1 
diabetes can be usefully extrapolated to people with 
Type 2 diabetes in general [9]. 
The UKPDS shows that good glucose control is attainable 
at least in the early years; this is consistent with many 
other intervention studies of different therapies. The 
issue of whether a microvascular control threshold might 
or might not exist for glucose control seems not to be 
relevant to most people with Type 2 diabetes, as the 
targets for glucose control for prevention of arterial 
disease are lower when set separately (by NICE [9] and the 
European Policy Group [6]); thus the issue is primarily that 
of arterial risk prevention. 
Epidemiological evidence shows a relationship between 
HbA1c and development of cardiovascular disease even 
within the normal range of HbA1c [10]. This suggests that 
normal or even low normal is to be preferred, if attainable 
at reasonable cost and effort. However, this is virtually never 
attained in clinical studies of therapies. What is clear is that 
arterial risk in a population with diabetes (UKPDS) decreases 
down to a DCCT-aligned HbA1c of 5.5 % (compared with 
normal range of <6.1 %), the lowest level achieved over 
time for a signiﬁ cant group of people in that study. Use 
of glucose-lowering therapies was highly cost-effective in 
UKPDS [11], and accordingly 6.5 % is the target/intervention 
level recommended in the NICE Type 1 [9] and Type 2 
guidelines [7]. 
Translation of this into self-monitored capillary (whole blood 
or plasma calibrated) levels is not simple. The upper level 
of fasting plasma glucose is usually taken as 5.5 mmol/l 
(100 mg/dl), which might then equate with a DCCT-aligned 
HbA1c of 6.1 %. Studies with newer insulins achieving 
pre-breakfast glucose levels of ~6.0 mmol/l (~110 mg/dl) 
typically return DCCT-aligned HbA1c results of ~7.0 % [12], 
but glucose proﬁ les in these studies show rising glucose 
levels through the day, explaining the inconsistency. 
Regression equations between capillary measured whole 
blood glucose or plasma glucose and HbA1c referable to the 
DCCT assay have been published for Type 1 diabetes [13,14], 
but these combine pre-prandial and post-prandial tests 
through the day, and reﬂ ect the different proﬁ les of glucose 
control seen in that type of diabetes.   
The case for targeting post-prandial blood glucose control 
can be made on many grounds, none of them RCT-based. 
Overall the case is compelling, not least by the simple logical 
observation that the outcome trials have established the 
utility of lowering blood glucose levels overall, while the 
highest levels of the day are generally after meals. That 
post-prandial levels may be particularly pathophysiological 
for the endothelium is generally based around arguments 
surrounding 2-h OGTT post-challenge glucose concentrations 
rather than post-prandial levels. As post-challenge levels seem 
closely related to the features of the metabolic syndrome the 
argument for a special relationship to vascular damage is still 
limited, and the approach adopted in this document is simply 
to use the average relationship to basal glucose levels in 
people in good blood glucose control. 
Consideration
The intervention level/assessment level has been taken as a 
DCCT-aligned HbA1c of 6.5 %, with a target level less than 
that if easily achieved. This is taken as translating to basal self-
Glucose control levels
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monitored plasma glucose levels <6.0 mmol/l (<110 mg/dl), 
with post-prandial target levels of <8.0 mmol/l (<145 mg/dl).
Implementation
These targets should be incorporated in local protocols and 
guidelines detailing methods for evaluating and advising on 
lifestyle and pharmaceutical therapies as the natural history 
of the condition evolves.
Evaluation
Glucose targets (as given above) should be present in local 
guidelines and protocols. Audit is of attained glucose control 
on different types of therapy. 
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Recommendations
n Standard care
MO1  Monitor blood glucose control by high-precision methods of HbA1c performed 
every 2 to 6 months depending on level and stability of blood glucose control, 
and change in therapy. 
MO2  Report all HbA1c results DCCT-aligned, pending internationally concerted policy 
changes.
MO3  Provide site-of-care measurement of HbA1c, or laboratory measurement before 
clinical consultation.
MO4  Communicate the HbA1c result to the person with diabetes. The term ‘A1c’ may be 
useful in some populations.
MO5  Use appropriate alternative measures where HbA1c methods are invalidated by 
haemoglobinopathy or abnormal haemoglobin turnover.
MO6  Do not use fructosamine as a routine substitute for HbA1c measurement; it may be 
useful where HbA1c is not valid. 
MO7  Site-of-care capillary plasma glucose monitoring at random times of day is not 
generally recommended.   
n Comprehensive care
MOC1  This would be as for Standard care, but continuous glucose monitoring is an 
additional option in the assessment of glucose proﬁ les in people with consistent 
glucose control problems, or with problems of HbA1c estimation.
MOC2  HbA1c estimation would be available at each visit, and provided in electronic or paper 
diary form to the person with diabetes. 
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Rationale
Type 2 diabetes shows progression of hyperglycaemia 
with time, and causes organ damage through controllable 
hyperglycaemia. Accordingly hyperglycaemia has to be 
monitored. Some of this will be performed by the person 
with diabetes, some by site-of-care tests, and some by 
laboratory methods which can be referenced to studies of 
control and complications. 
Evidence-base
In general the major national guidelines do not address this 
area in detail. An exception is the 2004 NICE guideline for 
Type 1 diabetes [1]. This can be seen as applicable in terms 
of the methods proposed for clinic and ofﬁ ce monitoring, 
and in particular for people using insulin therapy. Other 
guidelines and the ADA standards [2] do also centre on the 
HbA1c assay for clinic/ofﬁ ce monitoring of glucose control, 
while laboratory guidelines address available methods and 
their quality implementation [3]. 
The central role for the HbA1c assay largely derives from 
its position in the reports of the major outcomes studies 
(the DCCT [4] and the UKPDS [5]). These provide the main 
method by which clinicians can relate individual blood 
glucose control to risk of complication development [6], 
and make HbA1c mandatory where affordable/available. The 
laboratory and site-of-care assays are precise and accurate 
if appropriately controlled and aligned with international 
standards. However, a number of issues still surround the 
results reported, including problems affecting haemoglobin 
itself (turnover or structural abnormalities [7]) and the 
absolute assay standard used. These issues in turn affect the 
recommendation to use HPLC-based assays where feasible, 
in order to detect haemoglobin variants. Additionally there 
are recommendations in the published guidelines on site-
of-care testing, and on communication of the result to the 
person with diabetes. 
Random clinic plasma glucose testing is not seen as having 
a role in quality diabetes care. Where HbA1c is unavailable, 
timed glucose levels are often recommended as a substitute 
(see also Self-monitoring). Recommendations are then made 
over the quality control of devices used to make such site-of-
care tests. Continuous ambulatory blood glucose monitoring 
has become available in recent years. There is still no good 
evidence-base for its use, particularly in people with Type 2 
diabetes. 
Consideration
The central role for site-of-care quality-controlled DCCT-
aligned HbA1c testing was found to be solid. Blood glucose 
testing per se, using quality controlled methods, was 
noted to have a role in certain circumstances. The role of 
continuous monitoring remains to be established. 
Implementation
There should be access to a laboratory or site-of-care test 
that participates in a certiﬁ ed quality assurance scheme for 
measurement of HbA1c. People for whom HbA1c measurement 
is inappropriate must be identiﬁ ed; HPLC can detect 
haemoglobinopathies. Organization to allow site-of-care or 
prior-to-visit sampling is also needed. Provision of capillary 
blood glucose meters and strips needs to be assured (if used). 
It is essential to establish whether meters report values for 
plasma or blood and to ensure that schemes for monitoring 
the quality of their output are in place. 
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n Minimal care
MOM1  Fasting plasma glucose measurement could be used for monitoring.
MOM2  Site-of-care capillary blood glucose meters should be quality controlled by 
reference to laboratory methods.
MOM3  Visually read glucose test strips have a role in emergency and remote situations 
where maintenance of functional meters is not feasible.
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Evaluation
This is of the presence of records of HbA1c results in patient 
records, and documented evidence of the quality of 
performance of the assay system.  
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Recommendations 
n Standard care
SM1  Self-monitoring of blood glucose (SMBG) should be available for all 
newly diagnosed people with Type 2 diabetes, as an integral part of 
self-management education.
SM2  SMBG (using meter and strips) on an ongoing basis should be available 
to those on insulin treatment.
SM3  SMBG should be considered on an ongoing basis for people using oral 
agents, but not insulin, where it is used:
  ß  to provide information on hypoglycaemia
  ß  to assess glucose excursions due to medications and lifestyle changes
  ß  to monitor changes during intercurrent illness.
SM4  SMBG should be considered on an intermittent basis for people not using 
insulin or oral agents, where it is used:
  ß  to assess glucose excursions due to lifestyle changes
  ß  to monitor changes during intercurrent illness.
SM5  Structured assessment of self-monitoring skills, the quality and use made of 
the results obtained, and of the equipment used, should be made annually. 
n Comprehensive care
SMC1  This would be as Standard care, but SMBG (using meter and strips) on an 
ongoing basis could be offered to all people with Type 2 diabetes on insulin 
or oral agents. 
n Minimal care
SMM1  SMBG using meters with strips, or visually read blood glucose strips, should 
be considered for those on insulin therapy.
Self-monitoring
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Rationale
Self-monitoring of glucose is widely used in the care plans 
of many people with Type 2 diabetes. It is often used to 
complement HbA1c measurement to assess blood glucose 
control and, in the case of self-monitoring of blood glucose 
(SMBG), provides real-time feedback of blood glucose levels. 
Its use can be considered in relation to:
ß  outcomes (a decrease in HbA1c with the ultimate aim of 
decreasing risk of complications)
ß safety (identifying hypoglycaemia) 
ß process (education, self-empowerment, changes in 
therapy). 
Self-monitoring should only be considered when the person 
with diabetes is prepared to learn the skill, record the ﬁ ndings, 
understand the data, and act appropriately on the data. 
Urine glucose testing is cheap but has limitations. Urine 
free of glucose is an indication that the blood glucose level 
is below the renal threshold, which usually corresponds to 
a blood glucose level of about 10.0 mmol/l (180 mg/dl). 
Positive results do not distinguish between moderately 
and grossly elevated levels, and a negative result does not 
distinguish between normoglycaemia and hypoglycaemia.
Evidence-base
The rather unsatisfactory evidence-base surrounding self-
monitoring is addressed by guidelines from NICE [1,2] 
and the CDA [3]. Most of the evidence has focused on 
self-monitoring in relation to outcomes. Studies on self-
monitoring in Type 2 diabetes were found to have been 
limited by small numbers, short duration, inconsistencies 
in monitoring and in the training of patients in technique 
or use of data, and failure to stratify by treatment type. A 
meta-analysis in 2000 found eight randomized trials, but 
no evidence for clinical effectiveness of this component 
of care [4]. A large observational study subsequently 
found evidence for improved glycaemic control with more 
frequent self-monitoring, regardless of therapy, but there 
was no stratiﬁ cation of new and ongoing users [5], and 
the NICE working group drew attention to the problem of 
separating out the effects of motivation in observational 
studies [1]. 
It is generally accepted that SMBG is useful in insulin-
treated Type 2 diabetes [1,3,5]. Two recent meta-analyses 
of RCTs have examined its effect in people with Type 2 
diabetes not treated with insulin [6,7]. Both showed that 
SMBG achieved a statistically signiﬁ cant reduction of 0.4 % 
in HbA1c. However, it was acknowledged that the quality of 
the studies was limited and that a well designed RCT was 
needed to resolve this issue. Two accompanying point-of-
view papers reached opposite conclusions about the value 
of SMBG [8,9]. 
There are many unresolved questions about SMBG, including 
frequency and timing of testing, its value in new users and 
ongoing users, and if and how users act on the results.
There are limited data on the impact of SMBG on quality of 
life and treatment satisfaction. From the two studies which 
reported on this [10,11], there was no difference compared 
with people who were not performing SMBG.
Also there are few data on self-monitoring using urine 
glucose testing. The meta-analysis by Welschen et al. [7] 
included two studies which compared SMBG and self-
monitoring of urine glucose and reported a non-signiﬁ cant 
reduction in HbA1c of 0.17 % in favour of SMBG.
Two large cohort studies of self-monitoring of blood glucose 
in people with Type 2 diabetes, and including people not 
using insulin, have been submitted for publication at the 
time of writing (one presented at an ACE meeting in January 
2005, and one presented as late-breaking data at the 2005 
ADA Scientiﬁ c Sessions). The data of these studies support 
the recommendations given above. However, a very recent 
publication addressing the same issue could not ﬁ nd such 
supportive evidence [12].   
Consideration
Self-monitoring of blood glucose is accepted as an integral 
part of self-management of people on insulin therapy. 
However, the data are less clear for people who are not 
being treated with insulin, and therefore the decision as to 
whether to recommend SMBG for this group will largely 
be determined by cost and individual and health-care 
system resources. Priority lists may be needed to decide 
which individuals should be offered SMBG on an ongoing 
basis. These might include people recently diagnosed 
with diabetes, with more erratic lifestyles, people having 
problems of hypoglycaemia, and those particularly keen to 
tighten their blood glucose control. 
There is little evidence to support the use of urine testing. 
However, it should be noted that a recent IDF position 
statement has drawn attention to the fact that urine strips 
are cheap and that urine testing, although grossly inaccurate 
as a measure of blood glucose control, was used prior to the 
1970s as the only means of self-monitoring, and could still be 
useful if its limitations are clearly understood [13].  
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Implementation
Provision should be made for the supply of glucose strips 
on a continuing basis. When providing meters, education in 
their use and in interpretation of results from them should 
be given. Review of technique, data interpretation, and 
meter function should be a part of Annual Review (see Care 
delivery). 
Evaluation
Provision of self-monitoring education and equipment should 
be assessed, and protocols and a record of review as part 
of Annual Review should be available. There should be 
evidence of the results being made use of by the person with 
diabetes and in other clinical consultations with health-care 
professionals.  
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Recommendations
n Standard care
OA1   Begin oral glucose-lowering drugs when lifestyle interventions alone are unable 
to maintain blood glucose control at target levels (see Glucose control levels). 
  
   Maintain support for lifestyle measures throughout the periods of use of these 
drugs. 
 
   Consider each initiation or dose increase of an oral glucose-lowering drug as a 
trial, monitoring the response in 2-6 months.
OA2  Begin with metformin unless evidence or risk of renal impairment, titrating 
the dose over early weeks to minimize discontinuation due to gastro-intestinal 
intolerance.
 
   Monitor renal function and risk of signiﬁ cant renal impairment (eGFR <60 ml/min/
1.73 m2) in people taking metformin.
OA3  Use sulfonylureas when metformin fails to control glucose concentrations to 
target levels, or as a ﬁ rst-line option in the person who is not overweight. 
 
   Choose a drug of low cost, but exercise caution if hypoglycaemia may be a 
problem to the individual, including through renal impairment. 
 
   Provide education and, if appropriate, self-monitoring (see Self-monitoring) to 
guard against the consequences of hypoglycaemia.
 
   Once-daily sulfonylureas should be an available option where drug 
concordance is problematic.
 
   Rapid-acting insulin secretagogues may be useful as an alternative to 
sulfonylureas in some insulin-sensitive people with ﬂ exible lifestyles.
OA4  Use a PPAR-γ agonist (thiazolidinedione) when glucose concentrations are not 
controlled to target levels, adding it: 
  ß  to metformin as an alternative to a sulfonylurea, or 
  ß  to a sulfonylurea where metformin is not tolerated, or 
  ß  to the combination of metformin and a sulfonylurea.  
 
   Be alert to the contra-indication of cardiac failure, and warn the person with 
diabetes of the possibility of development of signiﬁ cant oedema.
Glucose control: oral therapy
35Global Guideline for Type 2 Diabetes
09
OA5  Use α-glucosidase inhibitors as a further option. They may also have a role in 
some people intolerant of other therapies.
OA6  Step up doses, and add other oral glucose-lowering drugs, at frequent 
intervals until blood glucose control is at target levels. Consider whether the 
rate of deterioration suggests insulin therapy will be needed early despite 
such measures. 
n Comprehensive care
OAC1  The principles of use of oral glucose-lowering drugs are as for Standard care. 
Metformin remains the drug of choice for ﬁ rst-line therapy.
n Minimal care
OAM1  Metformin and a generic sulfonylurea should be the basis of oral glucose-
lowering therapy. Where the costs of thiazolidinedione therapy are lower than 
those of basic insulin therapy, use of these drugs may be considered before 
transfer to insulin. 
OAM2  Where renal function tests are not routinely available for people on 
metformin, such tests are nevertheless required where the likelihood of renal 
impairment is high.
Rationale
The evidence that elevated blood glucose levels can result 
in various forms of vascular damage is discussed elsewhere 
in this guideline (see Glucose control levels). Lifestyle 
modiﬁ cation (see Lifestyle management) by itself can only 
provide control of blood glucose concentrations to safe 
target levels in a minority of people with diabetes, and then 
usually only for a limited period after diagnosis. Accordingly, 
supplementary pharmaceutical measures are needed, 
and these can be oral glucose-lowering drugs and insulin 
injection therapy, separately or in combination. 
Evidence-base
A number of systematic evidence-based reviews addressing 
oral glucose-lowering drugs have been published in recent 
years [1-4]. These nearly always use the UKPDS as the basis 
of a conclusion that glucose lowering with oral drugs is 
effective in protection against vascular complications [5]. 
They also conclude that the evidence on better prevention 
of arterial outcomes when using metformin in the overweight 
sub-study of UKPDS [6] supports the primary use of that drug 
in all overweight people with Type 2 diabetes, and indeed 
probably in all people with Type 2 diabetes. 
The reviews note that UKPDS in particular conﬁ rms that 
hyperglycaemia in people with diabetes is a progressive 
condition due to progressive islet B-cell failure, and thus 
requires continued monitoring and stepping up of therapies 
to maintain glucose control targets. The NICE guideline [2] 
notes the problem of concordance with multiple therapies 
(particularly as people will often be on blood-pressure-lowering, 
lipid-lowering, and cardiovascular medications), and suggests 
once-daily drugs may have advantage in many circumstances.
Review of effectiveness of glucose lowering concludes 
that the drugs from different classes are generally similar, 
except that α-glucosidase inhibitors may be less efﬁ cacious 
than sulfonylureas [1,2,7]. Other evidence suggests that 
nateglinide, a rapid-acting insulin secretagogue, is also less 
efﬁ cacious in this regard. 
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The two available PPAR-γ agonists (thiazolidinediones), 
while as effective as metformin and sulfonylurea in lowering 
glucose levels, are found to have other positive effects 
on risk factors associated with cardiovascular disease, 
but mixed effects on lipoproteins [8-10]. The former 
include improvements in vascular inﬂ ammation, albumin 
excretion rate, blood pressure, endothelial and clotting 
factors, and insulin insensitivity. At the time of review, no 
studies have conﬁ rmed that these effects give beneﬁ cial 
health outcomes, but some of the effects are qualitatively 
similar in nature, but quantitatively greater, than are found 
with metformin. Systematic reviews of the α-glucosidase 
inhibitors have not found reason to recommend them over 
less expensive and better tolerated drugs [1,2,7].  
Lactic acidosis is a rare complication (often fatal) of 
metformin therapy in people with renal impairment. 
Gastro-intestinal intolerance of this drug is very common, 
particularly at higher dose levels and with fast upward 
dose titration. Some sulfonylureas, notably glyburide, are 
known to be associated with severe hypoglycaemia and 
rarely death from this, again usually in association with renal 
impairment. Thiazolidinediones can cause ﬂ uid retention 
and are contra-indicated in the presence of higher grades 
of heart failure [11]. 
Generic metformin and sulfonylureas are available at very 
low cost. Proprietary oral glucose-lowering drugs are 
considerably more expensive, with limited evidence of extra 
beneﬁ t. Thiazolidinediones are relatively new drugs and are 
also usually expensive.  
Consideration
The outcome-based evidence from the UKPDS for the use 
of metformin in overweight people with Type 2 
diabetes, exceeding that for any other drug, leads 
to its recommendation for ﬁ rst-line use, although the 
sulfonylureas also protected against vascular damage 
in that study. Cheap generic versions of these drugs 
are available, and their glucose-lowering capacity is not 
surpassed by any newer drug, at least on a population 
basis. However, tolerance and safety issues are of concern 
with metformin, the latter particularly if renal impairment 
is present. Concern over hypoglycaemia with some of the 
sulfonylureas is also felt to be of signiﬁ cance, especially with 
renal impairment. The evidence on the thiazolidinediones, 
effective in glucose-lowering and in having positive effects 
on some cardiovascular risk markers, would now seem to 
justify an early role for these drugs in combination oral 
agent therapy. However, they remain relatively expensive 
in most health-care markets.   
Combination of oral glucose-lowering drugs with insulin 
therapy is discussed below (see Insulin therapy).
Implementation
Contracts should be in place for uninterrupted availability 
of at least one sulfonylurea, metformin and (for standard/
comprehensive care) at least one thiazolidinedione. 
Availability is needed of an HbA1c assay and visits to health-
care professionals at a frequency (sometimes 3-monthly) 
sufﬁ cient to titrate therapy where glucose control is 
deteriorating. Lifestyle measures, self-monitoring where 
appropriate, and education, as discussed elsewhere in this 
guideline, are integral parts of maintaining glucose control to 
target, and will enhance the effectiveness of oral drugs. The 
recommendations should be a basis of local clinical protocols 
and structured records.
Evaluation 
Evaluation of achieved blood glucose control should be 
by reference to the documented use of oral therapies and 
insulin in different combinations to identify appropriately 
early use of these drugs, and in the appropriate order. 
Reference to measures of renal and cardiac failure may be 
used to identify use where contra-indications apply. Local 
protocols should be identiﬁ able.
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Recommendations
n Standard care
IN1   Begin insulin therapy when optimized oral glucose-lowering drugs and lifestyle 
interventions are unable to maintain blood glucose control at target levels (see 
Glucose control levels). 
 
   Maintain support for lifestyle measures after introduction of insulin. 
 
   Consider every initiation or dose increase of insulin as a trial, monitoring the 
response.
IN2  Explain to the person with diabetes from the time of diagnosis that insulin is one 
of the options available to aid management of their diabetes, and that it may turn 
out to be the best, and eventually necessary, way of maintaining blood glucose 
control, especially in the longer term.
IN3  Provide education, including on continuing lifestyle management (see Education, 
Lifestyle management), and appropriate self-monitoring (see Self-monitoring).
 
   Explain that starting doses of insulin are low, for safety reasons, but that eventual 
dose requirement is expected to be 50-100 units/day.
 
   Initiate insulin therapy before poor glucose control develops, generally when 
DCCT-aligned HbA1c has deteriorated to >7.5 % (conﬁ rmed) on maximal oral 
agents. 
 
   Continue metformin. Additionally continue sulfonylureas when starting basal 
insulin therapy. α-Glucosidase inhibitors may also be continued.
IN4 Use: 
  ß  a basal insulin once daily such as insulin detemir, insulin glargine, or NPH 
insulin (risk of hypoglycaemia is higher with the last), or
  ß  twice daily premix insulin (biphasic insulin) particularly with higher HbA1c, or
  ß  multiple daily injections (meal-time and basal insulin) where blood glucose 
control is sub-optimal on other regimens, or meal-time ﬂ exibility is desired.
IN5  Initiate insulin using a self-titration regimen (dose increases of 2 units every 3 
days) or by weekly or more frequent contact with a health-care professional 
(using a scaled algorithm).
Glucose control: insulin therapy
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   Aim for pre-breakfast and pre-main-evening-meal glucose levels of <6.0 mmol/l 
(<110 mg/dl); where these seem not to be achievable use monitoring at other 
times to identify the proﬁ le of poor glucose control. 
IN6   Continue health-care professional support by telephone until target levels (see 
Glucose control levels) are achieved.
IN7  Use pen-injectors (preﬁ lled or re-usable) or syringes/vials according to choice 
of the person using them.
IN8  Encourage subcutaneous insulin injection into the abdominal area (most rapid 
absorption) or thigh (slowest), with the gluteal area (or the arm) as other 
possible injection sites. Bear in mind that reluctance to use the abdominal 
region may relate to cultural background.
n Comprehensive care
INC1  The principles of insulin use are as for Standard care.
INC2   Insulin analogues would generally be used.
INC3  Where permitted and appropriate, combination use of insulin and a PPAR-γ� 
agonist is an option, with cautions over cardiac failure. 
INC4  Insulin pump therapy may be an additional option. 
n Minimal care
INM1  The principles of insulin use, including professional support, are as for Standard 
care. Self-monitoring may be limited to pre-breakfast and pre-evening-meal.
INM2  Use a combination of an oral glucose-lowering drug (usually metformin) with 
NPH insulin twice daily (or once daily if initiated early), or twice-daily insulin 
mixes.
INM3  The supplied insulin should be of assured and consistent quality and type.
INM4 Use insulin syringes and vials.
Rationale
The rationale for the use of glucose-lowering therapy 
titrated to blood glucose targets is given in the section 
on oral agents. The natural history of Type 2 diabetes is of 
progression of islet B-cell failure – insulin remains the only 
glucose-lowering therapy which can maintain blood glucose 
control despite such progression. 
Evidence-base
The evidence-based guidelines addressing insulin use in 
Type 2 diabetes [1-3] draw on the evidence from UKPDS 
that insulin was among the glucose-lowering therapies 
which, considered together, reduced vascular complications 
compared with ‘conventional’ therapy [4]. The options for 
insulin therapy (preparations, delivery) have expanded 
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considerably since the UKPDS. The NICE evidence review 
found that studies on older preparations tended to be less 
highly rated for quality, while evidence for the newer insulin 
analogues was still emerging [1]. The more recent Canadian 
guidelines found indications for use of analogues in relation to 
postprandial glucose excursions, risk of hypoglycaemia, and 
weight gain [2]. A recent meta-analysis found good evidence 
of less hypoglycaemia with insulin glargine compared with 
NPH insulin [5]. Insulin glargine was the subject of speciﬁ c 
guidance from NICE [6] including a recommendation for 
use where once-daily injections would sufﬁ ce or NPH insulin 
gave troublesome hypoglycaemia. Other studies with insulin 
analogues or comparing basal analogues and analogue 
premixes have since appeared [7,8]. These suggest that basal 
analogues have advantage over NPH insulin for combined 
endpoints (HbA1c + hypoglycaemia), while there is a balance of 
advantage between biphasic analogues and basal analogues 
when HbA1c, hypoglycaemia and weight gain are considered 
together. Risk, and hence fear, of hypoglycaemia is greater 
with insulin than with any of the insulin secretagogues. 
There is supporting evidence for insulin use in combination 
with metformin, insulin secretagogues (sulfonylureas), 
metformin plus sulfonylurea (no meta-analysis), α-glucosidase 
inhibitors, thiazolidinediones [2,9]. The NICE review found 
that for people on insulin therapy, glucose control was 
improved and body weight and hypoglycaemia risk reduced 
when metformin was used in combination; the evidence that 
blood glucose control was improved when sulfonylureas were 
taken concomitantly with insulin was not conclusive [1]. 
Uncontrolled observations since that review support the 
hypothesis, notably in combination with basal insulin 
therapy [10]. Major outcome studies are not yet available 
for the combination of insulin with rapid-acting insulin 
secretagogues or thiazolidinediones. 
A 2005 Cochrane review including 45 RCTs with 2156 
participants found no differences in metabolic control or 
hypoglycaemic episodes between human insulin and animal 
insulin [11], although patient-oriented outcomes like quality 
of life, diabetes complications and mortality were not suitably 
addressed by high-quality RCTs. Although cost-effectiveness 
currently favours non-human insulin, this situation is changing.
Rapid-acting insulin analogues were the subject of a recent 
Cochrane review, which had some methodological weaknesses 
[12]. Modest beneﬁ ts were found for the analogues, which 
might be considered for patients using rather more intensiﬁ ed 
regimens or with more advanced insulin deﬁ ciency.
Intensiﬁ ed insulin therapy in Type 2 diabetes has been 
shown to improve metabolic control, improve clinical 
outcomes [13], and increase ﬂ exibility. Evidence on pump 
therapy in Type 2 diabetes is still insufﬁ cient to support 
a recommendation for use in general, although it is a 
potential option in highly selected patients or in very 
individual settings [14].  
Consideration
The evidence shows that a DCCT-aligned HbA1c level of 
around 7.0 % (population mean) is achievable with insulin 
therapy in combination with oral glucose-lowering drugs, 
provided insulin deﬁ ciency has not progressed too far. 
This suggests it is worthwhile starting when control has 
deteriorated to >7.5 %. Active titration of dosage by self-
monitoring and continued educational support is needed to 
achieve this. It is well recognized that personal preferences 
have a major role to play in the use of insulin. Long-acting 
analogue studies show less hypoglycaemia compared with 
NPH insulin. However, the evidence suggests that active 
use of combination oral agents is necessary in many people 
to maintain glucose control throughout the day, and that 
meal-time insulin (as biphasic preparations or with meal-time 
supplements) becomes necessary with time. 
Insulin analogues can be expensive. Where this is an issue, 
NPH insulin and human insulin mixes are still very useful 
alternatives. However, consistency of supply (quality, 
availability, insulin type) requires careful organization. 
Implementation
Contracts should be in place for uninterrupted availability of 
insulin and supporting materials (including for self-monitoring 
and education).
Availability of an HbA1c assay (except in Minimal care), and 
of health-care professionals for education and advice at high 
intensity when titrating doses, needs to be assured.
Avoiding delay in starting insulin therapy has been 
problematic in nearly all diabetes services. Structured 
guidelines and protocols and audit of glucose control of 
people on oral drugs appear to be an integral part of dealing 
with this problem. 
Evaluation 
Evaluation should be of achieved blood glucose control of 
people on oral drugs and those started on insulin therapy, 
with reference to the documented use of those therapies 
once insulin has been started. Local protocols and resources 
should be identiﬁ able.
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Recommendations
n Standard care
BP1  Measure blood pressure annually, and at every routine clinic visit if found to be 
above target levels (see below), or if on treatment:
  ß  use a mercury sphygmomanometer or validated meter in good working order 
and an appropriately sized cuff (large or normal depending on arm size)
  ß  measure after sitting for at least 5 min, with arm at heart level, using ﬁ rst and 
ﬁ fth phases of Korotkoff sounds
  ß  record all values in a record card held by the person with diabetes 
  ß  use 24-hour ambulatory monitoring (ABPM) if ‘white coat’ hypertension 
suspected, but adjust targets down by 10/5 mmHg. 
BP2  Consider secondary causes of raised blood pressure if there is evidence of renal 
disease, electrolyte disturbance or other features.
BP3  Aim to maintain blood pressure below 130/80 mmHg (for people with raised 
albumin excretion rate see Kidney damage). 
 
   Add further drugs if targets are not reached on maximal doses of current drugs, 
reviewing the preferences and beliefs of the individual concerned, and likely 
adherence problems as tablet numbers increase.
 
   Accept that even 140/80 mmHg may not be achievable with 3 to 5 anti-
hypertensive drugs in some people.
 
   Revise individual targets upwards if there is signiﬁ cant risk of postural 
hypotension and falls.  
BP4  Initiate a trial of lifestyle modiﬁ cation alone with appropriate education for 3 
months (see Lifestyle management), aiming to reduce calorie intake, salt intake, 
alcohol intake, and inactivity.
BP5  Initiate medication for lowering blood pressure in diabetes not complicated by 
raised albumin excretion rate, using any agent except for α-adrenergic blockers, 
with consideration of costs, and actively titrating dose according to response:
  ß  ACE-inhibitors and A2RBs may offer some advantages over other agents in 
some situations (see Kidney damage, Cardiovascular risk protection), but are 
less effective in people of African extraction
  ß  start with β-adrenergic blockers in people with angina, β-adrenergic blockers 
or ACE-inhibitors in people with previous myocardial infarction, ACE-
inhibitors or diuretics in those with heart failure
  ß  care should be taken with combined thiazide and β-adrenergic blockers 
because of risk of deterioration in metabolic control.
Blood pressure control
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n Comprehensive care
BPC1  This will in general be as for Standard care, but with the additional option 
of self-monitoring of blood pressure on validated semi-automatic devices to 
provide additional information and educational feedback. 
n Minimal care
BPM1  Measurement and targets will be as for Standard care.  
BPM2  Initiate a trial of lifestyle modiﬁ cation (as Standard care) with appropriate 
education (see Lifestyle management).
BPM3  Initiate medication for lowering blood pressure in diabetes not complicated 
by proteinuria, using generic diuretics, β-adrenergic blockers, calcium channel 
blockers, or ACE-inhibitors as available, increasing the number of preparations 
used according to drug availability locally. 
Rationale
Blood pressure is elevated in many people with Type 2 
diabetes. Increasing blood pressure levels are associated 
with a spectrum of later health problems in people with 
diabetes, notably cardiovascular disease (especially stroke), 
eye damage and kidney damage. 
Evidence-base
Review of the evidence-base on this topic is spread among 
guidelines primarily addressing diabetes [1-4] or hypertension 
[5,6], often embedded in consideration of cardiovascular 
disease [7] or kidney disease (see Kidney damage). The 
evidence may derive from trials involving primarily people 
with diabetes [8] or people with hypertension [9].
Recommendations on thresholds for intervention and targets 
of therapy vary narrowly across the guidelines. Some of this 
variation reﬂ ects concern at setting targets that are difﬁ cult 
to achieve in some people, and may appear unduly daunting, 
especially when many drugs are required. In the UKPDS, 
beneﬁ cial effects on complications, in particular stroke and 
retinopathy, were achieved at 144/82 mmHg in the tighter 
control group [8], consistent with results from the HOT study 
[9]. However, epidemiological analysis of UKPDS suggested 
beneﬁ ts well below this level, supported by achievement of 
blood pressure down to 128/75 mmHg in other studies [1]. 
The recommended target of <130/80 mmHg for people with 
Type 2 diabetes uncomplicated by nephropathy is in line with 
the more recent guidelines [1-3,5,6].
Evidence on methods for measuring blood pressure was 
reviewed by the Australian guideline [1]. A meta-analysis of 
use of self-monitoring of blood pressure found it resulted 
in a small but statistically signiﬁ cant reduction [10]. Lifestyle 
modiﬁ cation (including weight reduction, reducing salt intake, 
increasing physical activity, reducing alcohol intake) can 
reduce systolic blood pressure by 4-10 mmHg (see Lifestyle 
management). 
Many randomized trials have shown that blood-pressure-
lowering therapy reduces cardiovascular disease morbidity 
and mortality in people with diabetes. Many agents (ACE-
inhibitors, β-adrenergic blockers and low-dose thiazide 
diuretics) have proved effective. Choice of agent for a person 
with diabetes may be inﬂ uenced by a number of factors 
including their risk proﬁ le (cardiovascular, renal, end-organ 
damage), preferences, and previous experience of therapy, as 
well as costs. Thiazide diuretics may adversely affect glucose, 
lipid and potassium levels, and β-adrenergic blockers may 
adversely affect glucose and lipid levels, but no RCTs have 
shown these drugs to increase cardiovascular mortality in 
Type 2 diabetes [1]. Avoidance of α-adrenergic blockers as 
ﬁ rst-line therapy is based on evidence from ALLHAT [2].
Cost issues, and particularly the data from UKPDS [11], were 
considered in the Australian guideline [1], which concluded 
that controlling blood pressure in people with Type 2 
diabetes is cost-effective.
Achieving effective control of blood pressure, and 
consequent therapeutic beneﬁ ts, is reported to depend 
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on adherence to therapy. Cultural health beliefs, complex 
therapeutic regimens, adverse effects, tablet number burden, 
and poor social support are reported predictors of poor 
concordance with therapy. These issues need to be discussed 
with the person concerned, where response to drugs is poor. 
Consideration
Blood pressure management appears to be among the 
most cost-effective methods of prevention of vascular 
complications in people with Type 2 diabetes. Lifestyle 
measures are generally preferred as a trial before therapeutic 
intervention, but alone are generally insufﬁ cient. Because 
individual therapies are not particularly effective even 
in full dosage, the experience of the need for multiple 
therapies found in UKPDS is reﬂ ected in the guideline 
recommendations. However, this also implies the need for 
frequent monitoring and dose titration until targets, or the 
limits of therapeutic effect, are reached.
Implementation
There is need for equipment for measurement of blood 
pressure, maintenance of that equipment, and training 
of personnel in its use. Protocols using locally available 
drugs should be drawn up and followed to ensure drug 
prescription, and dose titration to target. Lifestyle education 
is described elsewhere (see Lifestyle management). 
Evaluation
A record of measurement of blood pressure within clinical 
records in the last 12 months should be found. Where that 
is elevated there should be evidence of action to lower it. 
The percentage of people in whom blood pressure achieves 
the target level 130/80 mmHg can be ascertained, and the 
percentage of those with blood pressure above target who 
are receiving treatment involving lifestyle modiﬁ cation and 
drug therapy. Availability of sphygmomanometers in working 
order, and appropriate cuffs can be ascertained, as can 
training and proﬁ ciency of staff measuring blood pressure.
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Recommendations
n Standard care
CV1  Assess cardiovascular risk at diagnosis and at least annually thereafter: 
  ß  current or previous cardiovascular disease (CVD) 
  ß  age and BMI (abdominal adiposity)
  ß  conventional cardiovascular (CV) risk factors including smoking and serum 
lipids, and family history of premature CVD
  ß  other features of the metabolic syndrome and renal damage (including low 
HDL cholesterol, high triglycerides, raised albumin excretion rate) 
  ß atrial ﬁ brillation (for stroke).
 
   Do not use risk equations developed for non-diabetic populations. The UKPDS 
risk engine may be used for assessment and communication of risk. 
CV2  Ensure optimal management through lifestyle measures (see Lifestyle 
management), and measures directed at good blood glucose and blood pressure 
control (see Glucose control, Blood pressure control).
CV3  Arrange smoking cessation advice in smokers contemplative of reducing or 
stopping tobacco consumption.
CV4  Provide aspirin 75-100 mg daily (unless aspirin intolerant or blood pressure 
uncontrolled) in people with evidence of CVD or at high risk.
CV5  Provide active management of the blood lipid proﬁ le:
  ß  a statin at standard dose for all >40 yr old (or all with declared CVD)
  ß  a statin at standard dose for all >20 yr old with microalbuminuria or assessed 
as being at particularly high risk 
  ß  in addition to statin, fenoﬁ brate where serum triglycerides are >2.3 mmol/l 
(>200 mg/dl), once LDL cholesterol is as optimally controlled as possible 
  ß  consideration of other lipid-lowering drugs (ezetimibe, sustained release 
nicotinic acid, concentrated omega 3 fatty acids) in those failing to reach lipid-
lowering targets or intolerant of conventional drugs. 
   Reassess at all routine clinical contacts to review achievement of lipid targets: 
LDL cholesterol <2.5 mmol/l (<95 mg/dl), triglyceride <2.3 mmol/l 
(<200 mg/dl), and HDL cholesterol >1.0 mmol/l (>39 mg/dl).
Cardiovascular risk protection through blood glucose control, blood pressure control, 
and lifestyle interventions is dealt with elsewhere in this guideline (see Glucose control, 
Blood pressure control, Lifestyle management). This section deals with cardiovascular 
risk assessment, lipid modifying therapy, and anti-platelet therapy.  
Cardiovascular risk protection
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CV6  Refer early for further investigation and consideration of revascularization 
those with problematic or symptomatic peripheral arterial disease, those with 
problems from coronary artery disease, and those with evidence of carotid 
disease.  
n Comprehensive care
CVC1  Assessment will be as for Standard care, but with more aggressive 
investigation of asymptomatic peripheral arterial disease, coronary artery 
disease, and carotid disease. Lipid proﬁ les may be investigated more 
extensively to give better direct assessments of LDL cholesterol and 
apolipoproteins. A specialist lipidologist may be consulted.
CVC2  Interventions will be as for Standard care but with aggressive lipid lowering 
for all, using multiple therapies and more expensive/efﬁ cacious statins except 
where LDL cholesterol, triglycerides and HDL cholesterol are all within target 
ranges. 
CVC3  Antiplatelet agents to consider might include clopidogrel substituted for 
aspirin, in particular for those with multiple CVD events/problems, peripheral 
arterial disease, or previous coronary bypass grafting. 
CVC4  Renin-angiotensin system blockers are an option for added CV risk protection. 
n Minimal care
CVM1  Assessment will be as for Standard care, with lipid proﬁ le measures if 
available.
CVM2  Management will be as for Standard care, but using statins or ﬁ brates only 
where these are available at reasonable cost from generics’ manufacturers, 
and in particular for those with known CVD. Statins may be used even if the 
serum lipid proﬁ le cannot be measured. 
CVM3  Revascularization procedures will generally not be available, but where 
possible those limited by symptoms should be so referred.
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Rationale
Cardiovascular disease is the major cause of mortality and 
morbidity in people with Type 2 diabetes. Indeed some 
studies have suggested a risk similar to that of people 
without diabetes but with declared CVD. While others 
‘merely’ show markedly increased risk, some cohorts with 
particular risk factors have shown extreme risk. Assessment, 
but more particularly aggressive management, of CV risk 
factors in Type 2 diabetes is then seen as a core part of care. 
Some of the risk relates to blood pressure control and blood 
glucose control and is addressed elsewhere in this guideline, 
as are the lifestyle interventions which generally beneﬁ t the 
whole spectrum of CV risk factors.  
Evidence-base
The epidemiological evidence that cardiovascular disease is 
the major cause of mortality in people with Type 2 diabetes 
is extensive, as is the evidence that the risk is considerably 
elevated above that of the background population, even 
where that population is itself prone to high levels of vascular 
disease. More controversy surrounds the extent of the 
increased risk. A much quoted paper by Haffner et al. [1] 
suggested that people with Type 2 diabetes have a CV risk 
equivalent to non-diabetic people with previous CVD, but 
this has not in general been supported by other data [2]. 
The evidence that people with Type 2 diabetes have an 
abnormal, atherogenic, lipid proﬁ le (high triglycerides, low 
HDL cholesterol, small dense LDL) is generally accepted, 
and leads all the major guidelines which have addressed the 
area to recommend assessment of a full serum lipid proﬁ le 
(total cholesterol, HDL cholesterol, LDL cholesterol (derived), 
triglycerides) as a guide to therapy [3-7]. 
Since people with Type 2 diabetes may or may not have 
a high LDL cholesterol (as in the general population), and 
may have triglyceride/HDL levels anywhere from normal to 
highly abnormal, decision paths to therapy are uncertain 
and do vary between evidence-based recommendations. 
A further problem is assessment of risk. The HPS study (of 
simvastatin) recruited people with diabetes even if they had 
no history of cardiovascular risk, and the results showed 
strong beneﬁ t [8]. CARDS similarly studied people with 
diabetes who had no overt evidence of CVD, and showed 
marked beneﬁ t with atorvastatin [9]. These studies suggest 
statin treatment for all people with Type 2 diabetes without 
assessment of risk, if over 40 yr of age. This view is not 
universally accepted.
The situation is complicated by the difﬁ culty of assessing 
CV risk in people with diabetes, due to a two-to-three-fold 
underestimation of risk from tables, charts and engines 
derived from the Framingham study. This led the NICE group 
to suggest risk estimation based on a lower threshold than 
used generally in the UK at that time [6], but the advent 
of the validated risk engine based on the UKPDS study 
does now allow CV risk to be appropriately calculated [10]. 
Nevertheless, since the calculation almost inevitably suggests 
high risk in people with other risk factors, the universal 
application of statins in the middle-aged and older groups 
may be justiﬁ ed. The Canadian guideline states that there 
is a strong evidence-base for considering nearly everyone 
with Type 2 diabetes as high risk [5]. However, little evidence 
is available on people with younger-onset Type 2 diabetes, 
or their CV risk, although this would seem likely to be high 
relative to their peers.  
Cost-effectiveness of statins is not generally addressed by 
the evidence-based guidelines, but rather is assumed. Lately 
simvastatin prices have collapsed in many parts of the world 
with expiry of patents. This is likely to make them cost-
effective in most parts of the world.
  
The guidelines also address the issue of management of 
serum triglyceride and HDL cholesterol levels, an area 
where the evidence-base is softer, but all conclude that 
management with ﬁ brates is indicated if serum triglyceride 
levels are raised (triglycerides and HDL cholesterol being 
inversely correlated). However, there is no easy consensus 
on the levels at which ﬁ brates should be introduced, or on 
how they should be introduced in combination with statins. 
The results of the FIELD trial may help to resolve this in late 
2005.
While there are safety concerns with lipid-lowering drugs, 
and notably even rare life-threatening problems related to 
muscle necrosis, the drugs are life-saving to a degree many 
times exceeding the safety risk (with appropriate therapeutic 
cautions), even when ﬁ brates (except gemﬁ brozil) are used in 
combination with statins in people with higher risk.    
The evidence-base for other lipid-lowering drugs 
(extended-acting nicotinic acid, concentrated omega 3 
fatty acids, ezetimibe) is weaker – indeed these are barely 
addressed by published evidence-based guidelines, except 
the Australian lipid control document [4]. These drugs are 
also expensive for the degree of lipid-lowering gained 
and, as noted in the Australian guideline, some may lead 
to minor deterioration of blood glucose control. It would 
seem, therefore, that their use should be reserved for 
uncontrolled hyperlipidaemia on the ﬁ rst-line agents, or 
intolerance of these. 
The use of anti-platelet agents is also addressed by some 
of the major guidelines (most extensively by the Australian 
macrovascular prevention guideline and the NICE lipid-
lowering guideline [3,6]), with a general recommendation 
of endorsement for the widespread use of low-dose aspirin, 
the most speciﬁ c evidence coming from within the ETDRS 
and HOT studies [11,12], and the most complete review 
that of Eccles and colleagues [13]. The Canadian guideline 
[5] notes a more recent meta-analysis of anti-platelet 
therapy showing a signiﬁ cant 22±2 % (±SE) reduction in 
vascular events among all high-risk patients in 195 trials 
but only a non-signiﬁ cant 7±8 % reduction in people with 
diabetes (9 trials) [14]. Nevertheless, efﬁ cacy is accepted, 
although the risk of bleeding results in advice in the NICE 
[6] and SIGN guidelines [7] restricting use to people at 
calculated risk (which would, however, be most people with 
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Type 2 diabetes) and with some caution over uncontrolled 
hypertension. The use of clopidogrel (at least as effective 
but much more expensive), where considered, is only 
recommended for people with aspirin intolerance. 
Most other aspects of CV risk protection, notably blood 
glucose and blood pressure control, physical activity, and 
body weight control, are addressed elsewhere in this and 
other guidelines. However, there is also an evidence-base 
for integrated multiple risk factor intervention in particularly 
high-risk people (with microalbuminuria), showing very 
powerful absolute and relative risk reductions [15]. Evidence 
on smoking and CVD is not generally addressed, the advice 
given simply being in line with general medical practice, 
based on consideration of evidence for the general 
population. 
Consideration
Cardiovascular risk protection for people with Type 2 
diabetes is an area which is found to be of high need, 
but with good and often strong evidence of ability to 
meet that need. One obvious problem is the need to 
extrapolate evidence in some areas from groups of people 
who do not have diabetes, for example as regards aspirin 
therapy. However, because event rates are much higher in 
people with diabetes (particularly with regard to ‘primary’ 
prevention) the gains and cost-effectiveness are also 
potentially much better, so that the risks of extrapolation of 
evidence are relatively low. This is especially true because the 
processes of arterial damage in people with Type 2 diabetes 
are similar pathologically to those occurring in the general 
population, though usually present (as in the case of platelet 
abnormalities) to a more abnormal degree. 
Accordingly, the recommendations are for very active 
management. Statins and aspirin use are given prominence, 
as best founded in evidence, but the associations of 
hypertriglyceridaemia and low HDL cholesterol with poor 
outcomes, together with the limited trial evidence, lead also 
to strong recommendations over use of ﬁ brates. In these 
circumstances assessment of risk has a relatively minor role, 
but is found useful educationally, and clearly can only be 
done formally using a risk engine properly validated for 
cohorts of people with diabetes in continuing care. 
Implementation
The recommendations require access to measurement of a 
full lipid proﬁ le and supporting biochemistry, and to aspirin 
and statins and ﬁ brate drugs as a minimum. Structured 
annual assessment and record-keeping should be instituted.  
Evaluation
Evaluation is by achieved lipid levels, especially LDL 
cholesterol and triglycerides, and numbers of people 
treated (and in particular with elevated levels or existing 
cardiovascular disease) with statins, ﬁ brates, and aspirin. In 
general, cardiovascular outcome rates are difﬁ cult to assess 
except in very large populations.
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Recommendations
n Standard care
ES1  Ensure that examination of the eyes of people with Type 2 diabetes is 
performed around the time of diagnosis and then annually as part of a formal 
recall process:
  ß  measure and document visual acuity, corrected with glasses or pinhole
  ß assess retinopathy: 
  -  using retinal photography through dilated pupils, performed by an 
appropriately trained health-care professional, or 
    -  by examination by an ophthalmic specialist. 
ES2  Discuss the reasons for eye examination with the person with diabetes. 
ES3  Use tropicamide to dilate pupils, unless contra-indicated, after discussing the 
implications and obtaining agreement of the person with diabetes. 
ES4   Classify the ﬁ ndings of eye examination as requiring: routine annual review, 
earlier review, or referral to an ophthalmologist (if not making the examination). 
 
   The following frequency of screening is suggested:
  ß  12 months if no or minimal unchanged retinopathy
  ß  3 to 6 months if worsening since last examination
  ß  more often during pregnancy.
ES5   The following situations require specialist referral:
 
  ß  the same day:
  -  sudden loss of vision
    -  evidence of retinal detachment  
  ß  within 1 week:
    -  evidence of pre-retinal and/or vitreous haemorrhage
    -  new vessel formation or rubeosis iridis  
These guidelines are concerned with preventative diabetes care. No advice is given on 
the further investigation of retinopathy by an ophthalmic specialist, or the subsequent 
use of laser or other retinal therapy, of vitrectomy, or other tertiary care. It is noted 
that a substantial evidence-base does exist for these techniques in the prevention of 
visual loss.
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  ß  within 1-2 months:
    - advanced retinal lesions
    -  unexplained deterioration of visual acuity 
    - macular oedema
    - unexplained retinal ﬁ ndings 
    - cataract
    - inability to visualize fundus.
ES6   Advise that good control of blood glucose, blood pressure, and blood lipids 
(see relevant sections of this guideline) can help to reduce the risk of eye 
damage developing or worsening. 
ES7   Advise that diabetic retinopathy is not a contra-indication for use of aspirin if 
this is indicated for prevention of cardiovascular disease.
ES8   Advise that tests of intra-ocular pressure should be made periodically. 
n Comprehensive care
ESC1  Retinal screening will be as for Standard care in most respects, but could use 
seven-ﬁ eld stereoscopic colour fundus photography interpreted by a trained 
reader (where a retinal ophthalmological specialist is not anyway performing 
the eye check). 
n Minimal care
ESM1  Use direct fundoscopy through dilated pupils, performed by a member of 
the health-care team who is properly trained and has appropriate experience 
to assess retinopathy.
ESM2  Check visual acuity.
ESM3  Repeat review, referral, and preventative therapy are as for Standard care. 
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Rationale
Diabetic retinopathy is the most common complication 
of diabetes and a major cause of visual loss. Damage 
(maculopathy) to the area of the retina used for ﬁ ne and 
central vision (the macular area around the fovea) is the 
largest problem in people with Type 2 diabetes, though 
classical retinopathy with new vessels and consequent 
problems is also important. Measures to control blood 
glucose and blood pressure (discussed elsewhere) can help 
to prevent onset and delay worsening of retinopathy, but 
most people with retinopathy will be asymptomatic until 
the damage is far advanced. Early detection by regular 
surveillance is thus essential if people with sight-threatening 
retinopathy are to be identiﬁ ed in time to offer them the 
laser treatment which can prevent visual loss. 
Evidence-base
General diabetes guidelines which address the subject 
of eye screening [1-4] draw on an evidence-base going 
back to the 1970s, including the ﬁ ndings of the American 
studies WESDR, DRS and ETDRS which provide the 
framework for retinal screening and laser treatment [5-7]. 
The ‘gold standard’ screening test of seven-standard ﬁ eld 
stereoscopic colour fundus photography and associated 
grading scheme were established by these studies. 
In recent years technological developments in digital 
photography have offered expanding opportunities for 
recording and transmitting images, with potential for 
automated grading, reviewed in the NICE Type 1 diabetes 
guideline [8].
The importance of screening people with Type 2 diabetes 
at diagnosis relates to the ﬁ nding that between 21 and 
39 % of them already have some retinopathy (which may 
already be sight-threatening) by this time [3]. In the WESDR 
1.6 % of people with Type 2 diabetes were legally blind [5]. 
For people who have no retinopathy at diagnosis of Type 
2 diabetes, the chance of developing sight-threatening 
retinopathy within 2 years is less than 1 % [1]. Although there 
is some argument as to whether such people need to receive 
screening as often as annually, and the Canadian guideline 
recommends every 1 to 2 years [3], the other three favoured 
annual systematic review [1,2,4] pending further information 
identifying sub-groups which might safely have longer review 
periods [2]. Cataract is another important cause of visual loss 
in people with diabetes, being twice as common as in people 
without diabetes [1]. 
Support for optimized glucose control and tighter blood 
pressure control (see elsewhere) derives from the reduction 
in risk of microvascular complications found in the UKPDS 
[9,10]. The effects of aspirin were investigated in the ETDRS 
(reported in reference 3). High levels of LDL cholesterol were 
associated with hard exudates in the ETDRS [11]. 
Recent review of screening methods found that digital 
photography best met the needs of appropriate sensitivity/
selectivity, feasibility and opportunities for quality assurance 
[8]. SIGN found that direct ophthalmoscopy only rarely 
achieved 80 % sensitivity even when carried out by properly 
trained operators [1]. Where cost issues were considered [2], 
attention was drawn to the dependence of cost-effectiveness 
on features such as sensitivity and speciﬁ city of screening 
tests, attendance and prevalence. 
Consideration
The core issue is how to provide regular structured 
review using either ophthalmological expertise or camera 
technologies. With regard to the latter, use of digital cameras 
with eyes dilated to reduce the incidence of screen failures 
is found to be desirable and cost-effective. However, camera 
technologies cannot detect macular oedema, so visual acuity 
testing must accompany photography. Where neither camera 
technologies nor ophthalmologists can be made available, 
ophthalmoscopy by a trained observer can detect many 
problems (though with signiﬁ cantly poorer sensitivity) and is 
thus recommended in these circumstances. 
The availability of laser therapy is currently limited in many 
parts of the world due to cost and lack of trained expertise. 
It is noted that raising awareness of eye problems by 
examination and recording of detected problems can both 
help individual preventative care (blood glucose and blood 
pressure control) and provide the necessary evidence for 
establishment of a laser service. 
Implementation
Staff requirements are sufﬁ cient numbers of experienced 
ophthalmologists, optometrists and other health-care 
professionals to perform the screening, and sufﬁ cient 
ophthalmologists to perform laser therapy, and training 
of such staff. Equipment for screening and treatment will 
be required, as will a structured recall system and record. 
All screening modalities require quality assurance checks; 
for retinal photography it has been suggested this should 
happen for around 1 % of photographs [1]. 
A national or regional advisory group, including 
representation of ophthalmologists, optometrists, internists 
and people with diabetes, can work with health funders to 
deﬁ ne such issues as: criteria for screening and treatment; 
training and education programmes; provision of accessible 
facilities; awareness programmes; strategies for programme 
implementation and guideline dissemination; information 
systems (for monitoring diabetic eye disease, follow-up and 
recall, collection of baseline and annual data); annual reports 
based on deﬁ ned indicators.
Evaluation
The percentage of records containing the results of eye 
examination within a 12-month period is easily evaluated. 
Where such records are of sight-threatening retinopathy or 
decrease of visual acuity, evidence of review by (or referral 
to) an ophthalmological specialist should be present. Eye 
screening services can be checked for appropriately trained 
personnel, and facilities sufﬁ cient to ensure diabetes 
population coverage. Evidence of quality checks should be 
assessed. Evidence of control of rates of visual loss is more 
difﬁ cult to gather unless the records of ophthalmological 
services can be linked to those of diabetes services.   
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Recommendations
n Standard care
KD1  Check annually for proteinuria in an early morning urine sample (or a random 
sample otherwise) using a dipstick. 
  ß  if dipstick test positive, 
  - check for urinary tract infection
  - obtain a laboratory urine protein:creatinine ratio (PCR)  
  ß  if dipstick test negative, check urine albumin using:
  -  laboratory or site-of-care urine albumin:creatinine ratio (ACR), or
  -  a semi-quantitative reagent strip if ACR test is unavailable.
 
   Measure serum creatinine annually, and calculate GFR (‘eGFR’). 
KD2   If PCR or ACR is raised (microalbuminuria ACR >2.5 mg/mmol in men, 
>3.5 mg/mmol in women; or 30 mg/g), repeat twice over the following 4 months.  
  ß  conﬁ rm as positive if proteinuria or raised urine albumin on two of three 
occasions   
  ß  if both repeat tests are not raised, check again annually. 
KD3  Manage those with raised urine albumin or proteinuria or reduced eGFR 
(<90 ml/min/1.73 m2 and falling) as follows:
  ß  use ACE-inhibitor or A2RB titrated to maximum tolerated dose 
  ß  intensify management of blood pressure (actively target <130/80 mmHg) 
using drugs and dietary modiﬁ cation (low salt intake)
  ß  intensify management of blood glucose (target DCCT-aligned HbA1c <6.5 %)
  ß  monitor progression by ACR or PCR, serum creatinine and potassium; 
calculate eGFR; discuss results 
  ß  advise limiting protein intake to 0.8 g/kg daily if proteinuric
  ß  intensify other renal and cardiovascular protection measures (not smoking, 
aspirin therapy, lipid-lowering therapy).
KD4  Measure Hb/ferritin every 6 months if eGFR <90 ml/min/1.73 m2, give iron or 
other haematinics if indicated, and refer to nephrologist if still anaemic despite 
supplements (Hb <11 g/dl in pre-menopausal women, <12 g/dl in others). 
KD5  Refer to a nephrologist when eGFR <60 ml/min/1.73 m2, or earlier if 
symptomatic or biochemical or ﬂ uid retention problems occur. 
These guidelines are concerned with preventative diabetes care. No advice is given on 
further investigation of kidney disease by a renal specialist, or subsequent tertiary care.
Kidney damage
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n Comprehensive care
KDC1  This is in general as for Standard care, but assessment of albuminuria would 
always be by a laboratory quantitative method (ACR). 
KDC2  Investigations to exclude other possible causes of renal disease for all with 
raised ACR or PCR might include auto-antibodies, ultrasound, biopsy. 
n Minimal care
KDM1  Check annually for proteinuria in an early morning urine sample (or a random 
sample otherwise) using dipstick or sulfosalicylic acid method. 
  ß  if test positive,
  -  exclude urinary tract infection by microscopy (and culture if possible)
  -  if possible, obtain a laboratory protein:creatinine ratio (PCR) and repeat on 
two occasions over the following 6 months (proteinuria conﬁ rmed if positive 
on two of three occasions) 
  ß  if test negative, check again annually. 
 
  If available measure serum creatinine (or urea) annually. 
KDM2 Manage those with proteinuria as follows:  
  ß  advise to avoid risk factors (analgesic use, alcohol consumption, illicit drug 
use), to limit protein intake (to 0.8 g/kg daily), and not to smoke
  ß  aim for blood pressure <130/80 mmHg using any anti-hypertensive drug 
and control of salt intake
  ß  consider use of ACE-inhibitors if available 
  ß  aim to achieve targets for blood glucose control
  ß  aim to improve lipid proﬁ le using available drugs
  ß  check proteinuric status/progression annually
  ß  measure serum creatinine or urea every 6 months.
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Rationale
Diabetic renal disease has only received less attention in 
people with Type 2 diabetes in the past because their life 
expectancy was limited by cardiovascular disease. However, 
because of the higher incidence of Type 2 than Type 1 
diabetes, renal failure in the former group has always been a 
signiﬁ cant cause of morbidity and mortality. With increasing 
numbers of people with Type 2 diabetes, younger age of 
onset, and better cardiovascular protection measures, the 
health impact of renal impairment in this population and in 
individuals is growing. While the major effort of management 
must go to primary prevention (good blood glucose and 
blood pressure control from early diagnosis), the success 
of interventions at a later stage (see below) suggests that 
detection of developing kidney damage would be useful.  
Evidence-base
The evidence-based diabetes guidelines which address the 
subject of nephropathy describe the early stages of kidney 
damage in terms of albumin excretion rate (AER) increasing 
through ‘microalbuminuria’ to ‘macroalbuminuria’ (at which 
point it equates with proteinuria, ‘overt nephropathy’) [1-6]. 
There is general agreement on annual screening, and 
on the albumin:creatinine ratio (which corrects for urine 
concentration) as the preferred method of detection, but 
cut-off values differ somewhat, microalbuminuria being 
deﬁ ned as 30 mg/g in the USA [1], 2.0/2.8 mg/mmol (men/
women) in Canada [2], and 2.5/3.5 mg/mmol in Europe [3-
6], and macroalbuminuria as 300 mg/g, 20/28 mg/mmol, 
and 30 mg/mmol respectively. Issues surrounding screening 
tests are reviewed in detail by the NICE Type 2 guideline [4], 
with attention drawn to the day-to-day variation in albumin 
excretion which underlines the need for conﬁ rmatory testing. 
Monitoring of changes in glomerular ﬁ ltration rate (which are 
not necessarily in line with changes in albumin excretion) is 
emphasized in all the guidelines, which recommend serum 
creatinine measurement, and more recently emphasize the 
need for calculation of estimated GFR [1,2].
UKPDS provided clear evidence for the beneﬁ ts of blood 
glucose control and blood pressure control in delaying the 
development of kidney disease [7,8]. Other evidence for 
the importance of blood pressure control in prevention 
comes from trials of various anti-hypertensive drugs, and 
evidence continues to emerge in this area (although there 
will be no more placebo-controlled trials). Choice of agent 
stems from evidence on the additional beneﬁ ts of agents 
which target the renin-angiotensin system in offering renal 
and cardiovascular (see Cardiovascular risk protection) 
protection, over and above the blood pressure-lowering 
effect. Both ACE-inhibitors and the newer A2RBs delay 
progression from micro- to macro-albuminuria in people 
with Type 2 diabetes and hypertension [1,2,9]. A2RBs have 
been shown to delay progression of nephropathy in those 
who have macroalbuminuria and renal insufﬁ ciency (serum 
creatinine >1.5 mg/dl (>130 µmol/l)) [1]. Of the other anti-
hypertensive agents which might be used, the ADA cites 
evidence that dihydropyridine CCBs do not slow progression 
of nephropathy so should not be used as ﬁ rst-line therapy in 
nephropathy [1]. 
Targets for blood pressure have been tightening in diabetes 
care generally and the advice to treat to tighter targets for 
those with albuminuria, 130/75 mmHg as against 140/80 
mmHg in people with Type 2 diabetes [4], is perhaps now 
a minority view, with general advice converging towards 
130/80 mmHg for all irrespective of AER [1,2,5]. NICE found 
that reduction of blood pressure to less than 135/75 mmHg 
reduced the rate of progression of renal disease, with lowest 
achieved mean blood pressure being 134/75 mmHg in 
studies showing beneﬁ t in people with Type 2 diabetes and 
albuminuria [4].
The recommendation on treatment of anaemia once GFR 
starts to decline is supported by the ﬁ nding in the RENAAL 
study that mild anaemia is associated with risk of renal 
disease progression [10].
Cardiovascular risk is increased in people with 
microalbuminuria, and further increased in those with 
proteinuria and/or reduced GFR. The issue of cardiovascular 
risk is addressed elsewhere in this guideline (see 
Cardiovascular risk protection). 
Consideration
Although it is possible to treat kidney failure by dialysis 
or transplantation, availability of these very expensive 
treatments is severely limited in a global context. This 
makes efforts at prevention all the more important. It has 
been estimated that, once a dipstick test is positive, time 
to kidney failure is about 9 years, but that this time-interval 
can be doubled through appropriate treatment of blood 
pressure. The issue of targets can be a particular problem 
in people with Type 2 diabetes who are often more elderly, 
and in whom attainment of 140/80 mmHg or less can seem 
impossible even with multiple drugs and reasonable lifestyle 
intervention. Nevertheless control around this level has 
been achieved in a number of studies, implying that around 
half the population can get to (and thus beneﬁ t from) lower 
levels. 
Implementation
Management of blood pressure overlaps with the advice 
given in Blood pressure control. Recurrent measurement 
and drug dose titration need good access for people with 
evidence of renal damage, where repeated measurements 
of potassium and creatinine are particularly important. 
Additionally the current section requires access to laboratory 
microalbumin estimation (or availability of semi-quantitative 
reagent strips), and availability of multiple blood-pressure-
lowering drugs and in particular renin-angiotensin system 
blockers. 
Evaluation
The percentage of people with appropriate urine albumin 
and serum creatinine measurements should be ascertained. 
Where abnormalities are detected, evidence of action to 
ensure tight blood pressure control is required, together with 
achieved blood pressure. Level of eGFR at which referral to 
nephrologists occurred may also be determined. 
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Recommendations
n Standard care
FT1 Assess feet of people with diabetes as part of an annual review:
  
  1.  history of previous foot ulceration or amputation, symptoms of peripheral 
arterial disease, physical or visual difﬁ culty in self-foot-care
  2.  foot deformity (hammer or clawed toes, bone prominences) and footwear; 
visual evidence of neuropathy (dry skin, callus, dilated veins) or incipient 
ischaemia; nail deformity or damage
  3.  detection of neuropathy by 10-g monoﬁ lament (or 128-Hz tuning fork); a 
biothesiometer is an option for quantitative assessment (cut-off point for ulcer 
risk >25 volts); non-traumatic pin-prick
  4.  palpation of foot pulses (dorsalis pedis and posterior tibial) and capillary 
return time; Doppler ankle:brachial pressure ratio (<0.9 for occlusive 
vascular disease) may be used where pulses are diminished to quantify the 
abnormality.
FT2  Discuss the reasons for foot review with each person with diabetes as part of 
the foot-care educational process.
FT3  Agree a foot-care plan based on the ﬁ ndings of annual foot review with each 
person with diabetes.
 
    Assess and provide necessary foot-care education according to individual need 
and risks of ulcer and amputation.
FT4 Classify according to ﬁ ndings:
  
   No added risk: if no loss of sensation, no signs of peripheral arterial disease, 
and no other risk factor.
  At risk: if neuropathy or other single risk factor.
  
  High risk: 
  ß  diminished sensation plus foot deformities or evidence of peripheral arterial 
disease
  ß  previous ulceration or amputation (very high risk).
  
  Foot ulceration or infection: foot ulcer present.
Foot care
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FT5  Manage according to classiﬁ cation level:
   
   No added risk: agree a management plan including foot-care education with 
each person. 
  
  At risk: arrange regular review, approximately 6-monthly, by foot-care team.
  At each review: 
  1.  inspect both feet – ensure provision of local management as indicated
  2.  evaluate footwear – provide appropriate advice
  3. enhance foot-care education.
  
  High risk: arrange frequent review every 3-6 months by foot-care team.
  At each review:
  1. inspect both feet – ensure provision of local management as indicated
  2.  evaluate footwear – provide advice and specialist insoles and shoes if 
indicated
  3. consider need for vascular assessment or referral 
  4.  evaluate and ensure the appropriate provision of intensiﬁ ed foot-care 
education.
  
   Foot ulceration or infection (including foot-care emergencies): refer to 
multidisciplinary foot-care team within 24 hours for:
  1.  appropriate wound management, dressings and debridement as 
indicated 
  2.  consideration of systemic antibiotic therapy (often longer term) for 
cellulitis or bone infection as indicated; generic penicillins, macrolides, 
clindamycin, and/or metronidazole as indicated as ﬁ rst-line, with 
ciproﬂ oxacin or co-amoxiclav as examples of second-line drugs
  3.  optimal pressure distribution (casting if indicated and not contra-
indicated), investigation and treatment (referral) for vascular insufﬁ ciency 
  4.  probing to bone, radiology and scans, MRI imaging, and biopsy where 
indicated for suspected osteomyelitis 
  5. optimal blood glucose control
  6.  specialist footwear and orthotic care (e.g. insoles), and individualized 
discussion of prevention of recurrence, when ulcer has healed.
FT6 Do not amputate unless:
  1. a detailed vascular evaluation has been performed by the vascular staff
  2.  ischaemic rest pain cannot be managed by analgesia or revascularization
  3. a life-threatening foot infection cannot be treated by other measures 
  4.  a non-healing ulcer is accompanied by a higher burden of disease than 
would result from amputation. 
A specialist foot-care team will include doctors with a special interest in diabetes 
foot care, people with educational skills, and people with formal training in foot care 
(usually podiatrists or trained nurses).
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Rationale
Foot ulceration and limb amputation are among the major 
drivers of impaired health and of health-care costs in 
diabetes care. While primary prevention of the underlying 
damage to nerves and vessels is addressed elsewhere in this 
guideline, secondary intervention in those developing such 
risk factors can reduce this burden and cost on both the 
person with diabetes and society.
Evidence-base
Because of the potential for improvement of health and 
reduction of health-care costs, the evidence surrounding 
diabetes foot-care has been extensively and formally 
reviewed many times in recent years [1-10]. 
The output from these documents is very consistent in 
suggesting that formal regular review to detect people at risk, 
more regular review of those found to be at risk, and intensive 
management of those developing foot ulceration and 
infection can produce major returns in avoiding the health and 
monetary costs of amputation. Providing foot-care education 
for all patients, with increased intensity for those at higher 
risk [11], and vascular interventions where critical ischaemia is 
identiﬁ ed (or is contributing to ulceration), are also common 
recommendations arising from the evidence-base. 
Consideration
There is little controversy over the system and needs of 
diabetes foot-care provision. Most of the recommendations 
of formal evidence-based guidelines can be implemented 
with little modiﬁ cation in situations where minimal health-
care funding resources are available, as simply removing 
shoes and examining feet can usefully save people from 
becoming disabled and unproductive members of their 
communities. 
Implementation
Appropriate protocols, structured records, and recall 
systems need to be supported by appropriate training 
for professionals providing screening and management 
services. In particular the training and provision of non-
medically qualiﬁ ed foot-care assistants (podiatrists or people 
fulﬁ lling that role) need to be assured. Liaison needs to be 
established with orthotists and footwear suppliers, and cast 
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n Comprehensive care
FTC1  In general this will be as Standard care, but the multidisciplinary foot-care 
team can be enhanced by on-site inclusion of vascular surgeons, orthopaedic 
surgeons, orthotists, social workers, and psychologists.
FTC2  Foot pressure distribution measurements might be made. Sophisticated 
vascular scanning and angiography could be available to the foot-care team.
n Minimal care
FTM1  Sensory assessment would be by 10-g monoﬁ lament or tuning fork, with or 
without non-traumatic disposable pin-prick only.
FTM2  Antibiotic therapy would be with generic penicillins, macrolides, and/or 
metronidazole, intravenously for deep tissue infections, and adjusted by 
response or culture results.
FTM3  Vascular assessment would be by peripheral pulses and capillary return times 
only.
FTM4  Vascular referral would be according to ﬁ ndings and local revascularization 
facilities.
technicians. Facilities for vascular scanning and vascular 
interventions will be by agreement with vascular surgical 
staff. Policymakers should be approached to consider the 
socio-economic burden of diabetes foot problems and assure 
structural and ﬁ nancial support for preventative strategies.
Evaluation 
Evaluation is by annual incidence of foot ulceration, foot 
hospitalization, foot ulceration healing rates within deﬁ ned time-
periods, and amputation rates at different levels of the limb.
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Recommendations
n Standard care
NU1  Diagnose sensorimotor nerve damage by history and examination 
(monoﬁ lament with or without temperature, non-traumatic pin-prick, vibration 
(tuning fork), ankle reﬂ exes), and/or simple quantitative testing (e.g. vibration 
perception).
 
   Use serum B12, thyroid function tests, creatinine/urea, and drug history to 
exclude other causes.
NU2  Diagnose symptomatic (painful) diabetic neuropathy by excluding other possible 
causes of the symptoms.
 
   Manage by stabilizing blood glucose control, and treatment with tricyclic drugs 
if simple analgesia is not successful. 
 
   Further treatment options include pregabalin/gabapentin and valproate, then 
tramadol, duloxetine, and oxycodone. Further management normally requires 
referral to a pain control team.
 
   Be aware of the psychological impact of continuing symptoms, particularly if 
sleep is disturbed.
NU3  Diagnose erectile dysfunction by history (including drug history), exclusion of 
endocrine conditions (measure prolactin and testosterone), and a trial of a PDE5 
inhibitor (where not contra-indicated by nitrate therapy).
 
   Consider other approaches such as intra-urethral or intracavernosal drugs and 
sexual and relationship counselling, where PDE5 inhibitors fail or cannot be 
used.
NU4  Diagnose gastroparesis by history, trial of a prokinetic drug (metoclopramide, 
domperidone), and if troublesome by gastric emptying studies.
NU5  Diagnose cardiovascular autonomic neuropathy by resting heart rate and heart 
rate response to provocation tests (lying-standing, Valsalva, deep breathing), 
and by lying and standing blood pressure. 
 
  Advise anaesthetists when relevant where this is present. 
Nerve damage
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n Comprehensive care
NUC1  This would be as for Standard care, but screening and diagnostic testing 
could also include a programme of quantitative sensory testing (vibration 
and temperature), electrophysiology, and autonomic function tests.
n Minimal care
NUM1  Screen and diagnose sensorimotor nerve damage by history of symptoms, 
and sensory assessment by 10-g monoﬁ lament or tuning fork with/without 
non-traumatic disposable pin-prick (as Foot care), and ankle reﬂ exes.
NUM2  Manage symptomatic (painful) diabetic neuropathy by excluding other 
causes, stabilizing glycaemic control, and treatment with tricyclic drugs if 
simple analgesia is not successful. Opiate analgesia may be necessary as 
locally available.
NUM3   Assess erectile dysfunction by history and examination, to consider possible 
contributions of other medication or disease.  
Rationale
Neuropathy (nerve damage) is a common late complication 
of Type 2 diabetes. It contributes not only to foot problems 
(see Foot care) but also to a range of troublesome symptoms 
including pain/paraesthesiae and (where the autonomic 
nervous system is involved) gastro-intestinal, bladder and 
sexual problems. New therapeutic options have emerged in 
recent years. 
Evidence-base
Aspects of neuropathy which do not relate directly to 
foot care have received less attention in evidence-based 
guidelines [1-4], and some divergence in recommendations 
can be accounted for by recently emerging evidence on 
treatment options for painful neuropathy [5,6]. There is 
general agreement that stabilizing glycaemic control is 
important in the medium and longer term, and that tricyclic 
drugs should be used as ﬁ rst-line therapy for painful 
neuropathy, although side-effects are common. 
Exclusion of non-diabetic causes of neuropathy is important 
because these may account for 10 % of cases of neuropathy in 
people with diabetes [7]. The range of tests available in clinical 
and research settings is detailed in two technical reviews [8,9].
Erectile dysfunction is addressed by three of the guidelines, 
which draw on evidence from Type 1 as well as Type 2 
Nerve damage
diabetes [1-3]. They conclude that the condition is rarely of 
simple causation, that it is important to consider the possible 
contribution of other medications and medical conditions, 
but that the expensive PDE5 inhibitors are worth a trial. 
The evidence-base on some of the rarer aspects of 
autonomic neuropathy is weak, including that for 
gastroparesis, and cardiovascular parasympathetic autonomic 
neuropathy. In general, other guidelines have relied on 
conventional wisdom in making recommendations over the 
management of gastroparesis, orthostatic hypotension, 
bladder dysfunction, and nocturnal diarrhoea.  
Consideration
The costs of newer therapies were felt to argue against their 
use in situations where resources could be better directed to 
prevention by measures aimed at improving and stabilizing 
glycaemic control. A limited number of tests were felt to be 
appropriate in the clinical setting, but the practice generally 
recommended in this area simply follows established medical 
lines. 
Implementation
Appropriate protocols should be developed for sensory 
testing. Recommended drugs should be available according 
to level of resources. Medical teams need to remain trained 
in the diverse manifestations of autonomic neuropathy. 
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Evaluation
 
Evidence should be available of records of regular 
surveillance for neuropathic symptoms, usually as part of 
direct questioning in programmed annual review. Where 
appropriate, record should also be available of direct 
questioning for erectile dysfunction. The availability of simple 
equipment for surveillance, and of drug supplies, can be 
evaluated.  
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Recommendations
n Standard care
Pre-pregnancy counselling
PR1  Identify possibility of pregnancy annually by direct questioning in all fertile 
women of child-bearing age with diabetes. Provide contraceptive advice where 
appropriate. 
PR2  Offer pre-pregnancy advice to all women so identiﬁ ed, including as appropriate:
  ß  education on the management of pregnancy with diabetes
  ß  optimization of blood glucose control (pre-conception target DCCT-aligned 
HbA1c <6.1 %)
  ß  stopping oral glucose-lowering drugs (metformin may still be indicated), and 
starting insulin where appropriate
  ß  optimization of blood pressure control (to <130/80 mmHg)
  ß  stopping ACE-inhibitors and A2RBs (use methyldopa, nifedipine MR, 
labetalol)
  ß stopping statins and ﬁ brates
  ß  assessment of eye and kidney damage (see Eye screening, Kidney damage); 
discuss and manage identiﬁ ed problems
  ß assessment of thyroid function
  ß advice on alcohol and smoking
  ß folic acid therapy.
Screening for undiagnosed or new (gestational) diabetes in pregnancy
PR3  In women at high risk of diabetes (previous gestational diabetes, obesity 
– especially abdominal obesity, population with high prevalence of diabetes) 
provide healthy lifestyle advice (nutrition and physical activity) from ﬁ rst pre-
natal visit; check for hyperglycaemia at ﬁ rst pre-natal visit; perform 75-g OGTT 
[1] if indicated. 
PR4  In all women, measure plasma glucose at ﬁ rst visit after week 20 (24-28 weeks in 
low risk women); perform 75-g OGTT if abnormal. 
Pregnancy
Whenever pregnancy is complicated by diabetes, close liaison between health-care 
professionals involved in diabetes, obstetric and neonatal care will help to achieve the 
desired outcome of a healthy mother and baby.  
This guideline only addresses areas of pregnancy care commonly affected by the 
co-existence of diabetes, and not routine obstetric care such as fetal scanning and 
monitoring.
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PR5  Manage as diabetes if fasting plasma glucose ≥7.0 mmol/l (>125 mg/dl) and/or 
2-h plasma glucose ≥7.8 mmol/l (≥140 mg/dl).
Management during pregnancy
PR6   Review understanding of management of diabetes in pregnancy, current 
drug therapy (see PR2), blood glucose control, diabetes complications, and 
presence of other medical conditions. Advise as appropriate.
PR7  Examine eyes at ﬁ rst pre-natal visit and each trimester.
PR8  Offer medical nutrition therapy and education. If overweight, advise a diet 
suitable for someone of optimal weight. Encourage moderate exercise such as 
walking.  
PR9  Review frequently, depending on achievement of blood glucose control 
targets, and management of other diabetes-associated and obstetric 
problems. 
PR10  Aim for DCCT-aligned HbA1c <6.0 %, or lower if safely achievable, using self-
monitoring of blood glucose to 3.3-6.7 mmol/l (60-120 mg/dl), four times daily 
(pre-breakfast and 1-2 h after each meal), and insulin therapy if indicated. 
PR11  Manage insulin therapy through careful and intensive self-monitoring and dose 
adjustment, expecting a rise in insulin requirements as pregnancy proceeds. 
Insulin requirements may be further disturbed by hyperemesis or use of 
steroid therapy, and in-patient care may be needed.  
PR12  Monitor weight gain and blood pressure and advise/treat accordingly. Blood 
pressure should be <130/80 mmHg, avoiding the use of renin-angiotensin 
system blocking drugs.  
Labour and delivery
PR13  Use intravenous insulin (if on insulin or if needed) during labour. 
PR14  Anticipate changed insulin requirements, and thus need for more frequent 
glucose monitoring, if continuing insulin postpartum and during lactation. 
PR15  Provide appropriate care and facilities for the newborn.
PR16  At 45 to 60 days after pregnancy, check for diabetes in women who had 
developed new diabetes in pregnancy. If then non-diabetic, advise on the high 
risk of future diabetes, and preventative lifestyle measures. Advise check for 
diabetes annually. 
Pregnancy
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n Comprehensive care
PRC1  This would be as Standard care for screening, except that screening for new 
diabetes after week 20 might go direct to OGTT in situations with high prevalence 
and where health facilities are available.
PRC2  Specialist ophthalmological review can be offered throughout pregnancy.
PRC3  Personal dietetic support and ﬁ tness training can be offered throughout pregnancy.
PRC4  Self-monitoring of capillary blood glucose during pregnancy would be performed 
more frequently, at times of likely peak and trough plasma glucose concentrations. 
Continuous glucose monitoring would be a further possibility.
PRC5  HbA1c will be performed at each clinical contact.
PRC6  Insulin delivery might be optimized by the use of continuous subcutaneous insulin 
infusion.
n Minimal care
PRM1  Most of the procedures under Standard care can be offered by a specially trained 
health-care worker. 
PRM2  If laboratory glucose testing is not easily available, capillary blood glucose 
measurement for fasting and 2-h OGTT estimation can be substituted, using a 
trained operator and a regularly validated meter system. 
PRM3  Where resources allow only very limited access to self-monitoring of blood glucose, 
use in pregnant women should be a priority.
PRM4  If insulin availability is problematic, consider oral glucose-lowering drugs (not 
PPAR-γ agonists), with the proviso that safety in pregnancy is not fully established. 
Rationale
With increasing numbers of women around the world 
developing Type 2 diabetes, and doing so at a younger age, 
and with women in many cultures tending to delay starting 
a family, the issue of diabetes complicating pregnancy has 
become increasingly important. These guidelines do not 
address prevention of Type 2 diabetes, so the increased risk 
of later development of diabetes in those who experience 
gestational diabetes (GDM) is not our principal concern 
here. We focus rather on the care of women with new 
diabetes in pregnancy, as well as the care of those who 
already have Type 2 diabetes. Although management of 
diabetes in pregnancy has been improving, women and their 
infants remain at higher risk for a number of complications 
Pregnancy
compared with non-diabetic pregnancy. The frequency of 
congenital anomalies is still high among infants of women 
with diabetes. 
Evidence-base
The evidence-base for much diabetes pregnancy management 
is poor, and relies on some cohort studies, an occasional 
RCT, some retrospective analysis, and considerable clinical 
experience. Much of the data pertaining to Type 2 diabetes 
derives from people with Type 1 diabetes or studies of mixed 
populations. The only guideline formally addressing the area 
(Type 2 diabetes) is the Canadian guideline (in which most of 
the recommendations are consensus) [2], though consensus 
guidelines based on non-formal evidence review were also 
Global Guideline for Type 2 Diabetes68
prepared by IDF (Europe) [3]. The SIGN guideline [4] includes 
pregnancy, focusing on Type 1 diabetes, while ADA standards 
of care include pre-conception care and screening for diabetes 
in pregnancy [5]. 
Screening for GDM (deﬁ ned as glucose intolerance of 
variable severity with onset or ﬁ rst recognition during 
pregnancy – which will include undiagnosed Type 2 diabetes) 
is a controversial issue (and the ongoing HAPO study may 
help here) [2]. Whether or not, and whom, to screen is likely 
to depend on prevalence of Type 2 diabetes in women of 
child-bearing age in the population under consideration; 
it is difﬁ cult therefore to develop universally appropriate 
recommendations. GDM is an asymptomatic condition 
most of the time, and there has been no RCT to test the 
effectiveness of its detection. Diagnostic and management 
levels remain uncertain. Cohort studies have shown increased 
risk of adverse outcomes according to levels of plasma 
glucose, independently of age, obesity and other risk 
factors. RCTs have shown that treatment of hyperglycaemia 
in pregnancy reduces macrosomia. The Canadian guideline 
recommends all pregnant women be screened for GDM 
between weeks 24 and 28 [2], while different strategies 
are outlined in other guidelines which address this [4,5,6]. 
A recent paper has supported the utility of detecting and 
managing GDM [7].
The guidelines present a confusing picture as regards 
screening tests for GDM. The use of a 4.7 mmol/l (85 mg/dl) 
cut-off for fasting plasma glucose is suggested from two 
analyses [8,9], but other studies have suggested higher 
cut-offs. Fasting glucose may not be the most appropriate 
measure, however, and the 75-g OGTT (fasting and 2-h 
values) advocated by WHO [1] is increasingly used 
internationally, as noted in a Brazilian study [10]. 
The Canadian and IDF (Europe) guidelines note the 
importance of blood glucose control in the ﬁ rst trimester for 
avoidance of fetal malformation, and the adverse effects of 
hyperglycaemia throughout pregnancy. Insulin is regarded 
as the natural means of improving blood glucose control in 
pregnancy where lifestyle measures fail, although metformin 
is increasingly regarded as safe. Frequent self-monitoring of 
blood glucose is a normal part of insulin therapy, in particular 
where insulin requirements are changing as in pregnancy, and 
where stricter targets may lead to increased risk of serious 
hypoglycaemia [2]. Special considerations surrounding labour 
and delivery have been reviewed recently [11]. 
Experience with rapid-acting insulin analogues has been 
reassuring for insulin lispro although no formal trials are 
available [12]. Experience with long-acting insulin analogues 
is still very thin [2], and unless other clear advantage is 
apparent (previous major gain in blood glucose control 
over NPH insulin-based regimens) they are not generally 
used in pregnancy. Use of oral glucose-lowering drugs 
is still controversial, and mostly derives from experience 
of widespread use in some developing countries and in 
polycystic ovarian syndrome (see Canadian guideline [2]), 
but this mostly applies to glyburide and to metformin. 
Newer drugs are therefore assumed to be contra-indicated.     
Consideration
Despite the poor evidence-base, it is clear that the 
consequences of poor management of diabetes in pregnancy 
(high risk of maternal and neonatal complications, dead 
and deformed babies) are such that this is a prime area 
where investment of health-care resources is appropriate. 
Furthermore, considerable consensus exists over the need 
for continued monitoring of complications for acceleration 
of diabetes-induced damage, and the early use of insulin 
therapy to tight targets backed by self-monitoring. While the 
issue of methods and schedules for screening for new-onset 
diabetes in pregnancy is diverse and confused, the need for 
detection is not in dispute, and again there is clear consensus 
that the OGTT in some form has an important role, and that 
tight blood glucose management in those testing positive is 
indicated. Some other areas of care, such as the need for folic 
acid supplementation, and the high risk of future diabetes 
in those remitting from diabetes after delivery, also seem 
secure. A particularly difﬁ cult issue relates to the use of oral 
glucose-lowering drugs during pregnancy in places where 
insulin supply is tenuous, and Type 2 diabetes in pregnancy 
common. However, while it is nearly impossible to exclude a 
low incidence of adverse effects (<1 in 100), the potential gain 
– if this (glyburide/metformin) is the only means of improving 
glucose control – would seem to be higher.  
Implementation
Liaison with obstetric colleagues is a ﬁ rst step in 
implementation of these recommendations, such that 
joint protocols can be devised for screening for diabetes, 
and for pregnancy and post-pregnancy management. 
Health-care professionals need to be trained on pregnancy-
speciﬁ c lifestyle adaptation, insulin use, and complications 
screening. Availability of such staff needs to be assured. 
Where resources are scarce, the availability of insulin and 
self-monitoring equipment may need to be prioritized to this 
area, and supplies assured. Laboratory resources for clinical 
monitoring of glucose control and assessment of renal 
damage should be provided. Pre-pregnancy services may 
need to be organized separately.   
Pregnancy
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Evaluation
Monitoring of outcome of diabetic pregnancy (healthy and 
unhealthy neonates) may seem logical, but because of small 
number problems is not a powerful tool of quality assurance. 
Investigation of each neonatal death may be more useful. 
Delivery weight of the infant and achieved maternal HbA1c
in each trimester are useful surrogate outcomes. Structural 
review should be of the existence of joint management 
protocols addressing the above recommendations, and 
appropriate availability of staff.  
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Recommendations
n Standard care
CH1  Diagnose symptomatic children using plasma glucose and WHO 1999 criteria [1].
CH2  Attempt to assign type of diabetes, using history and physical examination, 
including weight, BMI, urine ketones, pH, electrolytes.
 
   When the diabetes appears to be Type 2 diabetes, remain alert to the possibility 
and associated risks of Type 1 diabetes or MODY.
 
   Where differentiation is uncertain, islet-cell related antibodies and C-peptide 
estimation may add further information. 
CH3  Provide initial care appropriate to age and developmental stage, including 
lifestyle counselling, diabetes education with the family, blood glucose 
monitoring, management with insulin or oral agents (metformin) according to 
clinical features, and psychological assessment.
CH4  Provide continuing care and support including: 
  ß lifestyle measures in the context of the family
  ß  self-monitoring of blood glucose, with attention to continuity from the 
management team, and to ensure care for diabetes at school
  ß HbA1c every 2-6 months (see Clinical monitoring).
CH5   Arrange annual surveillance including weight and height, BMI, blood pressure, 
urine protein and albumin, eye review. 
n Comprehensive care
CHC1  Screening might also be extended to asymptomatic children who are at high 
risk in the particular population (criteria might include BMI, family history, age, 
race/ethnicity, insulin resistance as evidenced by acanthosis nigricans).
CHC2  Attempts to assign the type of diabetes after diagnosis could also include 
more routine testing for islet-cell related antibodies and C-peptide, and HNF 
and glucokinase genotyping.
CHC3  Initial care will be as for Standard care, while continuing care may also include 
routine psychosocial support; ongoing surveillance may include lipid proﬁ le.
Children
Global Guideline for Type 2 Diabetes 71
n Minimal care
CHM1  Diagnose symptomatic children by urine glucose or capillary plasma glucose.
CHM2  Attempt to assign type of diabetes by history and physical examination 
assessing weight, BMI, blood pressure, and urine ketones.
CHM3  Initial care should include lifestyle information, diabetes education with the 
family, monitoring of blood glucose, and management with insulin and/or 
metformin according to clinical features. 
CHM4  Provide continuing care including:
  ß  lifestyle measures in the context of the family
  ß  advice to the school on dealing with emergencies and avoiding 
discrimination. 
CHM5  Surveillance will include weight, height, BMI, blood pressure, urine protein, 
and eye review. 
Rationale
Type 2 diabetes in children is increasing in many populations 
around the world. Affected children may have a positive 
family history of Type 2 diabetes, and in most cases the BMI 
is above the 85th percentile for gender and age, deﬁ ned as 
overweight. However, this is not universal, notably in some 
Asian and Oriental populations. Overweight in childhood 
is associated with poverty in relatively developed areas but 
with afﬂ uence in developing areas of the world. Type 2 
diabetes in children is a severe disease with very poor 
outcomes over 10-20 years. It is associated with signiﬁ cant 
islet B-cell failure as well as insulin resistance, and is at 
least as demanding to manage as Type 1 diabetes in 
children. Children with Type 2 diabetes are more at risk of 
hypertension, dyslipidaemia and polycystic ovarian syndrome 
than those with Type 1 diabetes.  
Evidence-base
It is only relatively recently that the emergence of Type 2 
diabetes in children has been recognized. In Europid 
populations Type 1 diabetes remains the predominant form 
in children, but in Japanese populations 80 % of childhood 
diabetes is Type 2 diabetes, and the condition is increasing 
in incidence and prevalence in many parts of the world. It 
is usually diagnosed after the age of 10 yr, in mid- to late-
puberty, with the reduced insulin sensitivity of puberty 
apparently playing a role [2]. The evidence-base remains 
limited, and only the Canadian guideline deals speciﬁ cally 
with the condition [3]. There is a NICE guideline on Type 1 
diabetes in children, and this refers brieﬂ y to the need to 
distinguish children with Type 2 diabetes [4]. Many of the 
global issues, and the paucity of evidence, were considered 
at an IDF meeting in 2003 [5], while the topic has been 
addressed in a number of US publications [6-10]. 
Use of adult diagnostic criteria [1] reﬂ ects lack of other 
evidence and the problems of staging and normative 
values in the 10- to 13-year age group. The Canadian 
guideline states that insulin is required when there is severe 
metabolic decompensation at diagnosis (ketoacidosis, HbA1c
≥9.0 %, symptoms of severe hyperglycaemia); otherwise 
the recommended initial treatment is intensive lifestyle 
intervention, adding metformin as ﬁ rst-line therapy if 
glycaemic targets are not achieved [3]. An algorithm devised 
by Silverstein and Rosenbloom in a review of North American 
practice [6] suggests that in those started on insulin (plus 
lifestyle) achievement of a DCCT-aligned HbA1c <7.0 % allows 
tapering of insulin dose with addition of metformin, and 
attempts to ‘wean off’ insulin. However, the evidence-base 
for treatment is very limited, with data on insulin use mainly 
from Type 1 diabetes. The Canadian guideline cites evidence 
for efﬁ cacy and safety of metformin (over 16 weeks) in 
adolescents with Type 2 diabetes, and draws attention to the 
contra-indications in the case of kidney or liver disease [3]. 
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The gastro-intestinal side-effects of metformin are poorly 
tolerated by children and adolescents, yet other oral 
glucose-lowering options have barely been explored. 
Recommendations on surveillance for complications reﬂ ect 
evidence on microvascular complications in Pima Indian and 
Japanese populations, cited in the Canadian guideline [3]. 
The risks of pregnancy in this age-group need to be borne in 
mind in relation to drug therapy.
Consideration
Health-care professionals dealing with children need to be 
alert to the possibility of Type 2 diabetes, and aware of the 
seriousness of the condition. Most of these children are 
overweight at diagnosis, and most are in families with others 
who are overweight and at risk of Type 2 diabetes, so advice 
on lifestyle modiﬁ cation can usefully involve the whole family. 
Implementation
A continuing integrated package of care should be offered 
by a multidisciplinary paediatric diabetes team, trained 
in the difﬁ cult area of distinguishing Type 2 diabetes in 
children, outlining the pathways of care, and dealing with the 
possibility of multiple medication. Structured records and 
recall systems are essential, as is the need to address the 
transition to adult diabetes care services.
Evaluation
Systematic evaluation of an emerging epidemic will include, 
at all levels, numbers of patients, medications given, and 
complications at diagnosis. Standard care should also include 
documentation of BMI, glycaemic control, and complications 
on follow-up, while comprehensive care should additionally 
evaluate efﬁ cacy of treatment, cost, and criteria used for 
diagnosis. 
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Recommendations
n Standard care
In-patient care organization
HO1  Designate a diabetes-trained health-care professional to: 
  ß  manage and co-ordinate systems of care related to diabetes management 
of in-patients
  ß  co-ordinate training of hospital staff in awareness of the needs of people 
with diabetes
  ß  implement strategies to prevent disempowerment of those who could 
self-manage their diabetes
  ß  plan for discharge and follow-up.
HO2  Provide access for people with diabetes and hospital staff to a multidisciplinary 
diabetes team. 
HO3 Ensure laboratory/service support for: 
  ß  assays including plasma glucose, HbA1c, basic haematology and 
biochemistry, lipid proﬁ le and hormone assays 
  ß microbiological investigation 
  ß radiology and other imaging.
General ward care
HO4  Encourage self-management of diabetes (food choice, self-monitoring, insulin 
dose adjustment where appropriate) integrated into usual ward care.
Management during in-patient procedures 
HO5  Evaluate blood glucose control, and metabolic and vascular complications (in 
particular renal and cardiac status) prior to planned procedures; provide advice 
on the management of diabetes on the day or days prior to the procedure. 
HO6  Ensure the provision and use of an agreed protocol for in-patient procedures 
and surgical operations.
HO7  Aim to maintain near-normoglycaemia without hypoglycaemia by regular 
quality-assured blood glucose testing and intravenous insulin delivery where 
needed, generally using a glucose/insulin/potassium infusion.
In-patient care 
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HO8  Ensure awareness of special risks to people with diabetes during hospital 
procedures, including risks from: 
  ß neuropathy (heel ulceration, cardiac arrest) 
  ß  i ntra-ocular bleeding from new vessels (vascular and other surgery requiring 
  anticoagulation) 
  ß  drug therapy (risks of acute renal failure causing lactic acidosis in people on 
metformin, for example with radiological contrast media).
Critical care situations 
HO9  Provide access to intensive care units (ICU) for life-threatening illness, ensuring 
that strict blood glucose control, usually with intravenous insulin therapy, is a 
routine part of system support for anyone with hyperglycaemia. 
HO10  Provide protocol-driven care to ensure detection and immediate control of 
hyperglycaemia for anyone with a presumed acute coronary event or stroke, 
normally using intravenous insulin therapy with transfer to subcutaneous insulin 
therapy once stable and eating.
n Comprehensive care
HOC1  General principles are as for Standard care, but would include repeated review by 
a diabetes specialist where general health state is changing or glucose control is 
problematic.
HOC2  Use telematic review of blood glucose control to a specialist’s ofﬁ ce for people in 
critical situations.
HOC3  Maintain staff trained in aspects of diabetes management on any ward or 
procedure area with a signiﬁ cant throughput of people with diabetes.
n Minimal care
HOM1  General principles are as for Standard care, but hospitals should designate an 
individual in charge of matters relating to in-patient diabetes, to co-ordinate 
training in awareness of the needs of, and provision of in-patient care to, people 
with diabetes, and the provision and use of guidelines and protocols. 
HOM2  Laboratory assays should include plasma glucose and basic biochemistry; basic 
radiology should be available.
HOM3  Management of plasma glucose levels during in-patient procedures will generally 
be as for Standard care. Where this is impossible or carries special risk, frequent 
intramuscular insulin with frequent monitoring may be useful in emergency 
situations, or frequently monitored subcutaneous insulin therapy (e.g. with NPH 
insulin) for minor procedures or more stable health states.
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Rationale
Hyperglycaemia is found, and requires management, in 
hospital settings not only in people with known diabetes 
but also in people with previously unrecognized diabetes 
and in people with hospital-related hyperglycaemia which 
reverts to normal after discharge. Prevalence of diabetes in 
hospitalized adult patients is 12-25 % or more [1]. Hospital 
care for people with diabetes may be required for metabolic 
emergencies, in-patient stabilization of diabetes, diabetes-
related complications, intercurrent illnesses, surgical 
procedures, and labour and delivery (see Pregnancy).  
Evidence-base
Recent growth in the literature on hospital hyperglycaemia 
is reﬂ ected in the inclusion of sections on in-patient 
management in diabetes guidelines. The 2005 ADA 
standards have added a section on diabetes care in the 
hospital [1], drawing on a technical review [2] and the 
position statement of the American College of Endocrinology 
(ACE) [3]. The Canadian guidelines include separate sections 
on peri-operative and peri-acute coronary syndrome 
glycaemic control [4]. NICE reviewed evidence from people 
with Type 2 diabetes when developing recommendations for 
in-patient care in Type 1 diabetes [5].
The recent ACE position statement was based on a review 
of the literature on in-hospital hyperglycaemia [3]. They 
found multiple studies conﬁ rming that hospitalized patients 
with hyperglycaemia suffer signiﬁ cant excess mortality and 
morbidity, prolonged length of stay, unfavourable post-
discharge outcomes, and signiﬁ cant excess health-care 
costs. They found RCTs as well as prospective observational 
and retrospective studies demonstrating improved 
outcomes (mortality, infection, intubation time, length of 
hospital stay) resulting from more aggressive treatment 
of hyperglycaemia. They strongly support the need for 
early detection of hyperglycaemia in the hospital and an 
aggressive management approach to improve outcomes. 
ACE propose upper limits for blood glucose targets 
(ICU 6.1 mmol/l (110 mg/dl); non-ICU 6.1 mmol/l pre-
prandial, 10.0 mmol/l (180 mg/dl) maximum), with the 
proviso that those for non-intensive care patients are 
less well supported by the evidence. They list indications 
for intravenous insulin infusion therapy (critical illness, 
prolonged nil-by-mouth status in insulin-deﬁ cient patients, 
peri-operative period, post transplantation, total parenteral 
nutrition therapy, elevated glucose exacerbated by high-
dose glucocorticoid therapy, stroke, dose-ﬁ nding prior to 
subcutaneous (SC) insulin injections, other illnesses requiring 
prompt glucose control). For SC insulin they discourage 
the use of sliding scales. They found some evidence for a 
diabetes team approach (reduced length of stay, fewer re-
admissions). 
The Canadian guidelines also make recommendations on 
blood glucose levels, emphasizing tight control (4.5-6.0 
mmol/l, 80-110 mg/dl) for post-operative ICU patients if 
random plasma glucose >6.1 mmol/l (>110 mg/dl) [4]. They 
found strong evidence for recommending that all patients 
with acute MI and blood glucose >12.0 mmol/l (>215 mg/dl) 
should receive insulin-glucose infusion therapy to maintain 
blood glucose between 7.0 and 10.0 mmol/l (125-180 mg/dl) 
for at least 24 h, followed by multi-dose SC insulin for at least 
3 months.
Neither ACE nor the Canadian guideline addresses the issue 
of oral glucose-lowering drugs in the hospital setting, but 
the ADA [1] draws attention to limitations for in-patient use 
(especially with regard to ﬂ exibility) of the major classes. For 
metformin, the fact that many speciﬁ c contra-indications 
(related to risks of renal impairment) to its use are found 
in the hospital setting was seen as limiting its use. For 
thiazolidinediones haemodynamic changes were felt to be 
an issue, and for sulfonylureas risk of hypoglycaemia.
One cost study, cited by ACE, found cost per QALY for 
intravenous insulin therapy in patients with acute myocardial 
infarction to be comparable to that for other well-accepted 
medical interventions.
NICE additionally notes the utility and importance of a 
holistic approach, using the skills and knowledge of a person 
with diabetes developed over years or decades [5].
Consideration
It was considered important that hospitals should designate 
a ‘diabetes lead’ individual, who would be in charge of 
matters relating to diabetes, and could co-ordinate training 
of staff in awareness of the needs of those with diabetes, 
and develop strategies to prevent disempowerment 
of those who could self-manage their diabetes. Major 
considerations were that diabetes should not complicate 
the management of whatever condition resulted in 
admission to hospital, and that a person’s diabetes 
should not emerge from hospital worse than when they 
were admitted. While the evidence over use of protocol-
driven intravenous insulin regimens is not conclusive, 
the widespread and general adoption of these regimens 
globally appears telling (for more detail of methods see 
references 6, 7).
Global Guideline for Type 2 Diabetes
In-patient care 
76
Implementation
Systems of care and protocols need to be put in place and 
staff trained to ensure their effectiveness. Standardized 
protocols, developed by multidisciplinary teams, should 
specify insulin dose, include guidelines for identifying 
patients at risk for hypoglycaemia, and actions to be taken 
to prevent and treat hypoglycaemia. Bedside glucose 
monitoring requires deﬁ ned administrative responsibility, 
a procedure manual, training, policies regarding frequency 
(hourly to twice-daily) and procedures for alert values, quality 
control, and regular maintenance of equipment.
Evaluation
Evaluation should consider evidence of the availability 
of trained staff (and training courses) and of protocols as 
above. Audit can be made of ward blood glucose control, 
and blood glucose control during surgery, after myocardial 
infarction and in intensive care. Admissions to coronary care 
can be reviewed to ensure measurement of blood glucose 
is occurring, and appropriate actions are then taken while in 
the unit and during follow-up.
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A2RB  angiotensin-II receptor blocker
ACE  American College of Endocrinology
ACE-inhibitor  angiotensin converting enzyme inhibitor
ACR  albumin:creatinine ratio
ADA  American Diabetes Association
AER  albumin excretion rate
BMI  body mass index
BP  blood pressure
CCB  calcium-channel blocker
CCT  controlled clinical trial
CDA  Canadian Diabetes Association
CV  cardiovascular
CVD  cardiovascular disease
DCCT  Diabetes Control and Complications Trial
DSME  diabetes self-management education
eGFR  estimated glomerular ﬁ ltration rate
FPG  fasting plasma glucose
GDM  gestational diabetes
Hb  haemoglobin
HDL  high density lipoprotein
HNF  hepatocyte nuclear factor
HPLC  high-performance liquid chromatography
ICSI  Institute for Clinical Systems Improvement
ICU  intensive care unit
LDL  low density lipoprotein
MI  myocardial infarction
MNT  medical nutrition therapy
MODY  maturity-onset diabetes of the young
MRI  magnetic resonance imaging
NICE  National Institute for Clinical Excellence (England and Wales)
NPH  neutral protamine Hagedorn
OGTT  oral glucose tolerance test
PCR  protein:creatinine ratio
PDE5  phosphodiesterase type-5
QALY  quality-adjusted life year
RCT  randomized controlled trial
SC  subcutaneous
SIGN  Scottish Intercollegiate Guidelines Network
SMBG  self-monitoring of blood glucose
UKPDS  United Kingdom Prospective Diabetes Study
WHO  World Health Organization
Acronyms and abbreviations
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Disclaimer
The International Diabetes Federation (IDF) does not provide 
individualized medical diagnosis, treatment or advice, nor 
does it recommend speciﬁ c therapies or prescribe medication 
for anyone using or consulting the Global Guideline for Type 2 
Diabetes.  IDF is not engaged in the practice of medicine and 
nothing contained in the Global Guideline for Type 2 Diabetes
is intended to constitute professional advice for medical 
diagnosis or treatment for speciﬁ c persons. The information 
contained in the Global Guideline for Type 2 Diabetes is 
intended and may be used for general educational and 
informational purposes only. 
Medical information changes rapidly; therefore, some of the 
information contained in the Global Guideline for Type 2 
Diabetes may be out of date and/or may contain inaccuracies. 
IDF assumes no responsibility for how readers use the 
information contained in the Global Guideline for Type 2 
Diabetes. Readers, in search of personal medical advice 
and direction, should seek advice from and consult with 
appropriately qualiﬁ ed medical and health-care professionals 
on speciﬁ c situations and conditions of concern.
Reliance on information contained in the Global Guideline 
for Type 2 Diabetes is solely at the reader’s own risk. Readers 
should exercise independent judgement and scepticism 
before applying any information contained in the Global 
Guideline for Type 2 Diabetes to their own health needs, 
or relying on any information in any other way. No one 
person’s medical needs are the same as another person’s, 
and therefore, information provided may be incorrect or 
misleading.
Reasonable endeavours have been made to ensure the 
accuracy of the information presented. However, IDF 
assumes no legal liability or responsibility for the accuracy, 
currency or completeness of the information provided 
herein. Any views, opinions, and/or recommendations 
contained in this publication are not those of IDF or 
endorsed by IDF, unless otherwise speciﬁ cally indicated 
by IDF. The International Diabetes Federation assumes no 
responsibility or liability for personal or other injury, loss, 
or damage that may result from the information contained 
within this publication.
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 Revised SEMDSA Guidelines for diagnosis and management of type 
2 diabetes mellitus for primary health care in 2002. 
 
CRITERIA FOR THE DIAGNOSIS OF DIABETES MELLITUS 
 
 
 
 
 
 
 
 
 
 
 
 
      Symptoms of diabetes plus: 
 casual plasma glucose concentration ≥ 11.1 mmol/l. 1  
OR 
     Fasting plasma glucose ≥ 7.0 mmol/l.2   
OR 
      2-h PG ≥ 11.1 mmol/l during an OGTT.3 
 
RECOMMENDATIONS FOR GLYCAEMIC CONTROL* 
Biochemical Index Optimal Acceptable Additional Action Suggested1 
 
Capillary blood glucose values  
(finger-prick)2 
   
           Fasting (mmol/l) 4-6 6-8 > 8 
           2-hour post-prandial (mmol/l) 4-8 8-10 > 10 
    
Glycated hemoglobin (HbA1C) (%) < 7 7-8 > 8 
    
Weight    
          BMI (kg/m2) < 25  > 273 
          Waist circumference (cm): Male    < 94  >102 
                                                     Female        < 82  >88 
*These values are for nonpregnant adults.  
1. “Additional action suggested” depends on individual patient circumstances.  Such actions may include enhanced diabetes 
self-management education, co-management with a diabetes team, referral to an endocrinologist/diabetologist, change in 
pharmacological therapy, initiation or increased self-monitoring of blood glucose, or more frequent contact with the patient.  
HbA1c is referenced to a nondiabetic range of 4.0 – 6.0%. Note that often action should ideally be instituted before these 
levels are reached. 
2. Preferably assessed over several visits. 
3. In the presence of diabetes mellitus (DM) this level is 27 and not 30. 
1. Casual is defined as any time of day without regard to time since last meal.  The classic symptoms of diabetes include 
polyuria, polydipsia and unexplained weight loss. 
2. Fasting is defined as no caloric intake for at least 8 hours.  
3. The test should be performed as described by the World Health Organization, using a glucose load containing the 
equivalent of 75-g anhydrous glucose dissolved in water. 
Note: In the absence of unequivocal hyperglycemia with acute metabolic decompensation, these criteria should be confirmed 
by repeat testing on a different day.  The oral glucose tolerance test (OGTT) is not recommended for routine clinical use but a
many as 30% of people with diabetes will not be diagnosed if only fasting measurements are done.  Different criteria are used to 
diagnose gestational diabetes in pregnant women.  
s 
 
 
LIPID AND BLOOD PRESSURE GOALS  (For nonpregnant adults) 
Blood Pressure (mmHg) Lipids (mmol/l) 
 
Systolic        < 130 
 
Total-cholesterol   < 5.0 
Diastolic       < 80 LDL-cholesterol    ≤  3.0 1 
 
 
If persistent dipstick proteinuria (macroalbuminuria) 
Systolic       < 120 
Diastolic      < 70 
HDL-cholesterol     > 1.2  
Triglycerides           < 1.5 
  
 
1. American National Cholesterol Education Program (NCEP) III recommends a level of < 2.6 mmol/l, 
especially in the presence of existing vascular disease (stroke, peripheral vascular disease, and ischaemic 
heart disease). 
 
KEY TESTS / EXAMS (all initially) 
Test / Exam Frequency 
Glycated hemoglobin • Quarterly if treatment changes or not meeting goals 
 • At least 2 times/year if stable 
Dilated eye exam Yearly 
Comprehensive foot exam At least yearly (more often in patients with high-risk foot conditions) 
Lipid profile Yearly (less frequently if normal) 
Serum creatinine level Yearly   
Microalbumin measurement Yearly if no persistent dipstick proteinuria (macroalbuminuria) 
Blood pressure Each regular diabetes visit 
BMI (body mass index) & waist 
circumference 
Initially and weigh at each regular diabetes visit  
ECG Yearly if possible 
  
 
Patient education and nutritional counseling 
This is the cornerstone of effective diabetes care and sufficient time and resources should be made 
available in order to do this effectively.  As obesity virtually always accompanies type 2 diabetes it 
should be targeted in its own right. A weight loss of 5-10% should be the initial aim and as such 
has been shown to improve insulin resistance and all its associated parameters. Evidence 
demonstrates that structured, intensive lifestyle programs involving participant education, 
individualized counseling, reduced dietary fat and energy intake, regular physical activity and 
frequent participant contact are necessary to produce long-term weight loss of >5% of starting 
weight. 
 
 
 
 
 
 
 
 
 
Glucose Treatment Recommendations for type 2 DM. 
 
1. Always provide or refer for dietary and lifestyle advice at diagnosis and regularly (as often as 
possible, at least annually) thereafter. 
2. If random glucose values  > 15 mmol/L consider starting oral agents together with lifestyle 
modification from the start. 
3. If overweight  (BMI > 25) consider metformin unless contra-indicated. 
4. If postprandial glucose values constitute the major abnormality or sulphonylureas contra-indicated 
(e.g. renal failure) acarbose or meglitinides may be considered. 
5. If insulin resistance is the major abnormality (abdominal obesity [see waist circumference above], 
lowered HDL, raised triglycerides, hypertension) metformin should be considered as first line or 
add on therapy. If metformin contra-indicated or poorly tolerated (e.g. raised serum creatinine or 
major cardio-pulmonary) then thiazolidinediones may be used.   
6. Always start with monotherapy and titrate dosage to maximum over 1-3 months.  
7. If goals still not reached then add second agent (lowest dose, titrate when necessary).  
8. If goals still not attained despite good compliance and absence of major stressors such as infection 
consider insulin therapy. 
9.  In such cases insulin therapy may be initiated as intermediate or long acting insulin at bedtime 
(titrate against pre-breakfast reading) with or without oral agents. If possible self glucose monitoring 
should be done in all patients on insulin.  
10. Initial insulin dose is 0.2-0.3 U/kg.  
11. If more than 30 U per day are required or clinical judgment indicates, use twice daily biphasic 
insulin (2/3 intermediate, 1/3 short acting). Consider referral. 
 
Blood pressure treatment recommendations. 
 
1. If possible and affordable therapy should be angiotensin converting enzyme (ACE) inhibitor  based. 
2. Low dose diuretics (eg. hydrochlorothiazide (HCTZ) 12.5mg or Indapamide 1.25 -2.5 mg/day) may 
be appropriate first line agents in black patients and second line agents in others. 
3. Many, if not most, patients will require at least 2 agents to control blood pressure. 
4. In the presence of  micro- or macroalbuminuria   ACE inhibitors or angiotensin II receptor 
antagonists are of proven benefit.  
5. In patients over age 55 yrs with hypertension (HT),  or without HT but with another cardiovascular 
risk factor (history of coronary vascular disease, dyslipidaemia, microalbuminuria, smoking) an 
ACE inhibitor (if not contra-indicated) should be considered to reduce the risk of cardiovascular 
events. 
 
Aspirin recommendations. 
 
Use aspirin therapy as a secondary prevention strategy in individuals who have evidence of large 
vessel disease (a history of myocardial infarction, vascular bypass procedure, stroke or transient 
ischaemic attack, peripheral vascular disease, claudication, and/or angina). 
 
In addition to treating the primary cardiovascular risk factor(s) identified, consider aspirin therapy as 
a primary prevention strategy in high-risk men and women with type 1 or type 2 diabetes. This 
includes diabetic subjects with the following:  a family history of coronary heart disease, cigarette 
smoking, hypertension, obesity, albuminuria (micro or  macro), age >30 years or dyslipidaemia. 
 
Use of aspirin has not been studied in diabetic individuals under the age of 30 years.  
1. Use 150-300 mg aspirin per day (enteric coated if possible).  
2. People with aspirin allergy, bleeding tendency, anticoagulant therapy, recent gastrointestinal 
bleeding, and clinically active hepatic disease are not candidates for aspirin therapy.  
3. Aspirin therapy should not be recommended for patients under the age of 21 years because of the 
increased risk of Reye’s syndrome associated with aspirin use in this population.  
 
 
Lipid treatment recommendations. 
 
1. If LDL-cholesterol persists above 3 mmol/l refer for dietary advice. If despite adequate glycaemic 
control and dietary advice, LDL-cholesterol remains above 3 mmol/l consider a statin as therapy. 
2. If triglycerides are above 1.5 mmol/l check for secondary causes such as poor glucose control, 
alcohol, thyroid disease etc. and if negative refer for dietary advice. If remains persistently high  
       (> 4mmol/l) consider using a fibrate (especially if the HDL-cholesterol is  < 0.9 mmol/l). 
3. If both the LDL-cholesterol and triglycerides remain elevated following dietary advice initiate 
therapy with a statin. Consider adding a fibrate if raised triglycerides persist despite statin therapy 
but beware of drug induced rhabdomyolysis.  
4. Fibrates should be used with extreme caution in patients with impaired renal function. In these 
patients if statins are used they should be started at low doses and doses subsequently titrated as 
needed. Hyperlipidemia in this setting should preferably not be managed at a primary care level. 
 
Reference: 
ADA  Clinical Practice Recommendations 2002.  Diabetes Care 2002; vol 25: nr 1: supplement1 
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Measure HbA1c every 3 months depending on 
control and changes in therapy 
Continue to monitor 
HbA1c every 6 months 
Target HbA1c should be ≤ 7.0% 
Diagnosis of Type 2 
Have lifestyle modifications been successful? 
YES 
YES 
YES 
NO 
NO 
NO 
Consider oral hypoglycaemic agents 
Is there renal and/or cardiac dysfunction
Consider 
sulphonylurea  
Is Patient’s BMI > 25? 
Consider either metformin or a sulphonylurea 
depending on plasma glucose 
Use metformin 
Adequate control? 
Address other risk factors 
Lifestyle modification as part of initial management 
NO YES 
Continue to monitor blood 
glucose and HbA1c 3-6 monthly 
Disease 
identification card or 
disc recommended 
 Copyright: Council for Medical Schemes   Page 2 of 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continue to monitor 
blood glucose and 
HbA1c 3-6 monthly 
Monitor HbA1c 
every 3 to 6 months 
Consider adding / 
enhancing insulin therapy 
If patient on sulphonylurea and has normal 
renal function and has no cardiac dysfunction 
add metformin 
If poor renal function: 
Consider adding a thiazolidinedione or insulin
If patient on 
metformin 
consider adding 
a sulphonylurea  
YES 
YES NO 
NO 
Is control adequate? 
Optimise dose of oral hypoglycaemic agent 
Adequate control?
Glossary: 
• HbA1c – Glycosylated hemoglobin  
• BMI – Body mass index 
 
 
Applicable ICD 10 Coding: 
• E11 Non-insulin-dependent diabetes mellitus 
o E11.0 Non-insulin-dependent diabetes mellitus with coma 
o E11.1 Non-insulin-dependent diabetes mellitus with ketoacidosis 
o E11.2 Non-insulin-dependent diabetes mellitus with renal 
complications 
o E11.3 Non-insulin-dependent diabetes mellitus with ophthalmic 
complications 
o E11.4 Non-insulin-dependent diabetes mellitus with neurological 
complications 
o E11.5 Non-insulin-dependent diabetes mellitus with peripheral 
circulatory complications 
o E11.6 Non-insulin-dependent diabetes mellitus with other specified 
complications 
o E11.7 Non-insulin-dependent diabetes mellitus with multiple 
complications 
o E11.8 Non-insulin-dependent diabetes mellitus with unspecified 
complications 
o E11.9 Non-insulin-dependent diabetes mellitus without complications 
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Applicable ICD 10 Coding: (continued) 
• E12 Malnutrition-related diabetes mellitus 
o E12.0 Malnutrition-related diabetes mellitus with coma 
o E12.1 Malnutrition-related diabetes mellitus with ketoacidosis 
o E12.2 Malnutrition-related diabetes mellitus with renal complications 
o E12.3 Malnutrition-related diabetes mellitus with ophthalmic 
complications 
o E12.4 Malnutrition-related diabetes mellitus with neurological 
complications 
o E12.5 Malnutrition-related diabetes mellitus with peripheral circulatory 
complications 
o E12.6 Malnutrition-related diabetes mellitus with other specified 
complications 
o E12.7 Malnutrition-related diabetes mellitus with multiple complications 
o E12.8 Malnutrition-related diabetes mellitus with unspecified 
complications 
o E12.9 Malnutrition-related diabetes mellitus without complications 
 
• O24 Diabetes mellitus in pregnancy 
o O24.1 Pre-existing diabetes mellitus, non-insulin-dependent 
o O24.2 Pre-existing malnutrition-related diabetes mellitus 
o O24.3 Pre-existing diabetes mellitus, unspecified 
Note:   
 
1. Medical management reasonably necessary for the delivery of treatment 
described in this algorithm is included within this benefit, subject to the 
application of managed health care interventions by the relevant medical 
scheme.  
 
2. To the extent that a medical scheme applies managed health care 
interventions in respect of this benefit, for example clinical protocols for 
diagnostic procedures or medical management, such interventions must – 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into 
account considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the 
Medical Schemes Act, 131 of 1998 
 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children.  If this is the case, alternative paediatric clinical 
management is included within this benefit if it is supported by evidence-
based medicine, taking into account considerations of cost-effectiveness 
and affordability.  
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Improving Adherence to Diabetes
Self-Management Recommendations
Clyde B. Schechter, MA, MD,
FACPM, and Elizabeth A. Walker,
DNSc, RN, CDE
Improved health outcomes for individuals with diabetes depend on integrat-
ing self-management into daily life. A wide variety of educational, behavioral,
and affective interventions are available that individually produce modest
improvements in patient adherence to treatment recommendations in diabetes
and related chronic illnesses and that work somewhat better when used in
combination. A summary of selected successful interventions is presented.
Diabetes is one of the chronic illnesses
for which self-management plays a
central role in care. In this regard, it is
similar to hypertension or congestive
heart failure but quite different from
some other chronic illnesses such as
breast cancer.
To optimize their health, individu-
als with diabetes may be advised
regarding diet and exercise, frequent
medical examinations, annual special-
ized examinations of their eyes and
feet, and, for many, prescribed multi-
ple oral or injected medications every
day. Until there is a cure for diabetes,
these behaviors must be sustained for
a lifetime.
Matters are made more complicat-
ed by the high prevalence of comor-
bidity among adults with diabetes:
they are at increased risk of hyperten-
sion and lipid disorders. These condi-
tions may require still more medical
management, which must be integrat-
ed with the treatment of diabetes
itself. For those unfortunate enough
to develop the vascular complications
of diabetes, still more demands of self-
management are imposed.
Managing one’s diabetes is a com-
plex task that touches nearly every
important aspect of daily life, and we
providers might marvel that any indi-
vidual manages to do it at all. Success
requires an alliance between patients
and their health care providers, one or
more from a team including physi-
cians, nurses, dietitians, diabetes edu-
cators, pharmacists, and other special-
ized health professionals. In the cur-
rent organization of health care, it
falls to primary care providers to
monitor patients’ biological progress
and prescribe an appropriately tai-
lored treatment plan. Much of the dif-
ficult work of supporting and facili-
tating patients’ implementation of
these complex plans (i.e., self-manage-
ment education, behavior change
choices) is delegated to other members
of the team or not done at all. 
It is worth noting, of course, that
discrepancies between treatment rec-
ommendations and patient self-man-
agement are not the only cause of
poor diabetes outcomes: providers’
prescriptions and the advice of other
health professionals do not always
draw on the full base of knowledge
about treating diabetes. Whereas
guidelines for treatment of hyperten-
sion1 have been set out in algorithmic
detail, the more fluid evidence-based
guidelines for treatment of diabetes
may contribute to provider deviations
from best practices. In addition, the
multiple variables to be considered in
diabetes management increase the
complexity of the task. Health care
systems may place additional barriers
in the way of bringing what we know
about diabetes to bear on the care of
their patients. But systems design and
provider adherence to guidelines are
In Brief
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topics worthy of extensive separate
treatment and are not dealt with here.
We focus instead on what can be
done to ensure that patients are given
the opportunity to consider, adopt,
and maintain the central tasks of dia-
betes self-management: practicing
healthy lifestyle behaviors related to
nutrition and exercise, taking medica-
tions as prescribed, self-monitoring
glucose, and seeking medical care as
appropriate. The goal of this article is
to provide a useful summary for prac-
titioners: we will refer to methodolog-
ical issues only to the extent that they
organize and clarify the presentation.
We make recommendations for prac-
tice, but not for the research agenda.
We will not emphasize logistical inter-
ventions such as providing transporta-
tion or mobile services, which are
often not feasible in usual clinical set-
tings.
Our review will touch on several
areas: who is not likely to adopt self-
management recommendations, how
adherence can be assessed in clinical
settings, and what steps have been
demonstrated effective at improving
adherence. It is interesting to note that
this literature does not generally
report whether subjects have made
informed choices regarding the behav-
iors in question.
Although we appreciate the origin
of Haynes’2 definition of “compli-
ance” as the extent to which a
patient’s actual behavior conforms to
the advice dispensed by the health
care provider, we also subscribe to
the philosophy that individuals
should be given the opportunity to
make informed choices about their
lifestyle and health care.3 We try to
use the term “patient adherence” in
the context of patients’ choice to
adopt and maintain health behaviors,
although the research literature for
adherence/compliance does not often
share this context.
The body of research in this area is
manageable. For example, a Medline
search for clinical trials of interven-
tions specifically to enhance or pro-
mote adherence to prescribed medica-
tions among patients with diabetes
turns up only a few hundred studies.
Much of what we know about
improving adherence is, in fact, bor-
rowed from closely related areas fac-
ing similar behavioral issues, namely
hypertension and coronary artery dis-
ease.
Despite its modest size, the adher-
ence literature can be confusing.
Studies appear to contradict each
other, or findings appear to change
with only minor differences in the
described intervention or the popula-
tion studied. Fortunately, two excel-
lent meta-analyses4,5 and two excellent
reviews6,7 have been carried out, from
which a few simple conclusions have
been drawn: 1) nearly any interven-
tion that makes sense will be of some
benefit, 2) the effects of any particular
intervention are typically small, and
3) application of multiple interven-
tions of different types is more effec-
tive than any single intervention.
How Do We Recognize the Need for
Intervention?
The breadth of the gap between
providers’ recommendations and
those behaviors patients choose to
adopt, observed in either research or
clinical practice, depends in large part
on how it is assessed; estimates range
widely as a result. The most common
clinical practice is probably to ask
patients to estimate their own level of
adherence with diet and medications.
These self-reports typically provide
overestimates of adherence for several
reasons. First, they may rely on
patients’ own interpretation or memo-
ry of what advice was given and, if
accepted, how closely it has been fol-
lowed. Second, patients may tend to
report higher levels of adherence in
order to please health care providers
or avoid embarrassment. In addition,
recall is often disproportionately influ-
enced by the most recent events,
whereas it has been shown that adher-
ence increases in proximity to a health
care appointment.8
Lower estimates of adherence are
typically found when recall-indepen-
dent behavioral measures are used,
such as pill counts, food diaries com-
pleted contemporaneously with eat-
ing, and review of monitoring logs.
Of course, it is possible that patients
choose to discard pills or engage in
other misleading behaviors when
these methods are used, so there is
still room for error. The accuracy of
pill counts, for example, may be
enhanced (with a better picture of
adherence behaviors) when pill
counts are carried out on an unan-
nounced basis during the course of a
home visit. But this method of
appraising adherence would generally
be too intrusive and too labor-con-
suming for clinical settings, besides
perhaps jeopardizing the trust rela-
tionship between providers and
patients, unless specifically requested
by patients.
Indirect measurement of adherence
can sometimes be accomplished
through biological measurements:
drug or metabolite levels in body tis-
sues, weight gain or loss, assays for
inert tracers incorporated into com-
pounded medications, or nutrient
components of foods. It should be
remembered, though, that there is
substantial biological variability
among people in the drug levels that
will be achieved with the same level of
medication ingestion or the amount of
weight that will be lost with a given
degree of dietary restraint. And, like
recall-based reports, the results of
these measurements are typically most
influenced by recent behaviors, there-
by missing the greater degree of gaps
in adherence that occur in days more
remote from health care appoint-
ments. Their cost and discomfort also
relegate these methods largely to
research settings.
More recently, electronic devices to
measure medication adherence have
become available. These have not
attained a significant role in the man-
agement of adherence in clinical set-
tings at this time, and we do not dis-
cuss them here. 
In short, there are serious method-
ological problems with the most com-
mon methods of measuring adher-
ence. It is not surprising that pub-
lished estimates of adherence range
from very low to very high. It is prob-
ably best to consider all such estimates
suspect and to remain agnostic about
the extent of the challenges to adher-
ence in various self-management
behaviors for diabetes.
One area in which research is quite
clear, however, is that there are very
few characteristics that identify
patients at high risk for gaps in adher-
ence to recommendations.6 Neither
sociodemographic characteristics nor
aspects of personality predict treat-
ment adherence. With the exception
of relatively uncommon states such as
mental illness (particularly paranoid
thinking)2 and transient periods of
social instability9,10 (e.g., recent
divorce, loss of job), no useful risk
factors have been identified. Dunbar-
Jacob et al.,6 juxtaposing the results of
Morrell et al.11 and Park et al.12, have
suggested that older age improves
adherence, and cognitive impairment
is associated with lesser adherence.
But in practice, cognitive impairment
increases with advancing age so that
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these two effects tend to cancel each
other out, making each of little use in
identifying patients at risk. Indeed, the
conclusion of the literature is quite the
opposite: the risk of adherence
issues/gaps is essentially the same in
all types of patients.
If attempts to identify people at risk
for low adherence to recommenda-
tions have been largely fruitless, other
approaches to targeting efforts at
improving adherence may be useful.
Adherence has been found to occur at
very low rates early in the course of
new treatments. Dropout rates from
treatment for hypertension, cardiac
rehabilitation, and smoking cessation
are all high initially and then
decline.13–15 Furthermore, early adher-
ence is a good predictor of sustained
adherence later on.16 Common sense
then suggests that concentrating on
identifying and improving adherence
at the start of a regimen has greater
potential for benefit than targeting old
and new patients equally, although to
our knowledge, this approach has not
been tested in a clinical trial. Similarly,
adherence is diminished by factors
such as complexity of the treatment
regimen, occurrence of side effects,
and high treatment cost. While direct
action to improve these aspects of a
regimen is arguably the best approach,
when circumstances do not permit
this, these characteristics of the regi-
men can also be used to target efforts
at adherence improvement to individu-
als at greatest risk.
If adherence is difficult to measure
and high-risk subgroups are difficult
to identify, how can we best target
our efforts to improve adherence to
those most in need of them? Haynes2
has suggested three criteria to alert
providers to a potential adherence
problem:
1.  Patients with a poor record of
appointment-keeping are likely to
have issues with other aspects of self-
management as well. Fortunately,
adherence with appointment-keeping
is relatively simple to assess in most
clinical settings.
2.  Patients who do not respond to
treatment, particularly to increasing
intensity of treatment, in all proba-
bility are not adhering to treatment
recommendations. Although nonre-
sponse to increasing the dose of a
drug might indicate that the particu-
lar drug is ineffective for the patient,
when adding additional drugs or
switching to new drugs of a differ-
ent class does not bring about
improvement, an adherence issue is
a likely cause.
3.  The patients themselves may tell
you if you ask them. Although
patient self-reports of the extent
of adherence are likely to be over-
estimates, Haynes asserts that a
nonthreatening inquiry about self-
management behaviors will yield
answers with a sensitivity of 55%
and a specificity of 87%. That is,
55% of patients who are not
adhering will volunteer this infor-
mation, and 87% of patients who
are adhering will accurately affirm
their status.
What Approaches to Improving
Adherence Seem to Work?
In reviewing approaches to adherence,
it is helpful to consider separately the
aspects of adherence being improved
and the type of intervention being
considered. Haynes2 and Roter et al.4
classify interventions into three similar
categories (although they use slightly
different labels for them): educational,
behavioral, and affective.
Educational interventions seek to
improve adherence by providing
information and/or skills. The infor-
mation may concern the nature of the
disease, the array of diabetes self-man-
agement behaviors, and the positive
and negative consequences of not
adopting health recommendations.
But at least as important is informa-
tion about what to do if a dose of
medication has been missed or if
intercurrent illness or other problems
arise or if you are traveling across
many time zones.
Education may take the form of
individual instruction or group class-
es. It might be provided in writing or
through a visual medium such as
videotape, multimedia computer soft-
ware, or access to special Internet
sites. In any event, a key element of
successful educational strategies is
providing simple, clear messages,
hopefully tailored to the needs of the
individual, and verifying that the mes-
sages have been understood.
Behavioral approaches have their
roots in cognitive-behavioral psy-
chology and use techniques such as
reminders, memory aids, synchroniz-
ing therapeutic activities with routine
life events (e.g., taking pills before
you shower), goal-setting, self-moni-
toring, contracting, skill-building,
and rewards. As with educational
approaches, some of these approach-
es, such as skill building, may be pro-
vided individually or in groups and
through a variety of media. For
example, reminders may be mailed,
e-mailed, or telephoned. What is
important is that the behavior in
question has been negotiated with
and accepted by individual patients
so that adoption of the behavior has
a chance of succeeding in the long
term.
Affective interventions seek to
enhance adherence by providing emo-
tional support and encouragement;
recent diet and exercise intervention
studies17 have used lifestyle “coaches”
to help people adhere to the behavioral
changes to which they have commit-
ted. Examples include rapport building
through frequent telephone contact,
home visits when feasible, family-
based approaches (including family
contracting), and interventions to
enhance coping skills and self-efficacy.
The classification of interventions
is important because, as Haynes says,
“It is important to bear in mind that
no single intervention has been
shown to maintain long-term adher-
ence; one must combine strategies
from two or more of these three cate-
gories to achieve success.”2 Roter et
al.,4 in their more recent review of
this area, draw a similar, if less bold-
ly asserted, conclusion. What seems
clear from a systematic review of
studies of self-management training
in type 2 diabetes18 is that it takes
varying degrees of all three categories
of intervention to have a positive
impact on health or behavioral out-
comes in diabetes; this possibly
reflects the complex psychological
landscape of self-management in a
chronic disease such as diabetes. 
In the remainder of this section, we
identify specific interventions that
appear to be effective in enhancing
adherence with specific aspects of self-
management. Because the effects of
any particular intervention are usually
small and because of methodological
differences across studies, interven-
tions listed here have not necessarily
been found consistently effective. Nor
is our list restricted to approaches that
have been shown effective specifically
in the management of diabetes. We
include interventions, rather, when
they have been found effective at least
once and when they belong to a class
of interventions that have been identi-
fied in a meta-analysis as having a sig-
nificant effect on an adequate measure
of adherence for treatment of chronic
diseases. 
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Adherence with medications is
affected by many things. It is generally
agreed that simpler regimens such as
once-a-day dosing are associated with
better adherence than more compli-
cated ones. Nevertheless, even with
the simplest regimens, adherence can
be poor.19 Numerous approaches have
been used to improve adherence to
prescribed medication regimens.
Table 1 presents selected interven-
tions that have been found workable.
What is striking is the diversity of per-
sonnel who can implement interven-
tions successfully and the variety of
technologies that can be used. It
should also be noted that studies of
interventions to improve medication
adherence, both included and beyond
those shown in the table, have focused
on both prescription-filling and self-
administration of the medication.
Physical activity plays a vital role in
the self-management of type 2 dia-
betes. Exercise is the best predictor of
maintaining weight loss, and, inde-
pendent of weight loss, it decreases
insulin resistance. Unfortunately, it is
in the area of efforts to improve
adherence with exercise recommenda-
tions that we have, perhaps, the small-
est body of research. There are rela-
tively few studies, and they tend to be
small and brief. The most noteworthy
findings are reviewed here.
Carlson et al.20 sought not so much
to increase adherence to exercise ther-
apy among cardiovascular rehabilita-
tion patients as to see whether it could
be sustained using a less expensive
program that de-emphasized electro-
cardiographic monitoring and allowed
some of the sessions to be carried out
at home. They found, however, that
the less expensive approach, perhaps
because of its increased simplicity and
lower cost, was associated with
enhanced adherence.
In a study of exercise as a weight-
loss treatment, Jakicic et al.21 found
that women randomized to have
access to home exercise equipment for
short bouts of exercise were more
adherent and lost more weight than
those without access to exercise
equipment. Mahler, Kulik, and
Tarazi22 randomized patients being
discharged after coronary artery
bypass surgery to standard discharge
information or to viewing of one of
two educational videotapes. Both
videotape recipient groups exhibited
greater adherence with exercise rec-
ommendations, and those who viewed
the tape portraying the post-discharge
course as characterized by ups and
downs were more adherent than the
group whose tape portrayed it as
steady progress. Annesi23 found that a
computerized feedback system that
tracked progress, provided feedback,
and set goals reduced dropout rates
and delayed dropout from a pre-
scribed exercise program carried out
in a fitness center.
King et al.24 studied the use of
semi-weekly staff-initiated telephone
contact as a supplement to baseline
education to sustain participation in a
home-based exercise program. They
found the telephone intervention to
result in both greater participation
and improved fitness among those ini-
tiating the program and better mainte-
nance of the behavior among long-
term participants who had already
demonstrated improved fitness before
randomization. In the maintenance
phase of the study, they also found
that daily self-monitoring was superi-
or to weekly self-monitoring.
Jeffery et al.25 found that obese men
and women randomized to receive a
personal trainer or financial incentives
for participation in the exercise compo-
nent of a behavioral weight-loss pro-
gram achieved higher attendance levels
than those randomized to usual treat-
ment or usual treatment plus super-
vised walks. Notwithstanding this suc-
cess, the increased attendance did not
translate into increased energy con-
sumption or greater weight loss.
The types of interventions used in
these trials are similar to those used
for improving adherence to other
types of treatment. It is therefore rea-
sonable to assume that similar gener-
alizations about the increased effec-
tiveness of multiple interventions, as
established for other types of adher-
ence behavior, will apply to exercise
adherence as well.
Adherence to dietary recommenda-
tions to lower cholesterol and lose
weight has been studied extensively in
patients with or at risk for coronary
heart disease. Dietary recommenda-
tions for these people are similar to
those for patients with type 2 dia-
betes, so that similar interventions to
improve adherence may be applicable.
Metz et al.26 randomized 560 peo-
ple with hypertension, diabetes, or
lipid disorders to receive detailed
dietary plans or prepared meals. They
found that the group receiving pre-
pared meals had better dietary adher-
ence as measured by 3-day food
diaries. While providing patients with
meals is not a feasible intervention in
most clinical settings, this study and
others (e.g., the DASH trial27) suggest
that a market for meal provision for
medical nutrition therapy might be
developed. They also reinforce the
notion that dietary adherence is very
strongly influenced by the ready avail-
ability of healthy food choices and the
unavailability of unhealthy ones.
From a more practical perspective,
McCulloch et al.28 found that practi-
cal lunch time demonstrations or
videotape education were superior to
conventional diet-sheet instruction
among adults with poorly controlled
type 2 diabetes (average pretreatment
hemoglobin A1c [A1C] 13%). The
patients in the demonstration and
videotape groups showed improved
dietary knowledge, better adherence
Intervention Ref.
Educational
Teaching by nurse and psychologist supplemented with audiotapes 36
Affective
Home visit to increase family support, group sessions to increase patient 37
confidence and skills
Behavioral
Frequent follow-up by nurse at worksite clinic until treatment goals achieved 38
Feedback through patient record of medications and blood pressure response 39
Combination of medication chart and pill organizer 40
Mailed prescription refill reminder and special packaging 41
Nurse counseling plus reminder chart, structured counseling by pharmacist 42
At end of hospitalization, phasing in patient responsibility for medication 43
administration
Telephone reminders and monitoring using computerized telephone system 44
Educational videotape or picture book (note: subjects were asthmatic children) 45
Table 1. Selected Interventions to Improve Medication
Adherence
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on 7-day food diaries, and substantial
improvements in A1C (to 10.6 and
9.6%, respectively, versus no change
in the conventional diet-sheet group).
Although the Multiple Risk Factor
Intervention Trial (MRFIT) did not
achieve its primary goal of reducing
mortality from coronary heart
disease,29 it was highly successful at
reducing the prevalence of risk factors
for coronary disease in its special inter-
vention group. MRFIT may be the
longest, largest-scale success in
improving adherence to cardiovascular
dietary recommendations.30 In that
study, intensive and sustained counsel-
ing of middle-aged men with multiple
risk factors for cardiovascular disease
was provided by nutrition counselors.
Most remarkable is that dietary adher-
ence as measured by 3-day dietary
records and improvements in serum
lipid levels was largely sustained dur-
ing 6 years of follow-up.
The use of videotapes by Mahler et
al.22 cited earlier in connection with
exercise adherence was also successful
in reducing dietary fat intake after
coronary artery bypass surgery, and,
again, the tape presenting the post-
operative period as a series of ups and
downs generated greater success than
the other tape.
Compared to usual care and print-
ed information, dietary advice provid-
ed by nurses to healthy patients at risk
for coronary heart disease, along with
sustained follow-up by these nurses,
was associated with slightly greater
weight loss, lower intake of total fat
and saturated fat, and lower serum
cholesterol levels. Roderick et al.31
pointed out, however, that the modest
gains achieved would be proportion-
ate to the effort and resources
required only in patients at the highest
risk levels.
What is most striking about inter-
ventions to improve dietary adherence
is the key role played by health care
professionals such as dietitians and
nurses. In successful interventions, the
physicians’ role, if there is any at all,
is one of providing approval and ini-
tial encouragement. The actual inter-
vention is implemented by nurses or
dietitians. It is a matter of speculation
whether this reflects greater interest,
training in counseling skills, better
patient rapport, or more time to
devote to dietary matters. We were
unable to find any successful interven-
tions that relied primarily on physi-
cians to improve dietary adherence.
Appointment-making and -keeping
is another aspect of chronic disease
self-management. For diabetes, this
can involve both regular appoint-
ments for monitoring and care (typi-
cally several times a year) and annual
appointments for dilated fundus
examinations and comprehensive foot
examinations. As with interventions
to promote adherence, the track
record of any single approach is
mixed, but when the literature is
viewed as a whole, mail and telephone
reminders produce improvements in
appointment-keeping.
It has been harder to demonstrate
that these same interventions also
result in improved glycemic control or
reduced hospitalization. For example,
Feder et al.32 used mailed prompts to
both coronary heart disease patients
and their providers to attempt to
boost patient clinic attendance and
adherence by physicians to treatment
guidelines. While their intervention
did increase attendance and also
increased rates of referral to cardiolo-
gists for evaluation, they found no
improvement in other markers of
quality of care nor any change in
lifestyle modifications to reduce risk
of recurrent coronary events.
Similarly, in Smith, Weinberger,
and Katz’ trial33 of mailed informa-
tion, appointment reminders, and
intense follow-up of missed appoint-
ments, the intervention group kept
significantly more appointments than
the control group, but this improved
adherence to outpatient care did not
reduce hospitalizations. Of course,
management of diabetes was less
effective in 1987, and the intervention
in this trial did not attempt to
improve the quality of care delivered
at the visits. Thus, this result is less
surprising than that of Feder et al.
Basch et al.34 doubled the rate of
retinopathy screening among African
Americans with diabetes who had not
had an eye exam in the preceding 14
months using a multicomponent edu-
cational intervention. Their approach
relied heavily on telephone-based
problem-solving phone calls to over-
come barriers to screening.
Summary and Conclusions
Our glass is half full. A wide variety
of methods to improve all aspects of
patient adherence to treatment recom-
mendations for diabetes have been
studied. Even though many interven-
tions used have been applied broadly
to populations without tailoring to
individual patients’ stage of change,35
a modicum of success is often
attained.
Although meta-analyses have
shown that broad categories of inter-
ventions are, in aggregate, successful,
their effects are small. Simultaneously
applying several approaches drawn
from different modalities (education-
al, behavioral, affective) tends to pro-
duce better results than any single
modality. Practitioners seeking to
enhance adherence among patients
will find no “silver bullet.” Rather,
we have a collection of reasonably
useful tools at our disposal, which we
are challenged to use as effectively as
we can.
Our efforts are likely to bring the
most benefit if temporally targeted to
the patients at highest risk of adher-
ence problems and issues: patients
being newly introduced to a treatment
or patients with previous problems
with adherence or adoption of behav-
iors. If we respect the autonomy of
people who live with diabetes while
providing them with the educational,
behavioral, and emotional support to
manage their disease, we have proba-
bly fulfilled our health care profes-
sional role in promoting adherence. 
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Pharmacist copy 
 
Type 2 Diabetes Mellitus Research Project  Knowledge Questionnaire*  
* Reproduced with the permission of the University of Michigan Diabetes Research and Training Center   
 
1. The diabetes diet is: 
a) the way most South Africans eat 
b) a healthy diet for most people 
c) too high in carbohydrate for most people 
d) too high in protein for most people 
 
2. Which of the following is highest in carbohydrate? 
a) Baked chicken 
b) Swiss Cheese 
c) Baked potato 
d) Peanut butter 
 
3. Which of the following is highest in fat? 
a) Low fat milk 
b) Orange juice 
c) Maize 
d) Honey 
 
4. Which of the following is a “free food”? 
a) Any unsweetened food 
b) Any dietetic food 
c) Any food that says “sugar free” on the label 
d) Any food that has less than 80 kilojoules per serving 
 
5. Glycosylated haemoglobin (HbA1c) is a test that is a measure of your average 
blood glucose level for the past: 
a) day 
b) week 
c) 6-10 weeks 
d) 6 months 
 2 
 
6. Which is the best method for testing blood glucose? 
a) Urine testing 
b) Blood testing 
c) Both are equally good 
 
7. What effect does unsweetened fruit juice have on blood glucose? 
a) Lowers it 
b) Raises it 
c) Has no effect  
 
8. Which should not be used to treat low blood glucose? 
a) 3 hard sweets 
b) Half a cup of orange juice 
c) One cup of diet soft drink 
d) One cup of skim milk 
 
9. For a person in good control, what effect does exercise have on blood 
glucose? 
a) Lowers it 
b) Raises it 
c) Has no effect 
 
10. Infection is likely to cause: 
a) an increase in blood glucose 
b) a decrease in blood glucose 
c) no change in blood glucose 
 
11. The best way to take care of your feet is to: 
a) look at them and wash them each day 
b) massage them with alcohol each day 
c) soak them for one hour each day 
d) buy shoes a size larger than usual 
 
12. Eating foods lower in fat decreases your risk for; 
a) nerve disease 
b) kidney disease 
c) heart disease 
 3 
d) eye disease 
 
13. Numbness and tingling may be symptoms of: 
a) kidney disease 
b) nerve disease 
c) eye disease 
d) liver disease 
 
14. Which of the following is usually not associated with diabetes: 
a) vision problems 
b) kidney problems 
c) nerve problems 
d) lung problems 
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Pharmacist copy                                                                                                               
 
Type 2 Diabetes Mellitus Research Project Questionnaire*   
 
* Reproduced with the permission of the University of Michigan Diabetes Research and Training Center 
 
Your research identity number: 
 
 
 
Please tick one box only per question answered 
            
                                                                                                         
Q1* Do you test your blood sugar? 
 
Yes No 
 
 If Yes please continue with the questionnaire 
                                                                                                           Days per week 
Q2* How many days a week do you test your blood 
sugar?                                                                                                                  
1 2 3 4 5 6 7 
 
                                                                                                                 Times per day 
Q3* On the days that you test, how many times do you test your 
blood sugar? 
1 2 3 4 
  
     
Q4* Do you keep a record of your blood sugar results? 
 
Yes No 
 
                                                                                                                                     
Q5 Do you use your blood sugar test results to assist 
you in the management of your diabetes? 
Yes No Sometimes 
                                                                                                                                     
Q6 Does your medical practioner use your blood sugar 
test results in prescribing your diabetes therapy? 
Yes No Sometimes 
 
Q7 Does your pharmacist use your blood sugar test 
results to suggest adjustments to your medication 
therapy? 
Yes No Sometimes 
 
 
Thank you for completing the questionnaire 
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Pharmacist copy 
 
Diabetes Empowerment(DES-SF) Questionnaire* 
* Reproduced with the permission of the University of Michigan Diabetes Research and Training Center 
 
Below are some statements about diabetes. Each numbered statement finishes the 
sentence, “In general, I believe that..”  For each of the statements, please tick the 
box that is closest to your opinion . 
 
 In general I believe that I: Strongly 
agree 
Somewhat 
agree 
Neutral Somewhat 
disagree 
Strongly 
disagree 
1 
 
 
…know what part(s) of taking 
care of my diabetes that I am 
dissatisfied with 
5 4 3 2 1 
2 
 
 
…am able to turn my diabetes 
goals into a workable plan 
5 4 3 2 1 
3 
 
 
…can try out different ways of 
overcoming barriers to my 
diabetes goals 
5 4 3 2 1 
4 
 
 
…can find ways to feel better 
about having diabetes 
5 4 3 2 1 
5 
 
 
…know the positive ways I cope 
with diabetes-related stress 
5 4 3 2 1 
6 
 
 
…can ask for support for having 
and caring for my diabetes when 
I need it 
5 4 3 2 1 
7 
 
 
…know what helps me stay 
motivated to care for my diabetes 
5 4 3 2 1 
8 
 
…know enough about myself as 
a person to make diabetes care 
choices that are right for me. 
5 4 3 2 1 
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Pharmacist copy 
 
 
Understanding Self-care Practices Questionnaire* 
* Reproduced with the permission of the University of Michigan Diabetes Research and Training Center 
 
 
 
Please tick one box only per question answered 
 
 
 
Q3. Have you ever received diabetes education?           
1
 No                
2
 Yes    
 
 
Q4  How do you rate your understanding of:     
                                
Poor Good Excellent 
a diet and blood sugar control?           1 2 3 
b weight management? 1 2 3 
c exercise? 1 2 3 
d use of medication (tablets and or insulin)? 1 2 3 
e sugar testing? 1 2 3 
f foot care?   1 2 3 
g complications of diabetes? 1 2 3 
h eye care? 1 2 3 
i combining diabetes medication with other medication? 1 2 3 
j alcohol use and diabetes? 1 2 3 
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Pharmacist copy 
 
 
Medicines Adherence Report Questionnaire* 
* Reproduced with the permission of Professor Robert Horne   
 
Questions about using your medicines 
 
Many people find a way of using their medicines which suits them and this may differ 
from the instructions on the label or from what the doctor has said. We would like to 
ask you a few questions about how you use your medicines 
 
Here are some ways in which people have said that they use their medicines. For each 
of the statements, please tick the box that best applies to you 
 
 Your own way of using your medicines 
 
Always Often Sometimes Rarely Never 
1 I forget to take them 
 
1 2 3 4 5 
2 I alter the dose 
 
1 2 3 4 5 
3 I stop taking them for a while 
 
1 2 3 4 5 
4 I decide to miss out a dose 
 
1 2 3 4 5 
5 I take less than instructed 
 
1 2 3 4 5 
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 Annexure 6.7 
 
 
 
 
FACULTY OF PHARMACY 
 
Pharmacy Practice Research 
Patient Adherence to Self-Care Recommendations in Type 2 Diabetes Mellitus 
 
Dear name of pharmacist, 
I refer to my fax to you of 31 March 2007, in which I advised you of the names and 
contact details of your patients who remain participants in the research, and who need to 
present at your pharmacy for the final set of clinical data. Attached please find: 
 Ampath forms for the Lipogram, HbA1c and Creatinine  
 Post-baseline Clinical Data forms 
Ampath forms 
You will note that these forms have been coded as” Type 2 diabetes adherence research 
41676” by Ampath in order for the data to be directly communicated to me.  
Post-baseline Clinical Data Form 
You need not complete the Result & Date fields for tests 1, 2 and 3 as these will be sent 
directly to me by Ampath. I will forward your patients tests results for your records as soon 
as I receive them from Ampath. Tests 4, 5, 6 & 7 should be done in the pharmacy. A 
random urine sample will suffice for the dip-stick test for Proteinuria.  
 
Please fax the data forms to me at 046 6243575 by 31 May 2007. 
 
Kind regards and many thanks for your continued support  
  
 
Peter Hill 
Tel/fax 046 6243575 
                                                                                                                                 
Annexure 6.8 
 
                                                                                                         Faculty of Pharmacy 
 
PW Hill 
PO Box 275 
Port Alfred  
6170                                                                                                                                
Tel: 046 6243575  
Mobile: 0829285020 
E-mail: peterhill@intekom.co.za 
 
27 April 2007 
 
Dear name of pharmacist 
 
I would appreciate it if you would be so kind and have your patients complete the 
attached questionnaires as soon as possible. Please return the completed to me using 
the enclosed self-addressed postage paid envelopes. 
 
 
Best wishes and thanks once again for staying the course 
 
 
 
 
Peter Hill  
 
 
 Annexure 6.9 
 
 
FACULTY OF PHARMACY  
 
Type 2 Diabetes Research: Prescribed Medication & Refill Questionnaire 
 
 
Name of patient:        
 
Please √ boxes below that correspond with your answers. 
 
Q1. Please review the patient’s prescription medication refill records (“repeats”) for the     
6 month period 1 December 2006 to 31 May 2007 and indicate how many refills for 
each medicine were dispensed during this period. 
               
 *Please PRINT name of medication clearly 6 refills 5 refills  4 refills 3 refills  < 3 refills 
Oral hypoglycaemic medication      
1.       
2.       
3.       
Blood lipid lowering medication      
4.       
5.       
6.       
Anti-hypertensive medication      
7.       
8.       
9.       
 
 
Q2. Has the patient’s hyperglycaemia-related pharmacotherapy been changed during 
the past 12 months (May 2006-April 2007)? 
 
 Yes No 
10. Oral hypoglycaemic agent (OHA) dosage increased    
11. Alternative OHA prescribed   
12. Additional OHA added to existing regimen   
13. Insulin added to or substituted for OHA   
 
Please fax (046 6243575) or email (peterhill@intekom.co.za) the completed 
form as soon as possible.  Thank you. 
